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In the United States, high-risk drug use remains a significant social problem. Opioids and 
stimulants are two drug classes that have contributed to substantial recent increases in drug-related arrests, 
overdose, and mortality. Kentucky has been particularly devastated by high rates of opioid and stimulant 
use. Opioid and stimulant effects, while highly rewarding, can result in adverse consequences. Still, some 
people choose to use these drugs, and choose to continue using even after experiencing adverse 
consequences, such as incarceration. The aim of this study was to explore high-risk drug use among a 
sample of corrections-involved adults in Kentucky and to identify endogenous and exogenous factors with 
the potential to have influenced drug-related decision-making prior and subsequent to incarceration. 
Attention was paid to understanding concomitant opioid and stimulant use and heroin use. Survey data 
collected as part of an ongoing corrections-based substance use treatment program outcomes study were 
examined. The final sample (N=1,563) included adults released into Kentucky counties between 2012-
2017. Non-parametric statistical tests and multinomial logistic regression were used to identify factors 
associated with opioid, stimulant, and concomitant use; binary logistic regression was used to identify 
factors associated with heroin use. Results indicate that opioid and stimulant use was endemic in this 
sample, though rates of use subsequent to incarceration were lower than pre-incarceration rates.
 viii 
During the 30-day period prior to incarceration, 29.0% of participants reported concomitant use, 28.5% 
reported opioid use, and 18.0% reported stimulant use. During the one-year post-release period, 11.9% of 
participants reported concomitant use, 12.5% reported opioid use, and 8.3% reported stimulant use. During 
this post-release period, 10.7% reported heroin use. Concomitant and heroin use positively correlated with 
many factors with the potential to adversely influence cognition and constrain choice. Similar relationships 
between many of these factors and outcomes involving other drug or no drug use were not observed. 
Behavioral economics, a molar view of choice and behavior, was used to conceptualize how factors in the 
lives of participants had the potential to influence and constrain decision-making in respect to high-risk 
drugs. Findings are discussed in light of how they may inform future research, policy, and practice.  
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CHAPTER I 
INTRODUCTION TO SOCIAL PROBLEM 
AND CONCEPTUAL FRAMEWORK 
High-risk Drug Use 
Risky, or risk-taking, behavior is defined by Turner et al. (2004) as a volitional behavior with a 
potentially negative outcome in which the danger is recognized. Risk has been further conceptualized as 
outcome invariance (Real & Caraco, 1986). For instance, if two choices have equal value, the one with 
greater variance may be considered to have higher risk (Daly & Wilson, 2001). Use of addictive drugs is 
one type of volitional high-risk behavior (Bickel & Marsch, 2001). During a drug-related decision, use of 
high-risk drugs is one of many possible behavioral outcomes. Other potential outcomes include the 
substituted use of a relatively less risky but still desired drug, or no drug use, with the person otherwise 
engaged in behaviors unrelated to drugs (Vuchinich & Heather, 2003). The use of addictive high-risk drugs 
constitutes a significant economic, social, legal, and medical problem in the United States (Degenhardt et 
al., 2014; Schuchat, Houry, & Guy, 2017; Volkow & Collins, 2017). Although use of any drug entails some 
risk for the person using it, certain drugs are associated with comparatively greater risk. Opioids (e.g., 
heroin, non-medical prescription opioids) and psychostimulants (e.g., amphetamines, cocaine) are two drug 
classes that have several unique risks associated with their use, making them potentially more dangerous in 
both the short- and long-term, relative to other licit drugs (e.g., caffeine, nicotine, kratom, alcohol), 
prescription drugs (e.g., benzodiazepines), and illicit drugs (e.g., cannabis, psilocybin, LSD) (Bachi, Sierra, 
Volkow, Goldstein, & Alia-Klein, 2017; Chen, Storr, & Anthony, 2009; Paulozzi, 2012; Tomassoni et al., 
2017). For instance, analyzing 1991-2011 National Health Interview Survey data, Walker et al. (2017) 
found that among a nationally representative sample, lifetime use of heroin and cocaine was significantly 
associated with excess mortality risk. More broadly, opioids and stimulants account for a disproportionate 
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number of drug overdose fatalities in the US. (Jalal et al., 2018). Examining data for drug-related overdose 
deaths between 1979-2016, Jalal et al. (2018) found exponential growth for all drug-related overdose 
fatalities, with peak mortality rates for drug classes distinguished by time, geographic region, and 
population characteristics (e.g., sex, race). Heroin, semisynthetic prescription opioids (e.g., oxycodone), 
and synthetic opioids (e.g., fentanyl) contributed to a significant portion of accidental overdose deaths, as 
did cocaine and amphetamine drugs. Between 2016 and 2017, opioid overdose fatalities increased 
approximately 30% (Vivolo-Kantor et al., 2010). Presently in the US, 130 people a day die from an opioid-
related overdose, with opioid misuse comprising a nearly $80 billion a year cost (Centers for Disease 
Control and Prevention [CDC]). Since, 2012, cocaine-related overdose fatalities have also resulted in 
significant losses, particularly among non-Hispanic Blacks (Shiels, Freedman, Thomas, & de Gonzalez 
2018). 
 Considering this nearly 40-year exponential growth, two relevant conclusions might be made. 
First, the current “opioid epidemic” may be considered one of many interconnected drug epidemics, albeit a 
larger and possibly more insidious one, due to the continued need for analgesic drugs in the treatment of 
chronic pain in the US (Bowser, Fullilove, & Word, 2017; Dowell, Haegerich, & Chou, 2016). Second, 
both stimulants and opioids have been leading causes of drug-related overdose fatalities historically. 
Evidence suggests that in addition to stimulant-related overdose fatalities, stimulants may soon increase as 
a contributor of non-overdose drug-related fatalities, as many people who developed problematic cocaine 
and amphetamine use in the 1970s-1990s are growing older and are therefore more likely to start 
experiencing delayed consequences of use (Levandowski et al., 2016; Shiels et al., 2018; Yarnell, 2015). 
Taking a broader view of the problem of high-risk drug use in the US, rather than considering separable 
high-risk drug epidemics, it becomes clear that both opioid and stimulant use persist as leading contributors 
to poor outcomes for users and that both remain complicated social, economic, medical, and legal 
challenges to understand and address (Plunk, Grucza, & Peglow, 2018).   
Opioid and Stimulant Use in the United States 
Opioid Use 
Opioids are defined here as any natural (i.e., derived the poppy [Papaveraceae] family; e.g., 
codeine, morphine, heroin), semi-synthetic (i.e., substances produced by chemical synthesis; e.g., 
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OxyContin, Suboxone), or fully-synthetic (e.g., fentanyl, methadone) substance that acts as a partial or full 
agonist at one of the primary human opioid receptors (μ-opioid receptor, MOR; δ-opioid receptor, DOR; 
and κ-opioid receptor, KOR) and results in physiological and psychoactive effects (Feng et al., 2012; 
Pergolizzi, LeQuang, Berger, & Raffa, 2017; Taber, Neubert, & Rheingold, 2002). In humans, opioids 
produce both analgesic and euphoric effects (Webster, Johnson, Stauffer, Setnik, & Ciric, 2011). These 
effects are rewarding and memorable, and therefore behaviorally reinforcing, whereby people may be 
motivated to use again, even when it requires considerable effort or expense (Everitt & Robbins, 2005). 
Adverse consequences associated with opioid use and misuse have been studied and speculated 
about for some time; though the full scope of possible short- and long-term consequences is still 
incompletely understood (Baldo, 2016; Cheng & Lee, 2016; Kreek, 1996; Laorden, Fuertes, González-
Cuello, & Milanés, 2000). Given the scale of opioid use and misuse in the US, adverse consequences 
cannot help but have an outsized effect if left insufficiently understood and addressed (Epstein, Heilig, & 
Shaham, 2018)  In 2017, an estimated 6.0 million people in the US aged 12 and older reported past-month 
illicit prescription opioid use and nearly half a million of this same age group reported past-month heroin 
use (Substance Abuse Mental Health Services Administration [SAMHSA], 2017). Over the past two 
decades, rates of opioid prescribing and prescription opioid diversion increased, contributing to increases in 
opioid-related mortalities (Brady et al. 2015; Dart et al. 2015; Kolodny et al. 2015; Oquendo & Volkow, 
2018). In 2012 the annual prescribing rate for opioids peaked at 81.3 per 100 persons and remains elevated 
at a rate of 58.5 per 100 persons as of 2017 (CDC 2019).  
Wide-ranging efforts have been made over the past decade to address prescription opioid misuse. 
These have included the dismantling of predatory “pill mills”, increased access to treatment for opioid-
dependent offenders, harsher criminal sanctions for opioid dealers, revised CDC opioid prescribing 
guidelines, mandated prescriber participation in drug monitoring systems, and scientific advances in abuse-
deterrent opioid pill formulations (CDC, 2018; Freeman, Goodin, Troske, & Talbert, 2015; Lin et al. 2018; 
Makary et al. 2017; McCarthy 2017; Powell and Pacula, 2017; Worley, 2012). Despite these efforts, heroin 
use in the US has increased significantly since 2010 (Compton et al. 2016; Kanouse & Compton, 2015). 
Both prescription opioid and heroin use persist as significant public health threats. Between 1999 and 2016 
the age-adjusted rate of drug overdose deaths involving natural and semisynthetic opioids (e.g., oxycodone) 
 4 
increased from 1.0% to 4.4% (Hedegaard, Warner, & Miniño, 2017). Heroin and fentanyl-adulterated 
heroin overdose mortalities have also increased, with over 15,000 Americans dying from heroin-related 
overdose in 2017 alone (CDC, 2017b). Use of diverted buprenorphine (i.e., Suboxone) has also become a 
concerning new phenomenon within the broader opioid crisis (Molfenter et al., 2019). 
Among high-risk drugs of abuse, opioids are more likely than other drugs to result in overdose and 
overdose-related mortalities, and also to be perceived by survivors as comparatively worse overdose 
experiences (Bohnert et al., 2018; Dowell, Noonan, & Houry, 2017). As the opioid-related death toll has 
increased in the US, no socioeconomic or demographic group has been spared and no region has been left 
unaffected (Alexander, Barbieri, & Kiang, 2017; Plunk et al., 2018; Shiels et al., 2018). Areas in the 
southeastern US, including regions within and adjacent to Central Appalachia, have been particularly 
impacted by prescription opioid and heroin use over the past two decades (Jonas et al. 2012; Moody, 
Satterwhite, & Bickel, 2017; Slavova et al. 2017; Staton et al. 2018).  
One result of the dramatic uptick in opioid-related mortalities over a short period of time is that 
increased attention is being paid to the problem and more public resources are being devoted to addressing 
it (Collins, Koroshetz, & Volkow, 2018; Madras, 2017). Yet, even with increased attention and resources 
aimed at understanding and mitigating the current opioid epidemic, some of the most fundamental and 
enduring questions about the factors with the potential to influence a person’s decision to use opioids 
despite associated risks, and to persist in use despite adverse consequences, remain insufficiently answered. 
Psychostimulant Use 
Psychostimulants are defined here as any natural (i.e., derived from coca [Erythroxylaceae] 
family; e.g., cocaine), natural but processed (e.g., hydrochloride salt cocaine, bicarbonate of sodium 
solution, a.k.a. “crack” cocaine), or synthetic (e.g., 3,4-methylenedioxymethamphetamine, pharmaceutical 
methamphetamine) substance that acts primarily on human dopamine and serotonin receptors and results in 
physiological and psychoactive effects. (Johanson & Fischman, 1989; Kalivas, 2007; Koob, 1992). 
Stimulants produce a range of effects, including increased alertness, euphoria, locomotor activity, 
endurance, and arousal (Rush & Baker, 2001; Rush, Stoops, & Sevak, 2010; Uhl, Halll, & Sora, 2002).  
As of 2017 in the US, an estimated 2.2 people aged 12 or older reported past-month powder and/or 
crack cocaine use, while 1.8 million reported past-month prescription stimulant use, and 774,000 reported 
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past-month methamphetamine use (SAMHSA, 2017). Nationally, there has been an upward trend in the use 
of stimulant drugs. For instance, the number of people aged 12 or older who reported past-month cocaine 
use increased from 1.6 million in 2012 to 2.2 million in 2017, an increase of over half a million people 
(SAMHSA, 2012). There have been slight increases in prescription stimulant and methamphetamine use as 
well. For example, between 2012 and 2017, the number of people aged 12 or older reporting past-month 
prescription stimulant use increased from 1.2 million to 1.8 million, whereas past-month amphetamine use 
among people 12 or older increased between 2012 and 2017, from approximately 440,000 to 774,000, 
respectively (SAMHSA, 2012, 2017).  
Cocaine’s addictive potential has been well-documented for decades; however, increases in use in 
the 1970s and 1980s resulted in greater attention among researchers, medical professionals, and law 
enforcement (Associated Press, 1982; Fagan & Chin, 1989; Gawin, Allen, & Humblestone, 1989; Marriott, 
1989). This was partially a result of a sharp increase in cocaine-related emergencies and mortalities. Rates 
of cocaine-related deaths increased four-fold between 1976-1981 (CDC, 1982). In 1985, the smokable 
derivative of cocaine, “crack”, emerged as a serious drug of concern across many communities, particularly 
metro areas and within communities with a disproportionate number of people of color (Fryer, Levitt, & 
Murphy, 2013). Between the late 1980s and early 1990s, the total number of cocaine users in the US 
increased, in part due to new adopters of crack cocaine (Cornish & O’Brien, 1996; O'Malley, Bachman, & 
Johnston, 1988). This increase contributed to a rippling of adverse social, legal and health consequences 
(including drug-related violence) for users, their families, and their communities (Blumstein, 1995; Fagan, 
1994; MacGregor et al., 1987).  
Availability and use of diverted prescription stimulants, such as methamphetamine, 
methylphenidate (i.e., Ritalin), or dextroamphetamine (i.e., Adderall), increased in the 1990s and 2000s as 
these drugs became more widely used in the pharmacotherapy of attention deficit disorders (Wilens et al., 
2008). In the 1990s, clandestine labs, spanning drug cartels to home kitchens, began producing “street 
meth” (e.g., “crystal meth”, “ice”, or “stove top meth”) (Cunningham, Liu, & Callaghan, 2009; Maxwell & 
Rutkowski, 2008; Zernike, 2006). Thereafter, the availability and use of methamphetamine increased, 
becoming a fixture of many communities across the US, though use has often been more prevalent in 
smaller, mid-sized, and rural communities (Dombrowski, Crawford, Khan, & Tyler, 2016; Habecker, 
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Welch-Lazoritz, & Dombrowski, 2018; Lambert, Gale, & Hartley, 2008; Roussell, Holmes, & Anderson-
Sprecher, 2013). 
Concomitant Drug Use 
Another form of high-risk drug use includes concomitant use of more than one drug (Zoorob, 
2018). Polydrug use is a well-documented phenomenon among people with SUD, versus the general 
population, who may be more likely to use drugs recreationally, in moderation, and individually (verses 
concomitantly); however, less is known about controlled users, as they are seldom institutionalized and 
studied (Zinberg, 1984; Zinberg, Harding, & Winkeller, 1977; Waldorf, Reinarman, & Murphy, 1992). 
Oftentimes, people with SUD also present comorbidly with at least one other SUD (Anthony, Warner, & 
Kessler, 1994; Kandel, Chen, Warner, Kessler, & Grant, 1997). Polydrug use can include co-ingestion of 
more than one drug at the same time. For example, drinking alcohol while smoking cannabis, or injecting 
opioids and stimulants simultaneously (e.g., “speedballing”, “goofballing”) (Dolan, Black, Malow, & Penk, 
1991; Latkin, Edwards, Davey-Rothwell, Yang, & Tobin, 2018). It can also include contemporaneous use 
of multiple drugs over a particular time period (Kandel, Yamaguchi, & Chen, 1992).  
As opioid and stimulant use constitute high-risk forms of drug use singularly, co-use of these 
drugs is especially concerning. Specifically, opioids used in combination with other drugs, such as 
benzodiazepines and alcohol, is more likely to result in depressed respiration and possibly death 
(Calcaterra, Glanz, & Binswanger, 2013; Hobelmann & Clark, 2016; Jones, Mogali, & Comer, 2012). 
Similarly, cocaine used in combination with alcohol is known to significantly increase the likelihood of 
experiencing adverse health effects, including cardiac events and hyperthermia (McCance-Katz et al., 
1993). When used together, opioids and stimulants demonstrate more potent effects than either drug used 
alone, in part by synergistically increasing euphoria and decreasing unpleasant subjective side effects 
produced by each drug, a result that can increase overall abuse potential and encourage continued dosing 
(Jasinski & Preston, 1986; Guzman & Ettenberg, 2004; Leri, Bruneau, & Stewart, 2003). The co-use of 
opioids and stimulants, popular among many polydrug users, is associated with increased likelihood of fatal 
and non-fatal overdose (Coffin et al., 2003; Kaye & Darke, 2004; Warner, Trinidad, Bastian, Miniño, & 
Hedegaard, 2016).  
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While there may be some important within-group homogeneity across substance users, there may 
also be some considerable heterogeneity, including among polydrug users generally and polydrug users 
who use opioids and stimulants specifically (Bickel, Crabbe, & Sher, 2010; Shaw, Shah, Jolly, & Wylie, 
2008, Terracciano, Löckenhoff, Crum, Bienvenu, & Costa, 2008; Tetrault et al., 2008). This cautions 
against drawing overly broad generalizations about between- or within-group differences based on type of 
drug used. It is likely that people who use multiple drugs over a given time period or during a single drug-
taking episode, despite any overall tendency toward versatile drug use, are influenced by a variety of 
factors. It is also likely that polydrug users may indicate greater preference for certain drugs, and continue 
to choose to use them, even as they also choose to use other, less preferred drugs (Smith & Lawson, 2017). 
It is important to keep in mind that concomitant drug use, and particularly concomitant use of opioids and 
stimulants, entails extreme risk. Such risk has increased in recent years as fentanyl and fentanyl analogues 
have proliferated in the illicit drug supply, and are now found as additives and adulterants in opioid and 
stimulant drugs alike (Dai, Abate, Smith, Kraner, & Mock, 2019; Gladden, 2016; Nolan, Shamasunder, 
Colon-Berezin, Kunins, & Paone, 2019; O’Donnell et al., 2017).  
Purpose of Exploratory Study, and the Kentucky Context 
Because of the risks associated with opioids, stimulants, and concomitant use of opioids and 
stimulants, it is important to work toward developing a better understanding of what factors have the 
potential to influence decisions to use these high-risk drugs. This includes considering not only what 
factors may have influenced initial drug use, but also what factors may influence continued decisions to use 
high-risk drugs among adults with established histories of drug use and other high-risk behaviors.  
Although specific study aims will be introduced in the following chapter, the primary purpose of 
this study is to explore high-risk drug use among a sample of corrections-involved adults in Kentucky and 
to identify and discuss endogenous and exogenous factors with the potential to have influenced drug-
related decision-making prior and subsequent to incarceration. This will be achieved by identifying the 
prevalence of opioid and stimulant use and correlates of use. Of interest is identifying what individual 
(endogenous) and contextual (exogenous) factors were present in the lives of participants that had the 
potential to influence decisions to use high-risk drugs during both time periods.  
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Kentucky is an ideal state for such exploration, as it has experienced high opioid prescribing and 
diversion rates and continues to experience historically high rates of opioid-related morbidities and 
mortalities, in both rural and urban areas (CDC 2017b; Faryar et al. 2017; Hall et al. 2013; Kentucky Office 
of Drug Control Policy 2016; Luu et al. 2018). In 2016, the number of opioid-related overdose fatalities in 
Kentucky increased to 33.5 per 100,000, ranking the state fifth highest in the nation (CDC 2017a). Opioid 
users in Kentucky are situated in an interesting ecological context, where rates of opioid prescribing are 
comparatively greater to other states, even as heroin use continues to increase (Slavova et al., 2017). In 
2016, approximately 176,000 adults in Kentucky reported prescription opioid misuse and 17,000 reported 
heroin use (SAMHSA, 2017). 
Reflective of the broader US, barriers to the equitable provision of comprehensive, scientifically-
informed drug treatment remain in Kentucky (Epstein et al., 2018; Moody et al., 2017; Patrick et al., 2019). 
The availability of, and access to, medication-assisted treatment (MAT) is highly variable across the state. 
Although some Kentucky counties have few buprenorphine prescribers and experience challenges to 
implementing and delivering MAT, others have experienced significant increases in buprenorphine 
prescribing (Kentucky Cabinet for Health and Family Services, 2018a; Substance Abuse Mental Health 
Services Administration, 2018). Depending on where a person lives in the state, they may have more or less 
difficulty accessing MAT and, relatedly, comparatively greater or lesser access to purchasing 
buprenorphine illicitly. Diverted buprenorphine use remains a growing but underexplored phenomenon in 
the region and is important to consider, as it constitutes either a form of opioid misuse or medically 
unsupervised use for self-treatment, both of which are potentially dangerous (Carroll, Rich, & Green, 2018; 
Cicero, Ellis, & Chilcoat, 2018; Daniulaityte, Carlson, Brigham, Cameron, & Sheth, 2015; Mitchell, 
Gryczynski, & Schwartz, 2018; Smith et al., 2019).  
In addition to opioids, stimulant use remains a problem in many Southeastern regions, including 
Kentucky (Courtwright, 1983; Stoops et al., 2007; Stoops, Staton-Tindall, Mateyoke-Scrivner, & 
Leukefeld, 2005; Stover, Winstanley, Zhang, & Feinberg, 2018). As of 2016, approximately 59,000 adults 
in Kentucky reported cocaine use (SAMHSA, 2017), and methamphetamine use persists across urban and 
rural regions alike (Croft, Foppe, Huffines, & Subedi, 2018; Fernandez, Gohmann, & Pinkston, 2018). 
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As is the case in other states, many people in Kentucky who use opioids and stimulants become 
involved with the criminal justice system (Golder et al., 2014; Hall et al., 2018; Staton, Leukefeld, & 
Webster, 2003; Stoops, Staton-Tindall, Mateyoke-Scrivner, & Leukefeld, 2005). Kentucky’s high rates of 
opioid and stimulant use have contributed to the state’s increased incarceration and community supervision 
rates, relative to other states. Currently, Kentucky incarcerates 948 people per 100,000, making it eighth in 
the world for per capita incarceration rates (Prison Policy Initiative, 2018). As of 2017, approximately 
63,800 Kentucky adults were on community supervision (Bureau of Justice Statistics, 2018). These rates 
partially reflect the personal blame sometimes assigned to opioid and stimulant users and the moral and 
punitive approach historically taken to understanding and addressing drug use (Corrigan, 2000; Crisp, 
Gelder, Rix, Meltzer, & Rowlands, 2000; Corrigan & Wassel, 2008; Matheson et al., 2014). For medically 
untreated opioid users released from controlled environments, the risks of resumed use can be deadly. 
Considering findings from a meta-analysis conducted by Merrall et al. (2010), Epstein and colleagues 
(2018 )concluded that “for addicts who are incarcerated, failure to provide agonist treatment can convert a 
short jail term to a death sentence.” 
Because high-risk drug use is a complex behavioral outcome, and not attributable to any one 
factor, it can be challenging to exculpate or explain to the general public. It may be more challenging to 
explain a person’s continued use despite harsh drug-related consequences, such as incarceration. It is 
therefore important when exploring high-risk drug use among a sample of corrections-involved adults in 
Kentucky that endogenous and exogenous factors with the potential to influence a person’s decision to use 
opioids or stimulants despite known risks are examined. However, even if it is presumed that risks 
associated with opioids and stimulants are completely unknown to people prior to any decision to use them 
(however unlikely that is), the question of what factors might influence a decision to use even in the 
absence of perceived risk remains an interesting and important one, as the consequences associated with 
use are severe, ranging from incarceration to death.  
In order to help identify and understand some of the factors with the potential to influence 
decision-making about high-risk drugs among a sample of corrections-involved drug users in Kentucky, a 
behavioral economic approach will be used. Though behavioral economics is described in subsequent 
sections, it is briefly introduced here as an approach that characterizes the allocation of behavior within “a 
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system of constraint”, with particular emphasis on conditions that influence choice and the consumption of 
goods, including drugs (Bickel & Marsch, 2000; Bickel, Green, & Vuchinich, 1995, p. 258).  
Self-reported Opioid and Stimulant Use as Decisional Outcomes 
For this exploratory study, the self-reported use of high-risk drugs, such as opioids and stimulants, 
will be conceptualized as decisional outcomes, a behavior reflective of prior choice. Given the nature of 
choice and behavior, it is not possible to identify and measure all of the factors that influence decision-
making in real-time in the real world, or to retrospectively construct accurate models of how a person came 
to make decisions. This may be even more difficult for illicit commodities, such as drugs. However, it is 
possible to discern unitary or aggregated decisions and their behaviors (i.e., decisional outcomes), along 
with some of the factors that potentially influenced them. This can be accomplished in several ways using 
available data sources, including self-report data, institutional records (e.g., hospital emergency department 
admissions), and publicly available statistics (e.g., Drug Enforcement Administration data on drug price, 
purity, and availability estimates). Decisions pertaining to opioids and stimulants can be recognized post 
hoc, due to the dichotomized behavioral outcome itself. In other words, use of a drug establishes that a 
decision about that drug was made. Opioid or stimulant use reported for a given time period indicates that a 
decision was made to use these drugs at some point during this time period. In the case of repeated or 
continued use of a given drug over a given time period, multiple decisions would have been made. A 
decisional outcome for a given time period that does not involve opioid or stimulant use, but rather other 
drug use or no use, suggests several possibilities. The first possibility is that opioids and stimulants were 
directly encountered by the person and that the person chose not to use them. The second possibility is that 
opioids and stimulants were not directly encountered by the person, but that the person still had the 
potential to contemplate their use (by virtue of knowing that these drugs do exist and are procurable), and 
that the person decided not to procure and use them.  
Examples of the latter possibility abound in the real-world, even if they do not in lab conditions, 
where decision tasks often have mutually exclusive real or hypothetical choices presented to subjects 
(Cohen & Blum, 2002; Ratcliff & McKoon, 2008). For instance, chocolate cake and apple pie are two 
deserts that the vast majority of adults residing in the US have some awareness of. Even if an adult has 
never decided to eat chocolate cake or apple pie, they understand that both are available types of food. 
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People routinely make decisions based on information such as availability. If no stores in a person’s town 
sold cakes or pies, then this would change how decisions about cakes and pies, as choices, are made. Some 
people may decide that it is simply too much effort to drive to another town to purchase these items not 
sold in close proximity to them. Other, more curious, people might decide that it is worth a trip. If these 
cakes and pies were illegal to purchase, then the nature of the decision would change still further. It would 
involve not only more effort, but greater risk. But in all cases, the choices of chocolate cake or apple are 
available to decision-makers. Similarly, knowing that opioids and stimulants are potentially procurable is a 
type of information that drug users and would-be users have.  
Decisions to use opioids and stimulants does not suggest that decisions to use other licit, or 
comparatively less risky illicit drugs could not also have been made during a given time period. Use of 
drugs with well-known risks and use of drugs known to have comparatively less risk are not mutually 
exclusive. In examining self-reported drug use prior and subsequent to incarceration, use of drugs other 
than opioids and stimulants might also be identified. Additionally, concomitant use of opioids and 
stimulants may also be identified. Accordingly, part of this study includes exploring the problem of high-
risk drug use by identifying more than one possible drug use outcome. These outcomes include opioid use, 
stimulant use, concomitant opioid and stimulant use, other drug use that excludes opioids and stimulants, 
and no drug use. The latter two outcomes can be considered as comparatively less risky, as will be 
discussed further below. 
In practice, each decision to use drugs brings with it an increased probability of experiencing acute 
adverse events (e.g., injury, overdose, arrest, drug deal “gone bad”, blackout, driving under the influence, 
etc.), delayed economic and health consequences (e.g., more money spent on more drugs, damage to vital 
organs, dependence), and myriad opportunity costs. Therefore, it is important not only to identify if high-
risk drugs were used, and to identify some of the endogenous and exogenous factors with the potential to 
influence decisions to use, but also to assess participants’ overall drug use. As will be subsequently 
discussed, any solitary instance of use indicates a decision to use, but it may be that many decisions were 
made to use the same drugs during a given time period. The difference between deciding to use heroin once 
and deciding to use it 100 times is important (Herrnstein & Prelec, 1991; Heyman, 2003). The degree of 
drug exposure, taken to be the frequency and regularity with which drugs were used, may itself come to 
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reflect not just the behavioral referent of a decision, or may decisions, but also an additional influence on 
subsequent drug-related decision-making. In other words, regarded episodically, a drug-related decision 
and its behavioral outcome of “use” may be treated as a dependent variable, but when there are numerous 
decisions and many instances of use (particularly for the same class of drugs) over a given time period, a 
question is then raised about how the history of drug use comes to influence contemporaneous or future 
drug-related decisions.  
Selection and Description of Conceptual Framework 
There are roughly two broad approaches used to guide the study and treatment of drug use and to 
situate the phenomenon within a larger conceptual paradigm. The first can be approximately summarized as 
the “brain disease model of addiction” (BDMA), whereby neurobiological changes that develop from 
continued drug-taking are believed to contribute to a person’s development of and persistence in 
problematic use despite adverse consequences, due to the intrinsically rewarding effects of drugs (Volkow 
& Koob, 2015). The second can be approximately summarized as the “disorder of choice” approach, 
whereby a person may choose to use drugs, and to continue to choose to use drugs despite adverse 
consequences, due to endogenous and exogenous factors that influence and constrain decision-making 
capacity and choice (Bickel et al., 2014; Heyman, 2009, 2013b; Hyman, 2005, 2007). In this approach, the 
intrinsically rewarding effects of drugs are but one among many factors of with the potential to influence 
use. Despite ongoing debates and important differences in what both approaches emphasize, the two 
approaches have much conceptual overlap and are often in empirical, if not philosophical, agreement about 
some important aspects of drug use and addiction (Berridge, 2017; Bickel et al., 2014; Fenton & Wiers, 
2017; Hyman 2007; Leshner, 2001; Lewis, 2017; Shaffer et al., 2004; Szalavitz, 2017). Though both 
provide useful methods for understanding addiction, the “disorder of choice” approach, under which 
behavioral economics is subsumed, may provide additional explanatory power. This is because  behavioral 
economics seeks to explain both drug use and addiction, whereas the BDMA focuses on pathology without 
equal focus on non-pathological use, and because the behavioral economic approach emphasizes the 
importance of considering how dynamic conditions can influence drug-related decision-making and drug 
use at one time point and across time (Bickel, 2014; Higgins, Silverman, & Heil, 2008; Heyman, 2009; 
Müller & Schumann, 2011). By utilizing a behavioral economic approach, the neurobiological changes that 
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result from continued drug use (that some refer to as “disease”) are not overlooked, as this approach 
understands the same phenomenon as a reinforcer pathology that can be influenced by many additional 
factors of a person’s life (Bickel et al., 2014, 2016; Heyman, 2009; MacKillop, 2016).    
What Exactly is Behavioral Economics, and Why is it Relevant? 
 Broadly, behavioral economics conceives that people’s available choices, cognition, decision-
making, and behaviors are influenced and constrained by a variety of factors and across time, and that 
many of these influences may be beyond a person’s complete awareness or control (Chaloupka, Emery, & 
Liang, 2003; McClure, Laibson, Loewenstein, & Cohen, 2004; Newell & Shanks, 2014; Tomer, 2007). 
Fundamentally, and in relation to decisions involving drugs, behavioral economics is concerned with how a 
person’s history, environment, cognitive capacities, psychology, preferences, and available choices shape 
drug-related decisions (and drug use) in light of rewards and costs associated with all available choices 
(Camerer & Loewenstein, 2004; Vuchinich & Heather, 2003). In other words, high-risk drug use and 
addiction can be, among other things (e.g., habituated responding), described as one type of goal-directed 
behavior resulting from a goal-directed decision-making process (Brown & Madsen, 2018; de Wit, 2018). 
As Vuchinich & Heather (2003) explain, behavioral economics is:  
A system of specific concepts that applies general principles of relativism and molarity to 
understanding the use of psychoactive substances. In general, the value of substance use, and the 
extent to which it is preferred, can be viewed as a function of the benefit/cost ratio of substance 
consumption in relation to the benefit/cost ratios of other available activities (p. 5). 
 This molar view of choice simply means that activities, such as drug use, can involve local 
behaviors as well as behaviors extended in time, and that all behavior constitutes choice (Baum, 2004). The 
latter premise rests on the idea that in all situations, even the most constrained or restricted ones, more than 
one behavioral option is available (Baum, 1974). “In the molar view, behavior is a choice and choice a 
behavior. Whether local or extended, a relative response rate constitutes an allocation of behavior among 
alternatives and is a primary feature of behavior” (Baum, 2004, p. 355). Activities are considered here to be 
comprised of other activities and, in kind, to potentially comprise other activities. Activities have three 
properties: First, each part of an activity stands in relation, as a part, to its whole; second, parts cohere to 
function as a whole (toward some end); third, activities are subject to scaling (i.e., procuring heroin, fixing 
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heroin into a syringe, injecting the heroin; then, done with enough frequency, transitioning from someone 
who has injected heroin to someone addicted to heroin). Because activities are extended in time, measuring 
or otherwise making sense of a behavior involves considering what other behaviors precede and follow it 
and what else stands in relation to it. Again, a person who uses cocaine once differs from a person who uses 
cocaine every hour or every day. A person who studies for school once a week differs from someone who 
studies for school each day. The frequency of behavioral allocation provides information about activities 
which are comprised of many choices/behaviors.    Importantly, decisions to use drugs are not made in a 
vacuum. In addition to many other potentially influential factors, constraints on drug availability, access to 
non-drug alternatives (e.g., satisfying relationships), and perceived or real likelihood of cost (e.g., parole 
revocation, overdose), all stand to influence drug-related decisions, at one time point and over time (Bickel 
et al., 2014; Caprioli et al., 2009; Greenwald & Hursh, 2006; Klapproth, 2012).  
In his overview of behavioral economics, Tomer (2007) states that: 
The word, strand, is the right one for thinking about [behavioral economics]. A strand is a part 
that is bound together (as in a rope) to form a whole. Behavioral economics consists of quite a few 
strands as well as individual practitioners whose work does not fit neatly into any one of these 
strands. Because there is enough commonality in these strands, they do form a whole (p. 469). 
More recently, Bickel et al. (2014) referred to behavioral economics as “a discipline that 
hybridizes economics and psychology… that can be considered as the application of economic concepts 
and approaches to the molar study of individuals’ choices and decisions” (p. 643). Although behavioral 
economics began its departure from classical and neoclassical economics many decades ago, the pace of 
departure has accelerated in the last decade as behavioral economic researchers increasingly incorporate 
insights and methods from non-economic disciplines (e.g., psychology, neuroscience) (Becker, 2013; 
Thaler & Ganser, 2015; Tomer, 2007). Behavioral economics, and its extension neuroeconomics, continue 
to reconsider and refine fundamental assumptions of economics, in order to establish a more realistic 
understanding of decision-making and behavior, including drug use (Heshmat, 2015; Kahneman, 2003; 
Melrose & Monterosso, 2015; Thaler & Ganser, 2015). With increased knowledge about cognitive systems 
underlying information processing and decision-making (e.g., dual-process theories) and improved 
appreciation for how context can greatly influence decision-making, behavioral economics has 
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reconceptualized certain assumptions about how people make decisions involving drugs and other 
commodities (Evans & Stanovich, 2013; Kahneman, 2011). The application of behavioral economics to 
drug use and addiction has proliferated over the past decade and is increasingly used to help explain 
people’s persistence in drug use despite risk and cost (Vuchinich & Heather, 2003).  
Specific Rationale for Utilizing a Behavioral Economic Approach 
Accordingly, a behavioral economic approach is helpful for organizing an exploration of high-risk 
drug use among corrections-involved adults, both in terms of how it may help explain some findings and in 
terms of its potential to contextualize high-risk drug use, something often left undone when discussing and 
researching drug use. A more thorough contextualization of decision-making in relation to high-risk drug 
use may accomplish several things. For one, it may call into question the degree to which a person can be 
regarded as culpable or blameworthy for their use. Further, it may do this without necessarily calling into 
question a person’s agency, responsibility, and inherent dignity, which has important philosophical, policy, 
and clinical implications, several of which will be discussed in Chapter 5 (Heyman, 1996; Pickard, 2017).  
A behavioral economic approach was chosen to help conceptualize the phenomenon of high-risk 
drug use, formulate exploratory study aims, and interpret findings for roughly three reasons. First, this 
approach can help to scrutinize and explain different types of high-risk drug use. For instance, particular 
opioid or stimulant drugs may differ in their relative availability and value to corrections-involved people 
in Kentucky and may be more or less accessible at different times and regions within the state. This 
approach can help explain why decision-making about particular drugs might differ between people and 
potentially change over time.  
Second, this approach permits conceptualization of opioid and stimulant use as “decisional 
outcomes”. These can be understood as the behavioral referents of drug-related decisions (the other 
discernable behavioral referents of the decision being “no use”, or the use of non-opioid and non-stimulant 
drugs). This means that a dichotomized outcome (e.g., “use” versus “no use”) for particular drug can be 
examined and discussed in terms of what factors may have influenced the decision to use during a given 
time period, rather than merely influenced the probability that use would be observed without also 
acknowledging the role of a decision-making agent. This proximate step prior to use, the decision, is 
ultimately what all antecedents are influencing. By placing increased attention on decision-making and by 
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emphasizing its importance as the penultimate act of interest, interventions may be better developed to help 
people improve their decision-making capacities in both local and global ways (e.g., improving cognitive 
functioning, affect regulation, mindfulness, interoceptive awareness, inhibition, etc.) and policies can be 
developed to help “nudge” people into making more adaptive decisions (Aharonovich et al., 2006; Ahn et 
al., 2014; Chetty, 2015; Dunn et al., 2010; Naqvi & Bechara, 2010). By highlighting the capacity for some 
aspects of drug users’ decision-making and behavior to change under the right conditions (rather than 
suggesting that drug users have an incurable, chronic brain disease), self-efficacy may be better nurtured.  
Third, this approach understands that opioid and stimulant use can reflect trade-offs between 
short-term rewards of use and long-term benefits that develop from not using. In this study, at least two 
long-term rewards can be discerned (i.e., not incurring morbidities or mortalities related to these drugs; not 
becoming incarcerated for using these drugs) (Brinkley-Rubinstein et al., 2017; Dublin & Von Korff, 2018; 
Merrall et al., 2010). People in the US are disincentivized from using opioids and stimulants, yet, many 
people in this sample made a decision to use these drugs despite disincentives. Behavioral economics can 
help make sense of a person’s pursuit of reward in situations involving uncertainty and risk due to the fact 
that this approach considers what endogenous and exogenous factors may have contributed to how drug 
and non-options were framed, valued, and assessed (Bickel & Marsch, 2001; Heshmat, 2015; Kahneman, 
20013, 2011). That the context within which people make drug-related decisions is emphasized in this 
approach is also helpful, given that opioid and stimulant use cannot be divorced from the complex lives of 
people and the uniquely complex set of circumstances related to choice that corrections-involved people 
often find themselves in.  
To date, a behavioral economic approach for understanding decision-making and behavior has not 
been used as a conceptual lens by social science researchers concerned with examining opioid, stimulant, 
and other drug use among corrections-involved people using secondary data sources. Many controlled 
human and non-human animal studies have helped to advance behavioral economic and neuroeconomic 
understandings of drug use. Such lab-based experiments are essential for helping describe and elucidate 
discrete drug-related choice and behavior. They are nonetheless limited, oftentimes unable to sufficiently 
model the factors that shape choice, influence decision-making, and reinforce behavior among people in 
their everyday lives (e.g., threat of incarceration, social status, isolation and loneliness, desire to regain 
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child custody, fear of contracting HIV, poverty, chronic back pain, etc.) (Heilig, Epstein, Nader, & 
Shaham, 2016; Venirro, et al., 2018). The vast majority of people who use opioids and stimulants make a 
decision to do so within the complicated and changing conditions of their life, not within a controlled study 
or under hypothetical (or otherwise artificial) conditions.  
While it is crucial to continue studying drug-related decision-making and drug use using pre-
clinical animal models, even if they cannot fully account for real-world decision-making conditions, it is 
also crucial that in parallel to such lab-based work researchers outside of the basic sciences and economic 
disciplines increasingly seek to understand high-risk drug use by conceptualizing the phenomenon in a 
manner that takes into fuller account the inherent complexity of drug use. Part of this complexity requires 
more direct acknowledgement and study of the fact that the drug use is only ever a byproduct of the drug 
decision, and that both occur within broader conditions.  
Necessary, but not Sufficient 
Therefore, instead of asking what factors are associated with observing an outcome of opioid use 
during a given time, it may be helpful for social science researchers to begin asking what factors have the 
potential to influence a person’s decision to use opioids during a given time, as this helps to situate the 
problem with greater coherence and provides a way to achieve greater clarity by acknowledging the fact 
that the problem of high-risk drug use isn’t necessarily the primary problem. Rather, it is the person’s 
decision to use high-risk drugs and the conditions that give rise to the decision. It is coherent in the sense 
that unless drugs are forcibly given to someone, a person does indeed choose them. The drug use behavior 
does not exist without the prior decision. The decision does not exist without the conditions. If high-risk 
drug use is a problem, it is only secondary to decisions to use high-risk drugs. That drug use can assume the 
character of compulsion, but also may not ever have assume this character for many, may confuse how it 
should be conceptualized in relation to choice. However, if the decision to use drugs is also recognized as 
more or less voluntary (verses compelled), then it becomes possible to talk about constraint across levels 
(i.e., a person was compelled to decide to purchase and inject heroin despite a desire to not use heroin, or 
despite a desire to not make such a decision). The possibility is suggested here that the  
behavior of “use” cannot be performed without prior decision, however constrained and compelled the 
decision was. Put differently, there may be no “freedom of will” at any level, not just at the level of 
 18 
observable behavior of use. Here, desires, intentions, choice, and behavior would all be constrained, but 
decision would still precede action.  
This idea, that decision precedes action, is intuitive, yet, it is not always considered and is less 
frequently identified as an object of investigation, particularly among social scientists. This is the case for a 
variety of important problems. For example, the problem of hepatitis C infection that results from injecting 
drugs and sharing drug equipment is secondary to the injection itself. The observed outcome of disease is 
clear and measurable, and the sufficient conditions that actualize it (i.e., injecting drugs, sharing injecting 
equipment) are not typically confused with it. It is understood that one precedes the other, and that reducing 
new IDU-related hepatitis C infection rates means reducing IDU or syringe sharing. Since decisions are 
made prior to injecting drugs and sharing syringes, one legitimate focus might be on the factors that 
influence these high-risk decisions. In other words, to consider what factors are present so as to influence 
the decision to inject with a used syringe.  
To date, myriad “risk factors” have been identified as positively correlated with drug use and 
misuse, often considered as contributors to observed drug use outcomes (Dube et al., 2003; Kreek, Nielsen, 
Butelman, & LaForge, 2005; Nation & Heflinger, 2006). Although the presence of these risk factors may 
be sufficient contributors to the development of drug use and misuse, none of them are necessary 
(Newcomb, Maddahian, & Bentler, 1986). It is the decision to use drugs that is necessary for use to occur. 
Additional necessary, but not sufficient, conditions include the capacity to act and the actual existence of 
drugs as commodities.1 In other words, even if it may require considerable effort to procure a high-risk 
drug, they do (and must) exist as procurable commodities in order to be used.  Many other factors with the 
potential to influence drug-related decision-making are also only ever sufficient, but not necessary. Indeed, 
there is a vast array of possible influences on decision-making. The same factors may not reliably influence 
decision-making across people uniformly, or across the same person over time. Still, it may be that some 
conditions do influence high-risk decision-making involving opioids and stimulants among more people 
more of the time. Of course, the presence or absence of these factors could still be conceptualized in terms 
1 By “capacitary to act”, it is meant that not merely agency, in the most general sense, is implied, but that 
also, more specifically, the requisite capability for particular forms of high-risk drug use are accounted for. 
For example, swallowing a prescription opioid requires less procedural knowledge than preparing the same 
pill for intravenous injection. A person must, at a minimum, be capable of drug self-administration.  
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of “risk” or “protection”, though they need not be. In some cases, in which the factors influencing decision-
making are more proximate (i.e., milliseconds) it may be better not to think in terms of “risk”, but rather in 
terms of “constraint”. Irrespective of how endogenous and exogenous factors with the potential to influence 
drug-related decision-making are termed, they are worth considering. And, it is possible to do so using 
existing research on cognition, decision-making, and drug use.  
Shifting the focus of the discussion toward factors with the potential to influence drug-related 
decision-making--instead of remaining focused on factors with the potential to influence its behavioral 
referent (“use”) unmoored to the decisions themselves-- gets closer to the actual phenomenon of interest. 
As discussed in Chapter 5, such investigatory refocus may have the potential to help inform interventions 
that might attenuate high-risk drug use at its more proximate and potentially extricable roots.  
Coarse-grained Approach 
Exploring opioid and stimulant use by identifying endogenous and exogenous factors with the 
potential to influence drug-related decision-making can be accomplished to the extent that available data 
sources are able to discern and indicate, however indirectly, the presence or absence of such factors. It is 
important to emphasize that attempting to identify endogenous and exogenous factors with the potential to 
influence drug-related decision-making constitutes a “coarse-grained” approach, whereby conceptual 
expanse is gained at the expense of measurement detail and specificity. In the case of a secondary data 
analyses of survey data, such measurement detail is already largely absent. Coarse-grained models are 
sometimes used in science to simplify otherwise inscrutably complex systems (Marrink, Risselada, 
Yefimov, Tieleman, & De Vries, 2007; Noid et al., 2008). People can be conceptualized as stochastic, self-
organized complex systems, even if they cannot yet be measured or modeled as such (Bak, 2013; Bullmore 
& Sporns, 2009; Wagenmakers, van der Maas, & Farrell, 2012; Rubinov, Sporns, Thivierge, & Breakspear, 
2011). For this reason, the general study of dynamic human decision-making and behavior will, for the 
foreseeable future, remain coarse-grained and even somewhat philosophical, irrespective of the degree to 
which measurement error is present or absent. It is also for this reason that it may be reasonable to assume a 
coarse-grained approach when exploring high-risk drug use among a sample of corrections-involved adults. 
For the exploratory study proposed here, many lines of rapidly-developing research can be brought 
to bear in helping understand and think about the endogenous and exogenous factors in people’s everyday 
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lives with the potential to influence high-risk drug-related decisions. Using behavioral economics as a 
conceptual approach can help orient the study and its findings to this body of literature. Because data 
examined in this exploratory study were collected as part of an ongoing outcomes evaluation, the objective 
was not to pursue empirical validation of specific behavioral economic concepts. Rather, this study sought 
to apply ideas central to behavioral economics and the molar view of choice to the available data, and to 
use existing literature to help think about possible ways that endogenous and exogenous factors may have 
influenced decision-making about opioids and stimulants among participants across time periods. Many of 
these factors will be discussed in Chapter 2. As discussed below, the risk associated with these drugs is 
significant. This significant risk means that a decision to use opioids and stimulants is nothing less than 
puzzling, unless it is situated within the broader context of a people’s lives.   
 
The High-Risk Nature of Opioid and Stimulant Use 
Other Drug Use 
Before describing some of the specific risks associated with opioids and stimulants, it is worth 
briefly considering some of the risks associated with other commonly used drugs. Alcohol use, for instance, 
constitutes one of the greatest financial and social burdens on society. It results in more morbidities and 
mortalities in the U.S. than illicit drugs, due to the sheer volume of alcohol consumers (CDC, 2019; 
Jinjuvadia & Liangpunsakul, 2015). Excluding accidents, most alcohol-related morbidities and mortalities 
develop gradually (CDC, 2019). Alcohol poisoning can result in death; however, this accounted for only 
1.9% of annual alcohol related fatalities in the U.S. between 2006-2010 (CDC, 2019).  
Many potential social, psychological, educational, and occupational consequences can result from 
alcohol use; but these too may manifest gradually, suggesting many potential points for prevention or 
attenuation (Lee, Geisner, Patrick, & Neighbors, 2010 Patton et al., 2013; Schulenberg & Maggs, 2002). 
Some of the delayed adverse consequences of alcohol use can be attributed to the fact that alcohol is licit 
and socially normed, meaning that the criminalization, stigmatization, and social exclusion of alcohol users 
and people with alcohol use disorder (AUD) occurs to a lesser degree compared to people who use opioids 
or stimulants, or who have respective use disorders for these drugs (Janulis, Ferrari, & Fowler, 2013; 
MacArthur, Jacob, Pound, Hickman, & Campbell, 2017; Pachankis et al., 2017). The availability and price 
of alcohol is also such that many people who use or misuse it may not need to resort to serious criminal 
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offending or extreme measures to obtain the drug, even if there are fluctuations in alcohol prices that may 
nevertheless influence consumption (Felson & Staff, 2017; Mericle, Karriker‐Jaffe, Gupta, Sheridan, & 
Polcin, 2016; Ornstein & Levy, 1983; Shortt, Rhynas, & Holloway, 2017). For instance, someone wanting 
to consume alcohol need not meet a drug dealer. Since the repeal of the 18th amendment, which prohibited 
non-medical sale of alcohol, people in the US over the age 21 may drink without direct threat of legal 
consequences (Okrent, 2010). 
Lastly, with the exception of homemade spirits (e.g., “moonshine”), alcohol products sold in the 
US are held to strict regulatory guidelines and are subject to government monitoring to ensure that the 
package contents are concordant with labeling, advertising, etc. (Alcohol and Tobacco Tax and Trade 
Bureau, 2019; Holstege, Ferguson, Wolf, Baer, & Poklis, 2004). This means that consumers have access to 
information which may help them assess at least some risk. While information about opioids and stimulants 
is informally available to users within illicit drug markets and online, it may be unreliable and, given the 
nature of illicit drug markets, subject to change rapidly (Duxbury, 2018; Orsolini, Papanti, Corkery, & 
Schifano, 2017 Treloar & Abelson, 2005; Rönkä & Katainen, 2017). Further, information may only be 
available about specific illicit drug products via specific mediums (e.g., word-of-mouth, online, etc.) or 
about specific products sold by specific distributors (e.g., heroin advertised as “fentanyl-free” on the Deep 
Web and verified by customer reviews) (Becker, 2017; Quintana Mathé, 2017). In other words, illicit drug 
information is not reliable or durable, nor is it equally accessible to all would-be consumers. Taken 
together, the choice to use alcohol is one that entails serious risk, but it is one that, when compared to 
opioids and stimulants, has less relative risk.  
Other illicit drugs, such as psychedelics, benzodiazepines, barbiturates, and cannabis, are also used 
by people in the general population recreationally, experimentally, or for the self-treatment of health 
symptoms, in addition to being used by people with SUDs (Andersson, Persson, & Kjellgren, 2017; Jeffers 
et al., 2015; Ogborne, Smart, Weber, & Birchmore-Timney, 2000). Though these drugs may pose health 
and legal risks for users, they tend to have, overall, fewer social and medical consequences compared to 
opioids and stimulants, including being comparatively less stigmatized (Brown, 2015; Hall, 2015; Meurk, 
Carter, Partridge, Lucke, & Hall, 2014; Pachankis et al., 2017; Patorno, Glynn, Levin, Lee, & Huybrechts, 
2017; U.S. Department of Justice, 2015). Novel psychoactive substances (NPSs), such as synthetic 
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cathinones or cannabinoids, are used far less frequently than opioids and traditional psychostimulants, but 
are increasingly associated with adverse side effects and remain high-risk drugs of concern (Cohen & 
Weinstein, 2018). However, recent evidence suggests that, compared to traditional drugs, their availability 
and use is gradually declining and that they are not preferred over traditional drugs (Blackman & Bradley, 
2017; Smith & Staton, 2018; Smith & Stoops, 2019). Thus, while NPS use is high-risk, prevalence rates 
currently remain far lower than other drugs (Mathews, Jeffries, Hsieh, Jones, & Buckne, 2019; Palamar, 
Rutherford, & Keyes, 2019). This, coupled with their relative lack of appeal to many users, means that 
NPSs may be considered as concerning primarily among a narrow subpopulation of drug users, compared 
to opioids and stimulants, which are more popular and which have over a century of documented associated 
risks (Chaldecott, 1907; Scheltema, 1910; Wood, 1904).  
Indeterminate (but Potentially Perceived) Risks of Opioids and Stimulants 
The problem of high-risk drug use in the US has recently received increased local and national 
attention, as rates of drug-related mortalities have come to surpass mortalities attributed to firearms, car 
accidents, and HIV/AIDS at their respective peaks (Blackford, 2018; Katz, 2017). Among the general 
public and drug-using populations, opioid and stimulant use is known to have potential for health and legal 
consequences (Draus & Carlson, 2009; McGovern & McGovern, 2011; Norden et al., 2009; Small, Rhodes, 
Wood, & Kerr, 2007). In order to procure these drugs without prescription or by chance, one must first 
become aware that they are available for purchase through black markets and informal peer networks 
(Jonas et al., 2012)2. This means that potential legal consequences, even if underestimated or only vaguely 
perceived, are still known. As for potential health consequences, public health messaging around opioid 
and stimulant use has increased significantly in the past decade (Hernandez, Meyers-Ohki, Farkas, & 
Rotrosen, 2018; Parker, Strunk, & Fiellin, 2018).  
Although all drugs have been generically profiled in public awareness and prevention campaigns 
for decades (e.g., DARE program), cocaine/crack cocaine and methamphetamines have been presented to 
US citizens via graphic and disturbing images by the Drug Enforcement Administration and the Partnership 
2 “By chance” alludes to the fact that people may inadvertently come across prescription drugs and illicit 
drugs without meaning to. For instance, discovering them in a parent’s medicine cabinet or among a 
sibling’s possessions, etc.  
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for Drug-Free America (Buchannan & Wallack, 1998; Linnemann & Wall, 2013; Marsh, Copes, & 
Linnemann, 2017; West & O’Neal, 2004). News media and politicians have also drawn attention to the 
devastation that cocaine/crack cocaine and methamphetamine use can contribute to, though with a 
noticeably different tenor than that used in recent profiles of opioid use, and white opioid users in particular 
(Netherland & Hansen, 2016). For crack cocaine specifically, US media helped facilitate the creation of 
caricaturized social constructs that developed around both real and tragic realities, as well as exaggerated 
myths and misinformation (Brownstein, 1996; Hartman & Golub, 1999; Reinarman & Levine, 2017). 
Images and catch-phrases advertising the risk of crack cocaine use became commonplace, with many 
depreciatory and cautionary phrases persisting in the cultural lexicon (e.g., “crack babies”, “crack whores”, 
“crack mothers”) (Lyons & Rittner, 1998; Meyers, 2004). In addition to crack cocaine, methamphetamine 
use has been profiled in stark, graphic, and derogatory terms (Marsh et al., 2017; Peterson, Gubrium, 
Fiddian- 
Green, 2018). The media and politicians have portrayed methamphetamine use as a public menace rather 
than public health crisis, with methamphetamine use frequently associated with “white trash” (Hartigan, 
2013; Jenkins, 1994; Weidner, 2009). Film and TV have also portrayed some of the risks associated with 
opioids and stimulants, even as they have simultaneously glamorized their use (Allen & Alberici, 2018; 
Cape, 2003; Garriott, 2016).  
It should be noted that while both opioid and stimulant users have been blamed, caricaturized, 
maligned, and punished (as well as pejoratively labeled as “junkies”, “crack-heads”, “tweakers”, etc.), the 
public health messaging that predominates the current opioid epidemic was not as pronounced during the 
crack cocaine epidemics of the 1980s and 1990s. Despite that crack use was deemed a “plague” during this 
era, public safety, in the form of deterrence and retributive justice, was given greater priority than public 
health (Furst, Johnson, Dunlap, & Curtis, 1999; Lloyd, 2013; Mauer, 2004; Reinarman & Levine, 1997). 
Jail and prison terms, including mandatory minimum sentences, were given to crack cocaine users and 
sellers more frequently than treatment referrals (Graham, 2010 Kautt & Spohn, 2002). Beginning in the 
early 2000s, the same became true for many methamphetamine users who began receiving jail and prison 
terms, including mandatory minimum sentences, for methamphetamine-related offenses (Graham, 2010). 
Currently, people who sell opioids, irrespective of any personal use, are receiving harsh federal 
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punishments, including life without the possibility of parole; again, based on mandatory minimum statutes 
(Duncan, 2013; Mack, 2016; Offices of the United States Attorneys, 2017). However, in addition to 
punitive measures, public health measures are also being promoted in earnest, with the hopes of mitigating 
the opioid crisis (Collins et al., 2018).  
Beyond legal consequences advertising the risk of opioid and stimulant use, additional types of 
knowledge about the risks of use are available. These include information provided by drug-using peers 
and first-hand observations, as many people who come to use opioids or stimulants have also witnessed use 
of these drugs in their own families or communities (Alexander, Piazza, Mekos, & Valente, 2001; Barnard 
& McKeganey, 2004; Mohler-Kuo, Lee, & Wechsler, 2003). More directly, people can form experiential 
knowledge after initial or continued use. Should users experience adverse effects, they will have observed 
some potential consequences of use. In 2017, a majority of people in the US aged 12 or older (71.3%-
94.5%) believed that trying cocaine or heroin even occasionally was associated with “great risk” 
(SAMHSA, 2017). Thus, it may be concluded that, irrespective of the validity or quality of available 
information about opioids and stimulants, most US citizens associate opioids and stimulants with some 
measure of danger. For people who have encountered institutions or treatment facilities, the risks associated 
with these drugs may be known with even greater specificity. Although most people may not be able to 
articulate the specific risks associated with opioid or stimulant use, it is still reasonable to suggest that there 
is some indeterminate degree of understanding that opioid and stimulant use is not “risk-free”, in that there 
is considerable uncertainty associated with use.  
Some potential risks of opioid and stimulant use that may be discerned to varying degrees by 
people in the US include: 1) The potential to develop dependence or addiction, due to the high abuse 
liability of opioids and stimulants (Epstein, Preston, & Jasinski, 2006; Higgins, 1997; Koob & Volkow, 
2010); 2) The potential to develop problems in occupational, social, and daily functioning as a result of 
misuse or dependence (Cunha, Bechara, de Andrade, & Nicastri, 2011; Henry, Minassian, & Perry, 2010; 
Hoffmann & Larison, 1999; Leshner, 1999); 3) This can be extended to potential discord in relationships, 
in that it is likely that not all of the people in one’s life will be supportive of opioid and stimulant use, even 
if some are. In other words, smoking meth may upset a spouse or injecting heroin may result in rebuke 
from one’s mother. Some social censure might be expected (Amato & Rogers, 1997; Orford, Copello, 
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Velleman, & Templeton, 2010); 4) Here, social consequences of opioid and stimulant use may include 
stigmatization, social exclusion, rejection, and discrimination (Brown, 2015; Kennedy-Hendricks et al, 
2017; Pachankis et al., 2017). Stigmatization is public, persistent over generations, and consequential; it is 
why many users do not publicly disclose their drug-using identity voluntarily (Chalmers, Lancaster, & 
Hughes, 2016; Pachankis, 2007;  
Quinn & Chaudoir, 2009; Ross et al., 2007); 5) Potential short- and long-term financial problems 
associated with opioid and stimulant use. This can include consequences from money spent on drugs, as 
well as from potentially poorer lifetime employment and earning trajectories. (Mark, Woody, Juday, & 
Kleber, 2001; Simon et al., 2001); 6) The potential to incur injury or health conditions related to use (e.g., 
infectious diseases or abscesses), including the potential for drug overdose and death (Binswanger, Kral, 
Bluthenthal, Rybold, & Edlin, 2000; Cornish & O'Brien, 1996; O’Donnell, Gladden, & Seth, 2017; Zibbell 
et al., 2018); 7) Lastly, the purchase, possession, and use of opioids and stimulants is illegal, meaning that a 
person is aware of the increased likelihood of coming into contact with law enforcement and becoming 
involved in the criminal justice system (Mumola & Karberg, 2006; Webster, Dickson, Mannan, & Staton, 
2018). Moreover, opioid and stimulant use is expensive and often necessitates extralegal income-generating 
endeavors, including criminal ones (Biernacki, 1979; Schwartz et al., 2008). 
In Kentucky, between 2015-2016, approximately 76.5% of adults reported perceiving some risk 
from using cocaine at least once a month (SAMHSA, 2017). For this same period, approximately 89.1% of 
adults in Kentucky perceived some risk from “trying heroin once or twice” (SAMHSA, 2017). This means 
that within this region a majority of adults associated risk with at least one opioid and/or stimulant drug. 
Given the wide-ranging scope and severity of the aforementioned risks associated with opioids and 
stimulants, and the fact that most people are aware of these risks, it is unclear what factors could 
sufficiently influence a person to willingly use, or to continue to use, opioid or stimulant drugs.  
Why Might a Person Decide to Use, then? 
As noted earlier, it is likely that a variety of endogenous and exogenous factors increase the 
likelihood that a person decides to use opioids or stimulants, whereby short-term reward is pursued despite 
possible future costs. It is important to remember, though, that the nature of risk is that it exposes one to, 
but does not guarantee, unfavorable outcomes (Daly & Wilson, 2001). One commonality among many of 
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the risks described above is that their actualization, wherein the risk of harm becomes experienced harm, 
can be delayed. This is important for several reasons. First, because unlike a person touching their hand to a 
hot stove, the association between opioids or stimulants and harm (i.e., punishment learning) is often 
indirect (Skinner, 1938, 1953). Opioids and stimulants, however, have directly reinforcing effects (Bickel 
et al., 2014; van Ree, Gerrits, & Vanderschuren, 1999; Woolverton & Johnson, 1992). In other words, the 
reward of using them is not only salient, but directly associated, making learning rapid and the encoding of 
memories about these pleasurable drug experiences instantiated in key brain areas for “quick retrieval” in 
the future (Baler & Volkow, 2006; Stewart, de Wit, & Eikelboom, 1984). Conversely, larger future rewards 
(or punishments) are abstract and more difficult to envisioned clearly (e.g., episodic future thinking, 
episodic counterfactual thinking) or with the same salience as proximate rewards or punishments, 
particularly those for which there are episodic memories (i.e., associated conditioning), which serve to 
influence decision-making and behavior (O'Donnell, Daniel, & Epstein, 2017; Schacter, Benoit, De 
Brigard, & Szpunar, 2015).  
Second, many risks associated with high-risk drug use and many benefits associated with not 
using high-risk drugs are realized in the future, meaning that consequences or contingencies are not 
perceived in the same way as immediate “sure things” (Platt & Huettel, 2008). This decision-making under 
uncertainty means that a person may be less able to accurately assess and value information about high-risk 
choices and may experience less motivation to make decisions in the present that help achieve or avoid 
particular future outcomes, which are only ever contingent (Kahneman & Tversky, 2013).  
A decision to use opioids or stimulants constitutes an intertemporal choice, whereby people make 
a decision at one time point with awareness that this decision influences the availability of other 
possibilities in the future (Berns, Laibson, & Loewenstein, 2007; Kable & Glimcher, 2007). Utility, which 
can be thought of as the value (e.g., enjoyment, usefulness, pleasure satisfaction, etc.) associated with a 
given choice, may not always be maximized in the long-term by people (Herrnstein & Prelec, 1992; 
Machina, 1989). Oftentimes, future rewards and punishments associated with choices cannot be fully 
anticipated or accurately assessed, even if some risk/benefit is discernable (e.g., anticipated, remembered, 
inferred) (Broome, 1991; Loewenstein & Elster, 1992; Zauberman, Ratner, & Kim, 2008). Intertemporal 
choice poses problems for people in instances where choosing the option with the greatest local utility (i.e., 
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immediate value/reward) decreases overall utility (i.e., value/reward over time) (Herrnstein & Prelec, 
1992). This mismatched utility is not always the case for addictive drugs, but often can be. By choosing to 
use drugs repeatedly, drugs can become overvalued, and non-drugs undervalued. This can be considered as 
reinforcer pathology (Bickel et al., 2001). Thus, the risk, but not certainty, of future punishments and 
rewards associated with opioids and stimulants, coupled with their immediate or local appeal, for which the 
outcome expectancies of reward are often clear, makes high-risk decisions about drugs as challenging as 
they are consequential. Importantly, intertemporal choice, particularly between immediately rewarding (but 
risky) local outcomes and future contingencies, demands significant cognitive effort and flexibility to 
navigate (e.g., self-control, reframing, inhibition, working memory, metacognition, etc.) (Baumeister & 
Vohs, 2007; Heatherton & Wagner, 2011; Nichols & Wilson, 2015; Westbook & Braver, 2015; Yeung & 
Summerfield, 2012). As will be discussed, many factors can influence and impair needed cognitive 
capacities.  
The dynamic between immediate versus future, certain versus uncertain, poses a challenge for 
people, in that they must evaluate choices that cannot help but be weighted differently based on past history 
(and how past experiences are remembered during decision-making), present states and context, and beliefs 
about themselves, their abilities, and their future (i.e., prospection, self-projection, self-efficacy) (Buckner 
& Carroll, 2007; Kahneman, 2003; Kahneman & Tversky, 2013 Krueger & Dickson, 1994). Because the 
utility of opioids or stimulants is also relative and changing, it is important to consider not only what 
factors influence decision-making generally, but also what factors might reinforce use or no use of 
particular opioid and stimulant drugs. This could include considering what additional drugs might be 
available to people as substitutes (i.e., comparable replacements) or compliments (e.g., i.e., commonly co-
used drugs), as well as what rewarding non-drug alternatives (e.g., relationships, opportunity, jobs) are 
accessible (Bickel, Madden, & Petry, 1998; Etten, Higgins, Budney, & Badger, 1998; Morral, Iguchi, & 
Belding, 1999; Quick, Pyszczynski, Colston, & Shahan, 2011; Rogers et al., 2008; Waldorf et al., 1992; 
Yates, Bardo, & Beckmann, 2019). Given the multitude of influences on decision-making and behavior, it 
is likely that many factors constrain people’s choices and ability to choose in ways that maximize well-
being over time.  
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Even holding conditions constant, the starting point for making a decision between a smaller, 
immediate reward and a potentially larger, later reward is an uphill battle. This is because people and other 
animals evolved in states of uncertainty and scarcity to develop greater bias toward immediate consumption 
of rewarding things (e.g., food) over rewards situated in the future and rewards associated with greater 
trade-offs, uncertainty, or effort (Bickel, 2014; Kagel, Green, & Caraco, 1986; Rosati, 2017). It is also an 
uphill battle because some types of cognition are automatic, unconscious, and heavily influenced by factors 
that may not be readily perceived by the person (e.g., physiology, affect, surroundings) (Bubier & Drabick, 
2008; Evans, 2008; Kahneman & Egan, 2011). This type of cognition can be fast and useful, but comes at a 
cost; it can make information processing (e.g., assessment, valuation, prediction, etc.) and decisions prone 
to inaccuracies, bias, and error (Kahneman & Egan, 2011; Lee, 2013). Cognitive processes that are slower, 
more deliberative, and concerned with intertemporal or abstract reasoning rely more heavily on higher-
level cognition (e.g., attention, working memory and executive function) (Ash & Wiley, 2006; Evans & 
Stanovich, 2013). This type of cognition is both more effortful, but also necessary for the coordination of 
goal-directed behavior that is not habituated (Kahneman, 2011; Koechlin & Hyafil, 2007; Engle & Kane, 
2004; McCabe, Roediger, McDaniel, Balota, & Hambrick, 2010). In addition to being more laborious, this 
type of cognition is also influenced by a wide-range of endogenous and exogenous factors that can 
contribute to decision-making error. These two cognitive systems are believed to work in concert, but the 
latter system is crucial for deliberation and for inhibition.  
 Since decision-making relies on a person’s cognitive capacities (e.g., cognitive flexibility, 
inhibitory control, prospection), their cognitive repertoire, and the factors with the potential to influence it 
during decision-making, are of interest (Stanovich & West, 2000). As will be discussed in subsequent 
chapters, many traits and states can bias people toward greater impulsiveness or poorer self-regulation, 
making an already difficult job of weighing benefit/risk during a decision even more difficult (Baumeister, 
2014; Frederick, 2005; Vohs & Baumeister, 2016). For instance, people with fewer resources who live 
amidst or routinely experience highly stressful circumstances may be ill equipped to engage in attentional 
control, impulse inhibition, and deliberative decision-making, and may be more likely to prefer 
immediately rewarding choices, rather than choices with delayed reward (Mani, Mullainathan, Shafir, & 
Zhao, 2013; Shah, Mullainathan, & Shafir, 2012; Shah, Shafir, & Mullainathan, 2015; Spears, 2011).  
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Ultimately, some people may have or experience more factors that bias them toward a decision to 
use drugs than others. Yet, even considering only populations that may be statistically more likely to touch 
a hot stove in the first place, and to repeat touching it despite adverse consequences, there remains the 
question of what factors influence people within this group to use opioids or stimulants specifically. After 
all, highly rewarding effects can be produced from other drugs. It may be that there are important 
endogenous and exogenous factors that are implicated as influences on decisions to use opioids or 
stimulants, compared decisions to use other drugs or to not use drugs at all.  
The Road to Hell is Paved with Good Intentions 
Monterosso & Lou (2010) and others (Rachlin, 1995) articulate that, “goal-directed behavior can 
be conceived on a continuum from the molecular (e.g., trying to hit a nail with a hammer) to the molar 
(e.g., trying to build a house)”. For instance, a person may want and plan to inject heroin at a particular 
moment (molecular) but prefers and plans not to become addicted to heroin and not to incur costs 
associated with heroin addiction (molar).  
Ultimately, a person’s drug use involves choices and behaviors with the potential to reach across a 
lifetime. A person may have an immediate goal (to use heroin), that conflicts with other long-term goals (to 
stay out of prison indefinitely). Melrose et al., (2015) suggest that high-risk drug use and addiction is “a 
function of the individual’s overall set of motivations”, meaning that a person has multiple motivations for 
behavior and that these motivations can be at odds in one moment (ambivalence), or between selves over 
time. For instance, a person in the present may be conflicted about using or not using (this is called a 
“synchronic model of conflict”), or a person may value smoking crack cocaine more in the present, even if 
their future self would value it less, and instead value health and family more (this is called a “diachronic 
model of conflict”) (Melrose et al., 2015). In other words, for people who use high-risk drugs, there can be 
inconsistencies between what a person values or conceives of as being in their best interest (at least some of 
the time) and their decisions and behaviors, which are discordant with such valuation and conception.  
The melioration, or “primrose path”, behavioral economic model of drug use (Herrnstein & Prelec, 
1992) is in keeping with this understanding of inconsistent or conflicting preferences, and helps explain 
how a person who is motivated to avoid drug-related problems, or gain benefits that develop from not 
using, can still act in a manner (i.e., using high-risk drugs) so as to increase the likelihood that such 
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problems will materialize. In this model, people choose the option with the highest local reinforcement; that 
is, the highest local or immediate utility. Here, the choice selected among available options is the one 
perceived as the most immediately desirable or satisfying. Particularly for people who are drug dependent, 
drugs often have the highest local reinforcement value compared to other choices.  
As is often the case with decisions, people make them repeatedly. On a daily basis, people decide 
what to eat for dinner, how to use their leisure time, what route to take to work, etc. Decisions such as these 
can be repeated for many years. In the case of choosing to use a high-risk drug or choosing not to, and to 
instead pursue some non-drug alternative (e.g., jogging, work, watch TV, spend time with friends), if using 
the drug has the highest perceived local utility, then that is what will be chosen--again and again. Over 
some finite time (a month, a year, a lifetime), the overall or average utility associated with the choice to use 
a drug inevitably decreases, due to the nearly unavoidable negative long-term consequences of drug use 
and/or due to physiological changes that render the drug less rewarding (e.g., tolerance) or even punishing 
(e.g., hyperalgesia) (Li, Depoortere, & Emmett-Oglesby, White, 2004). It is important to note three points. 
First, the local utility of a drug will always be higher than other choices, so long as the drug is most 
preferred in the immediate (which is often the case for regular drug users). Second, the overall utility of 
using the drug decreases with repeated decisions over time. Third, in the case of addictive drugs, preference 
and enjoyment can become decoupled, meaning that a person can come to prefer what they no longer enjoy 
(Robinson & Berridge, 1993). Along this “primrose path”, a person is always one who is myopic or 
“meliorating”, always choosing the option with the highest local utility (immediate reward), even though 
repeatedly making this choice decreases the overall utility as a result. In order to maximize overall utility, a 
person would need to repeatedly, over time, choose the option with the lower local utility (doing something 
other than use, that isn’t worse than using). This model illustrates that immediate and long-term motivators 
may conflict and may require people to choose an option with less local utility in order to maximize overall 
utility. As Heyman (2003) notes: 
Because one cigarette does not cause cancer and one shot of heroin does not condemn a user to a 
‘junkie life style’, a person can quite correctly reason that since it’s ‘just for one last time,’ the 
drug is the best choice. However, a series of ‘one-last times’ turns into a relapse (p. 99). 
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It is easy to see, then, how people who use drugs may end up experiencing severe, even ruinous 
consequences from use even as they did not truly intend to achieve such ends. On this path, some people 
may be better able to reverse their course once the overall utility of using a particular drug has decreased. A 
person would then need to repeatedly choose a non-drug option, even if it had a lower local utility relative 
to the drug. In order to do this, a person would need to, among other things reduce present-bias and 
increase inhibition. Though all people may have time-inconsistent preferences, people with greater present 
bias may demonstrate greater inconsistency, wherein the value of the immediate reward is weighted more 
heavily than a future reward (O'Donoghue & Rabin, 1999; Takeuchi, 2011). In order to develop more time-
consistent preferences, a person would need to cognitively reframe the relative local utilities. Doing so may 
promote decisions that maximize overall utility. As will be discussed, many factors can influence a 
person’s cognition, their drug and non-drug choices, and their decision-making. It is not so simple for some 
people to “reframe” choices. Certain endogenous and exogenous factors can make it far more difficult for a 
person to become less present-biased and more future-oriented. These factors can also make it more 
difficult for a person to choose the option with less local, but overall greater, utility.  
An example to help illustrate is to consider someone who prefers eating sugary foods over other, 
non-sugary foods. In this model, the sugary foods would always have the greatest local reinforcement for 
the person, and therefore the highest local utility. However, over time, the person may grow lethargic, gain 
weight, develop diabetes, or experience some other decrease in their overall well-being related to the 
consumption of sugary foods. The person may then come to understand that the overall utility of sugary 
foods has decreased, even as the local utility of sugary foods remains constant (i.e., no less appealing in the 
immediate). At whatever point the overall utility of sugary foods clearly decreases, motivation to make 
different choices can develop and may potentially be nurtured, even if the relative appeal of sugary foods 
remains unchanged. Yet, motivation to change course after a decrease in overall utility is realized is still 
bound within the context of the person’s history and everyday circumstances. Consider in this example how 
decision-making might be influenced and constrained by several factors. These factors could include living 
in a home or community with a high density of sugary foods, or where other potentially rewarding 
alternatives to sugary foods are lacking. They could also include not having the capacity to adequately plan 
alternative strategies for acquiring non-sugary foods, due to lack of resources and constraints on cognition 
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brought about by stress or scarcity. Many additional factors might also be identified that make self-
regulation more or less difficult. Several such endogenous and exogenous factors with the potential to 
influence decision-making are discussed in Chapter 2.  
This “primrose path” model is a simplified way to understand several general points, which will 
be helpful to remember as decisional outcomes involving opioids and stimulants among corrections-
involved adults are explored. First, is that the options and outcomes in the immediate are distinct, whereas 
options and outcomes in the future are indistinct and contingent. For example, the proximate rewarding 
effects of methamphetamines are almost certain, but all else is speculation that requires cognitive effort to 
envision and become behaviorally motivated by. Second, the local utility of a drug is only appreciable in 
the greater context of a person’s life. Decision-making about specific drugs during a particular time period 
is not dissociable from prior and contemporaneous circumstances, such as other available choices, or from 
a person’s prospects for or beliefs about the future. Third, not all people are myopic or meliorating, or at 
least not in respect opioids or stimulants. Some people would never find themselves on such a path. Fourth, 
there is reason to believe that people who do end up on this path in relation to opioids or stimulants may be 
less able to reverse their course due to some endogenous and exogenous factors that impair decision-
making capacities more generally. Some of these factors may have predated drug use, while other may 
have developed as a result of use. Finally, this “primrose path” is not one that a person traverses due to 
immorality, willful defiance, or self-sabotage. Rather, it can be seen as a series of intertemporal decision 
errors pertaining to drugs that arise, in part, from time-inconsistent preferences (Kim & Lee, 2011). After 
all, most people do not desire or intend to become addicts. Rachlin (2003) reflects on such conflicting 
intertemporal preferences and some of the possible unintended consequences thusly:  
The alcoholic does not choose to be an alcoholic. He prefers not to be one. His preference ordering 
is: 1) Not being an alcoholic, 2) Drinking tonight, 3) Not drinking tonight. He just chooses to 
drink tonight, and tonight, and tonight—and ends up as an alcoholic without ever having chosen to 
be one (147). 
The lifestyle and future fate of an opioid or stimulant user may not be what is preferred and then 
chosen from a menu of options, but may nevertheless be what is received through solitary decisions over 
time. There is value in emphasizing the possibility that people who end up with drug-related consequences 
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did not choose this less rewarding path. Such emphasis has moral implications for how society addresses 
high-risk drug users, including how policies and interventions are developed and delivered.  
Exploratory Study Relevance 
Insufficient consideration of the many factors that can influence decision-making may lead to 
inaccurate conclusions about decision-making agents. Among correction-involved adults with a history of 
drug use, some will make decisions to use opioids and stimulants. Some will continue to use these drugs, 
despite the serious risks associated with use and despite experiencing significant consequences. Failing to 
consider the breadth of conditions with the potential to influence decisions to use high-risk drugs may 
contribute to the perpetuation of inaccurate attributions of corrections-involved people’s overall motives or 
intentions, whereby they may be viewed as more culpable, blameworthy, and morally responsible for their 
drug use and drug-related offenses (Corrigan, 2000, 2005; Lacey & Pickard, 2012; Meurk et al., 2014). 
Inaccurate intentions or attributions assigned to corrections-involved opioid and stimulant users 
can result in less pragmatic, humane, and effective interpersonal and systemic responses. For instance, 
evidence suggests that sanctions, rather than treatment, are more likely to be administered for drug use that 
is perceived as a willful act of “abuse” (Kelly & Westerhoff, 2010). That drug users and corrections-
involved people are often stigmatized and socially devalued means that they are potentially more likely to 
be blamed for using, while the mitigating endogenous and exogenous factors that influence decisions to use 
are less likely to be fully considered (Barry, McGinty, Pescosolido, & Goldman, 2014; Crawford, 2012; 
Earnshaw, 2013; van Boekel, 2015). Such blame and stigmatization can contribute to increased anxiety, 
shame, social withdrawal, and maladaptive forms of coping--including continued opioid or stimulant use 
(Ahern, Stuber, & Galea, 2007; Birtel, Wood, & Kempa, 2017; Luoma, O'Hair, Kohlenberg, Hayes, & 
Fletcher 2010; Ritsher, Otilingam, & Grajales, 2003; Schomerus et al., 2011).       
Ultimately, there are many limitations to a coarse-grained exploration of high-risk drug use among 
corrections-involved people using the methods proposed for this study. These are important and are 
discussed in Chapter 5. Challenges and limitations notwithstanding, examination of self-report data has the 
potential to be used as a means for fostering thoughtful discussions about decision-making and for forming 
critical questions about the appropriateness of attributing blameworthiness to corrections-involved drug 
users, who are often punished and stigmatized for their use and criminal offending (Maruna & King, 2009; 
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McCorkle, 1993; Phillips & Shaw, 2013; Pickard, 2011, 2017). Historically, the morality, decency, and 
worth of people who use drugs, or who become corrections-involved, has been doubted, and their actions 
treated as willful defiance and public threat; little consideration was given to their welfare (Foucault, 2012). 
For centuries, the collective instinct when responding to drug use, criminal offending, and other “deviant” 
behavior has been to punish for its own sake, or to punish in order to absolve or cure (De Tocqueville, 
2003; Foucault, 2003; 2012). Given this long-standing collective instinct, it is important to draw attention 
the fact that there are many factors with the potential to influence and constrain a person such that they 
would choose to use high-risk drugs and choose to continue to use at nearly all costs. By articulating the 
potential range and omnipresence of such influence and constraint in this preliminary study, it may be 
possible in future work to also consider how responsibility and culpability for high-risk drug use, and 
attendant criminal offending, may be more readily dissociated (Pickard, 2017).  
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CHAPTER II 
SOME INFLUENCES ON DRUG-RELATED DECISION-MAKING AND BEHAVIOR 
In the previous chapter, the risks associated with opioids and stimulants were described along with 
how decisions involving drugs constitute intertemporal choice. Intertemporal choice involving opioids and 
stimulants inevitably differs across people and time periods, given that the circumstances of people’s lives 
are wide-ranging and dynamic. This variance and potential for change means that, during drug-related 
decision-making, people will have many drug and non-drug options to evaluate, each choice differing in its 
probability of risk and reward in the immediate and the long-term. In short, decision-making about high-
risk drugs, such as opioids or stimulants, for which the range of outcomes is never completely certain, 
requires that many cognitive and affective capacities be brought to bear.  
Recall that self-reported use of a drug for a given time period indicates that a decision about using 
this drug was made during this time period. In this chapter some factors with the potential to influence a 
person’s ability to make decisions that involve risk and trade-offs between current and future rewards will 
be explored, along with how the options and opportunities available to people can constrain the overall set 
of drug and non-drug choices. In thinking about some of the factors that might be present prior or 
contemporaneous to high-risk decision-making so as to influence the likelihood that opioids or stimulants 
would be used, several factors specific to the person, their history, and the greater context within they live 
might be identified. Several such factors will be explored in this chapter in at least one of two ways. The 
first way includes identifying factors that might increase the likelihood of risky decision-making generally. 
These are factors that might diminish cognitive control, limit a person’s set of choices, and otherwise 
influence intertemporal choice such that a person makes decisions that do not maximize well-being over 
time. Such poorer decision-making could include choosing to use, or to continue to use, high-risk drugs. It 
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could also include choosing any option with high local but lower overall utility. These are factors that can 
influence cognitive capacities and decision-making more generally. The second way includes identifying 
factors that might increase the likelihood that opioids or stimulants specifically might be chosen, as 
opposed to choosing drugs with less relative risk, or choosing not to use drugs.  
Always Today, Never Tomorrow 
As noted earlier, because the future is uncertain, and therefore also less salient then the present, 
people may discount the utility of future rewards, typically referred to as delay or temporal discounting, 
where the perceived utility of a choice is reduced as time increases (Ainslie, 1992; Bickel et al., 2007; 
Rachlin, 2006). Temporal discounting can include discounting future rewards and punishments alike. While 
some economists understand a person’s discount rate to be time-consistent and exponential, behavioral 
economists consider instead that people’s discounting, and drug users’ discounting in particular, can be 
hyperbolic (or quasi-hyperbolic) and time-inconsistent (O'Donoghue & Rabin, 1999, 2002; Rachlin, 2006). 
When discounting is hyperbolic, people weight the “time until reward” is received as cost, and will choose 
a smaller, immediate reward over a larger delayed reward (e.g., $20 today versus $40 in three days) 
(Ainslie, 1992). As the delay in the second option increases, there is a decrease in preference for this 
delayed outcome, even as remote outcomes still do retain some small value. A person might also choose an 
option in the present for which there is larger later cost (e.g., $20 today that must be repaid two-fold the 
following week). In other words, people can be inconsistent in their preferences as a function of time. This 
can be detected, in part, by preference reversal if the choice is between two outcomes in the future; in this 
case, the person will select the larger amount (e.g., $20 in one year or $40 in one year and three days). 
Typically, though, the future self prefers the larger, later amount, while the present self prefers the smaller, 
sooner amount (O'Donoghue & Rabin, 1999). This dynamic inconstancy indicates that the value assigned 
to choices varies in proportion to how far away the person is from receiving the outcome associated with a 
given choice (Ainslie & Haslam, 1992; Green, Myerson, Lichtman, Rosen, & Fry, 1996; Loewenstein & 
Elster, 1992). The rewarding effects of drugs, of course, can be swift. Although many costs associated with 
drug use can be realized immediately (e.g., overdose, adverse side effects), others are realized only in the 
future (e.g., parole violation, liver failure, divorce), including ones that develop as a result of repeated 
solitary decisions over time (e.g., dependence, addiction).  
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The “primrose path” model described in the previous chapter, in which people shift decisions and 
behaviors to choices with the highest local utility, and without the ability to always adequately assess the 
utility of their distributed choices, can also be applied to decisions pertaining to other phenomena that are 
less destructive than addictive drugs. Distributed choice may still be suboptimal for these other decisions; 
but it may not be life-ruining and lethal. As Herrnstein & Prelec (1991) note, “In its most egregious form, 
the slippery slope of distributed choice leads to addiction, which is to say, a devastating level of 
overindulgence in some commodity or activity” (p.149).  
People who have steeper discount rates can be considered as more present-biased or “temporally 
myopic”, and therefore more likely to be meliorating consumers, in which they choose the option with the 
highest unitary return, thus propelling them further down this unintended trajectory (Bickel & Marsch, 
2001). Present-bias and steeper discounting are more common among current and remitted drug users, 
including opioid and stimulant users (Heil, Johnson, Higgins, & Bickel, 2006; Kirby & Petry, 2004; Kirby, 
Petry, & Bickel, 1999; Petry, 2001; Petry, Bickel, & Arnett, 1998; Reynolds, 2006). Petry et al. (2002) 
observed not only poorer decision-making performance among a sample of heroin users, evidenced by 
higher rates of choosing options with high immediate, but low overall reward, but also found that heroin 
users were less future oriented, including less capable of predicting events in the distant future and 
coherently organizing future events. It is important to note that while some people may evidence greater 
present-bias and steeper delay discounting rates for certain intertemporal decisions, they may not do 
similarly for others. Relatedly, a person may exercise greater self-regulation in one domain than in another. 
Thus, although a person may have some global propensity toward present-bias and delay discounting, and 
less ability to self-regulate or inhibit impulses, there can also be differences that depend on the choices 
themselves, other cognitive capacities, and the context in which learning and decision-making occurs 
(Mishel, 1973; Mischel, Ebbesen, & Raskoff-Zeiss, 1972; Mishel et al., 2010). 
However, evidence suggests that some people are simply more prone toward impulsivity and 
present-bias, such that irrespective of the nature of reward, they will more often tend to choose the option 
with highest immediate or local utility, as future rewards and costs are weighted differently than immediate 
or near-term outcomes (Madden & Bickel, 2010; Petry, 2001). Increasing evidence suggests not only a 
strong positive correlation between impulsivity, delay discounting, and drug use (de Wit, 2009; Madden & 
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Bickel, 2010; Verdejo-García, Lawrence, & Clark, 2008), but also a likely causal relationship (in some 
cases mediated by poorer executive function, including working memory), evidenced by steep discounting 
observed prior to drug use initiation (Anokhin, Golosheykin, Grant, & Heath, 2011; Audrain-McGovern et 
al., 2009; Khurana et al., 2013; MacKillop et al, 2001). Although some groups may be more prone to 
temporal discounting, certain endogenous and exogenous factors can also contribute to this tendency.  
Drug-related Influences on Decision-making 
When exploring factors with the potential to influence opioid and stimulant use among a sample of 
corrections-involved adults with a history of drug use—who by virtue of belonging to this group may 
already be estimated to have a propensity toward greater present bias and delay discounting-- it is important 
to consider additional factors that may have been present prior to or contemporaneous with time periods 
when decisions about opioids and stimulants were made. Prior drug use, including prior use of opioids or 
stimulants, is one such factor.  
Early Drug Use Initiation 
Early drug use initiation is defined here as psychoactive drug intoxication at or prior to age 14. 
Age 14 is consistent in the literature as a critical developmental juncture, in that there is less frontocortical 
density and less neural integration or “coupling” of brain areas prior and during this time (Gogtay et al., 
2004; Shaw et al., 2008). Early drug use initiation has been associated with a greater likelihood of 
developing drug-related problems and more severe use in later adolescence and adulthood, including 
dependence, SUD, and IDU (Anthony & Petronis, 1995; Chen et al., 2009; McCabe, West, Morales, 
Cranford, & Boyd, 2007; Trenz et al., 2012). It is therefore necessary to consider some of the possible 
implications of early drug use initiation on cognition and drug-related decision-making during adulthood.  
 Initial drug use can be considered as a form of experimentation and exploration. As such, it 
signals some proclivity toward curiosity. While curiosity is a universal human characteristic, it is 
particularly pronounced in youth (Piaget, 2005). Beyond age-typical curiosity, early drug use suggests the 
presence of pre-morbid traits known to correlate with steeper discounting and risk-taking, such as 
impulsivity, sensation-seeking, and novelty-seeking (Cloninger, 1987; Cloninger et al., 1988; Ebstein & 
Belmaker, 2002; Ersche et al., 2010; Lejuez et al., 2010; MacPherson, Magidson,  Reynolds, Kahler, & 
Lejuez, 2010; Wingo et al., 2016). In addition to being associated with early drug use initiation, these 
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characteristics have been implicated, singularly or in a synergistic manner, in the development and 
perpetuation of problematic drug use and addiction to a variety of drugs, including opioids and stimulants 
(Belin, Mar, Dalley, Robbins, & Everitt, 2008; Dawe & Loxton, 2004; MacPherson et al., 2010; Madden et 
al., 1999; Vuchinich & Simpson, 1998).  
Early drug exposure also indicates that neurophysiological and epigenetic changes transpired 
during critical phases of rapid neurocognitive development (Albertson, Schmidt, Kapatos, & Bannon, 2006; 
Andersen & Navalta, 2004; Cadet, 2016; de Wit, 2009; Guerri & Pascual, 2010; Stanwood & Levitt, 2004). 
This is important, in that during adolescence a person’s brain evidences greater plasticity and is not yet 
fully developed, meaning that some neural, genetic, cognitive, and behavioral changes may have enduring 
impacts on later functioning if not addressed and ameliorated; particularly when other factors (e.g., stress, 
deviant peer influence, parental SUD) or morbidities are present (Chambers, Taylor, & Potenza, 2003; 
Champagne, 2010; Fagiolini, Jensen, & Champagne, 2009; Post, 2016; Mistry, Bawor, Desai, Marsh, & 
Samaan, 2014; Tarter, Kirisci, Habeych, Reynolds, & Vanyukov, 2004; Vaughn, Beaver, DeLisi, Perron, & 
Schelbe, 2009; Witt, 2010). Incorporated within this latter point is the fact that opioids and stimulants are 
highly rewarding, meaning that they might lead to extreme “wanting” or craving among those that use them 
(i.e., sensitization of incentive salience; Robinson & Berridge, 2000), which includes dramatically altering 
learning and behavior (stimulus-response habituation; Robbins & Everitt, 1999), in either case, biasing a 
person toward continued use. Consequently, a decision not to use drugs one was previously exposed to 
becomes more difficult make.  
 The degree or frequency of drug use subsequent to initiation is important. Consider how a person 
who uses cocaine once at age 14 may differ from someone who used cocaine intermittently at age 14 and 
again in young adulthood, and how this person would differ still further from a person who used cocaine at 
age 14 and regularly throughout adolescence and later adulthood. Moreover, someone who used cocaine 
prior to age 14 might be expected to experience an overall poorer SUD trajectory in later adolescence and 
adulthood, in part due to a longer exposure window (Anthony & Petronis, 1995; Grant & Dawson, 1998; 
Gruber, DiClemente, Anderson, & Lodico, 1996; Tapert & Brown, 1999).  
The commonality here is that early age of drug use initiation indicates a greater likelihood of 
observing other traits associated with increased risk-taking and less adaptive decision-making in adulthood. 
 40 
Regardless of whether early age of initiation indicates the pre-morbid presence of traits (e.g., cognitive, 
personality, genetic) associated with poorer executive control, propensity toward use, and greater likelihood 
for developing SUD, or that early use casually contributes to the development of these things, the 
implications of early age of initiation (e.g., greater impulsivity, poorer drug-related decision-making in 
adulthood) are similar. This is particularly true in regard to impulsivity and lack of self-regulatory capacity 
(King & Chassin, 2007; Tarter et al., 2003), as evidence suggests that impulsivity can be considered marker 
for SUD development and other addictive behaviors (Petry, 2001; Verdejo-García, Lawrence, & Clark, 
2008).  
Impulsivity involves several components. These include action with less forethought; immediate 
gain at risk of larger, future loss; and “disposition toward rapid, unplanned reactions to internal or external 
stimuli without regard to the negative consequences of reactions” (Ainslie, 1974; Dickman, 1993; Moeller 
et al., 2001). DeYoung & Rueter (2016) consolidate the definition into two necessary parts: 1) The impulse, 
urge, motivation, or desire to act, and 2) A lack of inhibition, restraint, or control of the impulse (e.g., 
failure of self-regulation). Impulsivity is central to consider when discussing high-risk decision-making, in 
that people with higher impulsivity/poorer self-regulation are typically more likely to demonstrate other 
executive dysfunction (e.g., poorer working memory), have steeper discount rates, and exhibit greater risk 
propensity/neurodisinhibition (Hinson, Jameson, Whitney, 2003; Nichols & Wilson, 2015; Semple, Zians, 
Grant, & Patterson, 2005; Tarter et al., 2003). These have obvious implications for decision-making and 
risk-taking in relation to opioids and stimulants. Further, there is support for the idea that people who 
evidence greater impulsivity may perceive time differently than people with greater capacity for self-
regulation/impulse control, wherein the former group overestimate the duration of time intervals and 
commensurately devalue delayed rewards at steeper rates (Berlin & Rolls, 2004; Rubia, Halari, Christakou, 
&Taylor, 2009; Wittmann & Paulus, 2007, 2009). In other words, for these people, the future may feel like 
an eternity away and potential future states may resonate less intensely. Impulsivity, which involves 
premature decision and behavior, thus makes sense as a correlate of delay discounting, particularly in 
relation to drug use, where potent effects are gained in real-time (Paasche, Weibel, Wittmann, & Lalanne, 
2018).  
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Because early age of drug use initiation often positively correlates with other high-risk behaviors 
(e.g., smoking, unprotected sex, driving under the influence) and with disorders which positively correlate 
with SUD and diminished self-regulatory control (e.g., attention deficit hyperactivity disorder [ADHD]), 
people who began using earlier in life may be considered potentially more impulsive and less capable of 
self-regulation during decision-making in adulthood than people who began using later in life (Barkley, 
Edwards, Laneri, Fletcher, & Metevia, 2001; Eslami-Shahrbabaki, Fekrat, & Mazhari, 2015 Stueve & 
O’donnell, 2005; McGue et al., 2001; Vaughn et al., 2009).  
Considering early drug use initiation as a marker or proxy for impulsivity and poorer self-
regulation is not without limitations. Wittmann & Paulus (2007) offer a reminder that “impulsivity is 
determined by a complex set of processes and consists of multiple components,… [but that] nevertheless, 
impulsivity can be conceptualized as a pattern of behavior for which the potential of negative consequences 
has limited influence on the planning of actions”. Among a sample of corrections-involved people, early 
drug use initiation can be considered as one of many indicators of such a behavioral pattern.   
Drug Preferences, Drug Use, and Severity of Use 
A person’s drug preferences, drug-related decisions, and drug behaviors can change over time. For 
instance, a person might use heroin or cocaine heavily for several years and then later moderate or 
discontinue use (Lewis, 2015; Robins, Helzer, & Davis, 1975; Waldorf et al., 1992). However, when 
exploring factors with the potential to influence decision-making about opioids and stimulants during a 
particular time period, it is important to identify people’s prior and contemporaneous use of these drugs, the 
severity of their use, and their drug preferences.  
Reinforcer Pathology and Drug Preference 
People who exhibit greater present bias, impulsivity, delay discounting, and poorer self-regulation 
may be more likely to initiate drug use and persist in use. Despite these tendencies, it is important to 
consider that consumption of certain commodities may not ever lead to problems. In other words, the utility 
associated with unitary choices and their distribution (aggregation) may not appreciably differ. It is 
important to keep in mind that in addition to endogenous and exogenous factors that influence decisions to 
use opioids and stimulants, the drugs themselves comprise a unique form of consumption. Bickel et al. 
(2011) describe how the consumption of highly rewarding commodities, such as drugs, can result in 
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reinforcer pathology, defined as a “1) the persistently high valuation of a reinforcer, broadly defined to 
include tangible commodities and experiences; and/or 2) the excessive preference for the immediate 
acquisition or consumption of a commodity despite long-term negative outcomes” (p.407). In simplest 
terms, a reinforcer can be understood as the presence or absence of a stimulus that results in associative 
learning, and subsequent increases or decreases in particular behavioral responses (Sutton & Barto, 2018; 
Thorndike, 1998).  
People who misuse drugs, and persist in use despite costs, come to overvalue drugs in the extreme 
and demonstrate preference for immediate receipt of drugs. Thus, while certain factors, such as impulsivity 
and poorer executive control, may influence a person’s overall cognitive repertoire and decision-making 
capacities, the rewarding characteristics of the drugs themselves must be considered in relation to these 
other factors (Bickel et al., 2007, 2011; Bickel, Mueller, Jarmolowicz, 2011; Jentsch & Taylor, 1999; 
Monterosso et al., 2007; Stafford, LeSage, & Glowa., 1998; Xu et al., 2009). For some people, opioids and 
stimulants may produce rewarding effects that are greater relative to other drugs, therefore intensely 
motivating behavior toward the use of these, but not necessarily all other drugs with abuse liability (Bickel, 
Marsch, & Carroll, 2000; Kreek, Bart, Lilly, Laforge, & Nielsen, 2005; Kreek et al., 2012).   
As highlighted in Chapter 1, many drug users can best be considered as polydrug users. For 
instance, someone who used prescription opioids frequently during the past-year may have also used heroin 
during the same period with even greater frequency, but may have used buprenorphine with less frequency. 
They may also have used MDMA, inhalants, alcohol, and a variety of other drugs (Daniulaityte, Falck, 
Wang, & Carlson, 2009; Leri et al., 2003). Despite this polydrug use, it is likely that this person has a 
preferred drug of choice (O’Connor & Berry, 1990). As will be discussed, exposure to or accessibility of a 
particular drug, while important, is not the only potential influence on drug-related decision-making. 
Preference is also important to consider, as drug choices stand in relation to one another and vary in their 
utility and reinforcing effects.  
Although it might be measured in many ways, drug preference can be understood as the drug 
associated with the greatest behavioral response, which, for people, might be characterized as the drug used 
with greatest frequency or the drug that people spend more resources to acquire when other drug choices 
are also available (Katz, 1990). However, because many factors can constrain people’s choices during a 
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given time period, and therefore decrease use (e.g., not due to lack of preference but to decreased supply), it 
is also important to determine what drug a person would rate as their preferred drug of choice. Although 
stated preferences can diverge from choice and behavior, there is often strong correlation (Smith & Staton, 
2018). Consider how a person who prefers chocolate ice cream might always choose chocolate ice cream 
when it is available, but might eat vanilla or strawberry ice cream if chocolate is unavailable. This same 
person, however, would not eat pistachio ice cream, even if it was the only flavor of ice cream available. 
Indeed, because preference is in many ways conceptually similar, if not interchangeable, with utility 
(Bentham, 1996), a person’s preferred drug necessarily implies that it has a higher local utility compared to 
other drugs. Although such a preference doesn’t suggest that this drug is preferred to non-drug choices, it 
does suggest that this preference will influence drug-related decision-making. If a person prefers heroin, 
then this preference influences their decision to use heroin. For instance, it would be less likely that, given a 
choice between heroin and a substitute for heroin, which could include a drug with similar pharmacology 
(e.g., prescription opioids, buprenorphine) or a drug with dissimilar pharmacology that still produced 
rewarding effects, a person would not choose heroin.  
Prior Drug Use and Frequency of Use 
When exploring factors with the potential to influence decision-making about opioids and 
stimulants for a particular time period, prior and contemporaneous use of opioids and stimulants may serve 
as possible influences. For example, a person may have used prescription opioids every month for the past-
year or every day for the past month. Or, they could have used them seldomly, perhaps one month out of 
the past year and three days out of the past month. Clearly, there are differences between the two. Prior or 
contemporaneous use of prescription opioids influences current and future decisions about prescription 
opioids. At a minimum, any use of this drug indicates a willingness to use prescription opioids.  
Frequent and regular use indicates the possibility that prescription opioid use may have, to some 
degree, become habituated over time (Nelson & Killcross. 2006; Robbins & Everitt, 1999). By habituation, 
it is meant that certain behaviors, in this case the acquisition and use of prescription opioids, have been 
established as a result of stimulus-response learning, thus making future similar behaviors easier to perform 
and dissimilar future behaviors (in relation to prescription opioids) more difficult to preform (Gardner, 
2015). To help illustrate, consider how many common behaviors become habituated: Eating the same meal 
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for breakfast; putting contact lenses in after brushing teeth, beginning with the right eye; watching Netflix, 
eating chocolate, and drinking pinot noir every night after putting the children to bed; taking the same route 
home from work; using Apple operating software instead of Microsoft; ordering pizza every Friday night 
from the same restaurant (Aarts, Verplanken, & Van Knippenberg, 1998; Graybiel, 2008; Ouellette & 
Wood, 1998; Polites & Karahanna, 2012). Habits are efficient and certainly not always pathological 
(Desrochers, Jin, Goodman, & Graybiel, 2010). In the absence of habits, significant cognitive energy would 
be wasted processing previously encountered information, deliberating, forming goals, making decisions, 
and re-learning behaviors; indeed, maintaining habits requires less cognitive effort than inhibiting or 
“overriding” them, with habits strengthening over time (Gardner, 2015; Graybiel, 2008; Wood & Rünger, 
2016). When prescription opioid use becomes habituated, however, decision-making about this drug can be 
considered as significantly biased toward continued use and no longer necessarily associated with goal-
directed behavior; it may even be considered compulsive (de Wit, 2018). In relation to prescription opioids, 
cognition and behavior would be more implicit, automated, and reflexive, and less explicit and deliberative 
(Bechara, Noel, & Crone, 2006). Habits may still be consonant with goals or intentions, but they may also 
interfere with goal-directed behavior (Wood & Neal, 2007; see also Chapter 5 for further discussion).    
Additionally, more frequent and regular use of a drug (i.e., greater exposure) is associated with 
decreased capacity to regulate attention, affect, and make deliberative decisions about that drug (Bechara, 
2005; Naqvi & Bechara, 2010). This does not suggest that habituated behaviors, including drug taking, 
occur involuntarily or without an agent (e.g., a person with capacity to act), or without agency, defined as 
the exercise or manifestation of the capacity to act (Bandura 2006; Stanford Encyclopedia of Philosophy, 
2015; Wood & Rünger, 2016). Rather, it implies that the cognitive effort or self-regulation needed to “do 
otherwise” is much greater, and much more difficult to come by, given that habituation is shaped and 
constrained from inputs at multiple levels (Zimmerman, 2013).  
Thus, someone who has used prescription opioids frequently over the past-year or month, and who 
currently prefers prescription opioids to other choices, would require more cognitive energy and time when 
making a decision to not use prescription opioids following this time period; particularly if the general 
circumstances or context of their past use had not also changed (Lally, Van Jaarsveld, Potts, & Wardle, 
2010; Wood & Neal, 2007). Ultimately, this recent prior exposure to prescription opioids would serve as an 
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influence on decision-making, such that the person would be more likely to choose to use prescription 
opioids rather than a novel or infrequently used drug. This doesn’t mean that the person would always 
choose the same drug or self-administer drugs in the same manner, as habits and patterns of use can change 
and reform over a person’s life (Des Jarlais et al., 2007; Neaigus et al., 2001). Certainly, though, the 
presence of other factors will enable or frustrate both goal-directed and habituated behavior. For instance, 
in order for a person to make other decisions and act on them, there would have to be alternative choices to 
opioids with presumably greater perceived local utility (e.g., other drugs, other activities), or the overall 
utility of prescription opioids would have to be recognized by the person as lowered as a result of continued 
use (e.g., tolerance). In order to discern, reflect, and act upon this information, however, the person would 
need higher-level cognitive capacities (e.g., attentional control, prospection, counterfactual and abstract 
reasoning, self-regulation, etc.), both to identify the discrepancy between the local and overall utility of 
prescription opioids, but also to help enable decisions and enact behaviors discordant with habituated 
action. In other words, greater capacity to inhibit or “override” the habituated behavior and choose the 
option with greater overall utility.   
Severity of Drug Use 
Drug exposure, or frequency of use, is not synonymous with drug use severity. Indeed, some 
people may use drugs frequently or with regularity over days, months, or years, but in a moderated or 
otherwise controlled manner (Parker, Williams, & Aldridge, 2002; Waldorf et al., 1992; Zinberg, Jacobson, 
& Harding, 1975; Zinberg, 1984). Severity of use can be defined in several ways. DSM-V diagnostic 
criteria for SUD, indicators such as craving, persistence in use despite a desire or attempts to quit, and 
withdrawal are used to help diagnose both the presence and severity of the disorder (APA, 2013). The 
severity of a person’s drug use is relevant in that greater severity may indicate transition from goal-directed 
to habituated behavior in relation to drugs, as described above (Nelson & Killcross, 2006 Zapata, Minney, 
& Shippenberg, 2010). More frequent use and greater severity of use correlate with considerable 
neurobiological changes known to impair areas of the brain associated with capacities crucial for decision-
making (e.g., risk assessment, valuation, emotional regulation, self-regulation, attention, memory 
information-gathering) (Blanchard, Hayden, & Bromberg-Martin, 2015; Koob & Volkow, 2010; Strait, 
Sleezer, & Hayden, 2015). Therefore, the qualities of drug use severity (e.g., craving, unsuccessful attempts 
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to quit) occurring prior to or contemporaneous with drug-related decisions indicates the presence of 
significant influences on decision-making capacity, whereby a person becomes more biased toward use 
even if a multitude of other possible choices are available and even if the subjective feeling of choice or 
phenomenological sense of ability to choose freely is present (Lau, Hiemisch, & Baumeister, 2015). Here, a 
person with greater using severity might be considered to have fewer degrees of freedom for volitional 
action compared to a person with less severity (Dennett, 2015; O’Connor, 2009).  
Ultimately, greater drug use severity would likely influence a person to continue to make unitary 
(local) decisions over global ones that, in the aggregate, decrease overall utility, whereas someone with less 
severity might have greater purchase on the cognitive capacities needed to reframe choices, inhibit 
habituated behaviors, and choose another option with less local, but greater overall, utility (Heyman & 
Dunn, 2002).  
Craving and Utility 
One specific quality of drug use severity worth highlighting is craving (i.e., drug wanting), in part 
because it often correlates with use (Robinson & Berridge, 1993; Tsui, Anderson, Strong, & Stein, Sayette, 
2016). Throughout this discussion, utility has been used primarily to mean “decision utility”, the choice 
with the highest preference assigned to it; however, “experienced utility” (which is closely related to 
decision utility, but less frequently considered; see Kahneman, Wakker, & Sarin, 1997), may also be 
relevant, in that it reflects the choice that brings about the greatest satisfaction experientially. In other 
words, the utility for a decision based on one’s preference is separable from one’s actual experience of that 
choice. What is preferred or desired is not always synonymous with what is enjoyable or satisfying. These 
differences in utility are consonant with the well-known idea that “wanting” and “liking” can become 
cognitively decoupled among drug users (Berridge, Robinson, & Aldridge, 2009). “Remembered utility” 
refers to the satisfaction one gets after having made a choice and experienced it (Kahneman et al., 1997). 
Generally, after having made choices and experienced their outcomes, a person forms memories that enable 
them to make predictions about similar choices when making decisions in the future.   
Berridge & O’Doherty (2014) consider that, typically, “wanting” or “desire” would be informed 
by memories, would coherently map on to experiences, and that, “for such cognitive desires, decision 
utility=predicted utility, and predicted utility=remembered utility” (p.342) . However, incentive salience, 
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which is a cognitive process of wanting or craving that develops with repeated drug use (informed by both 
current physiology/neurobiological states and learned cue-induced stimulus response), is a reliable and 
potent behavioral motivator (Robinson & Berridge, 1993). For drug users, “situations exist where cue-
triggered decision utility>remembered utility from the past, and similarly decision utility>predicted utility 
for future reward value (Berridge & Aldrridge, 2008). In other words, it is possible to ‘want’ (and choose) 
what is not expected to be liked, nor remembered to be liked, as well as what is not actually liked when 
obtained” (Berridge & O’Doherty, 2014, p. 324).  
Again, craving is understood as a state of incentive salience. It is cognitive and visceral, it 
influences the perception of time, the relative value assigned to a drug, and potentiates behavioral responses 
(Bechara, Dolan, & Hindes, 2002; Grant et al., 2000; Loewenstein, 2000; Sayette, 2005; Volkow et al, 
1991; Wang et al., 2012). It has been proposed by Redish et al., (2015) as reflecting a possible interaction 
between systems of valuation characteristic of deliberation and Pavlovian conditioning. For people with 
extensive or pathological drug use, craving is one state that can influence decision-making by essentially 
cognitively decoupling a unitary choice from both past and future (e.g., cue-triggered decision 
utility>remembered utility from the past; decision utility>predicted utility for future reward value). Of 
course, for some, there may still be a desire for drugs in which incentive salience is not a component (e.g., 
decision utility=predicted utility, and predicted utility=remembered utility).  
For polydrug users, the person’s preferred drug and drugs most frequently used in the past would 
serve, along with severity of use (e.g., craving, attempts to quit), as influences on decisions about drugs. 
Again, preference may become separable from experience, but greater prior use of a drug and craving for 
that drug are likely to be associated. For example, incentive salience for a person who used alcohol every 
day, but used cocaine only every five months, would likely correspond to different alcohol versus cocaine 
wanting, assuming no prior cocaine dependence at an earlier time. In this way, a person would have greater 
or fewer degrees of freedom when making a decision about particular drugs based, in part, on their prior 
exposure to these drugs. A person who exhibited this same alcohol and cocaine use behavior over a year 
would more likely come to “want” cocaine in the traditional sense, but “want” alcohol in the pathological, 
behavior-inducing sense.  
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Taken together, it is reasonable to believe that drug-related decision-making is likely influenced 
by incentive salience and other drug-related factors described above if, during a given time period, a person 
reports experiencing greater severity of use (e.g., craving, failed attempts to quit using following a period 
of regular drug use, withdrawal, etc.) and also reports ongoing drug use during this period. 
Sorites Paradox 
Recall that on the “primrose path”, where decisions can be considered both unitarily as well as in 
the aggregate (i.e., many choices distributed over a time period), it is possible for a person to reverse course 
by choosing options with lower local, but higher overall utility through cognitive reframing and other 
efforts (e.g., seeking treatment, forming new non-drug habits, etc.) after the costs associated with continued 
use become apparent (Herrnstein & Prelec, 1992; Heyman, 2003, 2013). However, such cognitive 
reframing and behavioral change might be more or less difficult depending on how many unitary choices 
have been made to use thus far. As Heyman (2003) articulates:  
[A]lcoholism and abstinence (or controlled drinking) are states that reflect the cumulative effects 
of many smaller decisions …[where] no one decision is decisive. This could be considered, among 
other ways, in terms of severity of use and exposure (Heyman & Dunn, 2002) (p. 103).  
In other words, greater drug exposure and severity of use develop. “Frequent” use doesn’t begin as 
“frequent” and “severe” doesn’t begin as “severe”. These states or properties are acquired and therefore 
have the capacity to intensify or dissolve. Although earlier discussion considered how these states can 
influence decision-making, it failed to reconcile when these states change into something else. Similar 
irreconcilability exists for the idea of solitary versus aggregated decisions and local versus overall utility: 
There is the injection of heroin, and then there is the heroin addiction. It is therefore important to note that 
when exploring factors with the potential to influence opioid and stimulant use in real-world conditions, it 
is not possible to know the juncture at which a person--as necessarily both a state and a verb, as both the 
decision-maker and the embodied aggregate of his decisions--becomes precisely defined and influenced by 
prior drug use or using severity, or where the person is relative to past and future decisions. Instead, the 
parameters can only be drawn so as to define the field, or time period, of interest (which can still be 
arbitrary) during which solitary decisions are being made and in which their distributed effects are bounded 
(e.g., a day, a year, etc.), and to then identify what else stands in relation to those decisions. This doesn’t 
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suggest that with access to perfect information, or the acquisition of enough data points over time, 
decisions could not be plotted. In theory, they could. In practice, they seldom are outside of experimental 
conditions (and even within) due to obvious data collection limitations. Even here, choice is constrained to 
levels that are inconsistent with choice in the real-world.  
Therefore, important conceptual and measurement limitations remain, in that any cut-off point 
between “many unitary decisions to use heroin” and their distributed effect of “becoming a heroin addict” 
is still only ever obliquely, and rather inadequately, discernable. This is due, in part, to insufficient 
information, diagnostic and measurement limitations, lingering disagreement about what addiction is best 
defined as, and the fact that observable symptoms or indicators of pathologies such as “heroin addiction” 
may also be attributable to other pathologies. Some “heroin addiction” indicators may be attributable to 
other sources, including to unitary decisions having nothing to do with heroin. Put differently, the observed 
effects of distributed choice to use heroin (i.e., heroin addiction or OUD) present with features that are 
similar to other pathologies with distinct etiologies and neural correlates (Brooks, Lochner, Shoptaw, & 
Stein, 2017; Cuthbert, 2015; Kwako, Momenan, Litten, Koob, & Goldman). This is noted not to disparage 
any particular diagnostic method or detract from behavioral economic accounts of drug use and addiction, 
which have tremendous parsimony and empirical support, but rather to note, as others have, some of the 
unavoidable tension between theory and data (Bickel, Jarmolowicz, Mueller, & Gatchalian, 2011). Because 
this study is exploratory, it is important to emphasize the fact that much of what is worth discussing about 
the social problem of high-risk drug use approach cannot yet be sufficiently modeled or explicated in terms 
of real-world conditions. Limitations will be considered further in Chapter 5.  
Possible Constraints on Decision-making Capacity Among Opioid and Stimulant Users: Do the 
Differences Matter? 
Prior drug exposure, drug use severity, and preference may also be influential in ways that vary 
according to drug type. Unsurprisingly, pharmacological differences between drugs have the potential to 
influence a drug user’s neurocognitive capacities differentially. As decisions and behaviors only occur as a 
result of brains, the underlying neurobiology of drug use is recognized as relevant among researchers 
studying choice and behavior (Bickel et al., 2007). A person who frequently uses and prefers alcohol will 
experience different neurobiological changes than a person who frequently uses and prefers opioids or 
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stimulants. For instance, a person who frequently uses opioids or stimulants, but infrequently uses alcohol, 
would not develop Wernicke-Korsakoff syndrome (Dodge, Jacobson, & Jacobson, 2016).  
Even within opioid and stimulant drug classes, between-drug differences might be observed. For 
example, methamphetamine-dependent people have been found to have impaired risk-related processing 
due to alterations in brain areas necessary for higher-level cognitive functioning (e.g., working memory, 
self-regulation, attention, planning), interoception, and time perception compared to non-users and other 
drug users (including opioid users), and to evidence greater impulsivity and uncertainty salience (Ersch et 
al., 2005; Gonzalez, Bechara, & Martin, 2007; Gowin et al., 2013; Leland, Arce, Feinstein, & Paulus, 2006; 
Leland & Paulus, 2005; Pollatos, Laubroc, & Wittmann, 2014; Semple et al., 2005). One meta-analysis 
found that people with active and remitted methamphetamine use disorder exhibited moderate cognitive 
impairment across multiple domains, with the largest deficits observed for impulsivity/reward processing 
and social cognition (Potvin et al., 2018). Further, some evidence indicates that people with greater 
impulsivity and sensation-seeking report stronger rewarding effects from amphetamines (e.g., greater 
liking, wanting, and euphoria) (Kelly et al., 2006). Among MDMA users, attentional control, long-term 
memory, and sensory gating (i.e., ability to filter out non-relevant distractions and sensory information) 
were also found to be impaired, with deficits persisting over time (Lundqvist, 2005). 
Compared to healthy controls and other drug users (e.g. cannabis, opioids), cocaine dependent 
people have performed worse on decision-tasks (e.g., making less advantageous choices, commission 
errors) that require information acquisition, working memory, prediction, and attention (Cunha, Bechara, de 
Andrade, & Nicastri, 2011; Kjome et al., 2010; Mejía-Cruz, Green, Myerson, Morales-Chainé, & Nieto, 
2016). When compared to non-users and cannabis users, cocaine users performed worse on decision tasks, 
even after a short period of abstinence (Verdejo-Garcia et al., 2007). Among a clinical sample, crack 
cocaine users scored higher on measures of impulsivity and risk-taking compared to heroin users 
(Bornovalova, et al., 2005). However, some evidence also suggests that cocaine users’ performance can 
improve over time when valued contingencies (e.g., money) are introduced (Vadhan, Hart, Haney, van 
Gorp, & Foltin, 2009).  
More generally, stimulant users (cocaine, amphetamines) have demonstrated less adaptive and 
dynamic cognitive functioning (i.e., no increased shift toward frontocortical processing), and poorer 
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decision-making and behavioral performance during tasks that require learning, prediction, and cognitive 
flexibility, resulting in less adaptive error responding (Paulus, 2002; Paulus, Lovero, Wittman, & Leland, 
2008; Simon et al., 2001). Evidence remains mixed, though, for the degree to which cognitive functioning, 
impulsivity, working memory, and decision-making remains impaired or improves over time after 
stimulant use is reduced or discontinued, and whether cognitive, self-regulatory, and decision-making 
deficits are a contributor to or consequence of stimulant use (Frazer, Richards, & Keith, 2018; Hulka et al., 
2015; Kalechstein, Newton, & Green, 2003; McCann et al., 2008; Potvin, Stavro, Rizkallah, & Pelletier, 
2014; Potvin et al., 2018; Salo et al., 2009; Stewart et al., 2013; Wang et al., 2013).  
Chronic opioid use can alter and impair neurophysiology and neuroanatomy in areas associated 
with emotion, self-regulation, risk-taking, and goal-directed behavior (Baldacchino, Balfour, Passetti, 
Humphris, & Matthews, 2012; Pandria, Kovatsi, Vivas, & Bamidis, 2018). Among a sample of opioid 
users, poor performance on decision tasks measured at treatment admission predicted post-treatment 
relapse (Passetti, Clark, Mehta, Joyce, & King, 2008). In another study, patients receiving treatment for 
OUD made riskier decisions compared to controls and exhibited decisional deficits associated with 
impaired executive function (Brand, Roth-Bauer, Driessen, & Markowitsch, 2008). Additionally, current 
and former opioid users, including people maintained on agonist therapies, have evidenced steeper discount 
rates and less adaptive decision-making (Biernacki et al., 2018; Wollman et al., 2017), including 
discounting delayed heroin at higher rates than money (Madden, Petry, Badger, & Bickel, 1997). Heroin 
users have also shown to persist in poorer strategic task performance where learning and error correction 
would be expected (Orrnstein et al. 2000). One study examining impulsivity and strategic decision-making, 
found that active heroin users performed worse compared to healthy controls, people who take prescription 
opioids licitly (and do not have OUD), and abstinent heroin users receiving MMT (Baldacchino, Balfour, & 
Matthews, 2015). In another study, current and abstinent (1 year) opioid users and stimulant users 
performed worse than controls in terms of risk on decision tasks, but did not significantly differ by drug-
use group, meaning that both groups may be considered to have increased likelihood for some cognitive 
impairment, even after use is discontinued (Ersche et al., 2005).  
Taken collectively, though, findings provide support for the idea that both former and current 
opioid users have impairments in decision-making, working memory, attention, and inhibition/self-
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regulation, but with arguably greater variance across samples than across samples of stimulant users (Li et 
al., 2013; Yan, et al., 2014; Zheng et al., 2013). Specifically, evidence points to potentially worse cognitive 
effects for amphetamine (including “street meth”) users, compared to cocaine and opioid users, which may 
be partially attributable to greater exposure to synthetic compounds that produce greater neurotoxic effects 
(McConnell et al., 2015; Nordahl, Salo, & Leamon, 2003; Potvin et al., 2018). Badiani et al. (2011) 
considered the possibility that despite the fact that cognitive impairments (e.g., memory, cognitive 
flexibility, decision-making) are observed in both opioid and stimulant users, and share common 
neurobiological substrates (Bechara, 2005; Fernandez-Serrano, Pérez-García, M., Schmidt Río-Valle, & 
Verdejo-Garcia, 2010; Fu et al., 2008; McNamara, Dalley, Robbins, Everitt, & Belin, 2010; Muriach et al., 
2010; Orrnstein et al. 2000; Tramullas, Martínez-Cué, & Hurlé, 2008), there are nevertheless noteworthy 
differences in the degree of neuroanatomical difference and neurocognitive impairment between opioid and 
stimulant users, particularly for impulsivity and cognitive flexibility. The authors note that the 
preponderance of (albeit limited) evidence suggests that the latter group may exhibit significant and 
potentially longer-lasting deficits (Ersche et al., 2005; Ersche, Clark, London et al., 2005; London, 
Robbins, & Sahakian, 2006; Ersche, Roiser, Robbins, & Sahakian, 2008). Further, discontinuation of 
stimulants is associated with increased deficits in inhibition, whereas impulsivity did not increase with 
opioid discontinuation (Liu, Heitz, & Bradberry, 2009; Liu et al., 2011; McNamara et al., 2010). It may 
therefore be reasonable to believe that frequent stimulant use, more so than frequent opioid use, would 
adversely influence a person’s decision making and ability to self-regulate, even after periods of 
abstinence.  
When examining opioid and stimulant use during particular time periods, prior and 
contemporaneous exposure to these drugs might be considered then, not only in terms of potential 
influences described in previous sections (e.g., preference, habituation, craving), but also in terms of how 
use of these high-risk drugs may beget further high-risk decision-making in general.  
A limitation to some of the research described above is that opioid and stimulant users may also 
co-use other drugs. However, when concomitant use of opioids and/or stimulants was examined, people 
using opioids and/or stimulants still performed worse than alcohol and other drug users, including other 
polydrug users who did not use opioids or stimulants (Nixon, Paul, & Phillips, 1998). Additionally, some 
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findings indicate that dependence on multiple drugs is not associated with increased delay discounting 
(Businelle, McVay, Kendzor, & Copeland, 2010) and that cognitive effects from other drugs may not 
necessarily be additive to opioids or stimulants. For instance, one study examining cognitive abilities found 
alcohol users performed better than stimulant-only users and alcohol/stimulant co-users, but that stimulant-
only users performed worse than both the alcohol-only group and the alcohol/stimulant co-use group 
(Lawton‐Craddock, Nixon, & Tivis, 2003). However, as findings cannot definitively clarify if cognitive 
deficits associated with opioid and stimulant use pre-dated drug use initiation, resulted from, or were 
exacerbated by prolonged exposure to these drugs, opioid and stimulant use may be considered as a generic 
and approximated potential indicator of cognitive deficits. Irrespective of whether these deficits pre-dated 
or developed from use, evidence suggests a strong association between opioid and stimulant use and 
executive dysfunction, such that prior exposure to these drugs indicates that important decision-making 
deficits may be present.  
Demographic Characteristics with Potential to Influence Decision-making 
Age and Sex 
There are two demographic characteristics, younger age and male sex, that are commonly 
associated with risk-taking behavior generally and greater likelihood to use illicit drugs specifically (APA, 
2013; Blazer & Wu, 2009; Gullone, Moore, Moss, & Boyd, 2000; Miller, Naimi, Brewer, & Jones, 2007).  
Younger age is positively correlated with greater impulsivity, sensation-seeking, novelty-seeking, 
and risk-taking (Reimers, Maylor, Stewart, & Chater, 2009; Spear, 2000; Steinberg et al., 2004, 2008). 
Evidence suggests that while some younger people may underestimate risk, others may perceive it and their 
own vulnerability to unfavorable outcomes, yet, may still often pursue risky action (Benthin, Slovic, & 
Severson, 1993; Cohn, Macfarlane, Yanez, & Imai, 1995; Gardner & Steinberg, 2005). Evidence also 
suggests that reward salience is greater in youth, and that younger people may be more reward-sensitive 
and punishment-insensitive compared to older adults (Doremus-Fitzwater, Varlinskaya, & Spear, 2010; 
Spear, 2000). Further, younger people have less crystallized intelligence that is needed, along with fluid 
intelligence, to assess risk and make decisions (Li, Baldassi, Johnson, & Weber, 2013). Younger people 
have also simply made fewer decisions, including decisions involving uncertainty and risk, than older 
adults, indicating a general inexperience. Additionally, younger people also tend to be more present-biased 
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and to have steeper delay discounting rates on the same task compared to older individuals (Green, 
Myerson, & Ostaszewski, 1999; Meier & Sprenger, 2010; Steinberg et al., 2009). This means that younger 
age may be an indicator of poorer decision-making capacity, greater risk-taking, and present-bias.  
Many of these age-related differences are partially attributable to the related fact that, unlike adults 
over the age of 26, people in the first two and a half decades of their life do not yet have a fully matured 
prefrontal cortex, the region of the brain instrumental in higher-level cognition (Gogtay et al., 2004; Spear, 
2007). Younger people are generally more likely to experiment with drugs, including opioids and 
stimulants, and to persist in use despite adverse effects (Gfroerer & Brodsky, 1992). This is one reason why 
rates of dependence are far lower among people aged 50 and older in the US (Blazer & Wu, 2009). 
However, as “baby boomer” cohorts age, rates of SUD among older persons is expected to increase due to 
the larger number of young people who initiated use in the 1960s (Han, Gfroerer, Colliver, & Penne, 2009; 
Wu & Blazer, 2011). There remains, too, the phenomenon of late-adopters to illicit drug use and the 
development of opioid and stimulant use disorders later in life (Arndt, Clayton, & Schultz, 2011; Lofwall, 
Schuster, & Strain, 2008). Meaning that there are exceptions to general trends.  
Male sex, both before and after puberty, is frequently and strongly correlated with greater 
impulsivity/self-regulatory failure, steeper discount rates, and risk-taking behavior, including drug use 
(Byrnes, Miller, & Schafer, 1999; Cottle, Lee, & Heilburn, 2001; Hosseini-Kamkar & Morton, 2014; 
Myerson, Green, van den Berk-Clark, & Grucza, 2015; Gershon & Gershon, 2002). Taken together, 
evidence suggests that younger age and male sex may be factors with the potential to influence decision-
making about high-risk drugs like opioids and stimulants.  
Some Additional Indirect Indicators of Cognitive Functioning  
As noted above, how a person makes intertemporal decisions depends in part on a person’s ability 
to engage deliberative and higher-level cognition. In addition to age- and sex-related influences on 
decision-making capacities and neurocognitive deficits that developed subsequent to drug exposure, a 
person may have additional attributes that influence cognition, risk-taking, self-control, and decision-
making (Verdejo-García et al., 2008).  
Deficits in neurocognitive functioning and executive control could have developed as a result of a 
number of factors (e.g., early childhood exposure to pre- or perinatal environmental neurotoxins, trauma, 
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injury, abuse etc.) (Coles et al., 1997; Kim et al., 2013; Meehan & Mannix, 2010; Perry, Pollard, Blakley, 
Baker, & Vigilante, 1995). For instance, lead and other neurotoxin exposure is a large but overlooked 
problem in the US, despite the fact that lead exposure is associated with a cascade of neurocognitive and 
affective problems that include disinhibition, intellectual disabilities, behavioral problems, attentional 
deficits, and poor self-regulation (Cecil et al., 2008; Goodlad, Marcus, & Fulton, 2013). Such exposure is 
believed to have a causal contribution to conduct disorders, drug use, and to violent and non-violent crime 
(Boutwell et al. 2016; Farrington, 2018). This example highlights a few possibilities. First, there can be a 
wide-range of cognitive function and dysfunction among people generally and among corrections-involved 
drug users in particular. Second, not all cognitive dysfunction is necessarily attributable to drug use. Third, 
such dysfunction is still nevertheless relevant to consider as a potential influence on risk-taking and 
decision-making using available indicators. Oftentimes, the causal contributors to neurological deficits 
remain unknown and only indirect indicators of impairment are observed and assessed.  
Learning Disability and Poor Educational Performance  
Irrespective of what ultimately contributed to the development of cognitive deficits, many young 
people who experience deficits in cognition, impulse control, attention, and memory experience greater 
challenges in school, including conduct problems, poor performance on standardized tests, and unfavorable 
teacher evaluations (Mattison, Hooper, & Carlson, 2006). Increasingly, per state and federal mandates, 
children who consistently underperform against normative standards are assessed for learning disabilities 
(LDs) (Bowen & Rude, 2006). LDs, defined as “a neurobiological disorder of cognitive and/or language 
processing caused by atypical neurocognitive functioning”, have been associated with less adaptive 
cognitive functioning and poorer academic performance compared to controls (Mayes, Calhoun, & 
Crowell, 2000; Rubinsten, 2009; Silver et al., 2008). There is also a high rate of co-occurrence for LDs, 
ADD/ADHD, and externalizing disorders (DuPaul & Volpe, 2009; Semrud-Clikeman et al., 1992). Further, 
some research has found that young adult and adult participants who self-report having a LD and/or ADHD 
perform worse on neurocognitive tests and evidence greater stress and psychiatric symptoms (Elbin et al., 
2013; Wilson, Deri-Armstrong, Furrie, & Walcot, 2009; Zuckerman, Lee, Odom, Solomon, & Sills, 2013). 
Children with LDs or ADD/ADHD are sometimes enrolled into special education (SE) curriculum 
(Turnbull, 1995). SE services may be provided to students for a number of reasons, ranging from 
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intellectual and developmental disabilities, including LDs, to poor academic performance (Freeman & 
Alkin, 2000; Turnbull, 1995).  
Having been diagnosed with a LD or having been enrolled in SE may indicate the presence of 
some deficits in executive functioning, including inhibitory control, as there are high rates of co-occurrence 
for LDs and ADD/ADHD (Barkley et al., 2001; Biederman et al., 2004). LDs, ADD/ADHD, and SE 
enrollment are vastly overrepresented among both corrections-involved people and drug users (Allison et 
al., 1999; APA, 2013; Blanton & Dagenais, 2007; Bryan, Freer, & Furlong, 2007; Cottle et al., 2001; 
Kavanagh, Rowe, Hersch, Barnett, & Reznik, 2010). It is important to note that this association between 
LD diagnosis, SE enrollment, and high-risk behavior in adulthood may be partially attributable to 
neurocognitive deficits, but may also be due to a variety of other psychosocial and economic factors (Coles 
et al., 1997; Raine et al., 2005; Spencer et al., 2005). Indeed, while LD and SE enrollment may provide an 
indirect indicator of mild intellectual impairments or deficits in cognitive functioning (e.g., working 
memory, self-regulation) which can impede decision-making, they may also indicate other things, such as 
race-based structural and systemic inequities, teacher bias, and childhood poverty (Altarac & Saroha, 2007; 
Artiles & Trent, 1994; Skiba et al., 2008). There is the further possibility that the effects of being diagnosed 
with a LD and the effects of enrollment into SE curricula may contribute to, rather than necessarily reflect, 
cognitive challenges or developmental delays. For instance, being diagnosed with a stigmatized condition 
or state, such as LD diagnosis or SE enrollment, can increase stress, negative affect, which can hinder 
learning (Bender, Rosenkrans, & Crane, 1999; Kistner, Haskett, White, & Robbins, 1987; Mishna, 2003; 
Shifrer, 2013; Tabassam & Grainger, 2002). Students with intellectual disabilities often fare worse in SE 
than in integrated classrooms (Freeman & Alkin, 2000). In this way, irrespective of cognitive difficulties 
prior to LD diagnosis or SE enrollment, the diagnosis and enrollment may themselves contribute to 
important developmental delays that can have a lasting impact on cognition and decision-making.  
Difficulties with Comprehension, Concentration, and Memory  
In addition to using LD diagnosis or SE enrollment as an indirect indicator of cognitive deficits 
with the potential to influence decision-making capacities, there are some specific markers of poorer 
cognitive functioning that might be discerned through the self-report. For instance, self-reported difficulties 
in concentration, comprehension, and memory during the same time periods that drugs were used may 
 57 
indicate that a person was experiencing important constraints on their cognitive abilities (Bechara & 
Martin, 2004; Dreer, DeVivo, Novack, Krzywanski, & Marson, 2008). This may be particularly true if the 
person does not attribute these difficulties to acute drug intoxication.  
During intertemporal choice, it is necessary to weigh benefits against risks across a range of 
options and probabilities, and to consider one’s preferences over time. Impairments in executive control, 
including deficits in comprehension, concentration, and memory can all adversely influence a person’s 
capacity to do this. For example, concentration, which is the attentional process that involves focusing on a 
particular task while also gating non-relevant inputs, is implicated in working memory capacity, defined as 
the coordination of multiple short-term memory systems’ negotiation of attentional control to maintain 
information in a dynamic, readily retrievable fashion (Baddeley, 1992; Engle, 2002). Working memory is 
crucial for decision-making, particularly decision-making that involves risk and uncertainty (Paulus et al., 
2001). Memory impairments self-reported by a person may implicate impairments in multiple other 
cognitive areas, as some of the same networks within the brain concerned with memory are also implicated 
in related functions, such as prospection, autobiographical memories, and counterfactual simulation of 
events, all which can influence a person’s tendency toward present-bias and delay discounting, and their 
ability to make intertemporal choices (Abraham & Bubic, 2015; Schacter, Benoit, De Brigard, & Szpunar, 
2015; Spreng, Mar, & Kim, 2009).  
Incidence of Head Injury 
In addition to these indicators, a history of traumatic brain injury (TBI) or mild traumatic brain 
injury (mTBI) may be an indicator of poorer cognitive function in areas necessary for impulse control, 
emotional regulation, and decision-making (Bechara & Van Der Linden, 2005;  Bogod, Mateer, & 
Macdonald, 2003; Dockree et al., 2006; Fellows, 2006; Kim, 2002). While people with mTBI evidence 
affective and cognitive dysregulation contemporaneous to injury, symptoms often resolve within 3-6 
months (Belanger, Vanderploeg, Curtiss, & Warden 2007; Mayer, Mannell, Ling, Gasparovic, & Yeo, 
2011). However, people with a history of multiple head injuries may exhibit progressive neurocognitive 
degeneration (McKee et al., 2009). Longer-lasting deficits in cognition and behavior related to head injury 
may be expressed in terms of poorer self-regulation, concentration, and decision-making and may, in some 
cases, co-occur with anxiety and depressive symptoms (Arciniegas, Topkoff, & Silver, 2000; Greve et al., 
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2001; Newcombe et al., 2011; Walker, Hiller, Staton, & Leukefeld, 2003). Self-regulation is increasingly 
understood as a causal mechanism in successful intertemporal choice (e.g., not selecting the smaller, sooner 
reward over the larger, future reward), and is associated with frontocortical areas that are especially 
sensitive to head trauma (Figner et al., 2010). Head injuries are also overrepresented among corrections-
involved populations and drug users (Miller et al., 1992; Hestad, Updife, Seines, & Royall, 1995; Walker, 
Staton, & Leukefeld, 2003). Among younger corrections-involved people, higher self-reported rates of 
repeated TBI/mTBI positively correlated with higher rates of repeat offending (Williams, Cordan, Mewse, 
Tonks, & Burgess, 2010). When assessing the effects of drug use on decision-making, self-reported history 
of head injury has been controlled for as a possible confounding variable (Ersche et al., 2005).  
It is possible that people may self-report a history of multiple head injuries in addition to LD 
diagnosis and/or SE enrollment. In assessing TBI/mTBI, LDs and ADD/ADHD are increasingly 
recommended as factors to consider as potential confounders in the assessment process (Elbin et al., 2013; 
McCroy et al., 2009). Similarly, in assessing neurocognitive impairment, LD and ADD/ADHD in young 
people, self-reported mTBI/TBI may be controlled for among other factors (e.g., abuse), underscoring its 
potential impact on cognitive functioning, including memory and concentration (Cicerone, 1996; Raine et 
al., 2005; Walker et al., 2003). It may be that a greater number of these indicators suggests that there are 
multiple factors present with the potential to influence a person’s ability to make decisions involving 
opioids and stimulants. It also suggests that people with more of these indicators may be less enabled to 
deliberate and engage in the types of higher-level cognition needed to minimize risk and make decisions 
that maximize well-being over time, rather than choosing more immediate rewards.  
Vague and Distal, but Potentially Relevant 
Sophisticated, but still coarse-grained, conceptualizations of how multiple distal and proximate 
factors can influence decision-making and behavior are increasingly articulated, even as perfect 
information needed for fine-grained, more precise modeling of human behavior remains inaccessible. 
However, many potential coarse-grained inferences may be made using information about a person’s 
history. Such history can provide indirect clues as to what factors may have influenced cognition, decision-
making, and behavior during particular time periods. Although there are limitations to exploring self-
reported accounts of a person’s life and to examining indirect indicators with the potential to influence 
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decision-making (such as head injury, LD diagnosis, SE enrollment), there is also some merit. The Adverse 
Childhood Events Questionnaire (Felitti et al., 1998) is one example of how the dichotomized presence or 
absence of a set of conditions during childhood can be used to make directional hypotheses about, and to 
help understand, behavioral outcomes in adulthood (Baglivio et al., 2015; Dube et al., 2003; Julian et al., 
2018). Just as the self-reported presence of sexual abuse during childhood increases the odds of observing 
drug use problems in adulthood, so too might self-reported incidence of head injury or SE enrollment be 
used to consider the greater likelihood of observing impaired or high-risk decision-making in adulthood. 
The centrality of such distal, and sometimes imprecise, factors is increasingly made explicit during pre-
sentence investigations and death penalty mitigation defenses (Haney, 2007). Abuse, family interactions, 
mTBI, lead exposure, LD, and poor educational performance in early life are all considered as potentially 
mitigating factors in a person’s later commission of crime (Freedman, 2007; Haney, 1994, 2007). Given 
this precedent, head injury, LD diagnosis, and SE enrollment may be justifiably explored as potential 
influences on decision-making about high-risk drugs, though understood to be limited in what they have 
capacity to approximate and indicate.  
Economic and Social Influences 
Scarcity and Economic Hardship 
Some researchers have proposed that scarcity is a state that changes the way people think and 
behave, including how they prioritize and solve problems, perceive choices, and make decisions (Mani, 
Mullainathan, Shafir, & Zhao, 2013; Shah, Mullainathan, & Shafir, 2012; Shah, Shafir, & Mullainathan, 
2015; Spears, 2011). For people who experience scarcity, problems may appear larger, more urgent, and 
may often require greater attention, emotion, and energy to address--all of which can influence attentional 
control, perception of time, and the ability to make intertemporal decisions that maximize long-term well-
being (Jabs and Devine, 2006; Kahneman, 1973; Karlan, McConnell, Mullainathan, & Zinman, 2016; Shah 
et al., 2012; Zhu & Ratner, 2015). In other words, there is a quality of present-bias among people who are 
resource-scarce. Problems encountered by people who experience scarcity also require greater cognitive 
effort to address, in that trade-offs among limited resources necessitates careful deliberation that is not 
required to the same degree for people with abundant resources (Shah et al., 2012). Deprivation and 
scarcity can also increase cognitive load (e.g., “effort” involved in information processing), which can 
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further constrain a person’s capacity to engage in deliberative thinking during decision-making--a process 
that necessarily involves conceptualizing rewards/costs, weighing uncertainty, and considering preferences 
between a person’s current and future self (Hinson et al., 2003; Kurth-Nelson, Bickel, & Redish, 
2012;Ward & Mann, 2000; Vinoo, Ly, & Soman, 2016). Increased cognitive load has been associated with 
subsequently reduced cognitive capacity, or “bandwidth”, for self-regulation and with the ability to exercise 
“willpower”, both of which can hinder a person’s capacity to make decisions that will maximize overall 
utility, instead of choosing options with the highest local utility (Baumesiter, 2002a; Hofmann, Schmeichel, 
& Baddeley, 2012; Mani et al., 2013; Mullainathan & Shafir 2013; Schilbach, Schofield, & Mullainathan, 
2016). 
For a person who may already be attempting to self-regulate their drug use, by moderating or 
abstaining, ego depletion might also occur, in which sustained efforts at self-control can become partially 
and temporarily depleted (Baumeister, 2014). This temporary depletion in self-control can contribute to an 
increased desire for drugs and a failure to self-regulate when willpower is expended (Baumeister, 2014). 
For instance, a drug user who achieved abstinence in a controlled environment and subsequently reenters 
the community hoping to maintain abstinence, would need to exert considerable planning and self-
regulation. For some, it may be that continued efforts to not use drugs exacerbate the very ability needed to 
not use. When a current or former drug user is living in scarcity, they may experience increased ego 
depletion and cognitive load daily and across a variety of domains (e.g., not buying the sunglasses they 
want because they are too expensive and not shoplifting them due to the potential consequences; inhibiting 
desire to approach the dealer on the block near their house; deciding between buying groceries and paying 
the gas bill; deciding which household member will get to use the car today and who will take public 
transportation; saying “no” to old using friends who want to come over). For someone who is resource 
scarce, all of these seemingly small deliberations and inhibitions can exert a greater cognitive toll, making 
already difficult decision-making more taxing.  
Experiencing poverty and acute economic hardship both include aspects of scarcity. Lower 
earnings and transient periods of economic distress or hardship are associated with greater choice 
polarization, stress response, impaired cognitive functioning, and poorer self-regulation (Bernheim, Ray, & 
Yeltekin, 2015; Fry, Langley, & Shelton, 2017; Hackmam & Farah, 2009; Hunt, 2010; Loibl, 2017; Mani 
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et al., 2013; Nobel, McCandliss, & Farah, 2007; Zhu & Ratner, 2015). Across studies, low-income and 
poverty are associated with increased stress, negative affect, anxiety, depressive symptoms, and diminished 
cognitive capacity and control during decision-making (Green, Myerson, Lichtman, Rosen, & Fry, 1996; 
Santiago, Wadsworth, & Stump, 2011; Haushofer & Fehr, 2014; Spears, 2001; Weich & Lewis; 1998). 
Evidence suggests that it is the state of scarcity that results in suboptimal decision-making and cognition, 
not necessarily the converse (Mullainathan & Shafir, 2013; Shah et al., 2012; Sheehy-Skeffington, 2018). 
One result is that choices with higher local utility, but lower overall utility, are more likely to be made, thus 
potentially reinforcing some sources of scarcity and poverty (e.g., borrowing from a payday lender, 
purchasing lottery tickets, putting off a doctor’s visit, delaying minor repairs that become major repairs 
over time, spending on smaller essential and non-essential goods in the immediate instead of saving) (Bair, 
2005; Clotfelter, Cook, Edell, & Moore, 1999; Mullainathan & Shafir, 2009). Among heroin users, 
decisions have been shown to become more risk-prone as a function of deprivation (Bickel, Giordano, & 
Badger, 2004). Although all people tend to temporally discount, the consequences of this can be 
disproportionately greater among people with fewer resources (Bertrand, Mullainathan, & Shafir, 2004). 
Greater temporal discount rates have also been observed in conditions where people experience acute 
financial hardship or loss (Haushofer, Schunk, & Fehr, 2013).  
Mani et al. (2013) conducted two complementary experiments that help elucidate how low-income 
and financial hardship could potentially influence cognition and inhibitory control. In the first study, the 
authors found that lower-income participants (e.g., $20,000 annual income) and higher-income participants 
(e.g., $70,000 annual income) performed similarly on measures of fluid intelligence and cognitive control 
(inhibition) when randomized to an “easy condition”, in which they were primed by making hypothetical 
financial decisions involving smaller, less significant sums of money. However, when randomized to a 
“hard condition”, in which participants were primed by making hypothetical financial decisions involving 
larger, more consequential sums of money, low-income participants performed worse than high-income 
participants. Specifically, an interaction was observed for low-income + hard condition, whereby lower-
income participants making challenging economic decisions performed poorer than all other groups. This 
study, which controlled for test/math anxiety among other things, was repeated using incentives for correct 
responses and similar findings were observed, with effect sizes for the low-income + hard condition robust 
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across experiments (Cohen’s d 0.88-0.94). In other words, when making high-risk/high-consequence 
decisions, those with the least performed the worst.  
In the second experiment, Mani et al. (2013) found that farmers in India experienced greater 
financial hardship pre-harvest, compared to post-harvest, and that, after controlling for stress, farmer, and 
month fixed effects, there were significant differences between periods of economic hardship (pre-harvest) 
and economic stability/prosperity (post-harvest) on measures of fluid intelligence and cognitive control. In 
a study by Carvalho et al. (2016), a similar “liquidity constraint” on decision-making was found, whereby 
greater present-bias was observed for low-income households tested before payday, rather than after. 
Unsurprisingly, spending was also higher after payday. This finding is consonant with the notion that 
changes in liquidity constraints can account for changes in self-control. It also does not exclude the 
possibility that scarcity itself influences self-control and decision-making, highlighting the need for more 
research in this area.  
Still, taken collectively, there is support for the idea that being low-income is associated with 
poorer cognitive functioning under decision-making conditions, and that transient periods of economic 
hardship and distress are associated with declines in cognitive functioning. Having more unmet needs may 
conceptually correspond to a decision-making pattern referred to as “satisficing”, in which a person tends 
to seek out options with the potential to meet immediate needs (e.g., an available choice with high local 
utility), rather than maximizing utility by seeking out optimal long-term outcomes (Mishra & Lalumière, 
2010; Schwartz et al., 2002; Simon, 1956; Todd & Gigerenzer, 2000). For low-income people, or people 
experiencing financial difficulties, this satisficing tendency may be rational and helpful in the short-term, in 
that it minimizes labor expenditures and, prioritizes “good enough” options over “best solutions”. This 
makes existential sense, of course. Interestingly, satisficing, compared to maximizing, has been found to 
correlate with greater perceived happiness and satisfaction (Schwartz et al., 2002). A related finding 
suggests that while there is a ceiling on the “money equals happiness” correlation ($75,000 annually), 
perceived life satisfaction increases exponentially with income (Khaneman & Deaton, 2010). The 
implication is that people earning less (<$75,000) may be both less happy and less satisfied with their life 
and, as discussed earlier, may experience scarcity mindsets and satisficing tendencies.  
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One decision-making aspect related to income that is of additional interest here is that for opioid 
and stimulant users, increased spending power or relief from transitory economic distress may actually 
increase purchase and use of drugs (Bretteville-Jensen & Sutton, 1996;  Petry, 2000; Greenwald & 
Steinmiller, 2014; Roddy & Grenwald, 2009; Roddy, Steinmiller, & Greenwald, 2011; Shaner et al., 1995). 
This is due to the fact that demand for opioids and stimulants, among regular users of these drugs, can be 
income elastic, meaning that purchases will increase at rates higher than rates of income increase, with 
people demonstrating greater income elastic demand for drugs they prefer, are dependent on, or believe to 
be of higher quality (Goudie,  Sumnall, Field, Clayton, & Cole, 2007; Petry & Bickel, 1998).  
 Many drug users and corrections-involved people experience forms of scarcity, including low-
income and economic hardship (Garland, Wodahl, & Mayfield, 2011; Mulia, Schmidt, Bond, Jacobs, & 
Korcha). Further, because using a drug can serve an immediate need, and may assume a form of satisficing, 
but because the distributed choice of repeated drug use can be suboptimal or devastating, a scarcity mindset 
or satisficing tendency may be problematic. It is therefore important to consider how factors in a person’s 
life, such as income and economic distress, might be understood in terms of scarcity, but also how they 
may function to influence drug-related decision making in other ways, such as providing greater or lesser 
drug purchasing power.  
Community-wide Scarcity and Harsh Environments 
Scarcity of flexible resources and socioeconomic disparities may also be observed at the level of 
neighborhood, community, county, or region. For instance, some areas enjoy greater economic prosperity 
than others, whereby there are more households with higher earnings and fewer households living in 
poverty (Brown & Hirschl, 1995; Thorne, Tickamyer, & Thorne, 2004). Regional poverty and regional 
economic inequality are both associated with regional crime, violence, social mistrust, poorer self-rated 
health, and higher rates of non-natural and premature morbidities and mortalities, including higher infant 
mortality rates (Blakely, Lochner, & Kawachi, 2002; Graif, Gladfelter, & Matthews, 2014; James & 
Cossman, 2006; Hsieh & Pugh, 1993; Patterson, 1991; Santiago et al., 2011; Sparks, McLaughlin, & 
Stokes, 2009; Wilkinson & Pickett, 2009; Yen & Kaplan, 1999). Such environments are defined as “harsh” 
by Frankenhuis et al. (2016), who suggest that people living within such harsh places cannot develop a 
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sense of certainty about their lives or futures, and that such uncertainty changes their cognition. 
Frankenhuis et al. (2016) note that: 
In such conditions, present-orientation may be adaptive. This orientation can psychologically 
manifest in: first, vigilance used to detect threats and opportunities, second, impulsive reactions 
(little deliberation) in order to respond quickly; and third, steep future discounting to motivate the 
capture of immediate benefits, as future rewards are less likely to be cashed in” (pg.77).3   
In other words, growing up or living in high-stress, high-mortality, low-resource, and uncertain 
conditions may contribute to a person being more present-biased, in which they will discount the future at 
higher rates, and potentially take more risks when it comes to securing immediate rewards (e.g., sex, food, 
drugs) or avoiding perceived harms (Griskevicius et al., 2013; Griskevicius, Tybur, Delton, & Robertson, 
2011). 
Evidence has shown that both lower-income areas (e.g., neighborhoods, counties, regions) and 
areas with greater economic inequality have high associated rates of morbidities and mortalities, meaning 
that such counties can be considered as “harsh”, using criteria proposed by Frankenhuis and colleagues 
(2016) (Cheng & Kindig, 2012; Franzini, Ribble, & Spears, 2001; Huynh, Parker, Harper, Pamuk, & 
Schoendorf, 2005; McLaughlin & Stokes, 2002; Muramatsu, 2003). The implication is that people living 
within those areas would be expected to be more present-biased and risk-taking.  
Subjective Socioeconomic Comparison and Stress  
Scarcity, however, is not limited to economic circumstances. People may experience scarcity 
across flexible resources, which are resources that are dynamic, valuable, and applicable across situations 
(Phelan, Link, & Tehranifar, 2010). In addition to money, these resources might include time, knowledge, 
education, and status, closely associated with power, defined here as “asymmetric control over valued 
outcomes and resources” (Joshi & Fast, 2014; Phelan et al., 2010). People who have fewer of these 
resources and, more importantly, who perceive themselves as having fewer of these resources in relation to 
others in society, often experience greater subjective stress, poorer physical and psychological health, and 
3 Vis-à-vis evolution; in terms of biological fitness, not in terms of more adaptive health or well-being. 
Indeed, health and well-being, in the immediate and long-term, may actually decrease in order to better 
ensure transmission of genes under such conditions.  
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greater impulsiveness/decreased self-regulation (Adler, Epel, Castellazzo, & Ickovics, 2000; Kessler & 
Cleary, 1980; Marmot, 2004; Singh-Manoux, Marmot, & Adler, 2005).  
Lower subjective social status, experiencing social isolation as a result of lower status, and 
encountering others that one feels subordinate to, particularly when the socially dominant other is 
encountered in a domain that they control (i.e., social defeat; e.g., the boss at work, a wealthy customer’s 
home, probation/parole officer), may all result in increased stress response, defined as the body’s 
physiological reaction to a real or perceived stressor that has the potential to influence health, cognition, 
and behavior (Adler, Epel, Castellazzo, & Ickovics, 2000; Abbott et al, 2003; Cole, Logan, & Walker, 
2011; Covington & Miczek, 2005; De Kloet, Joëls, & Holsboer, 2005; Koob, 2009; McEwen & Gianaros, 
2010; Sapolsky, Alberts, and Altmann, 1997; Selye, 1975, 1998). Conversely, people who have, or 
perceive themselves to have, more relative power, resources, and status have been shown to have better 
health and to exhibit heightened executive functioning, abstract reasoning, and increased goal-directed 
focus (Overbeck & Park, 2006; Smith, Dijksterhuis, & Wigboldus, 2008; Smith & Trope, 2006; Wilkinson 
& Marmot, 2003).  
Among non-human animals, higher social rank and social dominance have been associated with 
less alcohol, cocaine, and opioid consumption, whereas lower and/or marginalized social status is 
associated with increased drug-taking (Heilig, Epstein, Nader, Shaham, 2016; Kuhar, 2002; McKenzie-
Quirk & Miczek, 2008; Nader et al., 2012; Wolffgramm & Heyne, 1995). Pre-clinical models examining 
hierarchical status, social defeat, and drug use have found that cocaine serves as a behavioral reinforcer in 
subordinate, but not higher-ranking primates (Covington & Miczek, 2005; Morgan et al., 2002; Nader et 
al., 2006), that rats increase alcohol, cocaine, and cocaine + heroin self-administration following social 
defeat or exposure to social stress (Caldwell & Riccio, 2010; Cruz, Quadros, Hogenelst, Planeta, & Miczek, 
2011), and that morphine- and cocaine-induced place preference is reinstated following exposure to various 
stressors, including social stressors (Do Couto et al., 2006; Do Couto, Aguilar, Lluch, Rodríguez-Arias, & 
Miñarro, 2009). Among non-human primates, holding a lower rank in the social hierarchy is also associated 
with higher stress (at resting levels, as measured by glucocorticoids), whereas higher rank, particularly in 
stable social hierarchies, is associated with the converse, and with greater cortical integration and coupling 
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(Gesquiere et al., 2011; Noonan et al., 2014; Sapolsky, 2017; Sallet et al., 2011)4. Increasingly, addiction 
researchers are emphasizing the importance of modeling social stressors, including low social status, in 
terms of how they may influence drug-taking (Heilig et al., 2016).  
Relative to decision-making, the importance of real or perceived higher social status is 
summarized in part by Joshi & Fast (2014) who state that, “Power activates a high-level construal 
orientation (Magee, Milliken, & Lurie, 2010; Smith, Dijksterhuis, & Wigboldus, 2008; Smith & Trope, 
2006). High-level construal expands temporal horizons (Troupe & Liberman, 2010), which results in the 
perception of the distant future as being closer and imminent and induces a sense of connection with the 
future self (Kantan, 2011)”. One implication is that people who have a lower perceived social rank are 
more likely to be present-biased, and therefore potentially more likely to temporally discount future 
rewards for smaller, immediate ones. Another implication is that people with real and perceived lower rank 
are, in general and without acute provocation, more physiologically aroused and “stressed” than higher 
ranking, more powerful people. This, as noted before, impairs cognitive ability. Corrections-involved drug 
users may subjectively perceive themselves as having an equal status to others in society. However, this 
should not be assumed, due to the fact that drug users and corrections-involved people are highly 
stigmatized and socially devalued in the US (Barry et al., 2014).  
In sum, experiencing forms of resource scarcity, such as economic distress or having a lower 
subjective social rank, along with living in a “harsh” region that fosters a sense of uncertainty about the 
future, all have the potential to influence cognition and high-risk decision-making. This is because all of 
these factors are associated with increases in stress response and temporal discounting, and with decreases 
in capacities needed for future-orientation, self-regulation, and other higher-level cognition (Bartels & 





4 Cortical integration or coupling is relevant to note due to the fact that it indicates what might be 
considered a “healthy brain”. That is, a brain better equipped for cognitive flexibility and higher-level 
cognition, including working memory, attention, emotional regulation, abstract thinking, impulse control, 
valuation, etc.  
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Stress, Psychiatric Symptoms, Pain, and Misregulation 
Stress-related Health Effects 
Although stress response can be immediately adaptive, in terms of increasing a person’s capacity 
to respond to threats and facilitating memory consolidation of specific threats, it disrupts homeostatic 
functioning and increases allostatic load, which has significant deleterious short- and long-term effects 
including impaired memory and cognition, fatigue, pain, lowered immunological function, affective 
dysregulation, elevated blood pressure, and premature mortality (Arnsten, 2000; Boyce, 2004; Chattarji, 
Tomar, Suvrathan, Ghosh, & Rahman, 2015; De Kloet et al., 2005; Goymann & Wingfield, 2004; Juster, 
McEwen, & Lupien, 2010; Lupien, Maheu, Fiocco, & Schramek, 2007; Lupien, McEwen, Gunnar, & 
Heim, 2009; McEwen, 1998, 2009; Sapolsky, 2004, 2005; Sapolsky, Alberts, & Altmann, 1997). In a 
variety of human and non-human studies, chronic stress, acute stress exposure, self-reported stress, and 
greater stress reactivity, have been associated with craving, addiction, and relapse to drugs, including 
opioids and stimulants (Back et al., 2010; Garland, Franken, & Howard, 2012; Kennedy et al., 2015; Leri et 
al., 2004; Preston et al., 2017; 2018; Sinha , 2001,2008; Sinha & Jastreboff, 2013; Sorge, Rajabi, & 
Stewart, 2005). Taken together, these findings suggest that people who experience stress (if only ever 
physiologically and not psychologically) may be influenced to use drugs, use them at higher rates, and 
resume use (e.g., lapse, relapse) during periods of greater stress.  
Chronic exposure to stress is also associated with insensitivities to changes in outcomes and with 
behaviors that are more habituated and rigid (and therefore less goal-directed) (Dias-Ferreira et al., 2009; 
Liston et al., 2006; Schwabe & Wolf, 2009, 2011; Soares et al., 2012). This is problematic, in that decisions 
involve contingencies. Imagining and deliberating various contingencies requires higher-level cognitive 
functioning and flexibility, including the capacity to utilize available information, generate abstractions, 
and initiate behavioral change in response to outcome change. For example, if someone was informed that 
instead of their next positive drug screen resulting in a one-week jail sanction it resulted in a 4-year prison 
term, a person would need to be able to attend to, understand, and envision these possibilities. They would 
also need to have the requisite cognitive flexibility for modifying decision-making patterns and behavior in 
light of this information. When decisions involve uncertainty, which is often the case during intertemporal 
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choice involving drugs, stress and stress-related health effects can increase, potentially further hindering the 
decision-making process (Morgado, Sousa, & Cerqueira, 2015; Peters, McEwen, & Friston, 2017). If a 
person’s life is characterized by uncertainty, as many corrections-involved drug users’ lives are, then stress 
may generally be higher.  
Interestingly, for some drug users, and for some people with subclinical psychopathy, 
underactivation rather than overactivation of visceral states (e.g., such as increased heart rate, stomach 
upset, perspiration) or “somatic markers” can adversely impair decision-making, in that the “cues” needed 
to help anticipate reward and punishment are inadequate or absent (Bechara & Damasio, 2002; van Honk, 
Hermans, Putman, Montagne, & Schutter, 2002). Thus, there is no reason to believe that there is complete 
homogeneity across drug users who are resource-scarce or who have been exposed to stressors in terms of 
how they are cognitively or behaviorally influenced by these states. Identifying the presence of health-
related stress symptoms, that include somatic as well as psychological indicators, during a given time 
period may be one way to discern if cognitive states are being adversely influenced by stress response. 
Psychiatric Symptoms 
In addition to the slower, deliberative, and higher-level cognition necessary for decision-making 
discussed earlier, faster, automatic cognition also facilitates adaptive decision-making (Evans, 2008). 
Emotions, or feeling states, can help a person intuit, reason, and make decisions, in part through viscera or 
somatic signals that steer them away from danger and risk (Bechara & Damasio, 2002; Damasio, 1994, 
2012). The somatic marker hypothesis posits that while decision-making is a process that often requires 
conscious, deliberative cognition, it is also a process facilitated by unconscious physiological states and 
their emotional referents (Bechara & Damasio, 2005).  
As with stress, feeling states--spanning affect, mood, and somatization---including those 
characteristic of anxiety and depressive disorders--can impair neurocognitive function, including working 
memory, attention, interoceptive accuracy, time perception, and risk assessment, thus influencing decision-
making processes (Darke, 1988; Dias-Ferreira et al., 2009; Furman et al., 2013; Gohier et al., 2009; Harvey 
et al., 2004; Marazziti, Consoli, Picchetti, Carlini, & Faravelli, 2010; Nebes et al., 2000; Schulz & Vögele, 
2015; Schwabe & Wolf, 2013; Scott et al., 2015; Shackman et al., 2006; Wittmann & Paulus, 2008). For 
instance, heightened emotional arousal corresponds to affective, rather than deliberative, decision-making, 
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which is associated with faster, simplified decision-making, risk-taking, and delay discounting (Figner, 
Mackinlay, Wilkening, & Weber, 2009; Figner & Weber, 2011). This makes some sense, in that affective, 
automatic/associative cognition is less effortful and demanding than deliberative reasoning and behavioral 
inhibition (Sanfey & Chang, 2008). But it is important to note that emotional states are not, as a rule, 
unhelpful during decision-making, given that the ability to make decisions relies heavily on emotion 
(Bechara & Damasio, 2005). Rather, it is important to understand that emotional states and psychological 
disorders have the capacity to alter cognition and decision-making processes. 
For instance, time perception can be influenced by affective states. During depressive episodes, 
people can experience time passing more slowly, whereas people in manic or anxious states may perceive 
time passing more quickly; all of which can influence attention, present-bias, and delay discounting, 
thereby increasing the probability of suboptimal decision-making (Bschor et al., 2004; Murphey et al., 
2001; Zauberman, Kim, Malkoc, & Bettman, 2009). Although investigations have examined how emotions 
common to psychiatric disorders, such as anxiety and depression, influence decision-making, the evidence 
is mixed (Paulus & Yu, 2012; Seymour & Dolan, 2008). For instance, some data suggest that anxiety-prone 
individuals are more risk averse and demonstrate biased attention to possible threats (Dugas, Gagnon, 
Ladouceur, & Freeston, 1998; MacLeod & Mathews, 1988; Maner et al., 2007). Although Rounds et al. 
(2007) found impulsive choice increased following increased exposure to social anxiety, this finding was 
not replicated (Jenks & Lawyer, 2015).  
People with depression have been shown to be less biased toward and responsive to reward, to be 
less accurate in evaluating outcome probabilities, and to experience more conflict during decision-making 
(Cella, Dymond, & Cooper, 2010; Elliott et al., 1996; Han et al., 2014; Harlé, Allen, & Sanfey, 2010; 
Lempert & Pizzagalli, 2010; Murphy et al., 2001; Pizzagalli, Bogdan, Ratner, & Jahn, 2007; Rubinsztein, 
Michael, Underwood, Tempest, & Sahakian, 2006; Smoski, et al., 2008; van Randenborgh, de Jong‐Meyer, 
& Hüffmeier, 2010). People with depressive symptoms are believed to have enhanced somatic markers for 
negative, but not positive stimuli, making punishment learning potentially more rapid and biasing them 
toward risk aversive decisions (Smoski, et al., 2008). However, during experimentally induced emotional 
states, Raghunathan & Pham (1999) found that people in the “sad” condition were biased toward high-
risk/high-reward decisions, whereas people in the “anxious” condition were biased toward low-risk/low 
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reward options. Further, among a sample of people with major depressive disorder (MDD), participants 
with MDD discounted rewards at steeper rates and were insensitive to increases in reward changes (Pulcu 
et al., 2013), which is in keeping with the finding of higher discount rates among depressed participants 
with and without suicidal ideation and previous suicide attempts observed by Dombrovski et al. (2011). 
Feelings of hopelessness and detachment from one’s future have been proposed as possibly contributing to 
temporal discounting (Pulcu et al., 2013). In other words, for a person without resonant connection to their 
future self, it may be easier to discount their future self’s preferences.   
Paulus & Yu (2012) conclude that, overall, findings suggest both trait-like (i.e., related to 
psychiatric disorder) and state-like (i.e., internal state and mood) decision-making dysfunction in relation to 
anxiety and depression. This means that both transient affective or mood states, as well as more enduring or 
reoccurring psychiatric disorders (which can, of course, still include these states), have the potential to 
influence decision-making. Anxiety and depressive symptoms are highly prevalent among both opioid and 
stimulant users (Grant et al., 2004; Merikangas et al., 1998). Given that drug use can impair brain areas 
associated with emotional processing and self-regulation, and given that abstinence can induce anxiety and 
depressive symptoms, it is possible that both active and abstinent drug users may experience affective and 
mood states that influence decision-making (Fernández-Serrano, Lozano, Pérez-García, & Verdejo-García, 
2010; Verdejo-García, Rivas-Pérez, Vilar-López, & Pérez-García, 2007). However, because findings are 
preliminary and inconclusive, more work is needed to understand the associations between anxiety and 
depressive disorder symptoms and high-risk decision-making and behavior, including the use of opioids or 
stimulants. Nevertheless, symptoms related to anxiety and depression might still be explored as possible 
influences on decisions to use high-risk drugs, as the presence of negatively valanced states may influence 
decision-making in other ways, as will be discussed subsequently.  
Chronic Pain  
Chronic pain is defined here as a condition in which “signals triggered by aversive stimuli and/or 
damaged tissue persist over time, beyond their normal duration” (Yoris et al., 2018). Typically, pain that 
persists for three or more months may be considered as chronic (Cleeland & Ryan, 1994). Chronic pain 
conditions, which often have high prevalence rates among people who are older, have fewer resources, 
SUD history, and corrections-involvement, can also potentially influence decision-making (Dunn, Brooner, 
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& Clark, 2014; Dunn, Finan, Tompkins, Fingerhood, & Strain, 2015; Johannes, Le., Zhou, Johnston, & 
Dworkin, 2010; Reingle-Gonzalez, Walters, Lerch, & Taxman, 2015; Rosenblum et al., 2003; Sapolsky, 
2004, Kristenson et al., 2004; Mallik-Kane & Visher, 2008; Smith et al., 2019). People who experience 
chronic pain have been shown to have impaired cognitive function and impaired decision-making, as 
indicated by poorer performance on decision-making simulations compared to healthy controls (Apkarian 
et al., 2004; Elvemo, Nilsen, Landrø, Borchgrevink, & Håberg, 2017; Landrø et al., 2013; Walteros et al., 
2011). 
Ordinarily, a multitude of physiological reactions occur prior to and during decision-making, both 
automatically and unconsciously, as well as consciously in the form of emotions or feeling states which, as 
noted earlier, can help guide learning, decision-making, and behavior (Bechara & Damasio, 2005; 
Berridge, 2007; Van den Bergh, Zacharioudakis, & Petersen, 2018). Recall that, as explained by dual 
process models of cognition, decision-making relies on more than one type of cognition (i.e., a variety of 
automatic, more visceral signals, and deliberative, higher-level cognitive functions), and that choice 
involving uncertainty is more cognitively demanding than choice with certainty and choice associated with 
habituation (Damasio, 1994; Evans, 2008). During complex tasks, such as intertemporal choice, cognitive 
systems may work together, rather than in explicit “competition” (Monterosso & Luo, 2010). Recall, too, 
that physiology and “feeling states” guide decision-making so as to improve adaptation and performance 
amidst uncertainty, ambiguity, and change (Bechara & Damasio, 2005; Damasio, 1994). Consider, for 
instance, the usefulness of disgust as an emotional state in the avoidance of spoiled food or refuse (Curtis, 
De Barra, & Aunger, 2001; Nesse, 1994). Consider, too, the usefulness of fear. When faced with perceived 
threat, pupils dilate to improve sight and to signal arousal, heart rate increases to pump needed blood to the 
body’s muscles for movement, and glucocorticoid production increases, readying the body for swift action 
and the consolidation of memory around threat (Clinchy, Sheriff, & Zanette, 2013; Leuchs, Schneider, 
Czisch, & Spoormaker, 2017; Mobbs et al., 2009; Neese, 1994; Perry et al., 1995; Schaefer, Larson, 
Davidson, & Coan, 2014; Sapolsky, 2003; Schulkin, Morgan, & Rosen, 2005). This state may indeed 
become interpreted as fear and associated with anxiety; however, the phenomenology of such states could 
also be appraised as excitement and associated with pleasure (Garfinkel & Critchley, 2016). Thus, a 
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person’s ability to accurately sense, detect, identify and appraise somatic states is important to decision-
making and behavior (e.g., one may “avoid” due to fear and “approach” due to excitement).  
Skin conductance response (SCRs), or electrodermal response, is one type of physiological 
reaction or “somatic marker” that occurs quickly and in response to arousing endogenous or exogenous 
stimuli (Dawson, Schell, & Courtney, 2011; Lykken & Venables, 1971). SCRs can help guide and optimize 
decision-making via anticipatory signaling, as evidenced by the graded relationship between SCR and other 
somatic marker signaling prior to choice, wherein people with weak or no signaling are more likely to 
make the riskiest choices (Crone, Somsen, Beek, & Van Der Molen, 2004). Evidence indicates that people 
with chronic pain are impaired in anticipatory SCR generation before making unfavorable outcomes 
(Elvemo et al., 2014). People who experience chronic pain have also been found to have less cortical 
volume in areas related to decision-making, emotion, and reward compared to healthy controls (Elvemo et 
al., 2014; Smallwood et al., 2013). Apkarian et al. (2004) propose that “chronic pain should be considered a 
‘cognitive state’ ….[that] may be competing with other cognitive abilities”, including emotional regulation, 
risk-assessment, inhibition, and decision-making, due to the preferential recruitment of the prefrontal cortex 
in chronic pain (Apkarian et al., 2001a-c; Apkarian et al., 2002). Still, such findings should be interpreted 
with caution, due not only to their correlational nature, but also due to the fact that differences in some 
neural areas associated with chronic pain vary by sex and potentially other factors as well (Gupta et al., 
2016).  
More generally, though, a variety of chronic pain conditions are associated with reductions in 
interoceptive sensibility, the ability to consciously detect and “make sense of” physiological changes, and 
with interoceptive accuracy, the ability to reliably detect interoceptive signals, with an inverse correlation 
observed between pain symptom severity and interoceptive accuracy (Borg et al., Di Lernia et al., 2016; 
Duschek, Montoror, & Reyes del Paso, 2015; Farb & Logie, 2018; Mehling et al., Pallatos et al., 2011). 
Findings cautiously interpreted from preliminary work suggest the possibility that people who experience 
chronic pain may also encounter disruptions in cognition, emotional regulation, and decision-making as a 
result of disruptions in interoceptive sensibility and accuracy (Dunn et al., 2010; Füstös, Gramann, Herbert, 
& Pollatos, 2012).  
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Of additional interest here is that some burgeoning research suggests that stimulant dependent 
people may have increased or hyperinteroceptive accuracy (de la Fuente et al., 2019). It may be, too, that 
other drug use is associated with hyperinteroceptive accuracy, or with hypointeroceptive accuracy. 
Ultimately, interoceptive signaling that helps inform decision-making may become disrupted from drug use 
(Bechara & Damasio, 2002). However, some findings suggest that while opioid users evidence poorer 
decision-making, it may not be due to lower SCRs. For instance, Biernacki et al., (2018) found no 
differences in SCR between opioid users and non-users. Contrary to other findings, opioid users who 
evidenced emotional reactivity on par with healthy controls, and who were found to have higher 
anticipatory SCR than controls, still made significantly risker decisions (Biernacki et al., 2018). This 
suggests that even when somatic markers are present, drug users may have deficits in interoceptive 
awareness (i.e., the metacognitive awareness of accurately detecting somatic states) needed to clarify 
feeling states, consider their significance, and use them to guide choice (Craig, 2002). In other words, the 
signal is there, but not being adaptively “picked up” or interpreted.  
Considering how chronic pain may influence decision-making, as a result of altered somatic 
marker signaling or impaired interoception is just one of several ways that chronic pain might influence 
decision-making in relation to high-risk drugs, particularly opioids. Unsurprisingly, chronic pain is 
associated with increased odds of illicit opioid and other drug use, including use among corrections-
involved people (Alford et all, 2016; Cole & Logan, 2010; Hall et al., 2016; Prater, Zylstra, & Miller, 2002; 
Vowles et al., 2015). In addition to chronic pain potentially influencing risk-taking and decision-making, 
via impaired somatic markers as described above, chronic pain may influence the perceived utility of 
opioids due to their analgesic properties and may increase the likelihood that a person might choose to use 
of these drugs despite associated risks (Volkow & McLellan, 2016). In other words, being in a state of pain 
can motivate behaviors believed to mitigate pain or increase pleasure (Leknes & Tracey, 2008).  
People with pain conditions who also have a history of SUD and/or who are receiving MAT are 
often undertreated for their pain, meaning that illicit use of opioids may become an appealing option 
(Baldacchino, Gilchrist, Fleming, & Bannister, 2010; Dunn et al., 2014; Hines, Theodorou, Williamson, 
Fong, & Curry, 2008; Jamison, Kauffman, & Katz, 2000; Karasz et al., 2004; Rosenblum et al., 2003). 
Motivation to use opioids to alleviate pain does not suggest that people who choose to take opioids to 
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address pain, licitly or illicitly, would not also be influenced by other factors, such as negative affective 
states or craving (Butler, Fernandez, Benoit, Budman, & Jamison, 2008; Garland, Brown, & Howard, 2016; 
Havens et al., 2009; Martel, Dolman, Edwards, Jamison, & Wasan, 2014; Martel, Jamison, Wasan, & 
Edwards, 2014; Tsui et al., 2016). Though some evidence suggests that pain severity does not necessarily 
correlate with opioid craving (Martel et al., 2016). Put differently, the local utility, or relative value, of 
opioids could increase due in part to a person’s chronic pain, but chronic pain may not be the only factor 
influencing how opioids are valued.  
Misregulation  
 As noted earlier, neurobiological changes from drug use can make people potentially less able to 
engage in the kind of self-regulation and higher-level cognition (e.g., prospection, deliberation, inhibition, 
cognitive reappraisal, mindfulness) needed to mitigate or “reframe” negatively valanced states 
(Baldacchino et al., 2012; Bechara, 2003; Buhle et al., 2014; Bush, Luu, & Posner, 2000; Hoffman & Vohs, 
2016; Schoenbaum, Roesch, & Stalnaker, 2006). However, not all decisions to use high-risk drugs can be 
considered as a failure to cognitively reframe or self-regulate, or as a temporary deficit in willpower (e.g., 
ego depletion). People may choose to use drugs in what they may perceive to be pragmatic ways. These 
could include using as means to improve mood, cope with stress, anxiety, or depression, reduce pain, 
mitigate drug-related harms, lose weight, or to increase endurance and performance (Alford et al., 2016; 
Assanangkornchai, Muekthong, Sam-Angsri, & Pattanasattayawong, 2007; Baumeister et al., 1994; 
Conklin & Perkins, 2005; Daniulaityte, Carlson, & Kenne, 2006; Greely et al., 2008; Levine et al., 2010; 
Kopetz, Woerner, & Briskin, 2018; O’Connor & Berry, 1990; Smith & Lawson, 2017; Tice, Bratslavsky, & 
Baumeister, 2001). Such choices, when they have a high local but potentially low overall utility, can be 
conceptualized as misregulation, a self-regulation failure that includes attempted control or regulation, but 
in a way that fails to achieve the desired longer-term outcome (Baumeister et al., 1994; Baumeister & 
Heatherton, 1996). For instance, a person may intend to moderate or discontinue their drug use, but may 
still use, “lapsing” or “relapsing”, not due to a self-regulatory failure, but rather due to choosing to use 
drugs to cope with negatively valanced states. As noted throughout this discussion, states and contexts can 
influence a person’s cognition and decision-making capacities. They can also influence the relative value of 
opioids and stimulants, with value attributable to potentially multiple factors (e.g., taking opioids to 
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simultaneously achieve a feeling of euphoria, to cope with stress, and to blunt lower back pain so as to be 
able to function at work and remain employed) (Redish, Schulheiss, & Carter, 2015). Misregulation is in 
harmony with the concept of satisficing and is also consonant with the idea that drug use may have a high 
local utility and may be rational for someone experiencing stressful or painful states, even as overall utility 
still decreases (Kopetz et al., 2018; Rachlin, 1997). In exploring high-risk drug use, it is important to 
understand if people making decisions to use drugs are doing so in part to reduce unpleasant states. 
Identifying such influence on decision-making has some practical implications, insofar as tendencies 
toward misregulation may be more amenable to intervention compared to other influences.   
Access to Drug Markets and the Costs of Using 
As discussed earlier, the area that a person lives in can influence a person’s perception of risk and 
their decision-making capacities. Importantly, it can also determine what drugs are available or more 
readily accessible, along with some of the costs associated with acquiring them. Costs can be measured in 
terms of money, time, effort, and opportunity cost (e.g., money spent on heroin cannot also be money spent 
on rent, time spent obtaining heroin is not time spent with children) (Bickel et al., 2014; Caulkins & Reuter, 
2004). Indeed, regions can sometimes differ considerably in terms of drug availability (e.g., drug type, 
number of different suppliers, time required to acquire drug), all of which can influence demand and 
consumption (Roddy & Greenwald, 2009; Taylor et al., 2011). This can include differences in accessibility 
of alcohol (e.g. “dry” versus “wet” counties), illicit drugs, and drugs that can be obtained via prescription 
(Cicero, Surratt, Inciardi, & Munoz, 2007; Cox, Motheral, Henderson, & Mage, 2003; Furst, Herrmann, 
Leung, Galea, & Hunt, 2004; Rigg & Monnat, 2015; Webster, Pimentel, & Clark, 2008).  
Differences in drug availability and cost may be attributable to features of a geographic location 
that impact drug distribution networks and the burden of drug acquisition (e.g., proximity to metro areas, 
highway systems, “pill mills”, pain clinics, MAT providers, etc.), but may also be attributable to variability 
in the demographic and health characteristics of a region’s population (Coleman, 2012; Furst, 2004; 
Paterline, 2013; Inciardi, Surratt, Cicero, & Beard, 2009; Inciardi, Surratt, Kurtz, & Burke, 2006). For 
example, areas densely populated with older, disabled, or chronically ill people may provide more 
opportunities for diversion of prescription drugs into illicit markets (Green et al., 2013; Inciardi et al., 2009; 
Rigg, Kurtz, & Surratt, 2012). Appalachian and rural areas in Kentucky have had historically high rates of 
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disability, cancer, and chronic health conditions, as well as rates of opioid prescribing and diversion that 
rank among the highest in the nation (Inciardi, Surratt, Lugo, & Cicero, 2007; Luu et al., 2018; Social 
Security Administration, 2016; Wilson, Ryerson, Singh, & King, 2016). Since greater exposure to drugs is 
positively correlated with increased likelihood for misuse, the ambient level of a given drug in accessible 
markets, including licit prescription drugs, is important to consider as a possible influence on drug-related 
decisions (Cicero et al., 2007; Daniulaityte et al., 2006). Indeed, prescription drugs provide considerable 
opportunity for diversion and use for a variety of drug classes, including stimulants (McCabe, Teter, & 
Boyd, 2006). In one study Daniulaityte et al. (2009) found that prescription tranquilizer and prescription 
stimulant use were the strongest predictors of prescription opioid use. Steep increases in drug prescribing in 
the 1990s and 2000s contributed to subsequent increases in prescription drug diversion and misuse (Inciardi 
& Cicero, 2009).  
For categorically illicit drugs, if a person lives in a place where there is a decreased availability of, 
say, cocaine, but an abundance of methamphetamine, then not only would the price of cocaine be expected 
to be higher and the price of methamphetamine lower, but additional costs associated with the acquisition 
of cocaine, in terms of labor and opportunity costs, would also be expected to increase (Kleiman, 1992). 
Drug preferences and the rewarding effects of drugs are important to consider here. Numerous pre-clinical 
studies have documented that the rewarding effect of a drug is positively correlated with learned behavioral 
responses, indicating increased willingness to work to obtain the drug (Everitt & Robbins, 2005). This 
means that people will be likely to spend more money and work harder for drugs associated with greater 
reward (and less punishment), or which are preferred relative to other drug choices (Herrstein, 1961, 1970; 
Katz, 1990). 
It is also consonant with the idea of own-price elasticity of demand, which is the variation in 
demand to a commodity in response to variation in price (Bickel et al., 1992)5. Demand may be elastic, 
wherein increases in price significantly decrease consumption (e.g., a 35% price increase for OxyContin 
pills results in a 70% reduction in OxyContin pill purchases), or demand may be inelastic, wherein 
increases in price may only result in marginal decreases (e.g., a 35% price increase of OxyContin pills 
results in a 9% reduction in purchases). Heroin and cocaine are two specific drugs with price inelastic 
5 Understood to be holding other factors constant. 
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demand, though demand and consumption is still responsive to fluctuations in price (e.g., at some cost they 
would be unattainable) (Bretteville-Jensen & Sutton, 1996; Bretteville-Jensen & Biørn, 2003; Gallet, 2014; 
Olmstead, Alessi, Kline, Pacula, & Petry, 2015; Roddy & Greenwald, 2009; Saffer & Chaloupka, 1999). If 
cocaine was a person’s preferred drug, then demand for cocaine for this person would be expected to be 
more inelastic. The person would be more likely to expend greater effort and resources to obtain cocaine 
should costs increase, with only very extreme or prohibitive costs modifying consumption. For some 
people with strong drug preferences, decisions to use their preferred drug may persist over time, 
irrespective of broader drug trends and fluctuations in price or availability (Brecht, Huang, Evans, & Hser, 
2008; Falck, Wang, & Carlson, 2007). In addition to paying higher prices in local drug markets to acquire a 
preferred drug, a person might expend more effort (e.g., driving greater distances to purchase it), or might 
try accessing the drug on bourgeoning avenues such as the Internet and Deep Web (Gilbert & Dasgupta, 
2017; Kassab & Rosen, 2019; Quintana Mathé et al., 2017).   
However, a person who prefers cocaine might also choose to substitute it with other drugs. These 
could include drugs with stimulant properties (e.g., amphetamines, cathinones), but could also include 
drugs with dissimilar pharmacology, but for which the associated costs are less than that of cocaine. In 
other words, changes in costs associated with one drug affect the consumption of others (i.e., cross-price 
elasticity of demand) (Bickel et al., 1995). For instance, following increased restriction of 
methamphetamine precursors in the US, methamphetamine cost temporarily rose, purity declined, and rates 
of methamphetamine-related service utilization and arrests decreased, while rates of cocaine use increased 
in some, but not all local drug markets (Borders et al., 2008; Cunningham, & Liu, 2003, 2005, 2008; 
Dobkin, & Nicosia, 2009; McKetin, Sutherland, Bright, & Norberg , 2011.  
For people who prefer or frequently use heroin and cocaine concomitantly, (e.g., “speedballing”), 
it is conceivable that as demand for cocaine decreases due to increased price that heroin demand would also 
decrease (Ball & Ross, 1991; Leri, Bruneau, & Stewart, 2003). For this group, heroin and cocaine could be 
considered as compliments rather than substitutes, meaning that they are co-used with regularity and can be 
considered concurrent reinforcers (Bickel, DeGrandpre, & Higgins, 1995). For instance, alcohol and 
cocaine and nicotine and caffeine have been considered as compliments, demonstrating concurrently 
reinforcing effects and negative cross-price elasticity of demand (Bickel, Hughes, De Grandpre, Higgins, & 
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Rizzuto, 1992; Carrol, Rousaville, & Bryant, 1993; McCance-Katz et al., 1993). Again, it may be that 
cocaine is simply substituted for another stimulant, such as methamphetamine (e.g., “goofballing”), or that 
demand for heroin is independent, with changes in cocaine prices not resulting in commiserate changes in 
heroin demand and consumption. Research has demonstrated, though, that polydrug users are willing to 
substitute drugs across drug classes, even as drugs such as heroin and cocaine have demonstrated inelastic 
demand among regular users (Olmstead et al., 2015; Petry, 2001; Sumnall, Tyler, Wagstaff, & Cole, 2004).   
 Over the last decade, drug substitution has occurred en masse. Many prescription opioid users 
began purchasing heroin as prescription opioid supply decreased, prices increased, and abuse-deterrent pill 
formulations proliferated (Evans et al., 2018; Compton et al., 2016; Mallatt, 2017; Mars et al., 2014; Peavy 
et al., 2012; Rutkow et al., 2015). One result has been increased heroin demand, greater availability, lower 
prices, and increased consumption (Cicero, Ellis, Surratt, & Kurtz, 2014; Kanouse & Compton, 2015; 
Kilmer et al., 2014). Additionally, the supply of fentanyl and fentanyl analogues have proliferated, due in 
part to fentanyl’s potency and low distribution burden (Armenian, Vo, Barr-Walker, & Lynch, 2018; 
Ciccarone, 2017; Misailidi et al., 2018). However, the use of prescription opioids remains higher than 
heroin in some areas, particularly rural areas, even as rates of heroin use in suburban and rural areas 
continue to steadily increase (Borders & Wen, 2018; Cicero, Ellis, Surratt, & Kurtz, 2014; Day, Conroy, 
Lowe, Page, & Dolan, 2006; Havens et al., 2009; Wunsch, Nakamoto, Behonick, & Massello, 2009). The 
use of stimulant drugs differs across metro and non-metro areas and geographic regions, with cocaine often 
more available in metro areas, but methamphetamine increasingly available across localities (Brownstein, 
Mulcahy, Fernandes-Huessy, Taylor, & Woods, 2012; Gfroerer, Larson, & Colliver, 2007; Stover, 
Winstanley, Zhang, & Feinberg, 2018). It is important to emphasize, though, that cocaine has, to varying 
degrees, remained accessible in rural areas (Booth, Leukefeld, Falck Wang, & Carlson, 2006; Borders, 
Booth., Stewart, Cheney, & Curran, 2015). 
It is also worth noting, that not all people who have used prescription opioids or who have access 
to heroin would choose to substitute the latter for the former, as heroin may be perceived to have higher 
relative risk (Daniulaityte, Falck, & Carlson, 2012; Inciardi et al., 2009; Inciardi & Cicero). Additionally, 
some drug users, including polydrug users, may have developed drug preferences and patterns of use over 
time that make them less likely to substitute their preferred drug for other drugs with similar psychoactive 
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effects and more likely to persist in the use of their primary drug. Evidence suggests that long-time cocaine 
and crack cocaine users may be less likely to use other stimulant drugs, and that co-use of cocaine and 
other stimulants is low among groups with greater cocaine use severity or longer use history (Booth et al., 
2006; Borders et al., 2008; Falck et al. 2007; Wu et al., 2009). Further, drug users for whom cocaine is their 
primary drug, have persisted in cocaine use over time (>10 years), whereas primary users of 
methamphetamine and heroin showed gradual decline in respective use for the same duration of time 
(Brecht et al., 2008). 
 Lastly, it is important to consider that preference and decisions to use can be shaped by perceived 
drug quality and cost, with people reversing preferences for drugs based on increases or decreases in price 
and effort needed to obtain the drug (Caulkins, 1995; Goudie et al., 2007; Jacobs & Bickel, 1999). 
Preference for drugs may develop around a variety of factors beyond subjective effects. Conversely, some 
people may simply be less discriminant in their drug choice and therefore more willing to substitute 
preferred drugs with less preferred, but more accessible and affordable, drugs despite differences in 
subjective effects, quality, and known risk (e.g., substituting with fentanyl, synthetic cathinones, etc.) 
(Mars, Rosenblum, & Ciccarone, 2018; Smith & Staton, 2018).  
In sum, drug accessibility and cost comprise part of the larger “system of constraint” within which 
people make decisions and allocate resources, as options in accessible drug markets provide choices with 
differing values, risks, and costs--all of which can motivate behavior differentially (Bickel, Mueller, 
MacKillop, & Yi, 2016). Although the region that a person lives in puts them in proximity to different 
markets, and therefore different drug choices, this proximity is just one factor that shapes drug-related 
decision-making and drug use. It is therefore also important to also consider the non-drug choices available 
to people.   
Non-drug Alternative Reinforcers 
As noted throughout this discussion, numerous aspects of a person’s history and everyday life 
have the potential to influence cognition and choice, and the potential to reinforce behavior. Recall that 
opioids and stimulants are potent reinforcers that can result in reinforcer pathology. This is due to the 
rewarding drug effects that can contribute to repeated use and/or habituated use that persists despite adverse 
consequences, including criminal justice involvement (Bickel, et al., 2011; Everitt & Robbins, 2005). 
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Aspects of a person’s life apart from drugs may also be considered in terms of how they reinforce behavior. 
The importance of considering the role of non-drug alternative reinforcers using behavioral economics can 
be summarized by Bickel et al. (2014) thusly:  
[The] behavioral economics perspective gives equal weight to the larger environmental context 
within which addictive behavior takes place and, more specifically, the alternative reinforcers to 
which a person has access....A behavioral economics perspective is a molar account of addiction, 
focusing on aggregates of behavior, not instances, and both the endogenous conditions of the 
organism and exogenous characteristics of their environment. Put simply, a person’s internal 
motivational state and the alternative reinforcers available in the environmental context are 
theorized to jointly determine the decision to use or not to use a drug. From this perspective, the yin 
and yang of addiction are high levels of endogenous factors (high [drug] demand and impulsive 
discounting) and low levels of exogenous factors (alternative reinforcers). Furthermore, a recursive 
etiological process is proposed to be operative for alternative reinforcers over the course of the 
development of a substance use disorder. For example, an individual may begin drinking 
recreationally and as part of a diverse repertoire of positively and negatively reinforcing behaviors. 
But, as use escalates and negative consequences mount (e.g., dissolution of a relationship, loss of a 
job, legal difficulties), the availability of these alternative reinforcers diminish, which 
commensurately increases the reinforcing effects of alcohol (Rachlin, 1997). This recursive 
etiological feedforward loop illustrates the classic vicious cycle of addiction (e.g., the primrose path 
model of addiction formulated by Hernstein & Prelec, 1992) (p.654).  
Many preclinical models have demonstrated that non-drug alternative reinforcers (e.g., saccharin, 
food, water, access to conspecifics/social interaction) are chosen over drugs such as cocaine or morphine, 
depending on the dose and effort associated with choice (Ahmed, 2010; Tarou & Bashaw, 2007; Cantin et 
al., 2010; Lenoir, Sere, Cantin, Ahmed, 2007; Venniro, Zhang, Shaham, & Caprioli, 2017; Zernig, 
Kummer, & Prast, 2013). Among humans, non-drug reinforcers could include a wide-range of things. Non-
drug alternatives might include exercise, money, work, school, close relationships with family or friends, 
hobbies, educational participation, or group membership (e.g., church, civic organizations, or mutual 
aid/12-Step groups) (Comer et al., 1998; Donlin, Knealing, & Silverman, 2008; Etten, Higgins, Budney, & 
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Badger, 1998; Greenwald & Steinmiller, 2009; Higgins, Bickel, & Hughes, 1994; Morral, Iguchi, & 
Belding, 1999; Petry, Tedford, J., & Martin, 2001; Quick, Pyszczynski, Colston, & Shahan, 2011; Rogers 
et al., 2008; Waldorf et al., 1992; Zlebnik, & Carroll, 2015). Although the possible number of non-drug 
alternative reinforcers that people could encounter is almost limitless, and could conceivably include 
abstractions (e.g., religious belief, life meaning, values), one type of non-drug alternative that may serve as 
a particularly effective behavioral reinforcer is social interactions and close connection with others (Laudet 
& White, 2008; Ostafin & Feyel, 2019). Although social interaction and close relationships are often 
associated with enhanced health and well-being, choice of relationships over drugs is not a given when the 
two are placed in direct competition. This is reflected indirectly by high divorce rates and low rates of 
sustained family reunification among active or recently remitted drug users (Brook & McDonald, 2009; 
Brook, McDonald, Gregoire, Press, & Hindman, 2010; Collins, Ellickson, & Klein, 2007; Lloyd & Akin, 
2014). 
Still, prosocial interactions and relationships may constitute one of the most potent non-drug 
alternatives a person could gain access to, given that social interaction, play, and bonding are intrinsically 
rewarding within and across sexes and species, and have demonstrated potential to attenuate drug use 6 
(Fritz et al., 2011; Heilig et al., 2016; Kohtz, Lin, Smith, & Aston-Jones, 2018; Peirce, Frone, Russell, 
Cooper, & Mudar, 2000; Smith, 2012; Strickland & Smith, 2014; Vanderschuren, Achterberg, & Trezza, 
2016; Zernig, Kummer, & Prast, 2013; Venniro et al., 2018).  
Ultimately, non-drug alternatives help define the range of choices available to people, but also 
have the potential to be rewarding in the short- and long-term (e.g., relationships, school, hobbies) 
(Herrnstein & Prelec, 1991). There is the possibility, then, that certain non-drug alternatives can have both 
a high local and overall utility (Herrnstein & Prelec, 1991). This is important in terms of their potential to 
influence decisions at one time point and across time, as well as in terms of providing satisfying, but 
durable, alternatives to drug use. Additionally, non-drug alternatives may reinforce behavior in terms of 
opportunity cost, wherein the opportunity cost for a given choice is defined as equal to the best alternative 
6 It is worth mentioning that, for people, studies have consistently found money to also be a potent 
behavioral reinforcer as well (see Higgins et al., 2008). Money, somewhat depressingly, was also ranked by 
Americans as one of the things that “gives their life meaning”, with money outranking family and other 
activities for some respondents (Pew Research Center, 2018). 
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not selected (Bickel et al., 1993, 2014). When drugs are in direct competition with a set of potentially 
rewarding  alternatives, the opportunity cost of drug use increases and may motivate decisions not to use 
drugs; for instance, if food and a drug were in direct competition, the opportunity cost of choosing the drug 
would be not eating and, over time, eventual starvation (Caprioli, Zeric, Thorndike, & Venniro, 2015).  
For corrections-involved people, community supervision and drug court (which includes drug 
monitoring and sanctions) have the capability to serve as additional behavioral reinforcers (Marlowe & 
Wong, 2008; Petry et al., 2006). Here, some abstinence-promoting behaviors may be reinforced by threat of 
unfavorable consequences. For someone who uses heroin while on probation, the opportunity costs 
associated with use and subsequent punishment may be extreme, such as incarceration.  
In real-world circumstances, it is not always clear when a decision to use drugs is in direct 
competition with alternatives. For instance, a person could choose to use hydrocodone while 
simultaneously engaging in other rewarding activities (Vanderschuren, Spruijt, Hol, Niesink, & Van Ree, 
1995). In other words, taking hydrocodone and pursuing non-drug choices are not necessarily mutually 
exclusive. Often, instead of direct competition between drugs and non-drug alternatives, there are 
contingencies that a person must navigate when making decisions. For example, a man’s romantic partner 
threatens to divorce him if he continues to smoke crack cocaine each weekend. Because smoking crack and 
being married are not necessarily mutually exclusive, it is possible for him to do both, until the point where 
they do become mutually exclusive (e.g., the partner leaves, with reunification explicitly contingent on 
abstinence from crack cocaine). Additionally, the credibility and likelihood of the partner’s threat coming 
true will influence its reinforcing effects, with less credible threats (e.g., divorce) or rewards (e.g., staying 
married) being discounted in terms of probability (Rachlin et al., 1991). 
In this scenario the man loves his partner and does not want her to leave. He discontinues his crack 
cocaine use. Here, the presence of the man’s partner in his life is rewarding and her stipulations, that in 
order for her to stay he must stop smoking crack, are sufficiently reinforcing. This rewarding non-drug 
alternative that has been put in direct competition with drugs has resulted in a decision to not use crack. 
Considering this same scenario between drugs and a relationship with another person, but where the 
relationship is not characterized as close or where the quality of it has deteriorated, suggests that the non-
drug alternative may not have a similarly reinforcing effect (Homish, Leonard, Kozlowski, & Cornelius, 
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2009). To put this in perspective, consider the effort a person might undertake for their child, but not for an 
acquaintance or co-worker. Consider, too, the difference in magnitude of reward received interacting with a 
partner, child, or close friend compared to that received from interactions with strangers or acquaintances.   
Take another example of a man who smokes crack cocaine on the weekends. In this scenario, 
however, the man is on probation and subject to drug monitoring. The man knows the date he will see his 
probation officer next month, but does not know for certain if he will be drug tested on this next visit. He 
also knows that his probation officer could make an unannounced visit to randomly drug test him. He has 
been told that if he has another positive drug test, his probation will be officially “violated” and a judge will 
determine his sentence. He could receive a minimum of one year and a possible maximum of six years in 
prison. Here, there are clear potential losses, but the probability of those consequences occurring is unclear. 
Further, the certain risk involved in meeting with the probation officer is one month away. The reinforcing 
effect of the probation officer and drug testing is real, but it is in the future, and the results of the interaction 
uncertain. This non-drug alternative reinforcer is thus influenced by the steepness of the man’s temporal 
and probability discounting which, as discussed earlier, may be influenced by many other factors. For this 
man on probation, there is a certainty that he will be drug tested in the future and that a negative drug 
screen will not result in arrest. There is no certainty of when the drug screening will occur or what the exact 
consequences of a positive drug screen would be. Here, the magnitude of the reinforcer may vary as a 
function of time (e.g., the closer to the next appointment with his officer the less likely he is to smoke crack 
cocaine).   
Both examples illustrate how the uncertainty associated with a behavioral reinforcer for which the 
effects are delayed makes decision-making more complicated, and also implies that people may be biased 
toward choosing drugs due to the fact the drug effects are nearly immediate and approximately certain.7 
Importantly, the risk of choosing drugs in both examples is clear, due to the uncertainty and severity of 
potential outcomes. In both examples, there are potential rewards (e.g., intact relationship, intimacy, 
companionship, not having probation violated, remaining free) and losses (e.g., divorce, incarceration) that 
7 By “approximately certain” it is meant that there is an outcome expectancy for drug reward or effect in a 
generic sense; it is, of course, inevitable that the potency of drug effects vary across doses due to changes in 
drug quality, as well as physiological states and contexts (e.g., possibility of have been sold ineffectual 
drugs, hormonal fluctuations, etc. ) (Kepler, Kest, Kiefel, Cooper, & Bodnar, 1989). 
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must be considered, in addition to the reinforcing effects of crack cocaine. In other words, smoking crack 
cocaine each weekend does not occur in a vacuum. In both examples, the opportunity cost of choosing not 
to smoke crack cocaine would simply be not getting to smoke crack cocaine8. For some, such an 
opportunity cost may be perceived as too great due to the overvaluation of the drug in the immediate, the 
undervaluation of non-drug alternatives.  
Restricted Opportunity for Accessing Non-Drug Alternatives 
Ultimately, it is the presence or absence, and the potential for variation, of these non-drug 
alternative reinforcers that defines the choices available to a person and serves to influence what decisions 
are made. One way to think about the role of alternative reinforcers is to consider that the more that a 
person has, or the more they have the opportunity to access, the greater the potential opportunity costs. 
Another way to think about them is to consider that in the absence of rewarding alternatives, drugs may 
retain a high local and conceivably, under extreme conditions, even a higher overall utility; in such extreme 
circumstances the overall utility, in the traditional sense, becomes irrelevant or nonsensical. Without, or 
with far fewer, non-drug choices the rewarding effects from drugs may be greater, potentially contributing 
to reinforcer pathology (Ahmed, Lenoir, & Guillem, 2013; Bickel et al., 2011). A person who does not 
have friends or family would not be able to choose these relationships over drugs. If a person does not have 
a romantic partner to enjoy the company of, then there is no reward to be had and no partner-loss to incur in 
its absence. It simply does not exist as a non-drug alternative and thus cannot motivate decision-making 
and behavior in relation to drugs. 
This idea may be extended to more broadly consider how the absence of abundant opportunity for 
accessing non-drug alternatives might influence decision-making. As noted in the first chapter, in order to 
influence decision-making, people need only know that certain options exist and that there is opportunity 
and ability to access them in order to motivate behavior (recall the chocolate cakes and apple pies). Thus, 
while a person may not currently have non-drug alternatives such as close friends, employment, group 
affiliation, or educational participation, they still have potential to acquire these things. However, for 
8 It is conceivable that there are also some other hidden opportunity costs under particular circumstances 
and for particular drugs. If a person is using opioids so as not to go into withdrawal or not to be crippled by 
pain so that they can go to work and keep their job, then there would be a string of related opportunity 
costs. In this example of irregular crack cocaine use, this would be less likely.  
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people with less proximity to opportunities for such acquisition, non-drug alternatives may remain limited, 
constraining choice proportionately. In line with some of the findings discussed earlier related to the 
detrimental effects of social isolation, studies have demonstrated that, compared to impoverished 
environments, enriched environments with greater access to rewarding non-drug alternatives (e.g., social 
interaction, food, activities) can attenuate drug-taking (Bardo, Neisewander, & Kelly, 2013; Imperio et al., 
2018; Marlatt, Baer, Donovan, & Kivlahan, 1988; Nader & Banks, 2014; Panebianco, Gallupe, Carrington, 
& Colozzi, 2016; Strickland & Smith, 2015; Solinas, Chauvet, Thiriet, El Rawas, & Jaber, 2008; Venniro et 
al., 2018). Yates et al. (2017) found that in enriched environments, demand elasticity for cocaine increased. 
Similarly, Hofford et al. (2017) found that value and reinforcer strength for remifentanil was lower among 
rats housed in enriched environments. 
 People who live in resource scarce, economically distressed, or otherwise “harsh” regions (e.g., 
higher poverty, greater prevalence of violence, disability, mortality, fewer treatment providers, etc.), or in 
areas with less social cohesion and fewer opportunities for prosocial connection, may be considered to live 
in impoverished (verses enriched) areas, in that they have comparatively less accessibility to non-drug 
alternatives (e.g., relationships, education, employment, money, school, group affiliation, entertainment) 
(Dew, Elifson, & Dozier, 2007;  Erickson, VanLooy, von Schrader, & Bruyère, 2018; Monnat, 2018; 
Zoorob & Salemi, 2017). Highly urban or highly rural areas, including those within central Appalachia, 
may be considered “harsh” environments, wherein some opportunities for accessing rewarding non-drug 
alternatives are restricted, despite the fact that close social, cultural, and spiritual connections can be found 
in both locales (Case & Deaton, 2017; Diddle & Denham, 2010; Donnermeyer, Jobes, & Barclay, 2006; 
Eller, 2008; Lee, Maume, & Ousey, 2003; Meit, Heffernan, Tanenbaum, & Hoffmann, 2017; Oser, Harp, 
O'Connell, Martin, & Leukefeld, 2012; Snell-Rood & Carpenter-Song, 2018; Tonkiss, 2005; Williams, 
Palar, & Derose, 2011). It is perhaps unsurprising that rates of SUD, and rates of opioid and stimulant use 
in particular, are high in these areas (Moody, Satterwhite, & Bickel, 2017). Sadly, prolific drug use within a 
region may come to further qualify it as “harsh”, insofar as drug use can initiate and perpetuate a cascade of 
loss and breakdown in social cohesion (Mack, Jones, & Ballesteros, 2017; Monnat, 2018; Orsi, Yuma-
Guerrero, Sergi, Pena, & Shillington, 2018; Oser et al., 2011; Zoorob & Salemi, 2017). This means that 
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drug use can potentially be understood as both cause and consequence of harsh environments. Bleakness 
begetting bleakness.  
  As noted earlier, living in “harsh” conditions can foster a sense of uncertainty about one’s future, 
influencing cognition and decision-making. In the last two decades, many rural and urban regions have 
experienced rapid changes due to globalization, deindustrialization, shifting demographics, and 
technological innovation, meaning that some areas that may have already engendered feelings of 
uncertainty about the future, had an increased potential to do so (Case & Deaton, 2017; McLean, 2016). In 
the presence of such existential uncertainty, and in the absence of opportunity for accessing rewarding non-
drug alternatives, opioids and stimulants, despite their deadly risk, may still hold value. This is not to say 
that suburban communities necessarily guarantee access to opportunity or ensure protection from 
conditions which might create a scarcity mentality (Allard, 2017). Therefore, when identifying how the 
region a person lives in might shape their decision-making, it is important to avoid overgeneralizations and 
to consider possible gradations in “harshness” between regions. 
 The counter to all this is that people may have few non-drug alternatives, have only very weakly 
reinforcing non-drug alternatives, or may live in areas with fewer opportunities for accessing rewarding 
non-drug alternatives, but may still choose to not ever use opioids or stimulants, to moderate their use, or to 
discontinue use without prospects changing; and that people with abundant access to non-drug reinforcers 
may still choose to use opioids and stimulants (Bozarth, Murray, & Wise, 1989); Davis, 2014; Grant, 2007; 
Premac, 2017; Miller, 2004). Indeed, there are ultimately many factors with the potential to influence 
decisions to use and decisions not to use. The importance of considering alternative reinforcers, however, is 
articulated in research showing that the presence or absence of certain conditions reliably influences 
behavior (Dayan & Balleine, 2002). It is also articulated by the possibility that the presence of rewarding 
non-drug alternatives, like a job, relationships, group participation,--and the sense of belonging, 
responsibility, and meaning that can come with these things (Laudet & White, 2008; Petry et al., 2001; Pew 
Research Center, 2018)-- has the capacity to make people more vested in their lives, helping to produce 
what Waldorf et al. (1992) refer to as “a stake in the conventional life”. This concept is important, because 
implicit in it is a connection between a person’s current and future self. For people who have a stake in the 
conventional life, who are truly vested in their everyday roles and in their future, the breadth of opportunity 
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costs from using high-risk drugs has the potential to be nothing less than heartbreaking. For people who 
continue to use high-risk drugs without access to the types of rewarding alternatives that might foster a 
stake in the conventional life, the unrealized human potential is no less heartbreaking.  
Study Aims Overview 
Having discussed how a behavioral economic approach considers that both endogenous and 
exogenous factors influence drug-related decision-making and behavior, and having detailed several factors 
with the potential to exert such influence in relation to opioids and stimulants, it is important to reiterate 
that these factors can vary across people, and that people’s lives are always in a state of flux. The same 
factors that may have contributed to a decision to use opioids or stimulants at one time may not be present 
at a later time. For corrections-involved people with a history of drug use, decision-making about opioids 
and stimulants may change subsequent to losses incurred as a result of their use, such as incarceration. 
Given the high-risk nature of opioid and stimulant use, and the many constraints on decision-
making and behavior, it is important to identify, explore, and describe what factors with the potential to 
influence drug-related decision-making and behavior are associated with opioid and stimulant use among 
corrections-involved adults residing in a state that continues to experience high rates of opioid and 
stimulant use, and where the risks associated with use are well-known (Havens et al., 2011; SAMHSA, 
2016). Kentucky is an ideal state for such exploration. Many corrections-involved adults in Kentucky with 
a history of drug use have likely experienced or observed adverse consequences related to high-risk drugs 
first-hand. As noted earlier, the region that a person lives in can influence cognition, behavior, and drug 
choices. Regional differences in Kentucky can be stark, meaning that the area that a person resides in has 
the potential to shape both choice and behavior. People who reside in Central Appalachia, the Easternmost 
part of the state, may be considered to live in a “harsh” region compared to people who live in Central and 
Western parts of Kentucky outside of Central Appalachia. Given the insular nature of Central Appalachia, 
the persistently high rates of morbidities and disabilities, and the region’s greater rurality, it is likely that 
drug markets within this area of Kentucky also influence drug-related decision-making and behavior.  
Using behavioral economics as a molar framework for exploring high-risk drug use among 
corrections-involved adults in Kentucky prior and subsequent to incarceration, several questions can be 
addressed: What endogenous and exogenous factors with the potential to influence decision-making about 
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high risk drugs prior and subsequent to incarceration can be identified using available data sources? What 
differences are observed between groups who use different types of high-risk drugs during these periods, 
including the geographic areas in which they reside? What factors are associated with an increased 
likelihood of observing high-risk drug use during these periods?  
Specific Study Aims 
The primary aim of this study is to explore high-risk drug use among a sample of corrections-
involved adults in Kentucky and to identify and discuss endogenous and exogenous factors with the 
potential to have influenced drug-related decision-making prior and subsequent to incarceration. This will 
be accomplished with three specific study aims.  
Aim One 
Provide a descriptive profile of a sample of adults in Kentucky with a history of drug use prior and 
subsequent to incarceration using self-report data collected during intake into a corrections-based drug 
treatment program and self-report data collected during the one-year period subsequent to incarceration for 
years 2012-2017. Determine the prevalence of concomitant opioid/stimulant use, opioid use, stimulant use, 
and other and/or no drug use that occurred during the 30-day period prior to incarceration and the one-year 
period subsequent to incarceration. Provide a description of these drug use groups and identify between-
group differences. This includes identifying differences in the use of specific opioid and stimulant drugs by 
participant residence across an urban-rural continuum, as well as differences in the use of specific opioid 
and stimulant drugs by participant residence within or outside of Central Appalachia.  
Aim Two 
Identify factors associated with a change in likelihood of observing concomitant use, opioid use, 
and stimulant use during the 30-day period prior to incarceration and the one-year period subsequent to 
incarceration, compared to an outcome with less risk, such as the use of other drugs and/or no drug use.  
Aim Three 
Because heroin was the drug associated with the highest risk in the US during the one-year post-
release period for participants in this sample (2012-2017), it is of interest to also determine the prevalence 
of heroin use that occurred during the one-year period subsequent to incarceration, the between-group 
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differences among those who did and did not report heroin use, and to identify factors associated with an 




Chapter 1 provided an overview of some of the well-known risks associated with opioids and 
stimulants. It also introduced behavioral economics as a conceptual approach for understanding drug-
related decision-making. In Chapter 2, many endogenous and exogenous factors with the potential to 
influence drug-related decision-making were discussed and situated within a molar view of choice and 
behavior. For instance, scarcity might contribute to a person to becoming more present-biased, more prone 
to discount the future, and more likely to evidence poorer decision-making. Stress and living in a harsh 
environment can contribute to greater reliance on more automatic, habituated, lower-level cognitive 
systems, rather than higher-level, deliberative cognitive systems. Prior opioid use can increase the 
likelihood of continued opioid use. Residing in an area that is more rural, may restrict access to a wider 
variety of drugs, compared to urban drug markets.  
A simplified way to think about the previously discussed factors (and others not discussed here), is 
to consider that they have the potential to influence decision-making in roughly one of two ways: 1) 
Influencing a person’s cognitive capacity to make decisions that maximize overall utility (versus choosing 
immediately rewarding options with higher local, but lower overall utility); and/or 2) Influencing the set of 
drug and non-drug choices available or accessible to people. This simplified conceptual model of how 
endogenous and exogenous factors have the potential to influence drug-related decision-making and drug 
use is displayed in Figure 1.  
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Figure 1. Concept model of endogenous and exogenous factors with potential to influence drug-
related decision-making by constraining cognitive capacities and by constraining choice. 
Importantly, both types of influence can occur at the level of the person or at the level of the 
person’s context or environment. When Bickel et al. (2014) describes the “yin and yang of addiction” as 
high levels of endogenous factors and low level of exogenous factors, this is, in part, what they are 
referring to. Behavioral economics understands that endogenous factors can also be influenced by 
exogenous factors so as to influence cognition, affect, and decision-making. This general idea, that 
organisms are influenced by their environment, spans many disciplines. That context can influence 




Ideally, that overview also made more apparent that the “system of constraint” in which people make 
decisions is not unidimensional (Bickel & Marsch, 2000; Bickel et al., 1995). Rather, people are 
constrained across levels. People are constrained by their capacities (traits and states), by their contexts, 
and by the choices for behavior available to them. The specific configuration of endogenous and exogenous 
factors that constrain people’s decision-making in relation to opioids and stimulants differs by person. At 
the group level, some endogenous and exogenous factors with demonstrated potential to influence decision-
making may be observed for given time periods. In this chapter, methods are proposed for identifying some 
of these factors among a sample of drug users prior and contemporaneous to incarceration and participation 
in corrections-based treatment. Discussion of findings and their implications will be considered in 
subsequent chapters.   
Data Sources and Sample 
Data Sources 
In order to address the aims of this exploratory study, secondary data analyses were conducted 
using individual-level and county-level data. All individual-level data were collected as part of the Criminal 
Justice Kentucky Treatment Outcome Study (CJKTOS). CJKTOS is ongoing evaluation of the KY DOC 
Substance Abuse Treatment Program (SAP). CJKTOS was initiated in April 2005 with the primary 
objectives of better understanding the population served by SAP and assessing the effectiveness of SAP in 
reducing drug use and recidivism. CJKTOS is conducted by the University of Kentucky’s Center on Drug 
and Alcohol Research (CDAR) and is funded on an annual basis through a contract with the KY DOC. SAP 
is available to adults involved with the KY DOC who have a history drug use or who are currently KY 
DOC-involved due to a drug-related offense. People may voluntarily enroll in SAP and SAP aftercare, or 
may be mandated by a judge or parole board. While the majority of SAP participants are mandated 
(approximately 75%), even those who volunteer are incentivized, in that SAP participation may be 
regarded favorably by the parole board. Moreover, all SAP participants who successfully complete the 
program receive a 90-day sentence reduction. SAP is delivered by trained clinicians in Kentucky jails, 
prisons, or in secure DOC-affiliated community residential facilities that constitute controlled environments 
and correctional custody.  
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SAP lasts approximately six months. During this time, it is expected that participants will indicate 
therapeutic progress in a variety of ways. Progress indicators include demonstrating a willingness to 
change, completing recovery-related assignments, engaging in group activities, adhering to institutional and 
SAP regulations, and holding themselves and other SAP participants accountable for attitudes and 
behaviors considered antithetical to the broad therapeutic goals of SAP. These goals include reducing or 
extinguishing drug use through cognitive, spiritual, and behavioral modification. Although there is 
variability across correctional institutions in terms of how SAP is delivered (e.g., amount of individual time 
with a counselor versus time spent in groups), all programs are styled as a residential therapeutic 
community grounded in 12-Step principles and cognitive behavioral modalities, and each uses structured 
materials (e.g., workbooks, readings) to facilitate treatment.  
Subsequent to release, SAP participants who still reside in Kentucky are either paroled onto 
community supervision or are released having “served out” their time, such that they are not mandated to 
community supervision. On any given year, a majority of CJKTOS participants are on community 
supervision subsequent to release. Some of the terms of community supervision include abstaining from 
alcohol and drug use, not associating with known felons, monthly reporting to a parole officer, random 
drug monitoring (e.g., urine analyses, breathalyzer), and mandated participation in recommended services 
(e.g., aftercare) and/or completion of reentry tasks (e.g., obtaining employment, driver’s license, etc.).  
CJKTOS data includes data collected by CDAR research staff, data collected by SAP clinicians, 
and institutional data provided by the KY DOC and community supervision officers. Parole officers, KY 
DOC officials, and social service clinicians enter information about offenders (e.g., supervision notes, 
program referrals, drug screen results, parole violation reports, reincarceration dates, institution location 
etc.) electronically into the web-based Kentucky Offender Management System (KOMS).  
Individual-level CJKTOS data include several different types of information (e.g., age, 
employment status) and also include the counties that participants resided in prior and subsequent to 
incarceration. County-level self-report data was used to determine the relative rurality of participants’ 
county of residence by examining urban influence designations, as well as the proportion of participants 
who resided in one of fifty-four counties in Kentucky that fall within Central Appalachia. In addition to 
CJKTOS data, publicly available data measured at the county-level were obtained for this study from state 
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and federal entities for all 120 Kentucky counties. These entities include: Alcohol Beverage Control, 
Appalachian Regional Commission, the Federal Communications Commission, the Kentucky Cabinet for 
Health and Human Services, the Social Security Administration, and the U.S. Census Bureau. Using 
participants’ counties of residence prior and subsequent to incarceration allowed for the possibility of 
matching individual cases with corresponding county data, thus potentially providing an additional level of 
measurement.  
Individual-level and county-level data have been successfully integrated and analyzed by many 
researchers, and are included among investigations examining county or regional influence on a variety of 
outcomes. Such outcomes include drug use, drug-related health outcomes, depression, recidivism, obesity, 
self-rated health, quality of life, and mortality (Blakely, Lochner, & Kawachi, 2002; Goodman, Huang, 
Wade, & Kahn, 2003; Jia, Moriarty, & Kanarek, 2009; Kim, Subramanian, Gortmaker, & Kawachi, 2006; 
Lochner, Pamuk, Makuc, Kennedy, & Kawachi, 2001; Muramatsu, 2003; Orrick et al., 2011; Patrick et al., 
2019; Subramanian, Kawachi, & Kennedy, 2001). The growth of social epidemiological methodology and 
the expanded awareness of multi-level social determinants of health have increased the availability of 
publications describing how the integration and analysis of multiple data sources and types can be 
accomplished, and how data may be examined within and across levels (Blakely & Woodward, 1999; Diez-
Roux, 2000; Duncan, Jones, & Moon, 1996; Galea, Hall, & Kaplan, 2009; Jia, Muennig, & Borawski, 
2004; Soobader, Cubbin, Gee, Rosenbaum, & Laurenson, 2006; Macintyre, Ellaway, & Cummins, 2002; 
Pickett & Peral, 2001).  
Data Collection 
In implementing CJKTOS, the KY DOC and CDAR worked to develop a baseline instrument that 
functions as a psychosocial assessment of incoming SAP participants as well as a data collection tool. 
Information self-reported by participants is used by SAP clinicians to help evaluate participants’ 
psychosocial and drug use histories. All SAP baseline data are de-identified, aggregated, and analyzed as 
part of CJKTOS (e.g., outcome evaluation reports). Every SAP participant completes a baseline survey 




Baseline Data Collection 
Baseline data are collected after a person has been referred to SAP, but prior to treatment 
initiation. Baseline data collection is conducted by a trained SAP provider at their respective location (e.g., 
jail, prison, community-based DOC facility). Baseline surveys are completed in one of two ways: 1) A 
trained SAP provider administers the survey by reading items aloud to participants and then recording 
responses into the secure, university-operated web-based Client Information System (CIS); 2) Participants 
self-administer the baseline survey electronically into the CIS online survey platform, seeking assistance 
from the SAP provider as necessary. The total number of baseline survey questions varies between years, 
and between participants within years, given that certain responses may prompt automatic follow-up 
questions, thereby increasing the number of questions asked. Across years 2012-2017, the maximum 
number of possible individual baseline survey items ranged from approximately 232-261, though this is 
likely far more questions than participants typically respond to. The baseline survey takes approximately 1 
hour to complete.   
Follow-up Data Collection 
Follow-up data are collected approximately 12 months subsequent to a participant’s release. To be 
eligible for follow-up, the person must have participated in SAP, consented to participate in the CJKTOS 
follow-up portion of the study, and have a release date from a KY DOC institution following SAP 
participation that is verified using KOMS. Consent for study participation is typically over half of all SAP 
participants. For instance, between 2010-2018, 57.3% of people who completed a CJKTOS baseline survey 
as part of their SAP assessment (N=43,390) consented to be contacted in the one-year post-release period 
as part of the CJKTOS follow-up study. CJKTOS uses randomized proportionate sampling, whereby SAP 
participants who consented to be contacted for follow-up interviews are randomly selected for inclusion 
into a given FY’s follow-up sample. This method is utilized to help ensure that each FY the follow-up 
sample reflects the entire SAP population released for the same FY period for characteristics such as 
gender, race, SAP program type (e.g., jail, prison, community-based), so that findings from the follow-up 
sample can be generalized (Shadish et al., 2002). The final FY follow-up sample is thus an approximate 
representation of the total state population of SAP participants (Lavrakas, 2008b). Participants included in 
the follow-up pool become eligible for contact and data collection 10 months from their release date. The 
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follow-up window closes 14 months from participants’ release date. The CJKTOS follow-up rate for FYs 
2013-2017 is as follows: FY13=82.0%, FY14=81.0%, FY15=80.0%, FY16=83.0%, FY17=84.0%. This 
means that of the total follow-up sample pool, 16-20% of participants for which contact attempts were 
made did not complete interviews, either because contact attempts were unsuccessful, or because the 
participant chose not to complete the interview. Follow-up refusal rates for FYs 2013-17 range from 4%-
7%. 
During the follow-up data collection window, trained CDAR research staff use information 
provided by participants at baseline, in conjunction with more current contact information obtained from 
KOMS, to facilitate contact. KOMS also provides contact information for relatives and associates of 
participants (e.g., mother, fiancé, children) and information about the known location of participants who 
are on community supervision or who have been reincarcerated. Facebook and VINELink, an online inmate 
search tool, are also used to search for participants who cannot be readily located using self-reported 
contact information or KOMS. The use of social media, including Facebook, for locating and contacting 
research participants is increasingly common and well supported, particularly among rural, drug-using, 
transient, or otherwise difficult-to-reach populations (Bolanos et al., 2012; Dickson et al., 2017; Staton et 
al., 2018).   
Research staff make repeated attempts to contact participants via telephone, direct mail, and social 
media until successful contact is made, or until the 14-month follow-up contact window closes. When 
making contact through these means, the study is referred to as a “UK Health Study” so that sensitive 
information related to correctional involvement and drug use is not inadvertently disclosed. Participants 
must verify their date of birth prior to study specifics being disclosed. At follow-up, participants are 
reminded of the voluntary nature of the study and asked if they would like to participate in the follow-up 
interview, which is conducted via telephone at their convenience. Approximately 30-35% of CJKTOS 
follow-up interviews are conducted with participants who are currently in jail or prison, meaning that 
subsequent to release they either violated the terms of their community supervision or were arrested for a 
new offense. Prison and jail interviews are also conducted via telephone and are scheduled by coordinating 
with correctional facility staff.  
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Before beginning any follow-up interview, the identity of participants is verified using birthdate, 
release date, and the SAP institution of record. Research staff read questions from the follow-up instrument 
aloud and enter participant responses into CIS. The number of follow-up survey items also varies between 
FYs and between participants within FYs based on response patterns. Between 2012-2017, the maximum 
possible number of unique follow-up survey items ranged from approximately 201-232. Again, it is 
unlikely that all questions would be asked. The follow-up interview takes approximately 30 minutes to 
complete. Compensation, in the form of a $20 check, is provided via direct mail only to participants who 
complete both baseline and follow-up surveys. Some information self-reported by participants (e.g., release 
or rearrest dates, program completion, recidivism, parole status) is cross-referenced and verified by CDAR 
research staff using KOMS and KY DOC records.  
Study Inclusion Criteria 
Cases were included in the sample if they met the following four criteria: 1) Verified SAP 
participation; 2) Completed CJKTOS baseline interview; 3) Completed CJKTOS follow-up interview for 
2012-2017; 4) Reported residing in a Kentucky county for the majority of months (>6) out of the one-year 
period prior and subsequent to incarceration. Kentucky residency for participants who became 
reincarcerated after release was determined using the county that participants self-reported that they would 
be residing in if not incarcerated, versus designating the county of incarceration as the county of residence; 
5) Reported alcohol or illicit drug use for the one-year period prior to incarceration. The latter criterion was
included due to the fact that some SAP participants are enrolled in SAP due to drug-related charges (e.g., 
drug trafficking), but not necessarily due to drug use. As lifetime history of drug use is not assessed as part 
of CJKTOS, but rather only past-year and past 30-day use, no satisfactory determination could be reached 
as to what the nature of participants’ drug use history entailed. Such ambiguity would hinder 
conceptualization of the sample and interpretation of findings. Further, even for cases where some history 
of drug use could be discerned using the variable of “age of illicit drug use initiation”, the inclusion of such 
cases into the sample was still untenable due to the numerous drug-related variables that were missing for 
the time periods of interest. 
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Final Sample and Missing Data 
The sample is comprised of men and women age >18 with a history of drug use who participated 
in KY DOC SAP between 2012-2017. As displayed in Figure 2, a total of 1,740 CJKTOS participants 
completed follow-up interviews for FYs 2013-2017. It was determined that the first three study inclusion 
criteria (i.e., SAP participation, completion of both baseline and follow-up surveys) were met for all cases. 
Using zip code or county residence self-reported by participants, a total of 102 cases were identified as 
residing in a county outside of Kentucky for the majority of months (>6) of the one-year period prior and 
subsequent to incarceration. Removing these cases resulted in a sample size of N=1,638. Cases were then 
examined to see if the last inclusion criterion of past-year alcohol and/or illicit drug use was met. This was 
accomplished by examining responses for the baseline survey item “I did not use any illegal drugs in the 12 
months prior to incarceration” (0=“no” vs. 1=“yes”), in conjunction with the dichotomized responses for 
the baseline survey item “During the 12 months before you were incarcerated, how many months did you 
use any alcohol?” (0= “no alcohol use” vs. 1-12= “alcohol use”). A total of 148 participants reported no 
past-year illicit drug use. Of these, 63 also reported no past-year alcohol use. These 63 cases with no past-
year illicit drug use and no past-year alcohol use were removed, resulting in a sample size of N=1,575.  
Two variables were identified as having missing data for unexplained reasons, as these variables 
appeared in all FY 2013-17 instruments. These included “age of illicit drug use” and “preferred drug of 
choice” for the past-year period prior to incarceration. Ninety-eight cases were missing values for “age of 
illicit drug use initiation”. This variable was analyzed to rule out the possibility of data missing completely 
at random (MCAR; Little, 1988). Tests indicated that data were not MCAR (p<.001). Upon further 
inspection, it was determined that missing values may have been due to the fact that these participants only 
had a history of alcohol use, not alcohol and/or illicit drug use. However, examining past-year and past 30-
day use rates indicated that some, but not all, of these participants had used illicit drugs. In order to 
partially address this issue, the variable, “age of drug use initiation” was created to reflect the estimated age 
at which participants began using any psychoactive drug (see “Independent Variables” subsection, pg. 
149). 
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Figure 2. CJKTOS sample size for FYs 2013-2017, removal of cases, and final sample size. 
For this variable, missing values for age of illicit drug use initiation were imputed with age of alcohol use 
initiation. Then, the lowest age for either alcohol or drug use initiation was used in creating the final 
variable. This combined variable allows for approximation of the age that participants first used a 
psychoactive drug. One limitation of the method is that the missing value for age of illicit drug use 
initiation could be significantly lower than age of alcohol use initiation. However, evidence suggests that 
alcohol use often predates use of illicit drugs (Beman, 1995; McGue, Iacono, Legrand, Malone, & Elkins, 
2001). Still, there are exceptions (Mackesy-Amiti, Fendrich, & Goldstein, 1997). Therefore, this variable 
has some limitations, but still adequately represents the underlying phenomenon of interest (e.g., 
approximate age of psychoactive drug use initiation).   
Even after combining alcohol and illicit drug use into a single variable, 11 cases remained that had 
missing values for “preferred drug of choice”, which was missing for 13 total cases. When analyzed, 
“preferred drug of choice” MCAR could not be ruled out (p<.001). Examining the merged data set, and 
copies of original baseline datasets, the reason for missingness could not be determined. All cases for 
which this variable were missing had affirmative responses for some past-year drug use, meaning that this 
question should have been applicable to them. As there is a meaningful difference between “preferred drug 
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of choice” and past-year use of a drug (even if it is frequent use), missing values for this variable were not 
imputed with the drug most frequently used during this time period, even though this single imputation 
method was considered.  
Several methods for handling missing data, (e.g., single imputation, multiple imputation, or 
pairwise deletion) were considered; however, it was determined that listwise deletion would be the most 
reasonable method, because missingness accounted for less than 1.0% of cases and because deleting these 
cases would result in the least disturbance to the data integrity, by not manipulating the raw data (Kang, 
Rowe, Barreira, Robinson, & Mahar, 2009; McKnight & McNight, 2011; McKnight, McKnight, Sidani, & 
Figueredo, 2007; Rubin, 2004; Schafer, 1999; Schafer & Graham, 2002). Mean substitution was considered 
for age of illicit drug use, but for the same reasons, was not performed. Removing the 13 cases that were 
missing data for past-year drug preference resulted in a complete dataset with 1,563 intact cases (shown in 
Figure 2).  
This exploratory study was approved by the University of Louisville Institutional Review Board 
(IRB) and the University of Kentucky IRB via an Institutional Authorization Agreement between the two 
university IRBs under the study name “Criminal Justice Treatment Outcome Study” (see Appendix A). The 
University of Kentucky served as the IRB of record. Permission to analyze CJKTOS data and disseminate 
findings was granted by the KY DOC.  
Measures 
Many CJKTOS survey questions, including those used as part of dependent variable measurement 
described below, were adapted for use by CDAR from the Addiction Severity Index (ASI) (5th edition) 
“Alcohol/Drugs” (McLellan et al., 1992). The ASI is a public domain clinical and research instrument that 
assesses drug use, drug treatment history, and drug-related problems across life domains (e.g., employment, 
criminal justice involvement) (McLellan et al., 1985). The ASI has been used as a data collection tool for a 
variety of drug-using populations, including corrections-involved drug users (Haas & Peters, 2000; Jaffe, 
Du, Huang, & Hser, 2012; Wahler, 2015; Zanis, McLellan, & Corse, 1997). The “Alcohol/Drugs” section 
of the ASI was adapted for use in CJKTOS instruments due to the fact that this section has demonstrated 
adequate criterion validity, convergent validity, and discriminant validity, as well as adequate internal 
consistency and test-retest reliability (Calsyn et al., 2004; Chermack et al., 2000, Mäkelä, 2004; McLellan 
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et al., 1985; Wertz et al., 1995; Zanis, McLellan, & Randall, 1994). ASI questions were adapted by CDAR 
for use as part of the CJKTOS surveys to serve as a standardized question format. Due to slight 
modifications, they are not utilized by CDAR, or in this study, as a validated measure, or as a measure 
based on calculating ASI substance use scores or perceived severity ratings; the latter of which is subjective 
and intended for clinical use. Use of the ASI as part of the CJKTOS surveys is noted so as to make clear the 
standardized formatting of drug-related questions across baseline and follow-up surveys and across FYs. 
Other adaptations of standardized instruments for inclusion into the CJKTOS surveys will be subsequently 
discussed.  
Dependent Variables 
Three dependent variables were examined in this study: Drug use outcomes that occurred during 
the 30-day period prior to incarceration, drug use outcomes that occurred during the one-year period 
subsequent to incarceration, and heroin use that occurred during the one-year period subsequent to 
incarceration.   
Detailed measures of these dependent variables are described in the following subsections. First, it 
should be noted that dependent variables were created using ASI “Alcohol/Drugs” section items that 
comprise part of the larger CJKTOS surveys. These include responses provided for past-year and past 30-
day drug use. Past-year drug use and past 30-day drug use was self-reported by participants at baseline and 
follow-up. At baseline, participants were asked to list the total number of months out of the past 12 (0-12), 
and number of days out of the past 30 (0-30), that they used alcohol or an illicit drug (e.g.,“During the past 
12 months before you were incarcerated, how many months did you use marijuana/hashish, pot?”; “During 
the past 30 days before you were incarcerated, how many days did you use marijuana/hashish, pot?”). 
Including alcohol, participants reported use for a total of 13 drugs/drug classes. At follow-up, participants 
were asked to self-report drug use for these same drugs, with use pertaining to the one-year post-release 
period (e.g., “During the past 12 months, how many months did you use cocaine/crack?”) in an identical 
manner.  
Drug Use Outcomes Prior to Incarceration 
For the 30-day period prior to incarceration, drug use outcomes were measured using of a 
categorical variable comprised of four mutually exclusive categories: past 30-day: 1) concomitant use of 
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both opioids and stimulants, 2) opioid, but not stimulant use, 3), stimulant, but not opioid, use, and 4) other 
drug use, that excludes opioid and stimulant use. As discussed earlier, opioids and stimulants can be 
considered as high-risk drugs. Concomitant use of these drugs may increase risk further. Use of opioids, 
stimulants, and concomitant use of both during the 30 days prior to incarceration represent decisional 
outcomes involving high-risk drugs for this period. Use of other drugs, while still entailing risk, can be 
considered to have comparatively less risk in many, but certainly not all, circumstances. Therefore, the drug 
outcome of “other drug use”, that excludes opioid and stimulant use, can be conceptualized as less risky 
relative to the other drug use outcomes examined. Because uncertainty is greatest, and the probability of 
adverse outcomes higher with opioid use, any outcome involving opioids can be considered as entailing 
greater risk than outcomes not involving opioids. Additional considerations in conceptualizing risk will be 
discussed in Chapter 5. 
The past 30-day period prior to incarceration was chosen for examination (versus past-year), 
because it provided a narrower time frame and because it could facilitate examination of outcomes in 
relation to other measures reflecting time periods prior to or contemporaneous with the 30-day period (e.g., 
past-year, past 30-day, and 7-days). For instance, it is logical to suggest that endogenous and exogenous 
factors of a person’s life in the past-year had the potential to influence past 30-day outcomes, but not the 
reverse.  
Past 30-day opioid use prior to incarceration was measured using data collected at baseline and 
was defined as use of any opioid agonist drug. These include heroin, prescription opioids (e.g., Oxycontin, 
Lortab, Demerol), methadone, and buprenorphine. For opioid drugs that might have been used licitly by 
prescription, participants were asked to affirm only illicit use (e.g., “In the 30 days prior to this 
incarceration, have you used methadone not prescribed for you?”). Use of any opioid drug for the this time 
period was summed in order to create a dichotomized variable (e.g., 0=“no use” vs. 1=“use”). 
Past 30-day stimulant use prior to incarceration was measured using data collected at baseline and 
was defined as use of any psychostimulant drug, which included powder cocaine, crack cocaine, 
amphetamines (e.g., Adderall, Dexedrine), MDMA, and methamphetamines. For stimulant drugs that might 
have been used licitly by prescription, participants were asked to affirm only illicit use (e.g., “In the 30 
days prior to this incarceration, have you used stimulants (e.g., Adderall, Dexedrine, Ritalin, etc.) not 
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prescribed for you?”). Use of any stimulant drug for the this time period was summed in order to create a 
dichotomized variable (e.g., 0=“no use” vs. 2=“use”). 
Past 30-day concomitant use of opioids and stimulants prior to incarceration was measured by 
summing the two dichotomized variables for past 30-day opioid and stimulant use in order to create a 
categorical variable that consisted of four categories (e.g., 0=“no opioid/stimulant use”, 1=“opioid but not 
stimulant use”, 2=“stimulant, but not opioid use”, and 3=“concomitant opioid and stimulant use”). 
Concomitant use of both opioids and stimulants was coded so as to include only cases for which both 
opioid and stimulant drugs were used within the same 30-day period prior to incarceration.  
Past 30-day other drug use is defined as use of any non-opioid/non-stimulant drugs (e.g., alcohol, 
cannabis, hallucinogens, sedatives, etc.) during this time period. For drugs that might have been used licitly 
by prescription, participants were asked during the baseline interview to affirm only illicit use (e.g., “In the 
30 days prior to this incarceration, have you used benzodiazepines (e.g., Xanax, Valum, etc.) not prescribed 
for you?”). Drugs excluding opioids and stimulants were summed and then a dichotomous variable was 
created by recoding all non-zero values equal to 4 (e.g., 0=“no other drug use” vs. 4=“other drug use”). 
This variable was then combined with the prior categorical variable described above. The result was a 
single polytomous dependent variable, reflecting the four decisional outcomes of interest for the 30-day 
period prior to incarceration (e.g., 1=“opioid, but not stimulant use”, 2=“stimulant, but not opioid use”, 
3=“concomitant opioid and stimulant use”, 4=“other drug use”). 
Drug Use Outcomes Subsequent to Incarceration  
Subsequent to incarceration, drug use outcomes were examined for the one-year post-release 
period. This was done for four reasons. First, rates of drug use are significantly lower for the one-year and 
past 30-day periods subsequent to incarceration, compared to these respective periods prior to 
incarceration, and past-year use subsequent to incarceration is typically higher than past 30-day use 
subsequent to incarceration. Second, examining outcomes for the one-year post-release period broadens the 
timeframe during which a drug use occurred, permitting examination of drug use contemporaneous with 
other reported states (e.g., depression, cognitive difficulties) that were measured for the entire year. Many 
of the measures used in the CJKTOS follow-up interview pertain to the past year, rather than the past 30-
days or past 7-days. Third, looking at this longer period permits some discussion about the possibility that 
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reentry, as a process, influenced participants’ drug-related decision-making. Finally, examining this longer 
time period allowed the community supervision status (e.g., parole) of participants to be examined as a 
potential influence on decision-making (e.g., behavioral reinforcer). Some participants who reentered the 
community on probation/parole, and who may have been under supervision for the majority of the year, 
may not have still be on parole in the 30-day period prior to the follow-up interview. Therefore, for the 
purposes of this study, it was more important to examine the past-year period subsequent to incarceration 
rather than the 30-day period prior to follow-up interview completion.  
For this one-year post-release period, drug use outcomes were measured using of a categorical 
variable comprised of four mutually exclusive categories: past year: 1) concomitant use of both opioids and 
stimulants, 2) opioid, but not stimulant use, 3), stimulant, but not opioid, use, 4) other drug or/no drug use. 
Questions pertaining to past-year drug use were asked at follow-up in an identical manner to how questions 
pertaining to past 30-day drug use were asked at baseline. The final outcome variable was summed using 
the same process described above for the outcome variable of “past 30-day drug use outcomes” (see above 
subsection “Drug Use Outcomes Prior to Incarceration”).  
Past-year Heroin Use Subsequent to Incarceration 
 Past-year heroin use was measured at follow-up, by having participants respond to the question, 
“During the past 12 months, how many months did you use did you use heroin?”. Responses were then 
dichotomized (0=no use vs. 1=use).  
A Note on Fentanyl  
 It is important to note that, at baseline, participants reported drug use for the one-year and 30-day 
periods prior to incarceration, not simply prior to SAP entry. This means that there is some variance among 
the time periods of use reported by some, but not most, participants. For instance, a minority of participants 
may have been describing drug use that occurred in the late 1990s or early 2000s, while others may have 
described drug use that occurred in 2014 or 2016. This is due to the fact that some participants may have 
been incarcerated for several years prior to entering SAP, due to having longer sentences, whereas other 
participants, with shorter sentences, may have entered into SAP within a matter of months following their 
conviction. At follow-up, however, differences in the time period reported for is no longer a concern, 
making it possible to examine drug use outcomes for the same time period (2012-2017). This is noteworthy 
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insofar as fentanyl was introduced into the US drug supply during this time period (Daniulaityte et al., 
2019; O’Donnell, Halpin, Mattson, Goldberger, & Gladden, 2017; Peterson, 2016; Seth, Scholl, Rudd, & 
Bacon, 2018). In addition to fentanyl-adulterated heroin, stimulant products and counterfeit prescription 
drugs are increasingly identified as containing fentanyl analogues (Dai et al., 2019; Gladden, 2016; Green 
& Gilbert, 2016; Nolan et al., 2019; O’Donnell et al., 2017). It is likely that many people in this sample 
would not have known definitively that they were using fentanyl and that, prior to 2014, people would have 
been far less likely to encounter fentanyl-adulterated products. One limitation is that participants were not 
asked to report on use of fentanyl specifically. It may be that some participants intended to use fentanyl or 
were aware that they may be using fentanyl (Kenney, Anderson, Conti, Bailey, & Stein, 2018). This 
confounds an already challenging process of conjecture about the risks potentially known by participants 
and of assessing objective risk independent of user knowledge. The drugs that will be examined, (e.g., 
heroin, prescription opioids, buprenorphine, cocaine/crack cocaine, amphetamines) still reflect what is of 
interest: decisional outcomes involving high-risk drugs. Fentanyl, in some ways, may in future years 
become an equalizer, in the sense that greater uncertainty surrounding both opioid and stimulant use will 
likely only grow. The significance of fentanyl’s introduction into the drug supply during the time period 
will be considered further in Chapter 5.   
Independent Variables 
Drug-related Influences 
Age of drug use initiation was measured at baseline by having participants report the age at 
which they first used an illicit drug (e.g., “How old were you when you first began to use illicit drugs like 
marijuana, cocaine, heroin, tranquilizers, stimulants, sedatives, barbiturates, inhalants or prescription 
painkillers not prescribed for you?”). For participants who did not report any illicit drug use, or for which 
age of first illicit drug use was missing (N=54), the age of first alcohol intoxication was used (e.g., “How 
old were you when you had your first alcoholic drink, other than a few sips?”). In cases where there were 
responses for both alcohol and illicit drugs, the younger age was retained (see also, “Final Sample and 
Missing Data” subsection, pg. 138). Combining responses for age of first alcohol use or age of first illicit 
drug use and using the younger age reported, while not precise, does provide an estimate of the age that 
participants first used a psychoactive drug. As discussed earlier, age of drug use initiation indicates several 
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possibilities, any one of which, or any combination of which, has the potential to influence drug-related 
decision-making so as to bias a person toward further drug use. Response options were unlimited.  
Past 30-day drug use prior to incarceration was measured at baseline by summing the number 
of days that ten specific drugs (alcohol, cannabis, prescription sedatives, hallucinogens, synthetic drugs, 
cocaine/crack cocaine, amphetamines, heroin, prescription opioids, and buprenorphine) were used in the 
30-day period prior to incarceration (0-30). Ten dichotomous variables were then generated from these to 
reflect “use” or “no use” of a given drug for the 30-day period prior to incarceration. These items were 
examined as a possible influence on drug outcomes for the one-year period subsequent to incarceration.  
Drug use severity was measured using data collected at baseline by creating a composite variable. 
This variable consists of three questions pertaining to past 30-day drug problems contained in the 
“Alcohol/Drugs” subsection of the ASI-5 (range 1-40). At baseline, participants were first asked to report 
the total number of days out of the past 30 prior to incarceration that they experienced drug problems, 
“such as craving, withdrawal, wanting to quit but being unable to”. Participants then ranked on a 5-point 
Likert scale how troubled or bothered they were by these drug problems and how important receiving 
treatment for these drug problems was to them (1=Not at all—5=Extremely). Internal consistency of this 
composite variable was sufficient (α=0.76). Drug craving, withdrawal, and persistent problematic use 
despite a desire to moderate or abstain comprise some of the DSM-5 diagnostic criteria for SUD, meaning 
that this composite variable may be considered as an estimated, but inexact, indicator of drug use severity 
(APA, 2015). Including participants’ self-rated importance of receiving treatment for their problematic use 
also provides indication that the problems associated with use were significant enough so as to make them 
consciously registered and contemplated, rather than wholly unrecognized or dismissed (DiCemente, 
2018). 
Past-year drug use versatility prior to incarceration was measured by summing the number of 
different drugs that a participant reported using during the one-year period prior to incarceration (1-13). 
This was explored due to the fact that polydrug use is a high-risk form of drug use. Versatile drug use, 
wherein a greater number of different drugs are used during a given time period, versus fewer, may 
influence the likelihood that drugs such as opioids and stimulants are used concomitantly. It may also 
indicate the possibility the co-use of opioids and/or stimulants with other drugs (e.g., alcohol, synthetic 
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drugs, prescription sedatives) is occurring, which can be conceived as a higher-risk form of use (Smith & 
Staton, 2018). Using a greater number of drugs during a given time period may also indicate novelty-
seeking and higher tolerance for risk, uncertainty, and adverse consequences.  
Abstinence self-efficacy prior to treatment was measured at baseline by asking participants to 
respond on a 5-point Likert scale (0=very poor, 2=uncertain, 5=very good) the degree to which they 
believed they could refrain from alcohol and illicit drug use (e.g., “Based upon what you know about 
yourself and your situation, how good are the chances that you can get off and stay off of drugs/alcohol?”). 
Responses were recoded to reflect the presence or absence/ambivalence of abstinence self-efficacy (e.g., 
“moderately poor, very poor, uncertain”=0 vs. “moderately good, very good”=1).  
Past-year Drug Use Subsequent to Incarceration was measured using data collected at follow-
up pertaining to past-year drug use for the following drugs: Alcohol, cannabis, prescription sedatives, 
hallucinogens, synthetic drugs, cocaine/crack cocaine, amphetamines, heroin, prescription opioids, and 
buprenorphine. For each of the 10 drugs, the number of months out of the 12 months subsequent to 
incarceration was summed and then dichotomized to reflect past-year use (0=“no use” vs. 1=”past-year 
use”), resulting in ten separate drug use variables that were then dichotomized. These were used as 
independent variables for the outcome of past-year heroin use subsequent to incarceration.  
Demographic Characteristics  
Age was measured at baseline in years using participants’ dates of birth. Birthdates were 
confirmed for all participants at follow-up. Sex was measured at baseline by asking participants to select 
which gender they identified with (e.g., male, female, transgender). For baseline surveys prior to 2016, the 
“transgender” option did not include a specifier (e.g., “male to female” vs. “female to male”). However, no 
participants selected “transgender” for these years. In 2016, a specifier was included with the transgender 
option. However, because sex, rather than gender, is being considered as a potential influence on decision-
making, cases for which “transgender” was selected (N=3) were recoded to reflect biological sex which 
was cross-referenced by examining the correctional institution in which they were housed (i.e., all-male or 
all-female prison). More information would have been needed in order to determine if trans male or trans 
female cases were appropriate for this study’s conceptualization of sex. For instance, no information was 
available to clarify if these participants had undergone hormone replacement therapies or other elective 
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procedures. As the majority of the sample was male, a dummy variable was created (“not male”=0 vs. 
“male”=1).  
Indirect Indicators of Cognitive Functioning  
To measure the presence of some potential indirect indicators of cognitive functioning, three 
variables were examined, these included one composite variable denoting learning disorder diagnosis 
and/or prior special education involvement, as well as two dichotomous variables, past-year cognitive 
difficulties, and lifetime history of head trauma.  
The first variable, learning disorder (LD) diagnosis and/or special education (SE) involvement 
included summing responses for two questions asked at baseline pertaining to LD and SE enrollment. LD 
was measured by asking participants, “Have you ever been told that you have learning disability?”. 
Participants could respond “no” or “yes” for each item. SE enrollment was measured at baseline by asking 
participants, “Have you ever been in special education?”. Participants could respond “no” or “yes” for each 
item. Responses were dichotomized to reflect the presence or absence of these conditions (0=no LD 
diagnosis/no SE enrollment vs. 1=LD diagnosis and/or SE enrollment).  
The second indicator of cognitive functioning, past-year cognitive difficulties was measured by 
identifying the presence of cognitive deficits during the one-year post-release period with the potential to 
influence decision-making. For this item, participants were asked to report the number of months out of the 
past 12 that they experienced “trouble understanding, concentrating, or remembering, not as a direct result 
of alcohol and drug intoxication” (0-12). Responses were summed and recoded to reflect the presence or 
absence of past-year cognitive difficulties (0=“none” vs. 1=“some past-year cognitive difficulties”).  
The third indicator of cognitive functioning, lifetime history of head trauma, was measured at 
baseline by asking participants to self-report the number of times in their life that they experienced head 
trauma (e.g., “How many times have you ever had a head injury from being hit, having an auto accident, or 
another incident that resulted in being knocked out/unconscious?”). Response options were unlimited. 
History of head trauma was measured again at follow-up by asking participants to report any head trauma 
that occurred during the one-year post-release period. This response was summed with the number of head 
injuries reported at baseline in order to create a new head trauma variable with an updated lifetime head 
trauma incident total. However, this variable does not reflect head injuries sustained between a participant’s 
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completion of the baseline survey and their release date. For instance, head trauma could have occurred 
while incarcerated, meaning that the actual number of times that head trauma was sustained could be 
underestimated. Additionally, participants may have sustained head trauma as young children, but may be 
unaware of this history. Accordingly, a dichotomous variable was created for both time periods (0=“no 
reported history of head trauma” vs. 1=“reported of head trauma”).  
Scarcity and Social Influences 
As discussed in Chapter 2, scarcity, economic hardship, and lower social status can influence 
cognition and decision-making. Additionally, income can influence drug purchasing behaviors. These 
potential influences were explored using economic hardship, past-month income, past-year homelessness, 
and subjective socioeconomic status.  
Past-year economic hardship, defined as difficulty in meeting basic living (e.g., food, shelter) 
and healthcare needs (Beverly, 1999) was measured at baseline by combining two subscales in the 
CJKTOS survey. These subscales were adapted from the Survey of Income and Program Participation 
(SIPP), a longitudinal nationally representative survey of non-institutionalized adults conducted by the U.S. 
Census Bureau (Beverly, 2001; Iceland & Bauman, 2004; She & Livermore, 2007). The first subscale 
consists of five dichotomous questions (“no” vs. “yes”) and measures difficulty meeting basic living needs 
during the one-year period prior to incarceration (e.g., “In the 12 months prior to this incarceration, did you 
and/or your family have difficulty paying the full amount of rent or mortgage?”). Due to the increased use 
and cost of cellular telephones, one SIPP question pertaining to telephone disconnection was modified by 
CDAR to also reflect cell phones in addition to landlines. The second subscale consists of three 
dichotomous questions and measures difficulty meeting basic healthcare needs during the one-year period 
prior to incarceration (e.g., “In the twelve months prior to this incarceration was there a time when you or 
someone in your household needed to see a doctor or go to the hospital but wasn’t able to because of 
financial reasons?”). Because of the rising prescription drug costs in the U.S., a question about accessing 
prescription medication was included by CDAR as one of the three subscale items measuring difficulties in 
meeting basic healthcare needs (e.g., “In the twelve months prior to this incarceration was there a time 
when you or someone in your household needed to fill a prescription for medication but was unable to 
because of cost?”), though this item does not appear in SIPP. Among a clinical sample of drug users in 
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Kentucky (N=5,273) this revised economic hardship scale (range 0-8) demonstrated good internal 
consistency reliability (α=0.83), as did the subscales measuring difficulties in meeting basic living needs 
(α=0.76) and health care needs (α=0.83; Cole, Logan, Miller, & Scrivner, 2016). The combined scale 
among the current study sample demonstrated adequate internal consistency (α=0.85).  
Past-month income was measured at follow-up using self-reported income in US dollars from all 
past 30-day income sources. As discussed in the previous chapter, lower-income is believed to reflect a 
type of scarcity and uncertainty, whereas higher income is believed to reflect a state of that enables 
(comparatively) enhanced cognitive functioning, greater, choice, and potentially more purchasing power 
for drugs (or non-drug commodities). Questions pertaining to employment and income used as part of 
CJKTOS surveys were adapted from the ASI-5 “Employment/Support Status” subsection. Participants 
were asked at follow-up to report the income received from licit work (e.g., payroll, odd jobs), illicit work 
(e.g., drug dealing), alternative sources (e.g., gambling winnings), public assistance and benefits (e.g., 
Supplemental Nutrition Assistance Program, Social Security Disability Insurance), and money received 
from friends and family for the past 30 days. Amounts from all sources were summed for a total past 30-
day income amount.  
Past-year homelessness was measured at baseline by asking participants to respond (“yes” vs. 
“no”) to the question, “In the 12 months prior to this incarceration, did you consider yourself to be 
homeless?”.  
Subjective socioeconomic status was measured at baseline using an adapted version of the 
Subjective Socioeconomic Scale (Adler et al., 2000). This one-item measure is comprised of a 10-rung 
ladder, displayed vertically in the form of a drawing, that participants used to help respond to the 
accompanying question: “Overall, on a scale of 1 to 10, with 1 representing the people who are worst off, 
those who have the least money, least education, and worst jobs or no job, and 10 representing the people 
who are best off, have the most money, most education and best jobs, how would you rate yourself on that 
scale?”. Here, the ladder was used to help visualize the lowest status (e.g., 1) versus highest status (e.g., 
10). Due to instrument changes, the ladder only accompanied the question for 3 out of the 5 baseline years 
examined as part of this study. However, the wording of the question remained consistent across years. 
Lower scores for this item (range, 1-10) indicate lower perceived social and economic status.  
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Community-wide Scarcity and Inequality 
As discussed earlier, regional and household poverty, scarcity, and inequality can influence 
decision making and high-risk drug use in several ways. To examine this potential influence, county-level 
poverty and county-level wealth inequality were considered for examination.  
County-level poverty was measured at the county-level using Small Area Income and Poverty 
Estimates (SAIPE) for years 2013-2017 by using the median value for the proportion of households per 
county considered by the U.S. Department of Health and Human (HHS) to be living at or below the poverty 
threshold, which is calculated using household size and income (U.S. Census Bureau, 2018). For example, 
in 2019, a household size of one is considered to be living in poverty if annual income does not exceed 
$12,490, whereas a household size of five is considered to be living in poverty if annual income does not 
exceed $30,170 (HHS, 2019). Although median household income for counties provides an indicator of 
typical income, examining the proportion of households per county living in poverty provides an indication 
of how thinly spread annual income may be per household.  
County-level wealth inequality was operationalized using the GINI coefficient, a measure of 
income and wealth distribution that indicates financial resource inequality, whereby a value of 0 reflects 
perfect equality and a value of 1 reflects the maximum value of inequality (Atkinson, 1970; U.S. Census 
Bureau, 2019a). Using ACS data for years 2013-2017, GINI coefficients for each Kentucky county were 
considered for examination. As there are not significant fluctuations between years, the median coefficient 
value for the five-year period was selected for possible use.  
Psychiatric Symptoms, Stress, Pain and Misregulation 
As noted earlier, mood, affect, and symptoms related to psychiatric conditions, such as depression 
or anxiety, can influence drug-related decision-making and behavior. The potential influence of psychiatric 
symptoms was considered by examining past-year depressive symptoms, past-year suicidal ideation, and 
past-year anxiety symptoms. 
Past-year depressive symptoms was measured at baseline using items adapted from the 9-item 
Patient Health Questionnaire-9 (PHQ-9), an instrument that measures depression symptom severity using 
DSM-IV major depressive disorder (MDD) diagnostic criteria (Kroenke, Spitzer, Williams, 2001). 
Participants responded (“no/absent” versus “yes/present”) to questions pertaining to any two-week period 
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in the past-year prior to incarceration (e.g., “In the 12 months prior to incarceration, did you have two 
weeks in a row when you were consistently down or depressed most of the day, nearly every day?”). 
Overall, the PHQ-9 has demonstrated good criterion and convergent validity, with strong positive 
correlations observed between higher PHQ-9 scores and lower scores on measures of mental health, social 
functioning, overall functioning, and role functioning (Kroenke et al., 2001; Kroenke, Spitzer, Williams, & 
Löwe, 2010). Here, PHQ-9 items were adapted for use on the CJKTOS baseline survey by CDAR by 
dichotomizing response options, instead of using Likert scales (0-3), thus resulting in a range of 0-9 rather 
than the 0-27 PHQ-9 range. Good internal consistency reliability for this adapted PHQ-9 was found in a 
clinical sample of drug users in Kentucky (N=5,273; α = 0.95; Cole et al., 2016), as well as in the current 
sample (α = 0.94). A dichotomous variable was created using a cutoff point between those evidencing 
symptoms of MDD and those not, whereby participants were classified as having MDD symptoms if they 
responded “yes” to 5 out of 9 questions. At follow-up, the presence of past-year depressive symptoms was 
measured by asking participants to report the number of months out of the past 12 that any depressive 
symptoms were experienced (e.g., “In the past 12 months how many months have you experienced serious 
depression, that was not a direct result of drug/alcohol use?”). Responses can range from 0-12. Responses 
were dichotomized (e.g., zero months=0 vs. >1 month=1) so as to reflect the presence or absence of 
depressive symptoms for this period.  
Past-year suicidal ideation was measured at baseline by asking participants to respond (“yes” vs. 
“no”) to the question, “During the 12 months prior to this incarceration, did you have thoughts about 
ending your life or committing suicide?”. At follow-up, suicidal ideation was measured by asking 
participants to respond the question, “In the past 12 months how many months have you experienced 
serious thoughts of suicide that was not a direct result of drug/alcohol use?” for which they could report 0-
12 range. Responses were recoded to reflect the presence or absence of past-year suicidal ideation (“no 
suicidal ideation”=0 vs. “suicidal ideation”=1).  
Past-year anxiety symptoms was measured at baseline using an adapted version of the 
Generalized Anxiety Disorder scale (GAD-7), a 7-item measure designed to identify and assess symptoms 
of GAD using DSM-IV diagnostic criteria (Spitzer, Kroenke, Williams, & Löwe, 2006). The GAD-7 has 
demonstrated adequate convergent and criterion validity as well as good internal consistency (Delgadillo et 
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al., 2012; Löwe et al., 2008; Spitzer et al., 2006). Items were adapted by CDAR researchers by 
dichotomizing response options (“no/absent” versus “yes/present”), instead of using 4-point Likert scales to 
measure frequency of symptoms, resulting in a 0-7 range. Among a clinical sample of drug users in 
Kentucky, good internal consistency was found (N=5273; α = 0.98; Cole et al., 2016). In this sample, good 
internal consistency was also observed using this modified version of the GAD-7 (α =0.92). A cutoff point 
between those evidencing symptoms of GAD and those not was created whereby participants were 
classified as having GAD symptoms if they responded “yes” to 4 out of 7 questions, including the screener 
question: “In the 12 months before you were incarcerated, did you have a time period lasting 6 months or 
longer where you worried excessively or were anxious about multiple things on more days than not for all 6 
months?”. At follow-up, the presence of past-year anxiety symptoms were measured by asking participants 
to report the number of months out of the past 12 that any symptoms associated with anxiety were 
experienced (e.g., “In the past 12 months how many months have you experienced serious anxiety or 
tension that was not a direct result of drug/alcohol use?”). Responses can range from 0-12. Responses were 
dichotomized (e.g., zero months=0 vs. >1 month=1) so as to reflect the presence or absence of anxiety 
symptoms for this period.  
As noted earlier, increased stress response can impair decision-making in a variety of ways. 
Accordingly, past-week stress-related health effects was measured with data collected at baseline using 
11 items contained on the 15-item Stress-related Health Consequences Scale (HCS), developed to measure 
past-week stress indicators and stress-related health consequences (Logan & Walker, 2010). Participants 
were asked to respond using a 4-point Likert scale (1=None of the time – 4=All of the time) the degree to 
which they experienced indicators of stress in the seven days prior to incarceration (e.g., “In 7 days prior to 
incarceration, have you experienced anxiety and/or panic attacks?”; “In 7 days prior to incarceration, have 
you felt stressed out?”). For a total scale score, all 15 scale items are be summed, with higher scores 
indicating a greater degree of physical and psychological stress (15-60). Among a clinical sample of drug 
users (N=5,273), the scale demonstrated good internal consistency reliability (α= 0.90; Cole et al., 2016). 
The initial consistency for all 15 items was acceptable in this sample (α=0.88). 
However, because the content of the HCS is a multidimensional construct, seeking to measure 
states and experiences that are somatic or physiological (e.g., “experienced unexplained aches and pains”, 
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“increased heart rate”),  psychological (e.g., “experienced stress, anxiety, worry, or fear”), and behavioral 
(e.g., “used illicit drugs to reduce stress, anxiety, worry, or fear”) principal component analysis (PCA) was 
used to examine scale items in order to further scrutinize item correlations and to determine if subscales 
could be formed. Three components were extracted (KMO=0.93; X2=9410.79, df=105, p<.001). 
Component one, comprised of seven items pertaining to affect, sleep, fatigue, and changes in eating 
patterns, accounted for 40.2% of the total variance; component two, comprised of five items pertaining to 
somatic disruptions and the re-experiencing of trauma, accounted for 8.8% of the variance; component 
three, comprised of the three items pertaining to drug-related stress coping behaviors, explained 7.7% of 
the variance.  
Upon closer examination, one of the items comprising component two was identified as 
potentially invalid in this sample due to self-report limitations, as it asked participants to rate the degree to 
which they experienced high blood pressure, a physiological state that is not always subjectively felt or 
consciously recognized as high blood pressure (Greenstadt, Shapiro, & Whitehead,1986; Kollenbaum, 
Dahme, & Kirchner, 1996 Koroboki, 2010). For younger participants, high blood pressure, both 
conceptually and phenomenologically, may be less understood, even as interoceptive capacity may be 
greater in younger individuals (Khalsa, Rudrauf, & Tranel, 2009). Removing this item did not reduce the 
internal consistency (α=0.88).  
The three items pertaining to drug-related stress coping behaviors, that comprised component 
three were removed and retained for use as a composite variable indicating misregulation. Removing these 
component three items, along with the HBP item, resulted in a final 11-item measure (range, 11-44) of 
recent stress-related health effects with good internal consistency (α=0.89).  
Chronic pain, defined as pain lasting three months or longer (Treede et al., 2015), was measured 
by asking participants at baseline and follow-up to report (“no” vs. “yes”) any chronic pain experienced 
(e.g., “Do you have any chronic physical pain, that is, pain that has lasted three or more months?”) so as to 
reflect the presence or absence of chronic pain experienced during each period.  
Misregulation, defined as exerting control over one’s actions in a manner that achieves a short-
term end (e.g., reducing stress) at the expense of a long-term end via instrumental coping (Baumeister, 
Heatherton, & Tice, 1994; Tice, Bratslavsky, & Baumeister, 2018), was measured using the three 
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behavioral items contained on the HCS (e.g., “In 7 days prior to incarceration, have you used alcohol to 
reduce stress, anxiety, worry or fear?”). This question was asked in reference to alcohol, prescription drugs, 
and illicit drugs. Participants could respond using a 5-point Likert scale (0=None of the time-5=All of the 
time). Although these items differ in kind (i.e., drinking alcohol to cope with stress versus using illicit 
drugs) and, when grouped, did not demonstrate robust internal consistency (α=0.64), these behaviors all 
nevertheless indicate some propensity toward misregulation in that a non-zero response to any of these 
questions means that the participant has engaged in instrumental coping by using a psychoactive drug as an 
attempt to reduce stress. Responses were dichotomized where values of >1 were coded as 1= 
“misregulation occurred” and values of 0=“no misregulation occurred”. One limitation in using this 
variable is that participants who did not report any of the three behaviors indicative of misregulation during 
this 7-day period, either due to the fact they did not experience “stress, anxiety, worry, or fear” during this 
time or because they did not use drugs in this time (even as they used drugs within the larger 30-day 
period), may still have some proclivity toward misregulation, despite the fact that it was not captured for 
the week in question. As such, this variable should be considered as an approximation of misregulation that 
occurred contemporaneous to past 30-day drug use, indicating some propensity toward misregulation or 
“self-medication” during this time period.  
Access to Drug Markets  
As discussed earlier, the area that a person lives in and the access they have to drug markets can 
influence drug-related decision making and high-risk drug use by restricting the range of choices and/or 
influencing the cost and difficulty with which some drugs may be acquired. To examine potential 
influences, county Internet connectivity, county disability rates, county opioid and buprenorphine 
prescribing rates, and county alcohol availability were considered for examination. 
Internet connectivity was measured using the percentage the households per Kentucky county 
with internet access, 25 minimum broadband speed (i.e., the slowest speed option) for 2017 (Federal 
Communications Commission, 2018). This was examined due to the fact that Kentucky counties vary in 
their internet access, with some counties far more connected than others. Since the Internet is increasingly 
used as an avenue for accessing drug markets, the ease or difficulty for accessing these online markets is 
important to consider.  
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County disability rates were measured by creating a five-year average for the proportion of 
residents per Kentucky county receiving Social Security Disability Insurance benefits for years 2013-17 
(Social Security Administration, 2019). As noted earlier, areas with a higher density of people who are ill 
and/or are receiving prescription medications may influence local drug markets in terms of access to 
diverted medications.  
County opioid prescribing rates were measured using data collected from the Kentucky All 
Schedule Prescription Electronic Reporting (KASPER) surveillance program, which consists of an online 
database used to document and monitor the prescription and distribution of all Schedule II-V Controlled 
Substances in Kentucky (Kentucky Cabinet for Health and Family Services [CHFS], 2019). Prescribing 
medical professionals and pharmacists are mandated to enter data into KASPER and may utilize the system 
to generate reports and make clinical decisions. KASPER is also utilized by state government and law 
enforcement to monitor prescribing trends and to investigate potential prescription drug diversion (CHFS, 
2019). County opioid prescribing rates were measured by first summing all individual opioid prescriptions 
(e.g., Oxycontin, Hydrocodone, Methadone, and Tramadol) written and filled per county, creating five-year 
averages for years 2013-17, and then by calculating per 1,000 prescribing rates based on the 2013-17 five-
year county adult population ASC averages (U.S. Census Bureau, 2019b). County buprenorphine 
prescribing rates were calculated similarly, but instead by summing all Suboxone/Subutex prescriptions 
written and filled.  
Non-drug Alternative Reinforce  
As noted previously, many non-drug alternatives can reinforce behavior. Some of these are 
important to consider as possible influences on drug-related decision-making prior and subsequent to 
incarceration. Here, they were measured using close relationships, social interaction, perceived value of 
social interaction, social worth, leisure time, educational and vocational involvement, and post-release 
correctional status.  
Close relationships were measured using data collected at baseline and follow-up. Participants 
were asked to indicate from a 5-item list important people, such as family, romantic partners, with whom 
they had a relationship with (e.g., “Would you say you have had a close, long-lasting relationship with your 
children?”). Participants then had the opportunity to report (“yes” vs. “no”) if they had other people with 
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whom they had a close, long-lasting relationship with that were not already listed. Lastly, participants were 
asked “How many close friends do you have?”, for which there was an unlimited response option. The final 
number of close relationships was calculated by summing the dichotomous close relationship responses (0-
6) and then summing this total with the number of close friends, resulting in a variable with unrestricted
range. 
Social interaction was measured at baseline and follow-up by asking participants to select one of 
three response options to the following question “In the past 12 months, with whom did you spend most of 
your free time?”. Participants could select “Friends”, “Family”, or “Alone.” Responses were recoded to 
reflect the absence (0= “alone”) or presence (1=“friends, family”) of past-year social interaction.  
Perceived value of social interaction was also considered. To assess if social interaction was 
rewarding, participants were asked to rate their satisfaction with how their free time was spent (e.g., “Were 
you satisfied spending your time this way?”). Participants could respond “No”, “Yes”, “Indifferent”. 
Responses were recoded into a dichotomous variable reflecting the presence or absence of reward 
(0=“no/indifferent” vs. 1=“satisfied”).  
Some of the rewarding aspects of non-drug alternatives that are social in nature, such as close 
relationships, extend beyond the experiential pleasure that can come from being with others. One aspect is 
that, when relating to others, a person not only comes to value other people, but comes to be valued and 
supported by other people. A sense of worth and support can be experientially pleasurable and directly 
rewarding, which has the potential to reinforce behavior accordingly; but it can also, under the right 
conditions, buffer stress response, pain, and other negatively valanced states, which also has the potential to 
reinforce behavior (Cutrona & Russell, 1987; Hagerty & Williams, 1999; Heinrichs, Baumgartner, 
Kirschbaum, & Ehlert, 2003; Langford, Bowsher, Maloney, & Lillis, 1997; Yoshida et al., 2009). Further, 
social worth and support may also be in keeping with the idea of “having a stake in the conventional life”, 
insofar as a person may be more likely to invest in people and activities for which their presence matters, 
and is encouraged through supportive gestures. In other words, reciprocity of rewarding prosocial patterns 
might be established (Cropanzano & Mitchell, 2005). Social worth was measured at follow-up by asking 
participants to rate on a 5-point Likert scale (1=not at all—5=Extremely) the degree to which they felt 
valued and supported by others (e.g., “How much do you feel cared about or supported by the important 
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people in your life?”). Responses were recoded to reflect the presence or absence of feeling valued (0=“did 
not feel cared about/supported” vs. 1=“felt cared about and supported”).  
Leisure time was measured at baseline by asking participants to report the average number of 
days per week that they could pursue activities of personal interest (e.g., “In the 12 months prior to this 
incarceration, how many days per week, on average, were you involved in hobbies or activities that you 
liked to do?”). This item was considered because it indicates the presence of the flexible resource of time 
which is often needed to pursue potentially rewarding activities of interest.  
Past-year educational and vocational involvement was measured using data collected at 
baseline and follow-up. To first assess vocational involvement, participants choose from a list the 
employment designation that best reflected their status for the majority of months (>6) out of the 12-
months prior and subsequent to incarceration (e.g., unemployed, retired, disabled, working part-time, 
working, full-time, seasonal/irregular work, retired, student, etc.). Responses were dichotomized to reflect 
the presence or absence of regular vocational involvement (e.g., 0=“unemployed, retired, disabled, irregular 
employment” vs. 1=“full- or part-time employment”). For people who reported being unemployed, they 
could also specify that they were a student, thus indicating educational involvement even in the absence of 
vocational involvement (2=student). In a separate question, participants were also asked at baseline and 
follow-up to report any involvement in educational/vocational training, irrespective of employment (0=no 
training vs. 1=educational training). These two variables were summed and then recoded into a 
dichotomized variable to reflect the presence or absence of educational and/or vocational involvement 
(0=no educational/vocational involvement vs. 1=educational/vocational involvement) in the one-year 
period prior and subsequent to incarceration.  
Post-release correctional status was measured at follow-up by asking participants to self-report 
if they were on community supervision (i.e., probation, parole) at any point since their release. Post-release 
correctional status is considered as an additional behavioral reinforcer.  
Central Appalachia 
As described earlier, residing in a harsh region can have a profound impact decision-making and 
behavior. It can accomplish this by influencing cognition and one’s beliefs about their future, but also by 
narrowing choices and opportunities for pursuing rewarding non-drug alternatives. For people in Eastern 
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Kentucky, the portion of the state that falls within Central Appalachia, opportunities for accessing 
rewarding non-drug alternatives are more limited. Historically and presently, Central Appalachia is a region 
in which there are excess morbidities---including high rates of disability and psychiatric health disorders--
premature death, resource scarcity, and economic insecurity. Relative to other areas in the state, Central 
Appalachia portion of Kentucky may be considered as a harsh environment, even other regions in the state 
may have smaller, concentrated areas that might also be considered harsh. To explore this possible 
influence of residing in a “harsh” region, Central Appalachia was measured at baseline and follow-up 
using the zip code and/or county of residence that participants reported residing in for the majority of 
months (>6) out of the past 12, prior and subsequent to incarceration. At baseline, U.S. postal zip codes 
were converted into counties and coded as either “Central Appalachia” or “non-Appalachian” using 
Appalachian Regional Commission (ARC) designations (ARC, 2019). At follow-up, participants reported 
the county in which they resided in and similar codes were created. For participants reincarcerated at 
follow-up, the county of residence, rather than county of incarceration, was used to code responses.  
Control Variables 
In addition to the independent variables described above, which are believed to influence decision-
making in respect to opioids and stimulants, several additional participant characteristics with the potential 
to influence the outcomes of interest were also measured.  
High school diploma (HSD)/General Equiveillance Degree (GED) was measured using data 
collected at baseline. Participants were asked to select from a list the highest level of education they 
completed. Categories ranged from “1=never attended” to “21=doctoral degree”. Responses were summed 
and a cut-off point reflecting the attainment of HSD/GED was used to create a dichotomized variable (e.g., 
0=no high school diploma/GED vs. 1=high school diploma/GED or greater).  
Race/ethnicity was measured using data collected at baseline. Participants were asked to select 
from a list the race/ethnicity with which they identified themselves as (e.g., African American, Alaskan, 
Hispanic-Mexican, Hispanic-Cuban, Native American, White, etc.) or to write-in “other” for categories not 
already provided. Responses were dummy coded into a dichotomized variable (e.g., “non-white”=0 vs. 
“white”=1). This was done due to the small group sizes for all race/ethnic groups other than African 
American and White. State-wide, both Kentucky’s non-institutionalized population and KY DOC 
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population are majority White, making this category as a dummy variable an appropriate choice. 
Limitations for dummy coding race/ethnicity will be discussed in Chapter 6.  
Lifetime drug treatment episodes were measured using data collected at baseline by summing 
the number of times that participants reported having ever received any of the following substance use 
services: Medical detox, outpatient treatment, inpatient/residential treatment, for which the response range 
was unlimited.  
Ever IDU was measured at baseline by asking participants to respond to the question “Before this 
incarceration, did you ever inject any drugs?” for which they could respond “no” or “yes”.  
Nights spent in a controlled environment was measured at baseline for the 30-day period prior 
to incarceration (0-30). At follow-up, the nights spent in a controlled environment was measured for the 
entire one-year post-release period (i.e., the time period beginning the date of participants’ release and 
concluding the date of follow-up interview completion) (0-365).  
Mandated to SAP was measured using KOMS data (which comprises the broader CJKTOS 
datasets). Cases were coded 0=“voluntary participation” vs. 1=“mandated participation”.  
SAP completion was also measured using KOMS data, which provides a documented date of 
SAP graduation or termination. Participants who were terminated from SAP were coded as 0=“terminated” 
and participants who completed SAP were coded as 1=“graduated”.  
Descriptive Variables 
In addition to the independent and control variables described above, the below variables were 
also examined in order to provide a fuller description of the entire study sample and as well as richer 
descriptions of all drug use outcome groups, including how characteristics that differed between groups. 
Marital status was measured using data collected at baseline. Participants were asked to select 
from five categories (e.g., “married”, “widowed”, “separated”, “divorced”, and “never married”), the status 
that best reflected their marital situation.  
In addition to exploring past-year drug use versatility as an independent variable, past 30-day 
drug use versatility prior to incarceration was included for descriptive purposes. This item was 
measured by summing the number of different drugs that a participant reported using during the 30-day 
period prior to incarceration (1-13).  
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In addition to examining the dichotomized variable of past 30-day drug use prior to incarceration 
as an independent variable, past 30-day drug use prior to incarceration and past 30-day drug use 
frequency prior to incarceration are presented for descriptive purposes for all drug use outcomes. These 
items were measured at baseline by summing the number of days that ten specific drugs (alcohol, cannabis, 
prescription sedatives, hallucinogens, synthetic drugs, cocaine/crack cocaine, amphetamines, heroin, 
prescription opioids, and buprenorphine) were used in the 30-day period prior to incarceration (0-30). 
Responses were then dichotomized so that proportions for “use” versus “no use” of specific drugs could 
also be presented.  
Past-year drug use prior to incarceration and past-year drug use frequency prior to 
incarceration were measured using data collected at baseline pertaining to past-year drug use for the 
following drugs: Alcohol, cannabis, prescription sedatives, hallucinogens, synthetic drugs, cocaine/crack 
cocaine, amphetamines, heroin, prescription opioids, and buprenorphine. For each of the 10 drugs, the 
number of months out of the 12 months prior to incarceration was summed, resulting in ten separate drug 
use frequency variables (range 0-12). New variables were generated from these to produce an additional 
dichotomous variable of past-year use (0=no use vs. 1=past-year use).  
Past-year drug use subsequent to incarceration and past-year drug use frequency subsequent 
to incarceration were measured using data collected at follow-up in a manner identical to past-year drug 
use prior to incarceration, with the only difference being the time period (range 0-12). Although the 10 
“past-year drug use subsequent to incarceration variables” are considered as independent variables for the 
outcome of past-year heroin use subsequent to incarceration, they are also presented as means and 
proportions to help describe the sample and drug use groups during the one-year period subsequent to 
incarceration. 
Past-year preferred drug of choice was measured at baseline by asking participants to select 
from a list of 13 drugs the one which they most preferred using during the year prior to incarceration (e.g., 
“In the 12 months prior to this incarceration, what was your primary substance of choice?”). Responses 
were recoded into 9 categories for the most commonly reported drugs: alcohol, marijuana, cocaine/crack 
cocaine, amphetamine-based stimulants, heroin, prescription opioids, buprenorphine, prescription 
sedatives/barbiturates, and inhalants/hallucinogens/synthetic drugs.  
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Urban proximity was measured using the 2013 Urban Influence Codes, a 12-part classification 
scheme that categorizes counties by metropolitan (i.e., counties in metro areas with 20,000 to >1 million 
residents) and non-metropolitan (i.e., counties adjacent/not adjacent to metro areas, but not in metro areas) 
status into two metro and ten nonmetro designations (U.S. Department of Agriculture, 2013). Metropolitan 
counties are differentiated by population size of their metro area and nonmetropolitan counties are 
differentiated by size of largest city and proximity to metro and micropolitan areas (U.S. Department of 
Agriculture, 2013). Counties designations range from 1 (e.g., “Large-in a metro area with at least > 1 
million residents”) to 12 (e.g., “Noncore-not adjacent to a metro/micro area and <2,500 population 
(Department of Agriculture, 2013).  
Unrestricted alcohol sales was measured using data obtained from the Kentucky Alcohol 
Beverage Control (KY ABC) (KY ABC, 2017). A dichotomous variable was created that coded counties as 
either 1=“restricted” (i.e., alcohol is significantly restricted or completely prohibited) or 0=“unrestricted” 
(i.e., alcohol sales are unrestricted county-wide). Because alcohol is widely consumed, may be used as a 
substitute for or compliment to various illicit drugs, and because its use more difficult to detect among 
people on community supervision, it is important to consider how access to this licit, and overall less risky, 
drug may influence drug use outcomes.   
Days until post-release alcohol and/or illicit drug use was measured at follow-up by asking 
participants who reported alcohol use subsequent to incarceration to respond to the following question, “In 
12 months since your release, how many days were you on the street before you first used alcohol?”. For 
participants who reported illicit drug use subsequent to incarceration the same question was asked (range 0-
365). 
Intoxicated during offense was measured at baseline by asking participants to respond (“yes” vs. 
“no”) to the question, “Were you under the influence of alcohol and/or drugs when you committed the 
offense that led to your current incarceration?”.  
In addition to the independent variable of “chronic pain” described above, a description of chronic 
pain severity, for participants who reported experiencing chronic prior to incarceration, was measured by 
creating a composite variable composed of three scale items adapted from the Brief Pain Inventory (BPI; 
Cleeland & Ryan, 1994), a widely used instrument for assessing clinical pain caused by a variety of health 
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conditions that has demonstrated good validity and reliability (Cleeland, 2009). Participants were asked to 
rate the intensity of their chronic pain when the pain is at its “least”, “average”, and “worst” using a 10-
poing Likert scale (e.g., “Please rate the intensity your chronic at its worst in the 30 days prior to this 
incarceration”). Higher composite scores indicated overall greater pain severity (3-30; α=0.95).  
Analytic Plan Overview 
Data Handling and Preparation 
A total of ten datasets were obtained from CDAR along with four codebooks and all original 
survey instruments. Datasets included five baseline survey datasets and five follow-up data survey datasets 
for FYs 2013-17. Methods proposed by MacInnes (2017) for handling and preparing (e.g., inspecting, 
cleaning, merging) data obtained from secondary sources for preliminary examination and analyses were 
followed, along with other sources, as needed (Kiecolt & Nathan, 1985; Trzesniewski, Donnellan, & Lucas, 
2011). Variables and variable names were reviewed prior to merging datasets, as were all codebooks.  
Small instrument changes between FYs resulted in some survey versions containing slightly more 
or fewer questions. Although instrument changes were not extensive, they nevertheless resulted in some 
variables only being collected for one or two FYs. To include variables that were only collected for one or 
two years would have resulted in significant non-random missing data for many cases (>900). Rather than 
deleting a significant percentage of cases and drastically reducing the sample size, a decision was made to 
exclude variables that were not measured across all FYs, particularly if the same the same construct could 
be represented using a different variable or combination of variables, or if it was not relevant to the current 
study (e.g., military history, criminal offenses) (Cook & Campbell, 1979; MacInnes, 2017; Trzesniewski et 
al., 2011). Variables of interest to this study were renamed such that all variable names across datasets were 
uniform. Codebooks were annotated and dated with each change. Variables that were not of possible 
interest were not renamed and not included during merging. The final merged baseline and follow-up 
CJKTOS dataset contained 696 variables.  
In addition to visually inspecting the data, preliminary analyses such as frequency distributions 
and descriptive statistics were produced in order to preliminarily identify any potential data entry or 
merging errors, improperly coded variables, and missing data that was not expected (e.g., if participants 
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responded “no”  to lifetime incidence of head trauma, then there should be no value for “number of times” 
that head trauma was experienced). 
Statistical Software 
Data cleaning, merging, and preliminary analyses were conducted using IBM-SPSS version 27 
(IBM Corp., 2018). All subsequent analyses were conducted using Stata/SE version 15 (StataCorp LLC, 
2017).   
Analytic Plan Development 
 One of the conceptual assumptions underlying this study is that people and their decision-making 
cannot be divorced from the contexts in which they live. In this sense, they can be conceptualized as nested 
within and across contextual layers. In acknowledging that people are nested within larger contexts and 
conditions, it cannot be assumed that observations observed at the individual-level are truly independent. 
This is important, in that it violates assumptions for many families of statistical tests, including ordinarily 
least squares (OLS) regression (Robson & Pevalin, 2016). This can result in incorrect inference and inflated 
statistical significance based on too many degrees of freedom that are not truly independent (Tabachnick & 
Fidell, 2013). To help illustrate, a commonly used example is to consider outcome measures for students. 
Outcomes for a population of students who live in the same city, but who reside in different neighborhoods 
and attend different schools may vary not only due to student-level differences, but also due to contextual 
factors that influence learning and development. Here, variance might be observed at more one than one 
level. Student performance may differ as a result not only of student-level differences (e.g., measures of 
general intelligence), but also due to broader conditions, such the different classrooms they learn in, 
schools they attend, and neighborhoods they live in. In other words, observed effects or outcomes may vary 
as a function of individual characteristics and shared group characteristics identifiable at other levels. Even 
if study aims were not concerned with exploring possible contextual influences on drug use, the nature of 
the data used in this study (i.e., cases clustered at higher levels, such as counties) may violate the 
assumption of independence of errors, potentially contributing to incorrect estimations of the standard 
errors (Robinson & Pevalin, 2016; Tabachnick & Fidell, 2013).  
Because of this possibility, mixed-effects (random-intercept) multilevel regression models 
(MLMs) was explored first, prior to developing the final analytic plan, using the exploratory strategy 
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proposed by Hox (2002). Mixed-effect MLMs include fixed and random effects, needed to “nest” one 
subset of data in another. MLMs are an extension of OLS regression and can be highly versatile and 
customizable (Hox, Moerbeek, & Van de Schoot, 2017). As noted above, in some instances, individual-
level outcomes examined without taking into account the hierarchical structure of the data can produce 
inaccurate estimates. MLM addresses such an issue by permitting intercepts (means) and slopes (IV-DV 
relationship) to vary between levels (Hox et al., 2017). For example, the relationship between cocaine use 
and, say, misregulation would be allowed to vary between different second-level groups (Tabachnick & 
Fidell, 2013). Stata enables MLM model building and customization, with many available commands and 
online resources that can be utilized as models are built (Acock, 2016; Robson & Pevalin, 2016; StataCorp 
LLC, 2017).   
Power analysis  
Because MLM uses maximum likelihood estimation (MLE) and because there are numerous 
variables of interest in this study, it was important to determine that the final sample size of 1,563 would 
provide adequate statistical power (Maas & Hox, 2005). Although Long (1997) notes that >500 cases are 
likely sufficient be able to obtain reliable estimates of variance, that does not necessarily take into 
consideration the number of covariates across levels, of which there are several in this study, nor the power 
needed to detect smaller effect sizes (Acock, 2016; Hox, et al., 2017). 
In areas of exploratory, non-critical research, a power of 0.80 may be minimally adequate (Jones, 
Carley, & Harrison, 2003). Even though the current study is exploratory and heavily conceptual in nature, 
ideally it is desired that there will be sufficient power for accurately detecting a small effect size in terms of 
explained variance (f2=0.02; R2=0.02). However, it would be acceptable for the purposes of this study if 
power is sufficient for accurately detecting a medium effect size (f2=0.15; R2=0.13). A priori estimates of 
the required sample size, conducted using the software G*Power (Faul, Erdfelder, Buchner, & Lang, 2009), 
determined that for a small effect size f2=0.02, alpha=0.05, power=0.85, tested predictors=40, a sample size 
N=1,545 was required9. Setting the power=0.90 or 0.95 would have necessitated increasing the sample size 
to N=1,726 and 2,005, respectively. In order to be able to accurately detect a medium effect size f2=0.15 at 
9 Note that 40 variables was used to err on the side of caution. While there were many IVs proposed for 
examination, not all of them were included into the models, as some did not demonstrate any correlation to 
outcome variables and others were not included in order to avoid overfitting the model.  
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alpha=0.05, power=0.85, tested predictors=40, a sample size of N=232 would be required. Increasing this 
to power=0.90 or 0.95 would have necessitated increasing the sample size to N=256 or N=293, 
respectively. Preliminary analyses using the current study sample size (N=1,564) with f2=0.02, alpha=0.05, 
tested predictors=40, calculated achieved power=0.86.  
However, with MLM, needed sample size varies between levels. Although level-one had sufficient 
power at N=1,643, the overall power needed for each MLM varies based on the groupings and sample sizes 
for groupings across levels (Hox & Maas, 2002). Typically, MLE methods, which produce parameter 
estimates and asymptotic standard errors, is used in MLM as well as logistic and multinomial regression, in 
which only fixed effects are modeled (Hox et al., 2017). MLE is used to test the significance of specific 
parameters and to establish confidence intervals (CI). This means that there are assumptions of normal 
distribution of error, not just at level-1, but at level-2 and so on. (Maas & Hox, 2004). Small sample sizes 
(<50) for groups at higher levels can lead to biased estimates; specifically, the random effects at the second 
level may be inaccurate due to distribution assumptions at the second-level (or third-level, etc.) not being 
satisfied (Maas & Hox, 2004). It has been suggested that the number of level-2 or level-3 groups is 
generally more important than the number of observations within each grouping (Hox et al., 2017).  
In this study, variables measured at the level of the county were spread over >100 county 
groupings (N=119), meaning that there was sufficient sample size of counties to produce reliable error 
estimates (see Maas & Hox, 2005). Although the recommended sample size for groups varies from to 20-
30, the general consensus is that power increases as the number of groups increase (Duncan, 1998; Maas & 
Hox, 2005; Mox, 1995; Snijders, 2005). As noted above, the number of higher-level clusters is typically 
considered more important for conducting MLM than the number of observations within each cluster, with 
a recommendation of 20 clusters minimum (Hox et al., 2017). There is growing consensus that as the 
number of clusters increases the number of observations needed per cluster may decease without biasing 
estimates (Hox, 1998, 2010; McNeish & Stapleton, 2014; Snijders & Bosker, 2012). For instance, 50 
clusters with 20 observations or 100 clusters with 10 observations may produce a stable MLM (Hox 1998, 
2010). Dedrick et al. (2009) have proposed a “30/30” guideline based on a review of MLMs in which they 
found that just over 20% of reviewed studies did not have adequate clusters and observations per cluster to 
perform MLM or MLM that produced unbiases estimates.  
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Exploratory MLM Building Results 
With this recommendation in mind, the distribution of participant counties was examined to 
determine if the number of observations per group within the county-level cluster would permit MLM of 
county-level variables (e.g., household poverty, Internet access, etc.). When baseline data were collected 
participants reported living in 118 counties; at the time follow-up data were collected, participants reported 
living in 119 counties (out of a possible 120 counties). Although there were >100 groups at the county-
level, there were >10 observations for only 33.1% of the counties for the period prior to incarceration and 
for only 32.6% of the counties for the period subsequent to incarceration. Prior to incarceration, 
observations were identified as primarily clustered within Jefferson (N=228, 14.6%), Fayette (N=71, 
4.5%), Kenton (N=56, 3.6%), Hardin (N=54, 3.5%), and Daviess (N=51, 3.3%) counties. Subsequent to 
incarceration, observations were identified as still primarily clustered within Jefferson (N=259, 16.6%), 
Fayette (N=82, 5.2%), Kenton (N=53, 3.4%), Daviess (N=53, 3.4%), and, Hardin (N=48, 3.1%). In 
Appendix B, Figures 3.0 and 3.1 display frequencies of all counties with <10 observations per county. 
Frequencies for all counties with >10 observations are presented in Figures 4.0 and 4.1 in Appendix B.  
In order to demonstrate that MLM could not be pursued due to insufficient observations at the 
level-two grouping variable, models were built following the general sequence outlined by Hox (2002), 
which involved several steps. The first step included analyzing the intercept-only (null) model and 
examining the interclass correlation (ICC), (i.e., ratio of the variance between groups at higher levels and 
variance within groups at these levels), with high values indicating that the assumption of independence of 
errors had been violated. This was done for five drug outcomes. These included heroin (ICC=0.055, 
random intercept=0.0723; between-subject SD=0.2986, chibar=59.6, p<.001), prescription opioids 
(ICC=0.003, random intercept=0.0194, between-subjects SD=0.3492, chibar=0.24, p=.313), buprenorphine 
(ICC=0.0142, random intercept=0.0348; between-subject SD=0.2900, chibar=1.74, p=.094), cocaine/crack 
cocaine (ICC=0.000, random intercept=0.0348; between-subject SD=0.2610, chibar=0.0, p=1.00), 
amphetamines (ICC=0.0476, random intercept=0.0785; between-subject SD=0.3513, chibar=21.6, p<.001). 
Additionally, counties were ranked in order of random intercepts on outcomes to create confidence 
intervals (CIs) around the estimates of the random intercepts. Standard error bar charts were then used to 
graph the relative random intercept values. Tabachnick & Fidell (2013) note that if the ICC is sufficiently 
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small that a single-level regression analysis is appropriate. Still, as Robson & Pevalin (2016) note, it is not 
always clear when a non-zero ICC indicates a clear cut-off point. 
Second, models were analyzed using all level-1 IVs fixed, assessing contribution of each IV and 
model differences. IVs were selected for inclusion based on bivariate statistics indicating statistically 
significant correlation between an IV and outcome variables. Next, a MLM for heroin was built, using 
“county” as the higher-level group. This outcome was chosen because it had the largest ICC value. Here, 
the slope for each IV was permitted to be random, adding county-level IVs individually. Though the model 
converged after 10 iterations, SEs and CIs were not produced, indicating that the Hessian calculation had 
become unstable. Further, when comparing the saved fixed- and random-effects estimates, output reported 
that levels were “not nested”. It was therefore concluded there were insufficient cases for MLM in general 
and that, for some of the other drug outcomes explored in preliminary analyses, there was insufficient 
variance at the individual-level explained by the county-level to justify the use of MLM. Ultimately, due to 
insufficient cases, MLM was excluded as a means for examining drug use outcomes of interest. A revised 
analytic plan was created and is outlined below.  
Final Analytic Plan 
Aim One 
To address this aim, (described on pg. 126) descriptive statistics, such as means and proportions, 
were generated for the entire sample and for all four drug use groups (e.g., concomitant use, opioid use, 
stimulant use, other drug use and other drug/no drug use) using data collected at baseline and follow-up. 
Chi-square test of independence and the Kruskal-Wallis analysis of variance by ranks were used to 
determine if groups were statistically significantly different (p<.05) (Everitt, 1977; Meyers et al., 2013; 
Siegel & Castellan, 1988).  
Aim Two 
To address this aim (described on pg 126), multinomial logistic regression was used to examine 
the association between independent variables and concomitant, opioid, and stimulant use for each time 
period. Independent and control variables that differed significantly (p <.05) across drug use outcome 
groups in non-parametric tests were chosen for inclusion into regression models. Multinomial logistic 
regression was selected due to the polytomous outcome variable (Luke, 2004; Skrondal & Rabe-Hesketh, 
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2003). For the 30-day period prior to incarceration, the drug use outcome group of “other drug use” was 
used as the reference category, meaning that the coefficients for all other drug use outcome groups describe 
how the IVs are related to the probability of being in one of the drug use outcome groups, versus the 
reference group of other drug use. Because all participants reported some drug use in the 30-day period 
prior to incarceration, “no drug use” was not also used to define that group, but rather only “other drug 
use”. For the one-year post-release period, the drug use group of “other/no drug use” was used as the 
reference category. This is because, during the one-year post-release period, some participants reported 
using drugs other than opioids and stimulants while other participants reported not using any drugs, unlike 
the 30-day period prior to incarceration, in which all participants reported some drug use. These drug use 
outcome groups of “other drug use” and “other/no drug use” were selected to serve as the reference 
categories because they reflect decisions with the less relative risk compared to decisions involving opioids 
and stimulants.  
Aim Three 
To address this aim, (described on pg. 127) descriptive statistics, chi-square, and t-test were used 
to describe and examine differences between participants who reported heroin use during the one-year post-
release period and those who did not. Binary logistic regression was used to examine the relationship 
between independent variables and heroin use during the one-year post-release period. Independent 
variables that differed significantly (p <.05) between the heroin-use group and the non-heroin use group in 




Aim One Results   
Drug Outcomes During the 30-day Period Prior to Incarceration 
Table 1 displays means and proportions for the final sample (N=1,563) and for each drug use 
group for the period prior to incarceration. For the 30-day period prior to incarceration, 29.0% of 
participants reported concomitant use of opioid and stimulants, 28.5% reported opioid, but not stimulant, 
use; 18.0% reported stimulant, but not opioid use; and 24.4% reported use of drugs other than opioids and 
stimulants. 
The majority of the sample was White (81.5%), with the remainder African American (17.1%), 
Hispanic (0.8%), and other (e.g., Asian, American Indian, Middle Eastern; 0.6%). There was a higher 
proportion of White participants among those who reported past 30-day opioid (93.9%) and concomitant 
use (90.1%), compared to past 30-day stimulant (70.6%) and other drug use (64.7%, X2=161.71, df=3, 
p<.001). Approximately 71% of the sample had earned a high school diploma (HSD)/GED. The proportion 
of participants with a HSD/GED were equivalent across groups (X2=2.27, df=3, p=.519), with rates highest 
among participants who reported past 30-day concomitant use (73.3%) and lowest among participants who 
reported past 30-day opioid use (68.8%). Twenty percent of the sample was married and 47.6% reported 
never having been married, with the remainder widowed (1.6%), separated (7.5%), or divorced (23.3%). 
Marital status was similar across groups (X2=14.13, df=12, p=.292). Participants who reported past 30-day 
opioid use had slightly higher rates of  
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being currently married (22.0%) as well as divorced (25.8%). Participants who reported past 30-day other 
drug use had the highest rates of never being married (52.6%).  
Although the mean number of nights spent in a controlled environment out of the 30-day period 
prior to incarceration was low sample-wide (?̅? =1.3, SD=3.5), participants who reported past 30-day other 
drug use were incarcerated for 1.6 nights, whereas those who reported past 30-day stimulant use were 
incarcerated <1 night (0.9) (p=.011). For the entire sample, the mean number of lifetime drug treatment 
episodes was 2.2 (SD=3.8, range 0-62). Past 30-day concomitant use was associated with a greater average 
number of lifetime treatment episodes (2.8) compared to use of opioids (2.1), stimulants (2.2), and other 
drugs (1.8) (p<.001). Participants who reported past 30-day concomitant use had a higher rate of IDU 
history (64.2%; X2=238.35, df=3, p<.001), whereas history of IDU for the entire sample was 42.9%. 
Participants who reported past 30-day opioid use also had a higher rate of IDU history (53.1%) compared 
to participants who reported past 30-day stimulant (29.1%) and other drug use (16.0%).
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socioeconomic status  
(1-10) 
5.0 4.7 4.8 5.3 5.3 .001 
Misregulation 83.1% 91.4% 86.8% 83.7% 68.8% .001 
Close relationships 







































Table 1 (continued) 















Age of drug use 
initiation  
14.7 13.7 15.5 15.3 14.5 .001 
Severity of drug use, 
past 30-days  
(0-40) 
23.2 30.0 27.3 22.3 11.2 .001 
Intoxicated during 
offense 
78.2% 89.0% 81.8% 79.4% 60.2% .001 
Past-year drug use 
versatility  
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   3.4% 
7.1% 
1.3% 
Central Appalachia 31.8% 35.3% 43.9% 18.4% 23.3% .001 
Urban influence 4.6 4.7 5.1 4.3 4.0 .001 
Age and Sex 
Participants were 33.9 years old on average (SD=9.0, range=18-74) prior to entering SAP. 
Participants who reported past 30-day stimulant use were relatively older (36.9; p<.001) compared to 
participants who reported past 30-day opioid (34.0), concomitant (32.2), and other drug use (33.8). While 
the sample was majority male (80.9%), the proportion of males was highest among participants who 
reported past 30-day other drug (86.9%) and stimulant use (85.8%), whereas the proportion of males 
among participants reporting past 30-day opioid and concomitant use was lower, and  more similar, at 
76.5% and 77.3%, respectively (X2=22.95, df=3, p<.001).  
LD diagnosis, SE enrollment and History of Head Trauma 
Over a quarter of participants (28.6%) reported a history of LD diagnosis and/or SE enrollment. 
The proportion of participants reporting LD diagnosis and/or SE enrollment was similar across groups, with 
rates ranging from 28.3% among participants who reported using other drugs to 29.4% among participants 
who reported concomitant use (X2=0.22, df=3, p=.974). Nearly 42.0% of participants reported lifetime 
history of head trauma. Among those who did (N=655), the average number of head injuries reported was 
2.5 (SD=3.3, range=1-40, p=.009). Rates for any history of head trauma were highest among participants 
reporting past 30-day concomitant use and lowest among participants who reported past 30-day other drug 
use (X2=11.99, df=3, 47.1% vs 36.4%; p=.007).  
Psychiatric Symptoms 
During the year prior to incarceration, 44.5% of participants met or surpassed the GAD cutoff point, 
meaning that they experienced >4 anxiety symptoms during the one- year period prior to incarceration at a 
level of clinical significance. Approximately 46.0% of participants met or surpassed the     
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MDD cutoff point, meaning that they experienced >5 symptoms associated with major depressive disorder 
during the year prior to incarceration at a level of clinical significance. Groups significantly differed in 
terms of the proportion of participants who met these thresholds for anxiety (X2=53.14, df=3, p<.001) and 
depressive symptoms during this pre-incarceration time period (X2=77.19, df=3, p<.001). Rates of past-year 
anxiety and depressive symptoms were highest among participants who reported past 30-day concomitant 
use, with 57.0% reporting anxiety symptoms and 59.0% reporting depressive symptoms. Rates of anxiety 
symptoms were lower among participants reporting past 30-day opioid (44.6%) and stimulant use (41.1%), 
as were rates of depressive symptoms, with 49.1% of participants who reported past 30-day opioid use and 
42.2% of participants who reported past 30-day stimulant use reporting depressive symptoms. Participants 
who reported past 30-day other drug use had the lowest rates of both depressive and anxiety symptoms, 
32.2% and 29.8%, respectively. Suicidal ideation for this same time period was reported by 11.6% of the 
sample. For participants who reported past 30-day concomitant use, however, 15.7% reported past-year 
suicidal ideation, the highest among all groups (X2=17.92, df=3, p<.001). Approximately 12% of 
participants who reported past 30-day opioid and stimulant use also reported past-year suicidal ideation, 
still relatively high at nearly double the rates of those who reported past 30-day other drug use (6.3%).  
Chronic Pain 
Just under a quarter of the sample reported experiencing chronic pain in the one-year period prior 
to incarceration (24.8%). Of those who experienced chronic pain (N=387), the mean BPI chronic pain 
severity score was 15.6 out of a possible 30 (SD=5.5, range=3-30, p=.003). For subscales (0-10), pain “at 
its worst” was ranked 7.0, pain “on average” was ranked 4.8, and pain “at its least” was ranked 3.8, 
meaning that pain severity ranged from approximately 4-7 on a 10-point scale. Participants who reported 
past 30-day opioid and concomitant use evidenced the highest rates of chronic pain, 28.7% and 27.6%, 
respectively, whereas rates of chronic pain among participants who reported past 30-day stimulant and 
other drug use were slightly lower, 20.6% and 19.9%, respectively (X2=13.82, df=3, p=.004).  
Stress-related Health Effects 
In terms of past-week stress-related health effects reported for the 7-day period prior to 
incarceration, the mean score on the revised HCS was 23.5 (SD=8.1, range=11-44), indicating that, on 
average, moderate stress-related health effects were experienced during this time period by the majority of 
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participants (93.0% reported at least one stress-related health effect). Participants who reported past 30-day 
concomitant use scored the highest on the HCS, whereas participants who reported past 30-day other drug 
use scored the lowest (26.3 vs. 20.1; p<.001). Participants who reported past 30-day opioid and stimulant 
use had similar HCS scores, at 23.6 and 22.7, respectively.  
Economic Hardship, Homelessness, and Subjective Socioeconomic Status 
The mean economic hardship score for the entire sample during the one-year period prior to 
incarceration was 1.6 (SD=2.2, range=0-8), meaning that, on average, participants experienced fewer than 2 
episodes of economic hardship during the year prior to their incarceration. Measures of past-year economic 
hardship were highest among participants reporting past 30-day opioid (1.7) and concomitant use (2.2), the 
latter approximately double that of participants who reported other drug use (1.1) (p<.001). A total of 
14.8% of participants reported experiencing homelessness during this same time period. Experiencing past-
year homelessness was highest among participants who reported past 30-day concomitant use (19.4%), 
nearly double that of participants who reported past 30-day other drug use (9.9%, X2=17.01, df=3, p<.001). 
Participants who reported past 30-day opioid use also reported relatively higher rates of past-year 
homelessness (16.1%). 
The average subjective social comparison rating was 5.0 (SD=2.0, range 1-10). This means that 
perceived socioeconomic status for the sample was, on average, one in which participants’ subjective social 
comparison equated to being “worse off” than approximately one-half of people in US society in terms of 
social and economic status (or “better off”, depending on how one wishes to interpret this). Among 
participants who reported past 30-day opioid and concomitant use, the average rank of perceived 
socioeconomic status was just under the sample mean of 5.0, at 4.8 and 4.7 respectively, differing from 
participants who reported past 30-day stimulant and other drug use, which had the same mean rank of 5.3 
(p<.001).  
Misregulation 
In the 7-day period prior to incarceration, 83.1% of participants reported using drugs (e.g., alcohol, 
prescription drugs, illicit drugs) to reduce stress, anxiety, worry or fear. This means that not only did a 
majority of participants report experiencing stress, anxiety, worry, or fear for a portion of the 30-day period 
prior to incarceration, but also that a majority sought out drugs as a means of coping with these states. 
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Using a psychoactive drug to ameliorate fear, stress, worry, or anxiety in the week prior to incarceration 
was highest among participants who reported past 30-day concomitant use and lowest among participants 
reporting other drug use (91.4% vs. 68.8%, X2= 82.05, df=3, p<.001). Nearly 87.0% of participants who 
reported past 30-day opioid use also engaged in this form of coping or “self-medication”, as did slightly 
fewer, but still a majority (83.7%), of participants who reported past 30-day stimulant use. 
Non-drug Alternative Reinforcers 
On average, participants reported having fewer than 10 close relationships (?̅? =7.1) with people 
such as family members, friends, children, intimate partners, and other people with whom they felt close 
(SD=5.2, range=0-56). Participants who reported past 30-day concomitant and opioid use reported having 
fewer close relationships on average during the one-year year period prior to incarceration (6.7 and 6.5, 
respectively), compared to participants who reported past 30-day stimulant use (7.3). Participants who 
reported past 30-day other drug use had the highest average number of close relationships 7.9 (p=.010). 
Compared to spending the majority of time alone, 88.9% of the sample reported some social 
interaction (i.e., spending time friends or family) during the one-year period prior to incarceration. 
Participants who reported past 30-day other drug use had the highest rates of social interaction, though 
groups did not differ significantly overall (X2=4.33, df=3, p=.228). Specifically, 91.4% of participants who 
reported past 30-day other drug use reported spending time with friends or family, versus alone, whereas 
rates of spending time with friends or family were lowest among participants who reported past 30-day 
stimulant use (86.5%). Participants who reported opioid and concomitant use had similar rates at 88.1% 
and 89.2%, respectively. Compared to being indifferent to or not enjoying spending their time this way, 
70.8% of the sample reported that they received satisfaction from these social interactions. Participants who 
reported past 30-day concomitant use had the lowest rates of receiving satisfaction from past-year social 
interaction, whereas participants who reported past 30-day other drug use had the highest (61.8% vs. 
79.8%; X2=31.30, df=3, p<.001). Rates of satisfaction were similar among participants who reported past 
30-day opioid (71.3%) and stimulant use (73.4%). 
In the year prior to incarceration, the average number of leisure days per week, in which hobbies 
or enjoyable activities could be freely pursued, was 2.5 for the entire sample (SD=2.4, range=0-7). The 
mean number of leisure days was highest among participants who reported past 30-day other drug use 
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(3.3), but slightly lower among participants who reported past 30-day stimulant (2.5), opioid (2.2), and 
concomitant use (2.0, p=.002). 
Approximately 66% of participants reported being involved in educational and/or vocational 
pursuits in the one-year period prior to incarceration. Past-year educational/vocational involvement did not 
differ between groups (X2=4.29, df=3, p=.232), but was highest among participants who reported past 30-
day stimulant use (70.2%), followed by concomitant (66.2%), other drug (65.7%), and opioid use (62.8%). 
Age of Drug Use Initiation  
 The mean age of drug use initiation for the entire sample was just over 14 years old (?̅? =14.7, 
SD=4.9, range=4-56). Participants who reported past 30-day opioid and stimulant use were similar in terms 
of the average age at which drug use was initiated, at just over 15 years of age; however, age of first drug 
use occurred at a younger age among participants who reported other drug (14.5) and concomitant use 
(13.7; p<.001). 
Drug Use Severity 
In the 30-day period prior to incarceration, the mean drug use severity score was 23.2 (SD=15.8, 
range=2-40). Severity scores, which indicate higher degree of being bothered by drug-related problems and 
more frequent instances of craving, withdrawal, and/or unsuccessful attempts to quit, were highest among 
participants who reported past 30-day concomitant (30.0) and opioid use (27.3). Participants who reported 
past 30-day stimulant use had lower scores at 22.3, though even this was still approximately double that of 
the average severity score for participants who reported past 30-day other drug use (11.2; p<.001). 
Similarly, a greater proportion of participants who reported past 30-day concomitant use also reported 
being intoxicated at the time that they committed their offense, compared to participants who reported past 
30-day other drug use (89.0% vs. 60.2%, X2=106.96, df=3, p<.001). 
Drug Use Versatility   
Across the entire sample, the average number of drugs used during the one-year period prior to 
incarceration was 3.8 (SD=2.3 range=1-13). However, among participants who reported past 30-day 
concomitant use, the average was 6.1, higher than participants who reported past 30-day opioid (3.6) and 
stimulant use (2.6), and nearly three times more than participants who reported past 30-day other drug use 
(2.1; p<.001). Sample-wide, the average number of drugs used during the 30-day period prior to 
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incarceration was 3.0 (SD=2.1, range=0-13). However, among participants who reported past 30-day 
concomitant use, the average was 5.3, higher than participants who reported past 30-day opioid (2.9) and 
stimulant use (2.3), and nearly three times more than participants who reported past 30-day other drug use 
(1.1; p<.001).  
Past-year Drug Use Prior to Incarceration  
Among non-opioid and non-stimulant drugs, alcohol was used in the one-year period prior to 
incarceration by 63.5% of the sample, with rates similar among participants who reported past 30-day 
concomitant and other drug use, approximately 68%. Rates were lowest among participants who reported 
past 30-day opioid use (54.0%, X2=27.2, df=3, p<.001). Just over 60% of the sample reported past-year 
cannabis use. Participants who reported past 30-day concomitant use had the highest rates of past-year 
cannabis use (72.0%), followed by participants who reported past 30-day other drug use (63.6%). This 
differed from participants who reported past 30-day opioid and stimulant use, among whom just over half 
reported past-year cannabis use (X2=42.10, df=3, p<.001). Thirty-nine percent of the sample reported past-
year prescription sedative use, but only 14.2% of participants who reported past 30-day stimulant use and 
19.9% of participants who reported past 30-day other drug use reported past-year prescription sedative use; 
rates were highest among participants who reported past 30-day concomitant use (66.9%, X2=282.28, df=3, 
p<.001). Past-year hallucinogen use was relatively low sample-wide (6.1%), with rates among groups 
lowest among participants who reported past 30-day other drug use (2.1%) and highest among those who 
reported past 30-day concomitant use (13.0%, X2=26.27, df=3, p<.001). Synthetic drugs were also not 
widely used across the sample during the year prior to incarceration (10.1%), but similar to past-year 
hallucinogen use, rates were lowest among participants reporting past 30-day other drug use (4.2%) and 
highest among those reporting past 30-day concomitant use (19.6%, X2=66.63, df=3, p<.001). Still, 
between 7-8% of participants who reported past 30-day opioid and stimulant use reported past-year 
synthetic drug use.  
Although the rates of past-year use of stimulant and opioid drugs would necessarily differ as a 
function of past 30-day use of opioids and stimulants, it was important to determine differences for 
particular types of drugs used during the one-year period prior to incarceration, as it may be that 
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participants who reported past 30-day stimulant use used cocaine/crack cocaine, but not amphetamines and 
vice versa. Here, the proportions of use for a specific drug are more informative than the test statistic itself. 
 For stimulant drugs, 33.5% of the sample reported using cocaine/crack cocaine during the one-
year prior to incarceration. Rates of cocaine/crack cocaine use were highest among participants who 
reported past 30-day concomitant use (63.8%), followed by past 30-day stimulant use (47.5%, X2=380.04, 
df=3, p<.001). Participants who reported past 30-day opioid and other drug use had similar rates, at just 
over 12.0%. Nearly 37.0% of the sample reported past-year amphetamine use. Rates were highest among 
participants who reported past 30-day concomitant (72.0%) and stimulant use (62.5%) and lowest among 
participants who reported past 30-day other drug (10.2%) and opioid use (7.4%, X2=602.79, df=3, p<.001).  
For opioid drugs, 21.8% of the sample reported using heroin during the one-year period prior to 
incarceration. Rates were highest among participants who reported past 30-day concomitant use (40.0%), 
followed by participants who reported past 30-day opioid use (30.9%). Only 5.5% of participants who 
reported past 30-day other drug use and only 0.4% of participants who reported past 30-day stimulant use 
reported past-year heroin use prior to incarceration (X2=244.95, df=3, p<.001). Compared to heroin, a 
greater proportion of the sample reported past-year prescription opioid use (55.8%). Participants who 
reported past 30-day concomitant use had the highest rates of past-year prescription opioid use (91.4%), 
followed by participants reporting past 30-day opioid use (86.5%). These rates differed from those who 
reported past 30-day other drug (15.4%) and stimulant use (4.6%, X2=955.41, df=3, p<.001). Sample-wide, 
past-year use of buprenorphine was also higher, albeit slightly, compared with heroin, with 24.9% reporting 
use. While only 1.8% of participants who reported past 30-day stimulant use reported past-year 
buprenorphine use, 44.4% of participants who reported past 30-day concomitant use and 35.9% of 
participants who reported past 30-day opioid use reported past-year buprenorphine use; only 6.0% of 
participants who reported past 30-day other drug use reported past-year buprenorphine use (X2=274.12, 
df=3, p<.001).  
Past-year Drug Use Frequency Prior to Incarceration  
Frequency, measured in months (results not shown in table), that a particular drug was used during 
the one-year period prior to incarceration, varied from an average of 0.2 month to 6.2 months. Included 
among non-opioid and non-stimulant drugs was alcohol, used an average of 4.6 months, cannabis, used an 
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average of 5.1 months, prescription sedatives, used an average of 2.7 months, hallucinogens, used an 
average of 0.2 months, and synthetic drugs, used an average of 0.5 months. The average number of months 
out of the one-year period prior to incarceration that alcohol was used was fairly uniform across groups, 
ranging from 3.4 months among participants who reported past 30-day opioid use and 5.1 months among 
participants who reported past 30-day other drug use (p=.306). The average number of months that 
cannabis was used was highest among participants who reported past 30-day concomitant use (6.1), 
followed by participants who reported other drug use (5.2), though groups did not differ overall (p=.938). 
For prescription sedatives, the average number of months that these were used was highest among 
participants who reported past 30-day concomitant (4.8) and opioid use (3.2) compared to other groups 
(p<.001). Hallucinogens, which were less frequently used sample-wide, were used a greater number of 
months on average among participants who reported past 30-day concomitant use (1.1), whereas all other 
groups used hallucinogens 1< month on average (range= 0.2-0.4; p<.001). Synthetic drugs, also less 
frequently used, were used a greater number of months among participants who reported past 30-day 
concomitant use (2.2), compared to participants who reported past 30-day opioid (0.5), stimulant (0.9) and 
other drug use (0.6; p<001).  
For stimulant drugs, amphetamines were used on average 6.2 months, making it the most 
frequently used drug for this time period as measured in months. Cocaine/crack cocaine was used an 
average of 1.8 months. Unsurprisingly, the average number of months that cocaine/crack cocaine was used 
was highest among participants who reported past 30-day stimulant and concomitant use, 3.2 and 3.5, 
respectively (p<.001). Participants who reported past 30-day opioid use used cocaine/crack cocaine on 
average 1< month (0.3), as did participants who reported past 30-day other drug use (0.5). Similarly, 
amphetamine use was highest among participants who reported past 30-day stimulant and concomitant use, 
5.3 and 5.4, respectively (p<.001). Participants who reported past 30-day opioid use also used 
amphetamines on average <1 month (0.2) out of the one-year period prior to incarceration, as did 
participants who reported past 30-day other drug use (0.4).  
For opioid drugs, heroin was used for 1.4 months on average, prescription opioids 4.8 months, and 
buprenorphine 1.4 months. The average number of months that heroin was used was similar across 
participants who reported past 30-day opioid and concomitant use, at 2.2 and 2.4 months, respectively; 
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however, no participants who reported past 30-day stimulant use reported heroin use, and among 
participants who reported past 30-day other drug use, the average number of months heroin was used was 
<1 (0.2; p<.001). Prescription opioids were used an average of 7.9 months among participants who reported 
both past 30-day opioid use as well as past 30-day concomitant use. Among participants who reported past 
30-day stimulant use, the average number of months that prescription opioids were used was <1 (0.1), and 
among participants who reported past 30-day other drug use, was 0.7 (p=206). The average number of 
months that buprenorphine was used was highest among participants who reported past 30-day concomitant 
(2.5) and opioid use (2.0). The average number of months that buprenorphine was used among participants 
who reported past 30-day stimulant or other drug use was <1 month, 0.4 and 0.2, respectively (p<.001).  
Past 30-day Drug Use Frequency Prior to Incarceration 
Frequency of drug use that occurred during the 30-day period prior to incarceration also varied 
significantly from an average of 0.3 days to 11.2 days. Included among non-opioid and non-stimulant drugs 
was alcohol, used an average of 7.3 days, cannabis, used an average of 11.2 days, prescription sedatives, 
used an average of 5.2 days, hallucinogens, used an average of 0.3 days, and synthetic drugs, used an 
average of 1.1 days.  
Alcohol was used, on average, for approximately the same number of days out of the 30-day 
period prior to incarceration among participants who reported past 30-day stimulant (8.1), concomitant 
(8.4), and other drug use (8.3), whereas participants who reported past 30-day opioid use used alcohol for 
approximately 4.7 days (p<.001). The average number of days that cannabis was used during the 30-day 
period prior to incarceration was highest among participants who reported past 30-day concomitant use 
(14.9), followed by stimulant (11.1), other drug (10.1), and opioid use (9.1; p<.001). Prescription sedatives 
were used nearly 10 days on average by participants who reported past 30-day concomitant use, far higher 
than participants who reported past 30-day opioid (6.1), stimulant (1.1), and other drug use (1.6; p<.001). 
Hallucinogens were used <1 day on average across groups (range=0-0.5), with participants who reported 
past 30-day other drug use reporting zero days of hallucinogen use for this time period (p<.001). Synthetic 
drugs were used 2.2 days on average among participants who reported past 30-day concomitant use and 
approximately 1.0 day among participants who reported past 30-day stimulant use, still significantly more 
often than participants who reported past 30-day opioid and other drug use (p<.001). 
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Among stimulant drugs, amphetamines were used an average 6.4 days and cocaine/crack cocaine 
was used an average of 1.8 days. Between the two groups who reported past 30-day use of stimulants (i.e., 
stimulants and concomitant use), cocaine/crack cocaine was used for more days on average among 
participants who reported past 30-day concomitant use compared to stimulant use (7.4 vs. 6.6). 
Amphetamine use among these same groups was slightly more frequent among participants who reported 
past 30-day stimulant versus concomitant use (13.6 vs. 12.9).  
Among opioid drugs, heroin was used for 3.7 days on average, prescription opioids 10.4 days, and 
buprenorphine 2.7 days. Between the two groups who reported past 30-day use of opioids (i.e., opioids and 
concomitant use), heroin was used approximately the same number of days on average among participants 
who reported past 30-day opioid (6.1) and concomitant use (6.6). The frequency of prescription opioid use 
among these same groups was nearly equal, an average of 18 days out of the 30 days prior to incarceration. 
Among these two groups, buprenorphine was used slightly more days on average by participants who 
reported past 30-day concomitant use (5.1), compared to participants who reported past 30-day opioid use 
(4.2).  
Past-year Preferred Drug of Choice 
The most commonly preferred drugs across the sample were prescription opioids (25.2%), 
cannabis (21.3%), and amphetamines (15.2%). Heroin was preferred by 9.8%, and buprenorphine was 
preferred by 2.6% of participants. Cocaine was preferred at a comparable rate to heroin at 8.7%. Additional 
non-opioid and non- stimulant drugs included alcohol, preferred by 13.1% of participants, prescription 
sedatives, preferred by 2.9%, and less frequently used drugs such as inhalants, hallucinogens, and synthetic 
drugs, preferred by 1.3% collectively. Unsurprisingly, groups differed in terms of their preferred drug of 
choice for the one-year period prior to incarceration (X2=945.73, df=24, p<.001). Among participants who 
reported past 30-day concomitant use, prescription opioids (29.8%), heroin (13.9%), amphetamines 
(14.1%), and cocaine (11.0%) were the most preferred drugs. Among participants who reported past 30-day 
opioid use, prescription opioids (50.7%), heroin (17.3%), cannabis (14.1%) and alcohol (7.2%) were the 
most preferred drugs. Among participants who reported past 30-day stimulant use, amphetamines (38.7%), 
cocaine/crack cocaine (25.5%), cannabis (19.9%) and alcohol (11.3%) were the most preferred drugs. 
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Lastly, among participants who reported past 30-day other drug use, cannabis (50.7%), alcohol (44.5%), 
prescription opioids, (7.1%), and amphetamines (5.0%) were the most preferred drugs.  
Central Appalachia  
 Approximately one-third of participants (31.8%) reported residing within Central Appalachian, the 
Easternmost region of Kentucky, for the majority of the one-year period prior to incarceration. A greater 
proportion of participants who reported past 30-day opioid resided in Central Appalachia (43.9%), followed 
by participants who reported concomitant use (35.3%). These rates differed from the 18.4% of participants 
who reported past 30-day stimulant use and the 23.3% of participants who reported past 30-day other drug 
use (X2=68.90, df=3, p<.001).  
Specific opioid and stimulant drug use by region was also examined (chi-square results not shown 
in-table). Proportions of past 30-day opioid and stimulant drug use by region (Central Appalachia vs. non-
Appalachia) are displayed in Figure 5.  For past 30-day heroin use, rates were slightly lower among 
participants who resided in Central Appalachia compared to those who resided outside of Central 
Appalachia (16.3% vs. 18.4%, X2=0.88, df=1, p=.314). Groups by region differed, however, for rates of 
past 30-day prescription opioid (64.8% vs. 41.8%, X2=71.44, df=1, p<.001) and buprenorphine (30.0% vs. 
13.4%, X2=61.23, df=1, p<.001) use, with a higher proportion of participants residing in Central 
Appalachia for both groups. A greater proportion of participants who resided outside of Central Appalachia 
reported past 30-day cocaine/crack cocaine use  
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Figure 5. Opioid and stimulant use during the 30-day pre-incarceration period by Appalachia and 
Non-Appalachia Residence. 
(18.7% vs. 25.3%, X2=8.31, df=1, p=.005), though no difference was observed for past 30-day 
amphetamine use (30.6% vs. 31.6%, X2=0.18, df=1, p=.726). In addition to these drugs, past 30-day use of 
alcohol (41.2% vs. 53.4%, X2=19.47, df=1, p<.001) cannabis (45.9% vs. 55.6%, X2, 12.54, df=1, p<.001) 
occurred at higher rates for participants residing outside of Appalachia. Past 30-day prescription sedative 
use also differed by region, with a slightly greater proportion of users residing within Appalachia (36.8% 
vs. 30.2%, X2=6.78, df=1, p=.011). Because past 30-day use does not necessarily reflect use over a longer 
time period, use of specific opioid and stimulant drugs for the one-year period prior to incarceration was 
also examined. Proportions are displayed in Figure 6. 
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Figure 6. Opioid and stimulant use during the one-year pre-incarceration period by Appalachia and 
Non-Appalachia Residence.  
 
Among participants who reported past-year heroin use, 20.5% resided in Central Appalachia and 
22.4 % resided outside of Central Appalachia (X2=0.72, df=1, p=.435). For the one-year period prior to 
incarceration, differences were observed for past-year prescription opioid (72.6% vs. 47.9%, X2=82.84, 
df=1, p<.001) and buprenorphine (38.6% vs. 18.5%, X2=72.56, df=1, p<.001) use, with a higher proportion 
of participants residing in Central Appalachia. Groups by region did not differ significantly for past-year 
cocaine/crack cocaine use (32.0% vs. 34.2%, X2=0.67, df=1, p=.413) or past-year amphetamine use (36.4% 
vs 36.9%, X2=0.29, p=.864).  
Urban Influence 
In keeping with this finding, the mean urban influence for the entire sample, with 1 denoting the 
greatest urban influence and 12 denoting the least (i.e., more rural, less populated), was 4.6, indicating that 
the past-year residence of the sample was skewed toward metropolitan and urban areas, rather than toward 
rural, non-metropolitan areas. The average urban influence designation was higher among participants who 
reported past 30-day opioid (5.1) and concomitant use (4.7), and lower among participants who reported 
past 30-day other drug (4.0) and stimulant use (4.3; p<.001). Figure 7 displays the proportion past 30-day 
drug use prior to incarceration for specific opioid and stimulant drugs by urban influence designation.  
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Although higher proportions for all drugs were associated with greater urban and metro influence, 
the highest rate of use by urban influence designation for any specific drug was prescription opioids 
(60.0%), and this was associated with greater rurality. Apart from the two designations indicating greatest 
urban influence (1 and 2), the next two urban influence designations with the largest proportion of 
concentrated use were found among designations 8 and 9 (more rural, less populated areas), as evidenced 
by the modest uptick for all drugs other than heroin, which increased within these designations only 
slightly. Between designations of 7 and 10 is where rates of prescription opioid use, as noted before, 
substantially increase. Overall, higher rates of heroin and cocaine use were more likely to be found in 
designations indicating greater urban influence, whereas prescription opioid, buprenorphine, and 
amphetamine use showed greater overall dispersion across designations.  
Figure 7. Opioid and stimulant use during the 30-day pre-incarceration period by urban influence 
designation. 
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Drug Outcomes During the One-year Period Subsequent to Incarceration 
Table 2 displays means and proportions for the entire sample and for each drug use group for the 
one-year period subsequent to incarceration. For this post-release period, 11.9% of participants reported 
concomitant use of opioid and stimulants, 12.5% reported opioid, but not stimulant, use; 8.3% reported 
stimulant, but not opioid use; 22.9% reported use of drugs other than opioids and stimulants, and 44.4% 
reported no past-year use, a total of 67.3% for the other/no drugs outcome group.  
During the one-year post-release period, the largest proportion of White participants were found 
among those who reported past-year concomitant (95.2%) and opioid use (91.5%), compared to 
participants who reported past-year stimulant (77.7%) and other/no drug use (77.8%, X2=56.46, df=3, 
p<.001). The proportion of participants with a HSD/GED were equivalent across groups (X2=1.67, df=3, 
p=.643), with the highest proportion of HSD/GED among participants who reported past-year opioid use 
(74.4%), and the lowest among participants reporting past-year stimulant use (68.5%). Seventy-three 
percent of the sample was mandated (i.e., parole board ordered) to complete SAP, and 78.3% completed 
SAP. Participants who reported past-year opioid use had slightly higher rates of mandated SAP 
participation (76.4%), whereas participants who reported past-year stimulant use had the lowest (66.2%); 
though groups did not significantly differ overall (X2=5.10, df=3, p=.164). Rates of SAP completion did not 
differ between groups either (X2=3.35, df=3, p=.341).  
During the one-year post-release period, the mean number of nights spent in a controlled 
environment was 43.6 (SD=77.6, range=0-351), however, participants who reported past-year other/no drug 
use reported fewer nights in a controlled environment on average, particularly compared to participants 
who reported past-year concomitant use (31.7 vs. 78.2; p<.001). Compared to the sample-wide rate of 
42.9%, approximately 65.0% of participants who reported past-year opioid and concomitant use had a 
history of IDU, nearly double that of participants who reported past-year stimulant (35.4%) and other/no 
drug use (36.0%, X2=96.29, df=3, p<.001). 
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Table 2 
Sample Characteristics and Drug Use Group Means, Proportions, and Between-group Differences 




















White 81.5% 95.2% 91.5% 77.7% 77.8% .001 
HSD/GED 71.2% 72.6% 74.4% 68.5% 70.8% .643 
Mandated to SAP 73.0% 70.4% 76.4% 66.2% 73.7% .164 
SAP completion 78.3% 73.7% 81.0% 77.7% 78.7% .341 
Nights in a controlled 
environment, past-year 
43.6 78.2 54.4 75.1 31.7 .001 





























Past-year cognitive difficulties 26.4% 38.8% 25.6% 32.3% 23.7% .001 
Lifetime history of head 
trauma 
43.5% 49.5% 41.0% 41.5% 43.0% .321 
Past-year anxiety symptoms 
Past-year depressive symptoms 
Past-year suicidal ideation 

























































67.1% 60.8% 65.6% 57.7% 69.6% .008 
On community supervision 87.0% 92.5% 84.1% 92.3% 85.9% .014 
Age of drug use initiation 14.7 13.6 14.3 13.7 15.3 .001 














































































Table 2 (continued) 














Abstinence self-efficacy  
Prior to treatment 





















































































Drug use versatility, past year 
(N=869) 
2.4 4.5 2.4 2.3 1.4 .001 
Days until post-release use 
(N=869) 
Alcohol use 












Central Appalachia 30.3% 27.4% 42.6% 21.5% 29.7% .001 
Urban influence 4.5 4.4 5.0 4.3 4.5 .072 
Unrestricted alcohol sales 56.6% 58.6% 52.3% 49.2% 57.9% .148 
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Age and Sex 
During the one-year post-release period, the sample was 34.5 years old (SD=9.1, range=19-75) on 
average. Participants who reported past-year stimulant and other drug/no drug use were relatively older, 
35.6 and 35.3, respectfully, compared to participants who reported past-year opioid (32.1) and concomitant 
use (31.6; p<.001). The proportion of males did not differ by group (X2=6.07, df=3, p=.141), but was 
highest among participants who reported past-year stimulant use and lowest among participants reporting 
past-year concomitant use (88.5% vs. 79.0%).  
Past-year Cognitive Difficulties and History of Head Trauma  
For the one-year post-release period, 26.4% of participants reported experiencing past-year 
cognitive difficulties (i.e., trouble understanding, concentrating, or remembering). Rates of past-year 
cognitive difficulties varied by group. Participants who reported past-year concomitant use had the highest 
rates (38.8%), followed by participants who reported past-year stimulant (32.3%), opioid (25.6%), and 
other/no drug use (23.7%; X2=20.92, df=3, p<.001). Subsequent to incarceration, approximately 44% of 
participants reported a history of head trauma. Rates of head trauma history were highest among 
participants who reported concomitant use and lowest among participants who reported other/no drug use 
(49.5% vs 43.0%), though groups did not differ significantly overall (X2=3.50, df=3, p=.321).  
Psychiatric Symptoms 
Anxiety and depressive symptoms during the one-year post-release period were experienced by 
40.7% and 32.7% of participants, respectively. Groups differed in the proportion of participants who 
reported experiencing past-year depressive symptoms (X2=56.10, df=3, p<.001) as well as past-year anxiety 
symptoms (X2=37.47, df=3, p<.001). Experiencing past-year anxiety symptoms was more common among 
participants who reported past-year concomitant use and less common among participants who reported 
past-year other/no drug use (58.1.% vs. 36.1%). Over half of participants who reported past-year 
concomitant use reported past-year depressive symptoms (52.2%), nearly double that of participants who 
reported past-year other drug/no drug use (27.3%). However, over one-third of participants who reported 
past-year opioid and stimulant use also reported depressive symptoms, 35.4% and 45.5%, respectively. 
Past-year suicidal ideation was reported by 4.5% of the sample during the one-year post-release period. 
Past-year suicidal ideation was highest among participants who reported past-year concomitant use 
 152 
(11.3%), followed by participants who reported past-year stimulant use (6.9%.). Participants who reported 
past-year other/no drug use had the lowest rates (2.8%), followed by those who reported past-year opioid 
use (5.6%; X2=29.91, df=3, p<.001). 
Chronic Pain 
During the one-year post-release period, 32.5% of the sample reported experiencing chronic pain. 
Groups were similar for rates of chronic pain (X2=5.17, df=3, p=.160), with rates highest among 
participants who reported past-year concomitant use (39.8%). Among participants who reported past-year 
opioid use, 32.8% reported experiencing chronic pain.  
Past-month Income 
During the one-year post-release period, the average past-month income from all income sources 
(e.g., disability benefits, earned income, money received from friends and family) among participants was 
$1,290, meaning that all groups might be considered as low-income, when not taking into account the 
potential contributions of other household members’ income (which was not asked as part of this question). 
Participants who reported past-year other/no drug use had a higher average past-month income, whereas 
participants who reported past-year concomitant use had the lowest ($1,336 vs. $1,056, p<.001), a modest 
practical difference. 
Non-drug Alternative Reinforcers  
During the one-year post-release period, the mean number of close relationships that participants 
reported having was 6.1 (SD=5.5, range=0-78). The average number of close relationships ranged from 5.5-
6.4 across groups. Participants who reported past-year stimulant and other/no drug use reported more close 
relationships on average, 6.2 and 6.4, respectively. Participants who reported past-year concomitant use 
reported having the fewest close relationships (5.5, p<.001). 
Compared to spending the majority of time alone, 88.4% of the sample reported some social 
interaction with friends or family during the one-year post-release period. Groups were similar in terms of 
reported social interaction (X2=0.80, df=3, p=.851), with >85.0% of all groups reporting some social 
interaction. Compared to being indifferent to or not enjoying spending their time in this way, 88.9% of 
participants reported that they received satisfaction from these social interactions. Groups differed, 
however, in terms of the social satisfaction they received from this past-year social interaction (X2=72.22, 
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df=3, p<.001). Specifically, 75.1% of participants who reported past-year concomitant use received 
satisfaction from past-year social interaction, whereas 79.2% of participants who reported past-year 
stimulant use, and 84.6% of participants who reported past-year opioid use, reported receiving satisfaction 
from past-year social interaction. Among participants who reported past-year other drug/no drug use, 
93.3% reported receiving satisfaction from past-year social interaction, the highest rate of all groups.  
The majority of the sample (92.3%) reported feeling as though they had some social worth, 
meaning that they reported feeling cared about and supported by people in their lives. Rates were highest, 
however, among participants who reported past-year other/no drug use and lowest among those who 
reported past-year concomitant use (93.7% vs. 87.5%, X2=10.79, df=3, p=.013). Participants who reported 
past-year opioid and stimulant use had similar rates of approximately 90.0%.  
Approximately 67% of the sample reported being involved in either educational or vocational 
pursuits during the one-year post-release period, though such involvement was lowest among participants 
who reported past-year stimulant (57.7%) and concomitant use (60.8%), and highest among participants 
who reported past-year other drug/no drug use (69.6%, X2=11.72, df=3p=.008).  
Finally, while the majority of participants across all groups (87.0%) were on community 
supervision at some point during the one-year post-release period, rates were highest for participants who 
reported past-year concomitant (92.5%) and stimulant use (92.3%), and lowest among participants who 
reported past-year opioid (84.1%) and other/no drug use (85.9%; X2=10.68, df=3; p=.014). 
Age of Drug Use Initiation  
The mean age of drug use initiation was 14.7 (SD=4.9, range=4-56). Drug use groups for the one-
year period subsequent to incarceration differed, though, with older drug use initiation observed among 
participants who reported past-year other/no drug use (15.3), followed by participants who reported past-
year opioid use (14.3; p<.001). Age of drug use initiation was <14 for participants who reported past-year 
stimulant and concomitant use, 13.7 and 13.6 years of old, respectively.  
Past 30-day Drug Use and Drug Use Frequency Prior to Incarceration 
During the one-year post-release period, groups differed for both rates of use during the 30-day 
period prior to incarceration as well as frequency of use (frequency of use not shown in table), measured in 
days, for this same pre-incarceration time period.  
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For non-opioid and non-stimulant drugs used during the 30-day period prior to incarceration, rates 
of pre-incarceration alcohol use were similar across all groups examined (approximately 50.0%), except 
among those who reported past-year opioid use (39.0%, X2=9.94; df=3, p=.019). Pre-incarceration alcohol 
use was more frequent among participants who reported past-year other drug/non-drug (7.7) and stimulant 
use (7.6), whereas participants who reported past-year opioid use drank alcohol an average of only 5.5 days 
for this same time period (p<.001). Rates of pre-incarceration cannabis use did not differ between groups 
(X2=6.21, df=3, p=.102), however, cannabis was used prior to incarceration most often among participants 
who reported past-year stimulant use (13.9), whereas all other groups reported cannabis use for 
approximately 11 days prior to incarceration (p<.001). Participants who reported past-year concomitant and 
opioid use reported higher rates of pre-incarceration prescription sedative use, 52.2% and 40.5%, 
respectively (X2=51.1, df=3, p<.001). These groups used prescription sedatives an average of 7.5 and 6.9 
days, respectively (p<.001). Hallucinogens were used <1 day on average prior to incarceration across 
groups, though the average number of days was highest among participants who reported past-year 
concomitant use (0.6, p=.019); this group also had the highest rate of use (7.0%, X2=10.1, df=3, p<.001). 
Participants who reported past-year concomitant use also reported using synthetic drugs prior to 
incarceration at higher rates (11.8%) followed by participants who reported past-year stimulant use (10.8%, 
X2=9.12, df=3, p<.001). 
For stimulant drugs, rates of cocaine/crack cocaine use prior to incarceration were highest among 
participants who reported past-year concomitant (32.8%) and stimulant use (30.0%), though 17.9% of 
participants who reported past-year opioid use and 21.7% of participants who reported past-year other/no 
drug use also reported pre-incarceration cocaine/crack cocaine use (X2=17.37, df=3, p<.001). The average 
number of days that cocaine/crack cocaine was used prior to incarceration was greatest among participants 
who reported past-year stimulant (5.3) and concomitant use (5.0), differing from participants who reported 
past-year opioid (2.2) and past-year other drug/no drug use (3.0; p<.001). Groups also differed for rates 
(X2=60.15, df=3, p<.001) and average number of days (p<.001) of pre-incarceration amphetamine use. 
Fifty percent of participants who reported past-year stimulant use reported using amphetamines prior to 
incarceration, for 11.6 days on average. Nearly the same proportion of participants who reported past-year 
concomitant use (48.4%) also reported pre-incarceration amphetamine use, for 8.5 days on average. Still, 
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approximately a quarter of participants who reported past-year opioid and other/no drug use also reported 
pre-incarceration amphetamine use, using 3.9 and 5.6 days, respectively. 
For opioid drugs, rates of pre-incarceration heroin use were highest among participants who 
reported past-year opioid (35.4%) and concomitant use (27.4%, X2=78.61, df=3, p<.001). These groups 
also reported using heroin a greater number of days prior to incarceration, 8.4 and 5.4, respectively, 
compared to participants who reported past-year stimulant (0.9) and other/no drug use (2.8; p<.001). 
Similarly, participants who reported past-year opioid (70.8%) and concomitant use (68.8%) reported higher 
rates of pre-incarceration prescription opioid use compared to participants who reported past-year stimulant 
(36.2%) and other/no drug use (45.5%, X2=70.09, df=3, p<.001). Participants who reported past-year opioid 
and concomitant use reported using prescription opioids more days on average prior to incarceration, 16.2 
and 14.9, respectively, compared to participants who reported past-year other/no drug (9.8) and stimulant 
use (5.3; p<.001). Buprenorphine was used prior to incarceration by all groups, though rates were higher 
among participants who reported past-year opioid (30.8%) and concomitant use (26.9%, X2=36.81, df=3, 
p<.001). These groups also reported using buprenorphine more days on average (4.8 and 3.8, respectively), 
followed by participants who reported past-year other/no drug (2.2) and stimulant use (1.4, p<.001).  
Abstinence Self-efficacy Prior and Subsequent to Treatment  
Prior to entering SAP, 81.5% of the sample reported that they perceived their ability to abstain 
from alcohol and other drugs as “moderately good” or “very good”. Participants who reported past-year 
other/no drug use had the highest rates of pre-treatment abstinence self-efficacy (84.4%), compared to 
participants who reported concomitant (73.7%), stimulant (75.4%), and opioid use (77.4%; X2=18.87, 
p<.001). Interestingly, this was also the case for abstinence self-efficacy reported during the one-year post-
release period. At this time, participants who reported past-year other/no drug use had the highest rates of 
abstinence self-efficacy (90.7%) and participants who reported concomitant use had the lowest (60.2%; 
X2=121.5, p<.001). 
Past-year Drug Use Subsequent to Incarceration   
Among participants who reported any drug use during the one-year post-release period (N=869), 
non-opioid and non-stimulant drug use varied. Alcohol was used during the one-year post-release period at 
a fairly high rate sample-wide (56.7%), with rates of use higher among participants who reported past-year 
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other drug (72.6%) and concomitant use (53.8%, X2=72.36, df=3, p<.001). Participants who reported past-
year opioid use had the lowest rates of past-year alcohol use (37.9%). Rates of past-year cannabis use were 
highest among participants who reported past-year concomitant use (57.7%), followed by participants who 
reported past-year stimulant (47.7%) and other drug use (45.3%, X2=20.82, df=3, p<.001). For this time 
period, prescription sedatives were used at higher rates among participants who reported past-year 
concomitant use, with rates lowest among participants who reported past-year other drug use (32.8% vs. 
5.3%, X2=85.34, df=3, p<.001), though nearly one-fifth of participants who reported past-year opioid use 
also reported past-year prescription sedative use. Hallucinogens were used by <10% of all groups, but were 
used at higher rates among participants who reported past-year concomitant use (5.9%, X2=22.03, df=3, 
p<.001). Synthetic drug use was approximately equivalent between participants who reported past-year 
stimulant and concomitant use, at just above 17%. This differed from participants who reported past-year 
opioid (7.7%) and other drug use (11.2%, X2=11.52, df=3, p=.009). 
Among this subsample that reported any drug use during the one-year post-release period, 13.2% 
reported past-year cocaine/crack cocaine use. This was divided among participants who reported past-year 
concomitant and stimulant use, with 37.6% of participants who reported past-year concomitant use and 
34.6% who reported past-year stimulant use reporting cocaine/crack cocaine use specifically. Nearly 28% 
of this subsample reported past-year amphetamine use, with 80.1% of participants who reported past-year 
concomitant use and 68.5% who reported past-year stimulant use reporting amphetamine use specifically. 
Heroin was used by 19.3% of this subsample, with 47.8% of participants who reported past-year 
concomitant use and 40.5% of participants who reported past-year opioid use reporting heroin use 
specifically. Prescription opioids were used by 25.7% of this subsample, with 60.2% of participants who 
reported past-year concomitant use and 56.9% of participants who reported past-year opioid use reporting 
prescription opioid use specifically. Buprenorphine was used by 16.9% of this subsample, with 55.8% of 
participants who reported past-year concomitant use and 33.3% who reported past-year opioid use 
reporting buprenorphine use specifically. 
Among this subsample who reported drug use for the one-year post-incarceration period, the 
average number of different drugs used was 2.4. The highest rates were among participants who reported 
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past-year concomitant use (4.5). This differed from participants who reported past-year opioid and 
stimulant use, who used approximately 2.3 different drugs on average (p<.001).  
Days Until Post-Release Use  
Among this subsample, the number of days between participants’ release date and their first 
incidence of alcohol or other drug use was approximately the same, with 86.0 days out before the first 
incidence of alcohol use and 86.7 days out before the first incidence of illicit drug use. Participants who 
reported past-year concomitant use used alcohol and drugs earlier than participants in all other groups, with 
use occurring between 60-70 days on average subsequent to release. Participants who reported past-year 
other drug use went approximately 97-98 days subsequent to release before using alcohol or other drugs, 
the longest for all groups. This was followed by participants who reported past-year opioid use, who did not 
report using alcohol until nearly 88 days after their release and who did not report using illicit drugs until 
94 days after their release.  
Central Appalachia 
During the one-year post-release period, 30.3% of participants reported residing in Central 
Appalachia for the majority of time. A greater proportion of participants who reported past-year opioid 
resided in Central Appalachia (42.6%, X2=19.41, df=3, p<.001). This was followed by participants who 
reported past-year other/no drug (29.7%), concomitant (27.4%), and stimulant (22.0%). Specific opioid and 
stimulant drug use by region were also examined. Proportions of past-year specific opioid and stimulant 
drug use by region (Central Appalachia vs. non-Appalachia) are displayed in Figure 8.  
For past-year heroin use, rates were lower among participants who resided in Central Appalachia 
compared to those who resided outside of Appalachia (6.1% vs. 12.8%, X2=15.20, df=1, p<.001). Groups 
by region also differed for rates of past-year prescription opioid (17.9% vs. 12.7%, X2=7.47, df=1, p=.008) 
and buprenorphine (13.3% vs. 7.7%, X2=12.06, df=1, p<.001) use, with a higher proportion of participants 
residing in Central Appalachia. Groups by region differed for rates of past-year cocaine/crack 
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Figure 8. Opioid and stimulant use during the one-year post-release period by Appalachia 
and Non-Appalachia residence. 
 
 
cocaine use (4.0 % vs. 8.8%, X2=11.20, df=1, p<.001), but not past-year amphetamine use (13.9% vs. 
15.8%, X2=0.90, p=.385). In addition to these drugs, past-year alcohol (23.8% vs. 34.9%, X2=18.69, df=1 
p<.001) and synthetic drug use (4.2% vs. 8.3%,  
X2=8.26, df=1, p=.006) also differed by region.  
Urban Influence  
The mean urban influence for the sample during the one-year period subsequent to incarceration 
(?̅? =4.5) indicated that, similar to participant residence reported for the one-year period prior to 
incarceration, the sample was comprised of a greater proportion of people living in a metro or urban area. 
As displayed in Table 2, the average urban influence designation was higher among participants who 
reported past-year opioid (5.0) and other drug/no drug use (4.5), indicating greater rurality and less 
population density, but was slightly lower among participants who reported past-year stimulant (4.3) and 
concomitant use (4.4; p<.001), indicating greater population and urban influence.  
Similar to drug use prior to incarceration, higher proportions for all drugs were associated with 
greater urban and metro influence. However, instead of prescription opioids showing the highest use rates 
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in association with less urban influence, the highest rate of use for any drug by urban influence designation 
during the one-year period subsequent to incarceration was heroin, which was associated with the 
designation indicating greatest urban influence (56.0%). Apart from the two designations indicating 
greatest urban influence (1 and 2), the next two urban influence designations with the largest proportion of 
concentrated use were found in 6 and 8. Overall, only prescription opioids, buprenorphine, and 
amphetamines had rates of use across more rural areas that, while still significantly less than those found in 
areas with greater urban influence, approached something comparable. As shown in Figure 10, 
cocaine/crack cocaine and heroin use in designations 1 and 2 are over four- and five-fold compared to other 
designations.  
Figure 9. Opioid and stimulant use during the one-year post-release period by urban influence 
designation.  
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Access to Alcohol 
During the one-year post-release period, 56.6% of participants resided in a county with 
unrestricted alcohol sales for the majority of time. Groups were similar in the proportion of participants 
who resided in a county with unrestricted alcohol sales (X2=5.35, df=3, p=.148), with participants who 
reported past-year concomitant use having the highest rate (58.6%) and participants who reported past-year 
stimulant use having the lowest rate (49.2%).  
Aim Two Results 
Multinomial Logistic Regression Results for Drug Outcomes Prior to Incarceration 
Table 3 displays the results of the multinomial logistic regression examining opioid and stimulant 
outcomes for the 30-day period prior to incarceration, with “other drug use” as the reference group. 
Independent and control variables (as opposed to variables used for description purposes only; see 
Measures subsection “Descriptive Variables” pg. 171) which differed significantly by group when 
examined using nonparametric tests were included into the regression model. The only exception was the 
variable measuring past-year depressive symptoms, which was omitted due to collinearity with the variable 
“stress-related health effects”. Collinearity was assessed via variance inflation factor (VIF) and 1/VIF (1 
minus the R2 obtained with IV regressed on the set of other IVs); an approximate VIF <1.5 or 1/VIF>0.85 
was considered acceptable (Hair, Anderson, Tatham, & Black, 1995). VIFs for different models were 
calculated using different variable configurations (i.e., singularly removing or adding past-year depressive 
symptoms, stress-related health effects, suicidal ideation, and past-year anxiety symptoms to the model). A 
decision was made to remove the variable of past-year depressive symptoms, rather than the stress-related 
health effects variable. This decision was made for three reasons. First, stress-related health effects 
(measured for the 7-day period prior to incarceration) may have served as a potentially more proximate 
influence on past 30-day drug-related decision-making and is important in this regard. Second, depressive 
symptoms were considered as a stress-related health effect, as measured by one question contained in the 
revised HCS, meaning that by using the variable of stress-related health effects, depression is not entirely 
ruled out as still possibly exerting some, albeit less discernable, influence on drug use for this time period. 
That depression and, to a lesser extent, anxiety, were both positively correlated with stress-related health 
effects (i.e., revised HCS scores) may actually provide some oblique and partial support for the modified 
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scale’s construct validity. Lastly, past-year suicidality was retained as an independent variable. Though 
suicidality is not synonymous with depression, it is positively correlated with and conceptually related to it 
such that it may provide an indirect indicator of past-year depression even with the variable of past-year 
depressive symptoms removed. Model fit statistics, displayed at the bottom of Table 3, indicated acceptable 
model fit.  
In the first column of Table 3, robust standard errors are displayed. These were calculated to 
address the fact that some cases were clustered by county and to help establish a more “model-agnostic” 
model. The specific correction-method that produces robust errors (versus asymptotic standard errors) used 
was the Huber/White robust estimator of variance (Huber, 1967; Gutierrez & Drukker, 2019; White, 1982). 
The Huber/White estimator for obtaining robust variance estimates is available as a command in Stata, and 
has been utilized to address clustered or nested data, such as cases clustered by county or some other 
grouping (Froot, 1989; Gutierrez & Drukker, 2019; Rogers, 1993; Williams, 2000; Wooldridge, 2002). In 
the second column, corresponding confidence intervals are displayed. The third column displays regression 
coefficients calculated as relative risk ratios (RRR), which can be conceptualized as increases or decreases 
in log odds of being in one of the opioid or stimulant outcome groups (i.e., the ratio of the probability of 
one of the three outcome groups being chosen over the probability of the reference group of “other drug 
use” being chosen). By specifying that linear equations be exponentiated, regression coefficients that are 
the relative risk ratio for a unit change in the independent variables can be produced and displayed. This 
can be termed as relative risk, or odds. In column four, p values are displayed.  
Table 3 
Results of Multinomial Logistic Regression Examining Opioid and Stimulant Use During the 30-day 
Pre-incarceration Period 
Robust SE 95% CI RRR p value 
Concomitant  
White 0.304 0.68-1.92 1.15 .607 
Controlled environment, past 30-days 0.262 0.89-0.99 0.94 .893 
Lifetime drug treatment episodes 0.300 0.94-1.05 0.99 .865 
Ever IDU 0.879 2.43-5.88 3.81 .001 
Age  0.012 1.00-1.05 1.03 .015 
Male 0.383 0.74-2.32 1.31 .363 
Lifetime history of head trauma 0.208 0.66-1.50 0.99 .996 
Past-year economic hardship 0.057 0.951.17 1.06 .286 
Past-year homelessness 0.196 0.32-1.11 0.64 .122 
Subjective socioeconomic status 0.056 0.93-1.14 1.03 .588 
Past-week stress related health effects 0.016 0.97-1.03 1.00 .929 
Past-year anxiety symptoms 0.219 0.57-1.46 0.92 .716 
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Table 3 (continued) 
Past-year suicidal ideation 0.365 0.54-2.08 1.06 .858 
Chronic pain 0.261 0.64-1.70 1.04 .874 
Misregulation 0.524 0.94-3.12 1.72 .077 
Close relationships 0.017 0.97-1.03 1.00 .953 
Social satisfaction 0.195 0.52-1.31 0.82 .422 
Leisure time, in days 0.038 0.86-1.01 0.93 .084 
Age of drug use initiation  0.024 1.03-1.12 1.08 .001 
Severity of use  0.007 1.04-1.07 1.06 .001 
Drug use versatility, past-year 0.310 2.59-3.84 3.15 .001 
Central Appalachia 0.284 0.79-1.94 1.24 .344 
Opioids 
White 0.941 2.19-6.01 3.64 .001 
Controlled environment, past 30-days 0.022 0.92-1.00 0.96 .065 
Lifetime drug treatment episodes 0.027 0.93-1.03 0.98 .509 
Ever IDU 0.569 1.90-4.08 2.81 .001 
Age 0.010 0.99-1.03 1.01 .177 
Male 0.308 0.75-1.90 1.23 .425 
Lifetime history of head trauma 0.204 0.81-1.61 1.14 .465 
Past-year economic hardship 0.050 0.91-1.10 1.00 .959 
Past-year homelessness      0.277  0.51-1.62    0.91    .744 
Subjective socioeconomic status 0.048 0.91-1.10 1.00 .917 
Past-week stress related health effects  0.013        0.96-1.00         0.98    .193 
Past-year anxiety symptoms   0.189  0.60-1.35   0.90     .618 
Past-year suicidal ideation   0.361  0.66-2.14   1.19     .574 
Chronic pain 0.282 0.85-1.97 1.30 .236 
Misregulation 0.427 1.21-2.90 1.89 .005 
Close relationships 0.015 0.94-0.99 0.97 .040 
Social satisfaction 0.244 0.80-1.78 1.19 .399 
Leisure time, in days  0.033 0.86-0.96 0.92 .019 
Age of drug use initiation  0.021 1.05-1.13 1.09 .001 
Severity of use  0.006 1.04-1.07 1.06 .001 
Drug use versatility, past-year 0.161 1.51-2.14 1.80 .001 
Central Appalachia 0.316 1.13-2.39 1.64 .010 
Stimulants 
White 0.209 0.72-1.55 1.06 .774 
Controlled environment, past 30-days 0.023 0.89-0.98 0.94 .014 
Lifetime drug treatment episodes 0.030 0.93-1.03 1.00 .947 
Ever IDU 0.869 1.09-2.56 1.68 .019 
Age  0.012 1.03-1.06 1.05 .001 
Male .0383 0.78-2.34 1.35 .279 
Lifetime history of head trauma 0.208 0.73-1.48 1.04 .834 
Past-year economic hardship 0.057 0.91-1.10 1.00 .930 
Past-year homelessness 0.285 0.51-1.62 0.94 .842 
Subjective socioeconomic status 0.047 0.97-1.15 1.06 .179 
Past-week stress-related health effects 0.013 0.97-1.01 0.99 .657 
Past-year anxiety symptoms 0.198 0.60-1.35 0.98 .923 
Past-year suicidal ideation 0.466 0.79-2.74 1.48 .217 
Chronic pain 0.172 0.50-1.18 0.76 .234 
Misregulation 0.376 1.14-2.65 1.74 .010 
Close relationships 0.012 0.97-1.01 0.99 .452 
Social satisfaction 0.202 0.65-1.46 0.98 .921 
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Past 30-day Concomitant Use Prior to Incarceration 
Among participants who reported past 30-day concomitant use, having a history of IDU was 
associated with the greatest increased odds for observing the outcome of past 30-day concomitant use 
(RRR=3.81, p<.001). Younger age (RRR=1.03, p=0.15) was also associated with increased likelihood of 
concomitant use for this period. Younger age of drug use initiation (RRR=1.08, p<.001), greater severity of 
use (RRR=1.06, p<.001), and greater past-year drug use versatility, indicated by a greater number of drugs 
used (RRR=3.15, p<.001), were all associated with an increased likelihood of past 30-day concomitant use. 
Residing in Central Appalachia for the one-year period prior to incarceration was not associated with a 
statistically significant increase in likelihood of past 30-day concomitant use (RRR=1.24, p=.344). For the 
entire model, the overall effect of residing in Central Appalachia was significant (X2=25.01, p<.001). The 
effect of residing in Central Appalachia on predicting the probability of past 30-day concomitant did not 
differ from the effect of residing in Central Appalachia on predicting the probability of past 30-day opioid 
use (X2=2.84, p=.0918), but did differ modestly from past 30-day stimulant use (X2=9.37, p=.022).  
Figure 10 displays the percent change in odds for a one unit increase among binary independent 
variables and the percent change in odds for a one standard deviation increase among continuous or ranked 
independent variables (Long & Freese, 2005, 2014). Only independent variables significantly associated 
with changes in the likelihood of observing concomitant use for the 30-day period prior to incarceration are 
presented.  
Table 3 (continued) 
Leisure time, in days  0.033 0.86-0.99 0.92 .025 
Age of drug use initiation  0.020 1.00-1.08 1.04 .034 
Severity of use  0.007 1.03-1.06 1.05 .001 
Drug use versatility, past-year 0.109 1.13-1.56 1.33 .002 
Central Appalachia 0.135 1.13-2.39 0.63 .032 
Intercept-only: -2141.458 Model: -1522.240 Pseudo R2=0.289 
Wald Chi2 (df=66) =630.810, p<.001 Cox-Snell/ML=0.547   
Cragg-Uhler/Nagelkerke=0.585 
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Drug use versatility (i.e., the number of drugs used in the year prior to incarceration) increased the 
odds of observing past 30-day concomitant use the most, with the likelihood of past 30-day concomitant 
use increasing 1,426.7% for every SD increase (SD=2.4); an approximate 215.2% increase in odds for 
every 1 additional drug used. The likelihood of observing past 30-day concomitant use increased by 
281.1% when history of IDU was also reported. For every SD increase in severity of use (SD=15.8), past 
30-day concomitant use was 140.2% more likely (i.e., a 5.7% increase for every one-digit severity score 
increase). Observing past 30-day concomitant use was 44.7% less likely for every SD increase in age of 
drug use initiation (SD=5.0); an approximate 7.7% decrease for every one-year increase. Odds decreased 
29.6% for every SD increase in age (SD=9.0); an approximate 2.9% decrease for every year. 
Past 30-day Opioid Use Prior to Incarceration 
  Being White (RRR=3.64, p<.001) and having a history of IDU (RRR=2.81, p<.001) were both 
associated with an increased likelihood of using opioids during the 30-day period prior to incarceration. 
Misregulation was also associated with an increased likelihood of using opioids for this time period 
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(RRR=1.89, p<.005). Having fewer close relationships (RRR=0.97, p=.040) and fewer number of leisure 
days per week (RRR=0.92, p=.019) also increased the likelihood of past 30-day opioid use. Older age of 
drug use initiation (RRR=1.09, p<.001), greater severity of use (RRR=1.06, p<.001), and greater drug use 
versatility during the one-year period prior to incarceration (RRR=1.80, p<.001), were all associated with 
an increased likelihood that opioids would be used during the 30-day period prior to incarceration. Finally, 
residing the majority of the year prior to incarceration in Central Appalachia also increased the likelihood 
that past 30-day opioid use would be observed, with participants who resided in this region 1.64 times more 
likely to report past 30-day opioid use (p=.010). Figure 11 displays the percent change in odds for 
independent variables significantly associated with changes in the likelihood of observing past 30-day 
opioid use prior to incarceration.  
Figure 11. Percent change in odds of past 30-day opioid use prior to incarceration. 
Drug use versatility increased the odds of observing past 30-day opioid use by 305.0% for every 
SD increase (SD=2.4); an approximate increase of 80.3% for every 1 drug used. The likelihood of 
observing past 30-day opioid use increased by 264.1% when the person was also White and by 181% if 
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history of IDU was reported. For every SD increase in severity of use (SD=15.8) the likelihood of 
observing past 30-day opioid use increased by 143.6% (i.e., a 5.8% increase for every one-digit severity 
score increase). Past-week misregulation increased the likelihood of observing past 30-day opioid use by 
88.6%. Residing in Central Appalachia during the one-year period prior to incarceration increased the odds 
of observing past 30-day opioid use by 64.2%. Past 30-day opioid use was 51.0% more likely for every SD 
increase in age of drug use initiation (SD=5.0); an approximate 8.6% increase for every year. Close 
relationships modestly decreased the likelihood of observing past 30-day opioid use by 15.6% for every SD 
increase (SD=4.1); an approximate decrease of 3.3% in odds per relationship. Finally, for every SD 
increase in leisure days (SD=2.4), the odds of observing past 30-day opioid use decreased by 18.1%, about 
an 8.1% decrease for per day.  
Past 30-day Stimulant Use Prior to Incarceration 
Fewer number of nights spent in a controlled environment during the 30-day period prior to 
incarceration was associated with an increased likelihood of stimulant use for the 30-day period prior to 
incarceration (RRR=0.94, p=.014). History of IDU was also associated with and increased likelihood of 
past 30-day stimulant use (RRR=1.68, p=.019), as was older age (RRR=1.05, p<.001). Similar to past 30-
day opioid use prior to incarceration, misregulation was associated with increased likelihood of past 30-day 
simulant use (RRR=1.74, p=.010). The likelihood of past 30-day stimulant use also decreased in 
association with an increase in the number of leisure days per week (RRR=0.92, p=.025). Older age of drug 
use initiation (RRR=1.04, p=0.34), greater severity of use (RRR=1.05, p<.001), and greater number of 
drugs use versatility prior to incarceration (RRR=1.33, p<.002), were all associated with an increased 
likelihood that stimulants would be used during the 30-day period prior to incarceration. Unlike past 30-day 
opioid use, residing in Central Appalachia for the majority of time out of the year prior to incarceration 
slightly decreased the likelihood of stimulant use (RRR=0.63, p=0.32). The effect of residing in Central 
Appalachia on predicting the probability of past 30-day use differed between participants who reported past 
30-day opioid and past 30-day stimulant use (X2=24.24, p<.001). Figure 12 displays the percent change in 
odds for independent variables significantly associated with changes in the likelihood of observing past 30-
day stimulant use prior to incarceration. 
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Figure 12. Percent change in odds of past 30-day stimulant use prior to incarceration. 
For every SD increase in drug use severity (SD=15.8), the likelihood of observing past 30-day 
stimulant use increased by 111.8% (i.e., a 4.9% increase for every one-digit severity score increase), and 
for every SD increase in drug use versatility (SD=2.4) the likelihood increased 97.4%; an approximate 
33.2% increase for every one drug used. Past-week misregulation was associated with a 74.1% increase in 
the likelihood of observing past 30-day stimulant use. The odds of observing past 30-day stimulant use 
increased by 67.3% if history of IDU was reported and by 51.3% for every SD increase in age (SD=9.0), an 
approximate increase of 4.7% for each year. The likelihood of observing past 30-day stimulant use 
increased modestly by 22.9% for every SD increase for age of drug use initiation (SD=5.0); an approximate 
increase of 4.2% for each year. For every SD increase in leisure days (SD=2.4), the odds of observing past 
30-day stimulant use decreased by 17.4%, about a 7.7% decrease for per day. The likelihood of observing 
past 30-day stimulant use decreased by 20.0% for every SD increase in nights spent in a controlled 
environment (SD=3.6); an approximate 6.0% decrease for each night. Lastly, residing in Central 
Appalachia was associated with a 36.9% decrease in the likelihood of observing stimulant use for the 30-
day period prior to incarceration. 
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Multinomial Logistic Regression Results for Drug Outcomes Subsequent to Incarceration 
Tables 5.0 and 5.1 display the results of the multinomial logistic regression models examining 
opioid and stimulant outcomes for the one-year period subsequent to incarceration, with “other/no drug 
use” as the reference group. Variables considered as control variables and independent variables (as 
opposed to variables used for description only) which differed significantly by group when examined using 
nonparametric tests were included into the regression models.  
Due to the overall number of independent variables which differed significantly by group in non-
parametric analyses, two separate models were built to avoid model overfitting, as the events (i.e., taken to 
be the smaller number of cases reporting the outcome of interest, versus the number of cases for which the 
outcome was not reported; e.g., past-year opioid use rather than no use) for each outcome variable were 
smaller for the one-year post-release period compared to the 30-day pre-incarceration period. Specifically, 
N=186 for past-year concomitant use, N=195 for past-year opioid use, and N=130 for past-year stimulant 
use). The events per variable (EPV), the number of events divided by the number of independent variables, 
thus translates to approximately 19, 20, and 13, covariates respectively. A decision was made to examine 
the relationship between pre-incarceration drug use and opioid and stimulant outcomes that occurred during 
the one-year post-release period in a separate model. As prior drug use was not included in the multinomial 
regression model examining opioid and stimulant use outcomes for the 30-day period prior to incarceration, 
this decision allowed for some continuity between sets of analyses and related discussion. Examining the 
relationship between pre-incarceration drug use on opioid and stimulant outcomes subsequent to 
incarceration also permitted a narrower examination of premise discussed in earlier chapters that prior 
exposure to, or use of, drugs can significantly influence and constrain future decision-making about drugs, 
and therefore future drug behaviors, independent of other factors. Prior to examining the relationship 
between pre-incarceration use of specific drugs and opioid and stimulant outcomes for the one-year period 
subsequent to incarceration, it was expected (both for conceptual reasons as well as due to non-parametric 
test results) that specific opioid and stimulant drugs (e.g., heroin, buprenorphine, cocaine, etc.) used during 
the 30-day period prior to incarceration would demonstrate a positive correlation with drug outcomes for 
the one-year post-release period by drug class (e.g., opioids, stimulants) or combination of classes (e.g., 
concomitant) of which they are constituents. It was unclear, however, if all specific drugs for each drug 
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class would demonstrate a positive and statistically significant relationship with expected outcomes, or if 
instead, only certain drugs would. Further, it was uncertain what, if any drugs, might be associated with a 
decreased likelihood of observing a given outcome. 
 For the first model examining opioid and stimulant outcomes during the one-year period 
subsequent to incarceration, VIF indicated that collinearity was not an issue for either model. Model fit 
statistics for the first model, displayed at the bottom of Table 4.0, indicated acceptable model fit. 
Table 4 
Results of Multinomial Logistic Regression Examining Opioid and Stimulant Use During the One-year 
Post-release Period  
Robust SE 95% CI RRR p 
value 
Concomitant  
White 1.730 2.15-10.07 4.67 .001 
Nights controlled environment, past-year 0.011 1.00-1.08 1.01 .001 
Lifetime drug treatment episodes  0.022 1.00-1.09 1.05 .016 
Ever IDU 0.440 1.61-3.37 2.32 .001 
Age  0.010 0.93-0.97 0.95 .001 
Past-month income 0.007 0.99-1.01 1.00 .188 
Past-year cognitive difficulties  0.316 1.00-2.26 1.50 .058 
Past-year anxiety symptoms 0.251 0.73-1.74 1.13 .583 
Past-year depressive symptoms 0.473 1.33-3.25 2.09 .001 
Past-year suicidal ideation 0.898 1.23-5.05 2.49 .011 
Close relationships 0.017 0.97-1.03 1.00 .846 
Social satisfaction 0.085 0.22-0.55 0.36 .001 
Perceived social worth 0.266 0.46-1.57 0.86 .627 
Past-year educational/vocational 
involvement 
0.327 1.00-2.31 1.53 .046 
On community supervision 0.610 1.01-3.55 1.89 .049 
Age of drug use initiation 0.024 0.95-1.03 0.99 .556 
Abstinence self-efficacy prior to treatment 0.142 0.45-1.02 0.68 .066 
Central Appalachia 0.163 0.58-1.23 0.84 .376 
Opioids 
White 0.594 1.08-3.33 1.90 .026 
Nights controlled environment, past-year 0.001 1.00-1.01 1.00 .001 
Lifetime drug treatment episodes 0.020 1.02-1.10 1.07 .001 
Ever IDU 0.450 1.69-3.42 2.42 .001 
Age  0.011 0.94-0.98 0.96 .001 
Income, past-month 0.005 0.99-1.00 1.00 .834 
Past-year cognitive difficulties  0.209 0.70-1.54 1.04 .847 
Past-year anxiety symptoms 0.181      0.62-1.33       0.91       .618 
Past-year depressive symptoms 0.281 0.87-2.00 1.32 .187 
Past-year suicidal ideation 0.677 0.82-3.73 1.75 .154 
Close relationships     0.021      0.95-1.03      0.99  .640 
Social satisfaction 0.117 0.27-0.75 0.45 .002 
Perceived social worth  0.232      0.44-1.40       0.78       .405 
Past-year educational/vocational 
involvement 
0.255 0.83-1.81 1.25 .289 
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Past-year Concomitant Use Subsequent to Incarceration 
Being White was significantly associated with past-year concomitant use (RRR=4.68, p<001). 
Greater number of nights spent in a controlled environment during the one-year post-release period 
(RRR=1.01, p<.001), greater number of lifetime drug treatment episodes (RRR=1.05, p=0.16), and history 
of IDU (RRR=2.32, p<.001) were all associated with an increased likelihood of observing past-year 
concomitant use. While experiencing past-year cognitive difficulties approached statistical significance 
(RRR=1.50, p=.053), experiencing past-year depressive symptoms (RRR=2.09, p<.001) and past-year 
suicidal ideation (RRR=2.49, p=.011) were both associated with an increased likelihood of past-year 
concomitant use. Receiving satisfaction from past-year social interaction, as opposed to being indifferent to 
or not receiving satisfaction, decreased the likelihood of past-year concomitant use (RRR=0.37, p<.001). 
Past-year concomitant use was also significantly associated with educational and/or vocational involvement 
(RRR=1.53, p=.046), as well as being on community supervision during the one-year post-release period 
Table 4 (continued) 
 













Age of drug use initiation 0.019 0.96-1.02 1.00 .855 
Abstinence self-efficacy prior to treatment 0.169 0.55-1.22 0.82 .334 
Central Appalachia 0.279 1.12-2.24 1.60 .008 
     
Stimulants     
White 0.303 0.72-1.95 1.18 .520 
Nights controlled environment, past-year 0.001 1.00-1.01 1.06 .001 
Lifetime drug treatment episodes 0.025 1.00-1.10 1.05 .055 
Ever IDU 0.183 0.55-1.28 0.84 .420 
Age 0.011 0.99-1.03 1.01 .163 
Income, past-month 0.006 0.99-1.00      1.00 .650 
Experienced cognitive difficulties 0.259 0.66-1.71 1.07 .796 
Past-year anxiety symptoms 0.271 0.69-1.80 1.13 .635 
Past-year depressive symptoms 0.460 1.11-2.98 1.82 .018 
Past-year suicidal ideation 0.666 0.66-3.46 1.54 .310 
Close relationships 0.016 0.98-1.04 1.01 .360 
Social satisfaction 0.111 0.23-0.69 0.40 .001 
Perceived social worth 0.383 0.53-2.16 1.01 .844 
Past-year educational/vocational 
involvement 
0.246 0.66-1.66 1.05 .852 
On community supervision 0.652 0.93-3.62 1.86 .078 
Age of drug use initiation 0.027 0.90-1.00 0.95 .072 
Abstinence self-efficacy prior to treatment 0.140 0.38-0.94 0.59 .027 
Central Appalachia 0.179 0.45-1.17 0.74 .206 
     
Intercept-only: -1538.692/Model: -1342.738          Pseudo R2=0.127 
Wald Chi2 (df=54)=300.538, p<.001                     Cox-Snell/ML=0.222   
                                                                                 Cragg-Uhler/Nagelkerke=0.25 
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(RRR=1.89, p=.049). Residing in Central Appalachia during the one-year post-release period was not 
associated with changes in the likelihood of observing past-year concomitant use (RRR=0.84, p=3.76). The 
overall effect of residing in Central Appalachia for the entire model was significant (X2=11.52 p=.0092). 
The effect of residing in Central Appalachia on predicting the probability of past-year concomitant use 
differed from the effect on predicting the probability of past-year opioid use (X2=7.73, p=.0051), but not 
past-year stimulant use (X2=0.23, p=.6352). Figure 13 displays the percent change in odds for independent 
variables significantly associated with changes in the likelihood of observing concomitant use during the 
one-year period subsequent to incarceration. 
 Figure 13. Percent change in odds of concomitant use during one-year post-release period. 
 Being White increased the likelihood that concomitant use during the one-year post-release period 
would be observed by 367.4%. The likelihood of observing past-year concomitant use increased by 149.3% 
with past-year suicidal ideation. History of IDU increased the likelihood of observing past-year 
concomitant use by 133.0%, whereas past-year depressive symptoms increased the likelihood by 109.0%. 
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Being on community supervision for this same time period increased odds by 89.0%. For every SD 
increase in nights spent in a controlled environment during the past year (SD=77.7), the odds of observing 
past-year concomitant use increased by 67.6%; an approximate increase of 0.8% per night. Past-year 
educational/vocational involvement was associated increased 53.2% increased odds of observing past-year 
concomitant use. Past-year cognitive difficulties were associated with a 49.3% increase in odds of 
observing past-year concomitant use. The likelihood of observing concomitant use also increased by 22.0% 
for each SD increase in lifetime drug treatment episodes (SD=3.9); an approximate increase of 5.6% per 
treatment episode. For age, the likelihood of observing past-year concomitant use decreased by 37.3% for 
every SD increase (SD=9.1); an approximate 5% decrease for every 1 year. Lastly, receiving satisfaction 
from past-year social interaction decreased the odds of observing past-year concomitant use by 64.8%.  
Past-year Opioid Use Subsequent to Incarceration 
As with past-year concomitant use, being White (RRR=1.90, p=.026) was associated with 
increased odds of past-year opioid use. Greater number of nights spent in a controlled environment during 
the one-year post-release period (RRR=1.00, p<.001), greater number of lifetime drug treatment episodes 
(RRR=1.07, p=<.001), and history of IDU (RRR=2.42, p<.001) were all associated with an increased 
likelihood of observing past-year opioid use. Participants who reported past-year opioid use were also more 
likely to be younger (RRR=0.96, p<.001). Receiving satisfaction from past-year social interaction was 
associated with decreased odds of past-year opioid use (RRR=0.46, p=.002). Finally, residing in Central 
Appalachia for the majority of the year subsequent to incarceration was associated with an increased 
likelihood of past-year opioid use (RRR=1.60, p=.008). The effect of residing in Central Appalachia for the 
one-year post-release period on predicting the probability of past-year opioid use differed from the effect 
on predicting the probability of past-year stimulant use (X2=7.57, p=.0051) as well as concomitant use 
(X2=7.73, p=.0058).  
Figure 14 displays the percent change in odds for independent variables significantly associated 
with changes in the likelihood of observing opioid use during the one-year subsequent to incarceration. 
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Figure 14. Percent change in odds of opioid use during one-year post-release period. 
History of IDU increased the odds of observing past-year opioid use by 142.2%. Residing in 
Central Appalachia for the majority of time out of the past year increased the odds of observing past-year 
opioid use by 116.8%. Being White increased the likelihood of observing past-year opioid use by 90.1%. 
For every SD increase in nights spent in a controlled environment during the past year (SD=77.7), the odds 
of observing past-year opioid use increased by 34.3%, just 0.4% for each night. For each SD increase 
(SD=3.9) in lifetime drug treatment episodes, there was a 28.8% increase in the likelihood of observing 
past-year opioid use; an approximate 6.7% increase for each treatment episode. For every SD increase in 
age (SD=9.0), the likelihood of past-year opioid use decreased by 34.2%; an approximate 4.5% decrease for 
every 1 year. Lastly, receiving satisfaction from past-year social interaction decreased the odds of 
observing past-year opioid use by 55.1%.  
Past-year Stimulant Use Subsequent to Incarceration  
Unlike concomitant and opioid use for the one-year post-release period, being White did not 
increase the likelihood that past-year stimulant use would be observed (RRR=1.18, p=.520). Similar to 
past-year concomitant and opioid use, though, greater number of nights spent in a controlled environment 
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in the year following release was associated with an increased likelihood of past-year stimulant use 
(RRR=1.06, p<.001). Greater number of prior drug treatment episodes (RRR=1.05, p=.055) approached 
statistical significance. Experiencing past-year depressive symptoms was associated with an increased 
likelihood of past-year stimulant use (RRR=1.82, p=.018), whereas receiving satisfaction from social 
interaction was associated with decreased likelihood (RRR=0.40, p.<001). Reporting “moderately good” or 
“very good” abstinence self-efficacy prior to treatment was associated with decreased odds of past-year 
stimulant (RRR=0.59, p=.027). Residing in Central Appalachia for the majority of the one-year post-
release period was not associated with a change in odds of stimulant use for this same time period 
(RRR=0.74, p=.206).  
Figure 15 displays the percent change in odds for independent variables significantly associated 
with changes in the likelihood of observing stimulant use during the one-year period subsequent to 
incarceration. 
Figure 15. Percent change in odds of stimulant use during one-year post-release period. 
The likelihood of observing past-year stimulant use increased 82.1% when past-year depressive 
symptoms were also reported. For every SD increase in nights spent in a controlled environment during the 
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year subsequent to incarceration (SD=77.7), the odds of observing past-year stimulant use increased by 
59.9%, just 0.6% for each night. Lifetime drug treatment was associated with a 18.7% increase in the 
likelihood of observing past-year stimulant use for each SD increase (SD=3.9); an approximate 4.5% 
increase for each treatment episode. Having reported “moderately good” or “very good” abstinence self-
efficacy prior to treatment was associated with a 40.5% decrease in odds of observing stimulant use during 
the one-year post-release period. Lastly, receiving satisfaction from social interaction was associated with a 
60.5% decrease in the odds of observing stimulant use for this time period, similar to the percentage change 
in odds observed for past-year concomitant and opioid use. 
For the second model examining the relationship between specific drug use that occurred during 
the 30-day period prior to incarceration and opioid and stimulant outcomes that occurred during the one-
year post-release period, collinearity was not an issue and model fit statistics, displayed at the bottom of 
Table 4.1., indicated acceptable fit.  
For concomitant use during the one-year period subsequent to incarceration, drugs used during the 
30-day period prior to incarceration that were significantly associated with an increased likelihood of past-
year concomitant use included prescription sedatives (RRR=1.69, p=.006), heroin (RRR=1.52, p=.043), 
prescription opioids (RRR=1.74, p=.006) and amphetamines (RRR=1.97, p<.001). For opioid use during 
the one-year period subsequent to incarceration, drugs used during the 30-day period prior to incarceration 
that were significantly associated with an increased likelihood of past-year opioid use included heroin 
(RRR=2.55, p<.001) and prescription opioids (RRR=2.19, p<.001). Alcohol (RRR=0.64, p=.009), 
cocaine/crack cocaine (RRR=0.63, p=.034), and amphetamine use (RRR=0.62, p=.022) during the 30-day 
period prior to incarceration were all associated with a decreased likelihood of opioid use during the one-
year period subsequent to incarceration. For stimulant use during the one-year period subsequent 
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Table 4.1 Results of Multinomial Logistic Regression Examining Past 30-day Pre-incarceration Drug 
Use and Past-year Post-release Drug Use 
 
 
to incarceration, the only two drugs used in the 30-day period prior to incarceration significantly associated 
with an increased likelihood of past-year stimulant use during the one-year period subsequent to 
incarceration included cocaine/crack cocaine (RRR=1.92, p=.004) and amphetamines (RRR=3.0, p<.001). 
Heroin use during the 30-day period prior to incarceration was associated with a decreased likelihood of 
stimulant use during the one-year period subsequent to incarceration (RRR=0.23, p=.002). Buprenorphine 
was the only opioid drug used during the 30-day period prior to incarceration not associated with 
statistically significant change in odds for any of the outcomes of interest.  
 Robust SE 95% CI RRR p value 
Concomitant      
Alcohol 0.141 0.60-1.16 0.83 .241 
Sedatives 0.330 1.18-2.50 1.69 .006 
Hallucinogens 0.583 0.72-3.22 1.49 .291 
Synthetic drugs 0.306 0.58-1.84 1.01 .954 
Cocaine/crack cocaine 0.260 1.01-2.44 1.37 .101 
Amphetamines 0.343 0.95-2.00 1.97 .001 
Heroin 0.312 1.02-2.27 1.52 .043 
Prescription opioids 0.489 1.18-2.57 1.74 .006 
Buprenorphine  0.229 0.70-1.62 1.07 .757 
     
Opioids      
Alcohol 0.106 0.46-0.88 0.64 .009 
Sedatives 0.237 0.84-1.80 1.25 .241 
Hallucinogens 0.572 0.42-3.01 1.16 .763 
Synthetic drugs 0.375 0.64-2.20 1.19 .554 
Cocaine/crack cocaine 0.137 0.40-0.95 0.63 .034 
Amphetamines 0.127 0.41-0.93 0.62 .022 
Heroin 0.495 1.74-3.72 2.55 .001 
Prescription opioids 0.423 1.51-3.01 2.19 .001 
Buprenorphine 0.293 0.98-2.15 1.45 .066 
     
Stimulants      
Alcohol 0.171 0.61-1.29 0.92 .704 
Sedatives 0.209 1.99-1.30 0.87 .570 
Hallucinogens 0.471 0.80-3.03 0.79 .726 
Synthetic drugs 0.531 0.81-3.03 1.65 .144 
Cocaine/crack cocaine 0.420 1.19-2.89 1.92 .004 
Amphetamines 0.574 1.98-4.23 3.0 .001 
Heroin 0.107 0.09-0.57 0.23 .002 
Prescription opioids 0.152 0.44-1.06 0.68 .082 
Buprenorphine 0.255 0.40-1.46 0.77 .438 
     
Intercept-only: -1541.577/Model: -1423.094       Pseudo R2=.078 
Wald Chi2 (df=27) =214.211, p<.001                 Cox-Snell/ML=0.143    
                                                                              Cragg-Uhler/Nagelkerke=0.166 
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Figures 16, 17, and 18 display the percent change in odds for independent variables significantly 
associated with changes in the likelihood of observing concomitant, opioid, and stimulant use during the 
one-year period subsequent to incarceration, respectively. 
Figure 16. Percent change in odds of concomitant use during one-year post-release period by pre-
incarceration drug use.  
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Figure 17. Percent change in odds of opioid use during one-year post-release period by pre-
incarceration drug use.  
Figure 18. Percent change in odds of stimulant use during one-year post-release period by pre-
incarceration drug use.  
Amphetamine use during the 30-day period prior to incarceration was associated with the largest 
increase in odds for past-year concomitant use, with participants who reported using amphetamines during 
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the 30-day period prior to incarceration 96.5% more likely to have reported concomitant use subsequent to 
incarceration. This was followed by past 30-day prescription opioid (73.8), prescription sedative (69.3%), 
and heroin use (51.4%), which all increased the likelihood that concomitant use would be observed for the 
one-year period subsequent to incarceration.  
Heroin and prescription opioid use during the 30-day period prior to incarceration were associated 
with the largest increase in odds for past-year opioid use, with participants who reported past 30-day heroin 
use prior to incarceration 155.1% more likely to have reported past-year opioid use subsequent to 
incarceration and participants who reported past 30-day prescription opioid use 118.8% more likely. Past 
30-day use of alcohol, cocaine/crack cocaine, and amphetamines prior to incarceration decreased the odds 
of observing past-year opioid use subsequent to incarceration by approximately 20-40%.  
Amphetamine use during the 30-day period prior to incarceration was associated with the largest 
increase in odds for observing past-year stimulant use for the one-year period subsequent to incarceration, 
with participants who reported using amphetamines just prior to incarceration 199.6% more likely to have 
reported stimulant use subsequent to incarceration. This was followed by past 30-day cocaine/crack cocaine 
use prior to incarceration, which increased odds by 91.7%. Past 30-day heroin use decreased odds by 
77.1%. 
Aim Three Results 
Table 5 displays means and proportions of participants who reported using heroin during the one-
year period subsequent to incarceration. For this time period, 10.7% (N=168) of the sample reported past-
year heroin use. Only 2.1% of the entire sample reported heroin use within the 30-day period prior to 
follow-up data collection (approximately 10-14 months subsequent to release). 
Compared to the non-use group, the majority of the heroin-use group was White (96.4%, 
X2=26.86, df=1, p<.001). Groups were similar in terms of rates for HSD/GED (76.2% vs. 70.6%, X2=2.21, 
df=1, p=.161), mandated SAP participation (67.9% vs. 73.6%, X2=2.24, df=1, p=.133), and SAP 
completion (73.8% vs. 78.9%, X2=1.96, df=1, p=.160). However, during the one-year period subsequent to 
incarceration, the heroin-use group spent more nights on average in a controlled environment (68.7, 
SD=78.0 vs. 40.6, SD=77.0, t=-4.40, p<.001). This group also reported a higher number of lifetime drug 
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treatment episodes on average (3.3, SD=4.8 vs. 2.1, SD=3.7, t=-3.10, p=.002) and higher rates for IDU 
history compared to the non-use group (66.1% vs. 39.9%, X2=41.12, df=1, p<.001). 
Age and Sex 
 The heroin-use group was slightly younger than the non-use group (31.5, SD=7.3 vs. 34.9, 
SD=9.1, t=5.4, p<.001), though did not differ significantly from the non-use group in the proportion of 
males (76.8% vs. 81.4%, X2=1.81, df=1, p=.179).  
Past-year Cognitive Difficulties and History of Head Trauma 
Approximately 30% of the heroin-use group reported experiencing past-year cognitive difficulties, 
not significantly higher than the non-use group (29.8% vs. 26.0%, X2=0.89, df=1, p=.341). Rates for 
lifetime incidence of trauma history were essentially identical across groups, at approximately 43.0% 
(X2=0.00, df=1, p=1.00).  
Table 5 
Group Means, Proportions, and Between-group Differences Among Heroin and Non-heroin users for 













High School Diploma/GED 
Mandated SAP 
Graduated SAP 
Nights controlled environment, 
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Cognitive difficulties, past-year 26.4% 29.8% 26.0% .341 
History of head injury 43.4% 43.5% 43.4% 1.00 
Past-month income  $1,290 $1,128 $1,310 .144 
Anxiety symptoms  
Depressive symptoms 
Suicidal ideation 











































Perceived social worth 

















Age of drug use initiation 14.7 13.6 14.8 .010 
Abstinence self-efficacy prior to 
treatment 
81.5% 73.2% 82.5% .005 
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Psychiatric Symptoms and Chronic Pain 
Just under half of the heroin-use group reported experiencing past-year anxiety symptoms, similar 
to the rates among the non-use group (45.8% vs. 40.1%, X2=1.78, df=1, p=.180). Groups differed, though, 
in rates at which past-year depressive symptoms were experienced (45.2% vs 31.2%, X2=12.68, df=1, 
p<.001). Past-year suicidal ideation was nearly three-times higher among the heroin-use group (9.5% vs. 
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3.1%, X2=9.92, df=1, p=.002). Because of the high rates of past year suicidal ideation, the relationship 
between past 30-day heroin use and suicidal ideation was also explored (results not displayed). Among 
participants who reported heroin use during the 30-day period prior to follow-up data collection (N=33), 
24.1% also reported past-year suicidal ideation, compared to 4.1% of participants who did not report heroin 
use during this same time period (X2=26.3, df=1,p<.001). For rates of chronic pain, groups were nearly 
identical (31.5% vs. 32.7%, X2=0.45, df=1, p=.838).  
Past-month Income 
Past-month income did not differ between groups. Reflecting the generally low past-month 
income for the entire sample, both groups reported past-month income <$1,500. The heroin use group 
reported an average past-month income of $1,128, whereas the non-use group reported an average past-
month income of $1,320 (t=1.5, p=.144).  
Non-drug Alternative Reinforcers 
Groups were similar in terms of the average number of close relationships reported (5.8, SD=6.6 
vs. 6.2, SD=5.3, t=0.87, p=.379), rates of past-year social interaction (84.5% vs. 88.9%, X2=2.30, df=1, 
p=.122), past-year educational/vocational involvement (65.5% vs. 67.3%, X2=0.14, df=1, p=.705), and 
being on community supervision (88.1% vs. 86.8%, X2=0.11, df=1, p=.732). However, groups differed for 
rates of receiving satisfaction from their past-year social interactions as well as for rates of perceived social 
worth, as measured by feelings of being cared about and supported by others. Specifically, the heroin-use 
group had far lower rates of receiving satisfaction for past-year social interaction, with 76.2% of the heroin-
use group reporting satisfaction compared to 90.5% of the non-use group (X2=29.61, df=1, p<.001). 
Likewise, 86.3% of the heroin-use group reported feeling cared about and supported by others, compared to 
93.0% of the non-use group (X2=8.42, df=1, p=.004).  
Age of Drug Use Initiation and Abstinence Self-efficacy Prior to Treatment  
On average, the heroin-use group was younger at the time they first used alcohol or illicit drugs 
compared to the non-use group (13.5, SD=4.1 vs. 14.8, SD=5.1, t=2.6, p=.010). This group also had lower 
rates of  “moderately good” or “very good” abstinence self-efficacy prior to treatment (73.2% vs. 82.5%, 
X2=79.9, df=1, p=.005).  
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Past 30-day Drug Use and Drug Use Frequency Prior to Incarceration 
Groups differed for both pre-incarceration drug use rates as well as frequency of use, as measured 
in days, for the 30-day period prior to incarceration.  
For non-opioid and non-stimulant drugs used during the 30-day period prior to incarceration, rates 
of pre-incarceration alcohol use were similar across groups, with 44.6% of the heroin-use group and 50.1% 
of the non-use group reporting use (X2=1.58, df=1, p=.209). The number of days that alcohol was used also 
differed slightly from an average of 5.7 (SD=9.6) for the heroin-use group and 7.5 (SD=11.0) for the non-
use group (t=1.9, p=.034). Rates of pre-incarceration cannabis use did not differ between groups (X2=0.20, 
df=1, p=.653), with approximately half of both groups reporting use, nor did frequency of days used, with 
each group reporting 10-11 days of use on average (SD=13.0 for both groups) (t=1.1,p=.261). The heroin-
use group did report higher rates of prescription sedative use prior to incarceration (45.2% vs. 30.8%, 
X2=13.73, df=1, p<.001), reporting an average of 6.6 (SD=10) days of use, compared to 5.0 (SD=9) days 
for the non-use group (t=-1.9, p<.001). Hallucinogens were used <1 day on average prior to incarceration 
for both groups (t=-1.2, p=.346), with rates of use higher among the heroin-use group (5.4% vs. 2.9%, 
X2=2.10, df=1, p=.147). Similarly, the heroin-use group reported using synthetic drugs prior to 
incarceration at slightly higher rates (10.1% vs. 7.4%), though groups did not differ significantly (X2=1.22, 
df=1, p=.269). Both groups used synthetic drugs <2 days on average (t=-0.9, p=.385). 
For stimulant drugs, rates of past 30-day cocaine/crack cocaine use prior to incarceration were 
higher among the heroin-use group (32.1% vs. 22.2%, X2=7.85, df=1, p=.005). The average number of days 
that cocaine/crack cocaine was used prior to incarceration was also slightly greater among the heroin-use 
group (4.9, SD=9.6 vs. 3.2, SD=8.1, t= 2.1, p=.013). For past 30-day amphetamine use prior to 
incarceration, rates between groups were nearly equivalent, approximately 31.0% (X2=0.10, df=1, p=.922). 
However, the non-use group reported using amphetamines for slightly more days on average (6.4, SD=11.3 
vs. 4.6, SD=10.1, t=2.2 p=.032).  
For opioid drugs, rates of past 30-day heroin use prior to incarceration were, as anticipated, higher 
among the heroin-use group (54.2% vs. 13.3%, X2=168.67, df=1, p<.001), as was the average number of 
days that heroin was used (13.0, SD=14.0 vs. 2.5, SD=7.9, t=-9.4, p<.001). Similarly, the heroin-use group 
reported using prescription opioids at a higher rate (71.4% vs. 48.2%, X2=31.52, df=1, p<.001) and, again, 
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for a greater number of days on average (15.3, SD=13.4 vs. 10.3, SD=13.0, t=-4.6, p<.001).  For past 30-
day buprenorphine use prior to incarceration, the heroin use group reported higher rates than the non-use 
group, but by a narrower margin (25.0% vs. 17.9%, X2=4.49, df=1, p=.034) compared to the other opioid 
drugs examined. The heroin-use group did report using buprenorphine for slightly more days on average 
(3.3, SD=8.2 vs. 2.6, SD=7.4, t=-1.2, p=.245).   
Past-year Drug Use Subsequent to Incarceration 
During the one-year period subsequent to incarceration, the heroin-use group reported higher rates 
of use for all drugs, used 3.8 drugs on average, and went 71.7 days from the date of their release to the date 
that they first used illicit drugs.  
Among non-opioid and non-stimulant drugs, alcohol was most commonly used sample-wide 
(31.5%). Just over 40% of the heroin-use group reported past-year alcohol use compared to 30.3% of the 
non-use group (X2=9.47, df=1, p=.002). Cannabis was the next most commonly used drug during the post-
release period (25.5%). The heroin-use group had higher rates of cannabis use compared to the non-use 
group (45.8% vs. 23.0%, X2=39.96, df=1, p<.001). For this time period, prescription sedatives, used by 
8.0% of the entire sample, were used at higher rates among the heroin-use group (X2=76.57, df=1, 25.6% 
vs. 5.9%, p<.001). Hallucinogens and synthetic drugs were used by <10% of both groups. Higher rates of 
use were reported by the heroin-use group for both hallucinogens (5.4% vs. 0.6%, X2=25.25, df=1, p<.001) 
and synthetic drugs (8.9% vs. 6.8%), though groups did not significantly differ for the latter (X2=0.73, df=1, 
p=.393).  
For stimulant drugs, cocaine/crack cocaine, used by 7.4% of the entire sample, was used during 
the one-year post-release period at a far higher rate by the heroin-use group (28.6% vs. 4.5%, X2=120.81, 
df=1, p<.001), as were amphetamines (37.5% vs. 12.5%, X2=70.42, df=1, p<.001), which were used by 
15.2% of the entire sample. For opioid drugs, prescription opioids, used by 14.3% of the entire sample, 
were used by the heroin-use group during the one-year post-release period at a rate similar to that of 
amphetamines (38.7%), whereas 11.3% of the non-use group reported prescription opioid use during this 
time period (X2=89.57, df=1, p<.001). Sample-wide, buprenorphine was used during the one-year post-
release period by 9.4% of participants, nearly the same proportion that reported heroin use for this same 
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time period. Among the heroin-use group, however, 33.3% reported past-year buprenorphine use, nearly 
five times that of the non-use group (6.5%, X2=123.36, df=1, p<.001).  
Central Appalachia, Urban Influence, and Access to Alcohol  
The heroin-use group had a smaller proportion of participants who resided in Central Appalachia 
for the majority of time during the one-year period subsequent to incarceration (17.3% vs. 31.9%, 
X2=15.21, df=1, p<.001). Accordingly, the mean urban influence designation for the heroin-use group was 
lower, indicating greater urban and metro area influence, compared to the non-use group (2.7 vs. 4.7, 
p<.001). Accordingly, the heroin-use group had a higher proportion of participants residing in a county 
with unrestricted alcohol sales (74.4% vs. 54.4%, X2=23.6, df=1, p<.001), as urban and metro areas have 
overall fewer alcohol prohibitions. 
Binary Logistic Regression Results for Heroin Use Subsequent to Incarceration 
Tables 7.0 and 7.1 display the results of the binary logistic regression models examining heroin 
use (versus “other/no drug use”) for one-year period subsequent to incarceration. Variables considered as 
control variables and independent variables (as opposed to variables used for description only) which 
differed significantly by group in bivariate analyses were included into the regression models. Due to the 
overall number of variables which differed significantly by group, two separate models were used to 
examine the outcome, so as to avoid model overfitting. The first model examined factors correlated with 
heroin use that occurred during the one-year post-release period along with drug use that occurred during 
the 30-day period prior to incarceration. A second model examined the relationship between heroin and 
other drugs used during the one-year post-release period in order to identify what other drugs were 
significantly associated with a change in the probability that heroin use would be observed.  
A displayed in Table 6.0, participants who reported heroin use for the one-year period subsequent 
to incarceration were more likely to be White (AOR=4.84, p<.001). They were also more likely to have 
spent a greater number of nights in a controlled environment since their release (AOR=1.00, p=.005) and to 
be younger (AOR=0.96, p=.002). Though past-year depressive symptoms were not associated with 
increased odds of observing past-year heroin use (AOR=1.42, p=.089), past-year suicidal ideation was 
(AOR=2.55, p=.017). Receiving satisfaction from past-year social interaction was also associated with a 
slight, but significant, decreased likelihood of past-year heroin use (AOR=0.42, p<.001). Among drugs 
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used during the 30-day period prior to incarceration, amphetamines (AOR=0.58, p=.008), heroin 
(AOR=5.32, p<.001), and prescription opioids (AOR=2.05, p=.002) were all associated with an increased 
likelihood that heroin use would be observed for the one-year period subsequent to incarceration, whereas 
use of prescription sedatives (AOR=0.95, p=.812), cocaine/crack cocaine (AOR=1.43, p=0.80), and 
buprenorphine (AOR=0.72, p=.154) prior to incarceration were not. Residing in Central Appalachia for the 
majority of time during the one-year post-release period was associated with a decreased likelihood of past-
year heroin use (AOR=0.38, p<.001).  
Table 6.0  
Results from Binary Logistic Regression Examining Heroin Use for the One-year Post-release Period 
Figure 19 displays the percent change in odds for independent variables significantly associated 




95% CI AOR p value 
White 2.177 2.00-11.06 4.84 .001 
Nights spent in controlled environment 0.001 1.00-1.01 1.00 .005 
Lifetime drug treatment episodes 0.022 0.98-1.06 .1.02 .285 
Ever IDU 0.296 0.87-2.07 1.34 .180 
Age  0.011 0.94-0.99 0.96 .002 
Past-year depressive symptoms 0.290 0.95-2.11 1.42 .089 
Past-year suicidal ideation 0.996 1.17-5.42 2.55 .017 
Social satisfaction 0.101 0.25-0.67 0.42 .001 
Perceived social worth 0.175 0.36-1.08 0.62 .096 
Age of drug use initiation 0.022 0.95-1.04 0.99 .903 
Abstinence self-efficacy prior to treatment 0.192 0.60-1.37 0.90 .654 
30-day drug use prior to incarceration 
Prescription sedatives  0.203 0.62-1.44     0.95 .812 
Cocaine/crack cocaine  0.297 0.96-2.15 1.43 .080 
Amphetamines  0.121 0.38-0.87 0.58 .008 
Heroin  1.191 3.54-8.25 5.32 .001 
Prescription opioids 0.468 1.31-3.21 2.05 .002 
Buprenorphine 0.168 0.46-1.13 0.72 .154 
Central Appalachia 0.091 0.24-0.60 0.38 .001 
Intercept-only: -533.336/Model: -405.742 Pseudo R2 = 0.239 
Wald Chi2 (df=18) 220.306 Cox-Snell/ML= 0.151  
 Hosmer-Lemeshow Chi2=2.39, p=0.966 Cragg-Uhler/Nagelkerke=0.305 
 187 
Figure 19. Percent change in odds for heroin use during the one-year post-release period. 
Heroin use during the 30-day period prior to incarceration increased the odds of observing past-
year heroin use for the one-year period subsequent to incarceration by 432.1%. Being White increased the 
likelihood of past-year heroin use by 384.4%. Past-year suicidal ideation increased the odds of observing 
past-year heroin use by 154.2%. Use of prescription opioids prior to incarceration increased the odds of 
past-year heroin use subsequent to incarceration by 105.3%. For every SD increase for nights spent in a 
controlled environment (SD=77.7) the odds of observing past-year heroin use increased by 24.2%, just 
0.4% for each night. The likelihood of observing past-year heroin use decreased by 27.0% for every SD 
increase in age (SD=9.1); an approximate 3.4% decrease for every year increase. Amphetamine use during 
the 30-day period prior to incarceration decreased the likelihood of observing heroin-use subsequent to 
incarceration by 42.4%. Receiving satisfaction from past-year social interaction decreased the likelihood by 
58.7%. Finally, residing in Central Appalachia for the majority of the one-year period subsequent to 
incarceration decreased the likelihood of heroin use by 62.2%.  
Results of the second model are displayed in Table 6.1. Prescription sedatives (AOR=1.82, 
p=.043), cocaine/crack cocaine (AOR=5.70, p<.001), amphetamines (AOR=1.71, p=.029), prescription 
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opioids (AOR=1.72, p=.030), and buprenorphine (AOR=3.66, p<.001) used during the one-year period 
subsequent to incarceration were all associated with an increased likelihood of heroin use for this same 
time period. Alcohol (AOR=0.85, p=.446), cannabis (AOR=1.40, p=.119), and hallucinogens (AOR=1.61, 
p=.397) used during the one-year period prior to incarceration did not significantly influence the likelihood 
of past-year heroin use. 
Table 6.1  
Results of Binary Logistic Regression Examining Past-year Other Drug use and Past-year Heroin Use 
During One-year Post-release Period 
Figure 20 displays the percent change in odds for drugs used during the one-year period 
subsequent to incarceration significantly associated with changes in the likelihood of observing heroin use 
during the same time period. 
Robust SE 95% CI AOR p value 
Alcohol 0.179 0.56-1.28 0.85 .446 
Cannabis 0.302 0.92-2.13 1.40 .119 
Prescription sedatives 0.540 1.01-3.22 1.82 .043 
Hallucinogens 0.908 0.53-4.66 1.61 .397 
Cocaine/crack cocaine 1.44 3.48-9.34 5.70 .001 
Amphetamines 0.421 1.06-2.76 1.71 .029 
Prescription opioids 0.431 1.06-2.81 1.72 .030 
Buprenorphine 0.907 2.25-5.91 3.66 .001 
Intercept-only: -533.336/Model: -436.689 Pseudo R2 = 0.181 
Wald Chi2 (df=8) 189.581 Cox-Snell/ML= 0.116  
Hosmer-Lemeshow Chi2=15.56, p=0.082 Cragg-Uhler/Nagelkerke=0.235 
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Figure 20. Percent change in odds for heroin use during the one-year post-release period by co-used 
drug. 
For all drugs used during the one-year period subsequent to incarceration associated with a change 
in odds for past-year heroin use, past-year cocaine/crack cocaine use showed the most influence, increasing 
the odds that heroin use would be observed by 469.1%. This was followed by past-year buprenorphine use, 
associated with 265.9% increased odds of observing past-year heroin use. Past-year prescription sedative 
use increased the likelihood of observing past-year heroin use by 82.3%, whereas past-year prescription 





The use of high-risk drugs, such as opioids and stimulants, constitutes a significant economic, 
social, legal, and medical problem in the US (Degenhardt et al., 2014; Schuchat, Houry, & Guy, 2017; 
Volkow & Collins, 2017). Kentucky is a state that continues to experience high rates of opioid and 
stimulant use and related problems, and is also a state that incarcerates a disproportionate number of people 
who use opioids and stimulants (CDC 2017a, CDCb; Faryar et al. 2017; Prison Policy Initiative, 2018). It is 
important to better understand decisions to use high-risk drugs among corrections-involved people in 
Kentucky, in part because the adverse consequences of continued use for this population can be extreme 
(e.g., becoming reincarcerated, increased odds of overdose following release from correctional custody) 
(Merrall et al. 2010).  
  Accordingly, this study’s primary aim was to explore the social problem of high-risk drug use 
among a sample of corrections-involved adults in Kentucky and to identify and discuss endogenous and 
exogenous factors with the potential to have influenced drug-related decision-making prior and subsequent 
to incarceration. This was accomplished with three specific study aims. First, using self-report data, a 
descriptive profile of a sample of corrections-involved adults in Kentucky with a history of drug use was 
provided. The prevalence of concomitant opioid/stimulant use, opioid use, stimulant use, and other and/or 
no drug use during the 30-day period prior to incarceration and the one-year period subsequent to 
incarceration was determined. A description of these drug use outcome groups was presented, and 
differences between groups was determined. Differences in the use of specific opioid and stimulant drugs 
(e.g., heroin, prescription opioids, buprenorphine, cocaine/crack cocaine, and amphetamines) by participant 
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residence across an urban-rural continuum and by participant residence within or outside of Central 
Appalachia were also established. Second, factors associated with a change in likelihood of observing 
concomitant use, opioid use, and stimulant use during the 30-day period prior to incarceration and the one-
year period subsequent to incarceration, compared to an outcome with less risk (e.g., other/no drug use), 
were identified. Third, the prevalence of heroin use that occurred during the one-year period subsequent to 
incarceration was determined and the between-group differences among participants who reported heroin 
use and those who did not were identified. Factors associated with a change in the likelihood that heroin 
use would be observed were also identified.  
 Behavioral economics, a molar view of human choice and behavior, was used in earlier chapters 
to first conceptualize the problem of high-risk drug use and then to help situate and better understand the 
problem in relation to a large and growing body of empirical research. While only a small portion of 
research relevant to understanding how people’s decision-making and behavior can be influenced was 
reviewed in Chapter 2, the overview hopefully demonstrated the important point that many endogenous and 
exogenous factors have the ability to influence decision-making and behavior, not only in respect to high-
risk drug use, but in respect to all choice and action. It also hopefully articulated the idea that while many 
of these factors are not always knowable, observable, or readily modeled, they are nonetheless recognizable 
(and worth recognizing) using a molar paradigm.  
Because of the vast number of possible endogenous and exogenous factors exerting influence on 
human behavior, it is important to at times seek a broad understanding of specific behaviors, such as high-
risk drug use, as an expansive view acknowledges the inherent complexity and dynamic nature of choice 
and action (Sapolsky, 2017). Opioid and stimulant use specifically are important to understand, as use of 
these drugs constitutes a threat to both the people using them as well as to those around them. That opioid 
and stimulant use simultaneously represents the potential for pleasure and pain, and that only a small 
fraction of people will ever in their lifetimes pursue such risky choice, suggests the possibility that certain 
unique factors present among high-risk drug users, and among corrections-involved drug users in 
particular, are influencing decision-making and behavior. Why and how people choose to do something 
that they know is potentially detrimental, and then continue to choose it even after experiencing adverse 
outcomes, are important empirical questions generally. It is necessary, though, to explore this phenomenon 
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both conceptually and empirically; the latter helping to guide empirical exploration, and the former helping 
to refine conceptualizations of choice and behavior within a system of constraint. This chapter seeks to 
achieve limited accomplishment of this in respect to study findings in several ways. 
First, by revisiting the puzzling phenomenon of high-risk drug use, with attention paid to how 
participants might continue to choose to use opioids and stimulants even after problems related to using 
have become apparent. In earlier chapters, the conflict that can arise between a person during intertemporal 
choice was discussed along with the idea that people can have time-inconsistent preferences (Shane, 
Loewenstein, & O'Donoghue, 2002). Also discussed was how a person can want, and choose, what they 
don’t actually like, and which does not produce experienced utility (Berreidge & O’Doherty 2014). People 
can also prefer a particular outcome, but then act in a discordant manner by choosing to undertake a 
behavior that will bring about its opposite. Recall that while drugs have a high local utility, their repeated 
use over time decreases their overall utility (Herrnstein & Prelec, 1992). A person might prefer to not get 
arrested, overdose, or become dependent on heroin, yet may still repeatedly decide to use heroin due to its 
high local utility, thus increasing the probability that such unwelcome outcomes will occur. These ideas 
will be briefly revisited using information self-reported by participants as an example. This will be 
followed by considering how drug-related decision-making prior and subsequent to incarceration may 
differ. Not all people who use opioids and stimulants experience adverse outcomes, and certainly do not all 
experience an outcome as extreme or adverse as incarceration; however, many in this sample did. This 
makes the phenomenon of incarceration itself a point of interest. Among participants in this sample,  it 
reflects time spent in a controlled environment between two periods of decision-making for which self-
report information was available for examination.  
Second, several key study findings will be discussed, giving attention to some of the ways that 
they relate to a behavioral economic account of choice and behavior. Of the many findings presented in 
Chapter 4, those most illustrative of the concepts described in earlier chapters will be discussed. It will 
hopefully be made clear by the nature of the discussion that all findings, that is, all factors identified and 
explored in this study as having the potential to influence drug-related decision-making and high-risk drug 
use, are important--as are many other factors not explored as part of this study. An omission of a particular 
study finding is not meant to suggest its irrelevance or unimportance. As this is an exploratory study, 
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priority will be given to highlighting broad take-aways from study findings. In the examples that follow, it 
will be apparent that all factors with the potential to influence decision-making and the complex behavior 
of high-risk drug use are potentially relevant, even if it is impractical to enumerate, and impossible to 
measure, all such influences. Referring back to Figure 1 provides the “big picture” view that is of interest 
and which is applicable to study findings. For findings not specifically discussed, or not discussed at a 
length equal to others, the idea of choice and behavior as operating within a system of constraint can still be 
applied. The broader take-away when this conceptual framework is applied to any or all findings is 
unchanged; a testimony to its parsimony and flexibility. A summary of future directions, limitations, and 
concluding thoughts will be presented at the chapter’s end.   
Some Potential Differences in Drug-related Decision-making Prior and Subsequent to Incarceration 
As described earlier, the many endogenous and exogenous factors of a person’s life comprise part 
of the system of constraint within which they make decisions and behave (Bickel et al., 2014; 2016). These 
factors influence people’s cognition, choice, and capacity for action. Better recognition of these factors can 
help make sense of decisions to use opioids and stimulants despite known risks, and decisions to continue 
using despite adverse consequences. It can also be extended to help make sense of why use could continue 
despite a person’s desire or intention to stop. People who choose to undertake the steps necessary to acquire 
and self-administer drugs with the potential to kill them are an extreme example of how choice and 
behavior can be influenced in profound and counterintuitive ways. This is most poignant when a person at 
one moment desires to use opioids and then undertakes the actions required to use them, while a moment 
before desired not to use opioids and may have even resolved not to use them, indicating that people, their 
preferences, and their intentions are not necessarily consistent over time, or even within the same moment 
of time (Ainsile, 2001; Bratmann, 1999; Mann, 2004; Melrose et al., 2015; Monterosso & Lou, 2010; 
O'Donoghue & Rabin,1999). In part, self-control conflict involves tension between preference at different 
scales, the molecular (e.g., desire for crack cocaine right now) and the molar (e.g., desire not to be addicted 
to crack cocaine) (Rachlin, 1995). 
 This idea may be applicable to some participants in this sample and indirectly reflected among 
some survey responses. For instance, some participants made a decision to use opioids or stimulants 
subsequent to incarceration, but may have, during their incarceration, contemplated doing otherwise. 
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Examination of some of the constituent elements of the “drug use severity” variable used in this study may 
be illustrative Some of its specific qualities are considered here for the purposes of thinking about how 
discrepancies in utility, or preference, can occur between a person’s current and future self. For instance, 
the majority of participants who reported using opioids (74.2%) and stimulants (70.3%) during the one-year 
period subsequent to incarceration also reported being “moderately, considerably, or extremely troubled or 
bothered” by their drug use during the 30-day period prior to incarceration.  
Further, a majority of participants who reported using opioids (95.8%) and stimulants (94.9%) 
during the one-year period subsequent to incarceration also reported believing that receiving drug treatment 
for their drug problems was “moderately, considerably, or extremely important to them” at the time of 
treatment intake, which occurred weeks, months, and in some cases, years after their arrest. This means that 
participants had some time since their last period of regular using to possibly consider whether receiving 
drug treatment was a low or high priority. When answering this question, participants were presumably not 
intoxicated, nor were they presumably at their drug-using nadir--in a state of withdrawal or acute crisis 
common among regular opioid and stimulant users. In other words, a response to this question was likely 
provided during a period of relative stability. If responses are considered valid, it means that >70% 
participants who later used opioids and stimulants felt at these earlier times not only bothered by their drug 
problems, but also felt that receiving drug treatment was important in helping them address these problems. 
For the latter, rates were significantly higher among participants who reported opioid and stimulant use 
subsequent to incarceration, compared to those who reported other drug or no drug use (p<.05; results not 
displayed). Thus, despite acknowledgment of drug problems, despite an articulated belief that drug 
treatment was important, and despite receiving severe consequences as a result of drug use, opioid and 
stimulant use continued.  
That people who once used opioids and stimulants experienced adverse consequences as a result 
of use, expressed some interest in treatment, participated in treatment, and then subsequently chose to use 
opioids and stimulants, is not shocking. Rates of lapses and relapses subsequent to a variety of drug 
interventions or after periods of abstinence are well documented (Dodge, Sindelar, & Sinha, 2005; 
McLellan, Lewis, O'brien, & Kleber, 2000; Sinha, 2001). Indeed, the conceptualization of drug addiction as 
a chronic condition or “disease” relies in part on the fact that many people who once misused opioids and 
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stimulants go on to use them again even after intervention of periods of abstinence (Denis & Scott, 2007; 
McLellan, et al., 2000).  
There is, of course, no way to know whether participants who used opioids and stimulants both 
prior and subsequent to incarceration at any point developed in the interim a desire or intention to not use 
these drugs, but it is possible that many at some point did. It is possible for two reasons. First, participants 
who used opioids and stimulants during the one-year period subsequent to incarceration experienced 16 
days of drug-related problems on average during the 30-day period prior to incarceration. These problems 
included craving, withdrawal, and a desire but inability to quit using. It is possible that during this time 
period in which some very frustrating and painful symptoms were frequently occurring that an intention to 
modulate or discontinue use was formed by at least some portion of participants; though there are 
insufficient data to clearly support this proposition. This possibility is nonetheless noted to raise the point 
that people are capable of deciding to engage in a behavior that they previously indicated was problematic 
for them and after experiencing significant consequences, reflective of time-inconsistent preferences and 
the diachronic model of conflict (DiClemente, 2018; Melrose et al., 2015). Second, this 30-day period 
when frequent drug-related problems occurred climaxed with incarceration, which is itself comprised of 
multiple humiliations and punishments and involved, for participants in this sample, a period of 
confinement lasting many months or longer. This means that there were many occasions for these 
participants to possibly consider some of the benefits of not using opioids and stimulants upon release and, 
possibly, of developing some desire or intention not to use following release. Yet, many still used. Trying 
to better understand desire and intention related to high-risk drug use among people with history of high-
risk drug use will be important to explore in future work concerned with drug-related decision-making.  
Incarceration and Community Supervision 
The possibility that cognition and behavior in respect to opioids and stimulants was influenced by 
incarceration and treatment makes exploring high-risk drug use among this sample interesting, as there is a 
demarcation (pre- and post-incarceration) between two periods of decision-making. These periods are 
distinctive in several ways. For example, participants could have been influenced to use or not use 
following a period of incarceration by a variety of factors that could have materialized as part of the 
incarceration experience itself. On the one hand, these might include generally stabilizing experiences, such 
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as rebuilding relationships with family members, receiving treatment, engaging in spiritual, religious, or 
mutual-aid programs, exercising, developing a routine, etc.  (Buckaloo, Krug, & Nelson, 2009; 
Freudenberg, Wilets, Greene, & Richie, 1998; Stringer, 2009; Tasca, Mulvey, & Rodriguez, 2016). On the 
other hand, they could include experiences such as sexual and physical violence, social isolation, family 
estrangement, and overall decreased psychological health due to jail and prison conditions (Alarid, 2000; 
Bonner & Rich, 1990; Brinkley-Rubinstein, 2013; Kaba et al., 2014; Rokach, 1997). This study was not 
concerned with investigating highly personal and varied experiences that might influence a person’s overall 
cognitive health prior to re-entry, though they warrant investigation. Rather, the idea that incarceration may 
have influenced later decision-making about opioids and stimulants is noted because it applies to findings 
for the post-incarceration period when considered using a molar paradigm, such as behavioral economics. 
First, by having experienced the adverse outcome of incarceration as a direct or indirect result of 
use and by being under DOC supervision upon release, participants may have been influenced to modify 
their behavior so as to reduce the likelihood of their experiencing incarceration again. Experienced 
punishment and the threat of additional punishment could have influenced decision-making about opioids 
and stimulants subsequent to incarceration in several ways. For instance, whereas prior to incarceration the 
risks associated with opioid and stimulant use may have only been considered in terms of outcome 
uncertainty in the abstract--the known potential for adverse outcomes with contingent future states 
discounted as a function of time or probability (or both)--subsequent to incarceration, risks associated with 
opioid and stimulant use could have been partially reflected upon in terms of experienced adverse outcomes 
(Bickel et al., 2007; Rachlin, Raineri, & Cross, 1991; Vuchinich & Simpson, 1998). Future states would 
still be abstract and uncertain, and therefore have the potential to be discounted as a function of time and 
probability, but the salience associated with the experience of adverse outcomes from opioid and stimulant 
(and their memories) might have served as a behaviorally motivating influence on decision-making 
subsequent to incarceration for some, but certainty not all, participants (Blair, Morton, Leonard, & Blair, 
2006; He, Cassaday, Howard, Khalifa, & Bonardi, 2011; Newman, 1987). Just as reward can facilitate 
learning and reinforce behavior, so too can punishment; fear of threat and anticipation of reward both 
involve memory, outcome expectations, prospection, etc. (Bohnert et al., 2018; Herry & Johansen, 2014; 
Sigurdsson, Doyère, Cain, & LeDoux, 2007). For example, having overdosed once or having been arrested 
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once, a person would develop a clearer understanding and appreciation of what the possible future outcome 
of overdose or arrest entail (Warner‐Smith, Darke, & Day, 2002). However, people who experience adverse 
events related to drugs may differ in terms of how future behaviors are influenced by past experiences, as 
threat (of punishment) detection, fear processing, and risk-aversion may differ across people, drug use 
histories, and contexts (Hoppenbrouwers, Bulten, & Brazil, 2016; Mcgregor, Darke, Ali, & Christie, 1998; 
Wood & Anagnostaras, 2009). Relevant, too, is that some memories associated with drug pleasure may also 
be highly salient (Stacy, Ames, Wiers, & Krank, 2010). There is no way to know which may have been 
more influential at any given moment subsequent to incarceration: memories of drug-related pleasure or 
memories of drug-related pain; and, likewise, prospection about possible future drug-related reward or 
prospection about possible future drug-related punishment. 
Community supervision following release, which includes drug monitoring and the threat of 
sanctions, may have served as one specific influence on decision-making and behavior (Burdon, Roll, 
Prendergast, & Rawson, 2001; Franken et al., 2003; Marlowe & Wong, 2008). However, while rates of 
being on community supervision subsequent to incarceration differed by drug use outcome group, 
differences were <10%; not substantial. Further, a greater proportion of participants who reported 
concomitant and stimulant use subsequent to incarceration were on community supervision, meaning that 
being on probation/parole did not necessarily influence a decision not to use or to use less dangerous drugs 
in all instances. This is evidenced further by the fact that being on community supervision was associated 
with an 89% increase in odds that concomitant use would be observed.  
Experiencing incarceration and being on community supervision may partially explain why rates 
of opioid and stimulant use subsequent to incarceration decreased from rates of use prior to incarceration, 
but it does less to explain why use would continue. It is possible that participants on community 
supervision who chose to use may have discounted future outcomes not only as a function of time, but also 
probability (Rachlin, 2006; Rachlin et al., 1991). While some interaction with a probation or parole officer 
while on community supervision is an eventuality, the particulars of those interactions, such as the 
frequency of drug monitoring, are often irregular. One potential appeal of opioids and stimulants is that 
their metabolites are cleared from the body fairly rapidly, depending on the person’s age, weight, dosing, 
and drug type, meaning that it is possible that a portion of participants who used these drugs while on 
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community supervision did so with an expectation that they would be able to avoid detection via drug 
monitoring (Moeller, Kissack, Atayee, & Lee, 2017). The purposeful selection of drugs while on 
community supervision as a means of circumnavigating drug monitoring has been documented elsewhere 
(Smith & Stoops, 2019, Smith & Staton, 2019).  
Second, having spent time in a controlled correctional facility means that participants went from 
an environment where there were few restrictions to accessing drugs to a facility where access to drugs was 
significantly restricted. Even if it cannot be assumed that the facilities that participants resided in were 
100% drug-free 100% of the time, it can be assumed that the accessibility of alcohol and illicit drugs was 
still significantly less than the accessibility of alcohol and illicit drugs in the free world. This means that for 
many in this sample opioid and stimulant use either stopped or decreased significantly during their 
incarceration. Even if use only became irregular, rather than ceasing entirely, it still means that the frequent 
and regular use of drugs, characteristic of the 30-day period prior to incarceration, was moderated. This is 
relevant insofar as a period of intermittent use or complete abstinence, would have permitted the 
opportunity for some modest and heterogenic, but nevertheless potentially important, neurobiological and 
behavioral changes (Galinato et al., 2018; Hollander & Carelli, 2005; Pitel et al., 2009; Schulte et al., 2014; 
Volkow et al., 2001).  
There would have also likely been fewer drug-related cues in jail or prison capable of producing a 
conditioned-response, compared to places where participants spent time prior to incarceration, meaning that 
attention would be directed less frequently to drug stimuli. Even if participants’ attention was still largely 
pre-occupied with drugs during incarceration, by virtue of just thinking about drugs, these cognitions would 
not have had behavioral traction in most cases due to the decreased drug availability. Thus, for this sample, 
drug-related decision-making subsequent to incarceration could not have been undertaken with the exact 
same set of endogenous factors (i.e., not the same brain) that drug-related decision-making prior to 
incarceration was undertaken with. However subtle and ambiguous the changes were, there was still some 
change. This is important, because it means that at the time of participants’ release, drug-related visceral 
states, cognitions, and behavioral patterns would have be different than at the time of arrest. Put differently, 
their cognitive capacities would be, holding other factors constant, less constrained than they were prior to 
incarceration. Although a participant’s regular cocaine use prior to incarceration would still have the 
 199 
potential to bias them toward a decision to use cocaine subsequent to incarceration, this prior regular 
cocaine use would not necessarily be influencing decision-making subsequent to incarceration in the same 
manner or to the same degree as it did prior to incarceration. Consider how decision-making about cocaine 
might look for a person who had used cocaine every day for the past month compared to the same person 
who used cocaine for 30 days one year and one month ago. It is easy to envision how more or less 
constrained a person would be in their decision-making about cocaine between these two time periods. That 
prior decisions to use can still bias a person toward future use of the same drug is reflected in the findings 
that use of specific opioids and stimulants prior to incarceration increased the likelihood of the same, or 
similar, drug use subsequent to incarceration. But that many participants also did not use subsequent to 
incarceration reflects the possibility that they were potentially less constrained in their drug-related 
decision-making than they had been during the 30-day period prior to incarceration. These ideas will be 
described in more detail below. 
Upon re-entering the community, participants would have become exposed to significantly more 
actionable choices than they were while incarcerated. Greater access to drugs is, unsurprisingly, associated 
with greater likelihood of use and continued use. The mere knowledge that opioids and stimulants are again 
accessible would have been another factor with the potential to influence participants’ visceral, affective, 
and cognitive states subsequent to incarceration, including those associated with craving, which can be a 
profound influence on drug decision-making and behavior (Badger et al., 2007; Berridge & O’Doherty, 
2014; Paliwal, Hyman, & Sinha, 2008; Robinson & Berridge, 1993; Tiffany, Warthen, & Goedeker, 2008; 
Tsui, et al., 2016). Although access to rewarding non-drug choices would also have increased significantly 
upon reentry, not all participants would have had equitable access to the same types of non-drug 
alternatives. Ultimately, the context into which participants were released would have had significant 
influence on decisions to use and to continue using (Marlatt, 1996).   
Lastly, and perhaps most importantly, because reentry into the community following incarceration 
involves significant transition across all aspects of daily living means that it is likely that some participants 
experienced stress following their release (Bahr, Armstrong, Gibbs, Harris, & Fisher, 2005; Phillips & 
Lindsay, 2011; Shivy et al., 2007). Stress is toxic for higher-level cognitive functioning, such as 
deliberative decision-making, planning, prospection, and inhibition, meaning that participants may have 
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been generally less capable of engaging in adaptive decision-making in relation to drugs during this period 
of transition and possible stress (Kosten & George, 2002; Weiss, 2005; McEwen, 2006; McEwen & 
Sapolsky, 1995). That reentry-related stress or other daily life challenges would have occurred 
contemporaneous with a significant increase in potential exposure to drug-related cues suggests that 
community reentry should be considered a time period of heightened risk, insofar as stress + drug-related 
cue exposure is associated with craving and drug use among abstinent and current drug users (Fox, 
Bergquist, Hong, & Sinha, 2007; Hyman, Fox, Hong, Doebrick, & Sinha, 2007; Phillips & Lindsay, 2011; 
Sinha, Catapano, & O’Malley, 1999). Among participants who prefer opioids, a return to opioid use 
following a period of decreased use or abstinence would have the potential to be life-threatening, due to 
diminished tolerance, meaning that risk among this group may be greatest (Davidson, Wagner, Tokar, & 
Scholar, 2019). 
Drug-related Influences on Decision-making 
A person’s ability to make decisions that maximize overall utility are, even in the best of 
circumstances, not superb. People are generally biased toward the present more so than the future and can 
have time-inconsistent preferences (Loewenstein & Prelec, 1993; Monterosso & Lou, 2010). Certain 
endogenous and exogenous conditions can hinder decision-making capacities further, by either influencing 
cognition and executive function and/or by restricting available choices and opportunities (Bickel et al., 
2014). For participants in this sample with a history of opioid and stimulant use, the capacity for making 
decisions that maximize overall utility, instead of repeatedly selecting choices with higher local utility, but 
greater cost or risk, may be diminished compared to people without a history of such drug use (Badiani et 
al. 2011; Heil et al., 2006; Kirby & Petry, 2004; Kirby, Petry, & Bickel, 1999; Petry, 2001; Petry et al., 
1998; Reynolds, 2006; Rogers et al., 1999). This may be partially due to the presence of certain factors that 
may have pre-dated opioid and stimulant use, and which are found disproportionately among people who 
elect to use opioids and stimulants, or due to characteristics and states that developed as a result of opioid 
and stimulant use (Badiani et al. 2011; Petry, 2001; Potvin et al., 2018; Verdejo-García, et al., 2008). In 
either case, there is an implication that all participants who used opioids and stimulants during their lifetime 
may have been less able to engage in adaptive decision-making compared to people without such history.  
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The rates of opioid and stimulant use during the year prior to incarceration among this sample 
indicate fairly regular use. Although it is possible that participants who used opioids and stimulants during 
the 30-day period prior to incarceration did so regularly, but in a controlled manner not suggestive of 
disordered use, it is not likely, given the high rates of drug use severity, IDU history, and having been 
intoxicated during the commission of a crime. Overall, evidence suggests that the high rates of opioid and 
stimulant use during the one-year period prior to incarceration, and any use prior to that, would have served 
to influence participants’ decision-making capacities in respect to these drugs during the 30-day period 
prior to incarceration, insofar as neurocognitive changes associated with regular opioid and stimulant use 
correspond to impairments in impulse control, future-oriented cognition and behavior, metacognition, and 
working memory capacity, among other things (Bechara, 2005; Nichols & Wilson, 2015; Koob & Volkow, 
2010). Recall that a behavioral economic account of drug use and addiction describes changes in the person 
as a result of drug use over time, as well as changes in available choices as a result of drug use over time, 
with the person’s overall set of motivations informing the development and perpetuation of use (Bickel et 
al., 2011, 2014). While a person’s brain changes as a result of regular using, so too does their economic 
situation, their social standing, their health, the quality of their relationships, and their priorities, 
preferences, and goals, etc., all of which, in turn, change their brain, cognition, and behavior still further 
(Adophs, 1999; Cacioppo & Hawkley, 2009; Fiske & Taylor, 2013; Volkow, Baler, & Goldstein, 2011). 
These neurocognitive and social conditions, some more long-lasting than others, can have profound effects, 
including altering how drug and non-drug choices are perceived, valued, and acted upon (Heilig et al., 
2016; Kosten & George, 2002).  
During the 30-day period prior to incarceration, participants, by virtue of their prior regular use, 
may have already reached the point where opioids and stimulants were significantly overvalued and non-
drug choices, which would have likely already declined in number and quality for many, were significantly 
undervalued; this imbalance would have helped to further reinforce continued decisions to use (Bickel et 
al., 2001). Crucially, too, the very type of cognitive capacities (e.g., flexibly, ability for abstract, 
counterfactual, or prospective thinking, top-down cortical control to inhibit reflexive or habituated 
responding) that participants would have most needed to “do otherwise” would have  been either more 
diminished or impaired during the 30-day period prior to incarceration than at earlier times, due to the fact 
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that opioids and stimulants had, by that point, been used over a longer period of time and used fairly 
recently (Di Sclafani, Tolou-Shams, Price, & Fein, 2002; Jovanovski, Erb, Zakzanis, 2005; Potvin et al., 
2018; Verdejo-García, 2011; Verdejo-García, Bechara, Recknor, & Perez-Garcia, 2006).  
One possible result of regular opioid and stimulant use in the months leading up the 30-day period 
prior to incarceration is that degrees of freedom for the development of preference, intention, choice, and 
action would have decreased, rather than increased or remained in a state of equipoise, due to 
neurophysiological and psychosocial changes that developed as a result of continued drug taking (Bratman, 
1999; Brower, Guilfoy, 2004; Dennett, 2015; Mann, 2004; O’Connor, 2009; Volkow & Li, 2004). In this 
way, there would have been fewer mechanisms by which participants could have overridden the many 
conditions biasing them toward continued decisions to use during that 30-day period. These mechanisms 
might be cognitive, but they may also consist of resources and other tools external to the person that 
became degraded after a period of regular use (e.g., decrease in the number of avenues for pursuing non-
drug opportunities, decrease in amount of available help or support) (Peirce et al., 2000; Skinner, Feather, 
Freeman, & Roche, 2007). This means, in part, that the opportunity costs associated with continued use 
may have been fewer, the non-drug options slimmer, and understanding and assistance from others limited 
or difficult to access (Ahmed, 2013; Bickel et al., 2014).  
Participants who used opioids and stimulants during the 30-day period prior to incarceration who 
had a history of opioid and stimulant use can be considered to have already been at a disadvantage by the 
time they reached this point, in that their past use was likely exerting some influence on decision-making 
and behavior in relation to opioids and stimulants, and through whatever conditions of their lives were 
shaped as a result of prior using. This would have occurred to greater or lesser degrees depending on the 
nature of their respective past-year or lifetime using history. Because participants’ lifetime drug use history 
could not be examined as part of this exploratory study, due to the fact such data were not collected as part 
of the SAP clinical assessment and the CJKTOS evaluation, there are many limits to understanding the 
degree to which participants may have been influenced in their decision-making about opioids and 
stimulants. However, several pieces of information related to participants’ drug use history were able to be 
examined. These may help to further contextualize decisions about opioids and stimulants that were made 
prior and subsequent to incarceration.  
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Prior Drug Use 
Rates of drug use decreased between the one-year period prior to incarceration, the 30-day period 
prior to incarceration, and again between the 30-day period prior to incarceration and the one-year period 
subsequent to incarceration.10 Considered together, these basic findings convey several possibilities. For 
one, prior exposure to a drug does not guarantee continued use, but rather may only confer increased 
likelihood of use compared to people who have never previously used these drugs. This is evidenced by the 
fact that rates of use decreased over time, but did not decrease to zero. Some participants who used an 
opioid during the year prior to incarceration did not use an opioid during the 30 days prior to incarceration; 
fewer still used opioids and stimulants subsequent to incarceration. Thus, a history of use, while 
informative, is not a marker of some later fate. Other factors besides prior opioid and stimulant use may 
have also influenced the likelihood that participants would decide to use these drugs subsequent to 
incarceration, as will be discussed below in subsequent sections.  
Differences were found, though, between participants who reported concomitant, opioid, and 
stimulant use during the 30 days prior to incarceration for the number of months out of the year prior to 
incarceration that specific opioid and stimulant drugs were used. For example, participants who reported 
past 30-day concomitant use or past 30-day opioid use reported using heroin, prescription opioids, and 
buprenorphine more months on average during the year prior to incarceration compared to past 30-day 
stimulant users, even though the latter group did report some, albeit less, opioid use during this same one-
year period. Heroin was the only opioid drug that wasn’t used during the one-year period prior to 
incarceration among participants who reported stimulant use during the 30 days prior to incarceration. As 
was anticipated, participants who reported past 30-day concomitant use prior to incarceration used opioids 
and stimulants, and several other drugs, at higher rates, and for more months on average, than the other 
10 During the one-year period prior to incarceration 37.0% of participants reported concomitant use, and for 
the 30-day period prior to incarceration 29.0% reported concomitant use; for the one-year period 
subsequent to incarceration 11.9% reported concomitant use. For the one-year period prior to incarceration, 
63.7% of participants reported using opioids, and for the 30-day period prior to incarceration, 28.5% used 
opioids; for the one-year subsequent to incarceration 12.5% reported using opioids. For the one-year period 
prior to incarceration 56.7% reported using stimulants, and for the 30-day period prior to incarceration 
18.0% reported using stimulants; for the one-year subsequent to incarceration 8.3% reported using 
stimulants. 
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groups. The only exception was for alcohol, which was used by all groups at approximately the same rate 
and frequency.  
During the one-year period subsequent to incarceration, a portion of participants for all drug use 
outcome groups reported prior use of opioids and stimulants. The post-release rates of use for opioids and 
stimulants disproportionately fell along pharmacological lines, though. For instance, a greater proportion of 
participants who reported stimulant use subsequent to incarceration reported greater stimulant use during 
the 30 days prior to incarceration; likewise, participants who reported opioid use subsequent to 
incarceration had higher rates of opioid use prior to incarceration. Between 17.9%-22.6% of participants 
who reported opioid use subsequent to incarceration had used cocaine or amphetamines prior incarceration, 
but within this same group, between 30.8%-70.8% had used heroin, prescription opioids, or buprenorphine 
prior to incarceration. Similarly, between 3.8%-36.2% of participants who reported stimulant use 
subsequent to incarceration had used heroin, prescription opioids, or buprenorphine prior incarceration, but 
between 30.0%-50.0% had used cocaine/crack cocaine or amphetamines prior to incarceration. In other 
words, groups used across drug classes, though pre-incarceration rates of use for specific opioid and 
stimulant drugs corresponded to participants’ later use of either opioids, stimulants, or both.  
Results from the regression model examining the association between drug use during the 30-day 
period prior to incarceration and concomitant, opioid, and stimulant use during the one-year period 
subsequent to incarceration further articulate these relationships. For instance, heroin use and prescription 
opioid use during the 30-day period prior to incarceration significantly increased the likelihood that opioids 
would be used subsequent to incarceration, whereas alcohol, amphetamine, and cocaine/crack cocaine use 
during the 30-day period prior to incarceration decreased the likelihood of later opioid use. For stimulant 
use during the one-year period subsequent to incarceration, the converse was observed; amphetamine and 
cocaine/crack cocaine use during the 30-day period prior to incarceration substantially increased the 
likelihood of stimulant use subsequent to incarceration, whereas heroin use during the 30-day period prior 
to incarceration decreased the likelihood of later stimulant use. The odds of observing concomitant use for 
the one-year period subsequent to incarceration did not decrease in association with prior use of any drug; 
rather, amphetamines, prescription opioids, heroin, and prescription sedative use during the 30-day period 
prior to incarceration increased the likelihood of later concomitant use. Participants who reported 
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concomitant use subsequent to incarceration did have the highest rates of preferring prescription sedatives 
prior to incarceration, even though the proportion of concomitant users with this preference was low (3.8%) 
compared to preferences reported for other drugs. 
When examining heroin use for the one-year period subsequent to incarceration, similar findings 
were observed. Participants who reported heroin use subsequent to incarceration also reported having used 
both stimulants and opioids during the 30-day period prior to incarceration, with rates far higher for opioid 
drugs; the only exception being buprenorphine. For all drugs used during the 30-day period prior to 
incarceration, prescription opioids had the highest rates of use among participants who reported heroin use 
subsequent to incarceration. Heroin was the next most frequently used drug during the 30-day period prior 
to incarceration for this group. Approximately 11% of participants (N=158) did not report any heroin use 
subsequent to incarceration, but did report other opioid use. This group had lower rates of heroin, 
prescription opioid, and buprenorphine use during the 30-day period prior to incarceration compared to 
participants who used heroin subsequent to incarceration. Rates of use ranged from 13.3% for heroin, 
17.9% for buprenorphine, and 48.2% for prescription opioids. This indicates that prior use of opioids did 
not ensure later heroin use, even as this prior use was still positively correlated with later prescription 
opioid or buprenorphine use. 
Differences in heroin use subsequent to incarceration may be partially attributable to the frequency 
with which heroin and other drugs had previously been used. For instance, participants who reported using 
heroin subsequent to incarceration used prescription opioids 15 days on average out of the past 30 days that 
they were last on the street and used heroin for 13 days on average during this same time; buprenorphine 
was used only 3.3 days on average. Among this group, amphetamines and cocaine/crack cocaine were used 
at comparatively lower rates during the 30-day period prior to incarceration, but were still used at rates 
higher than buprenorphine. Both amphetamines and cocaine/crack cocaine were used less than a week on 
average during the 30-day period prior to incarceration, far less than the number of days that prescription 
opioids and heroin were used. Participants who did not report past-year heroin use subsequent to 
incarceration used prescription opioids and heroin fewer days on average during the 30-day period prior to 
incarceration, 10 and 2.5 days respectively. The relationship between drug use at an earlier time and later 
use of similar drugs was highlighted further by findings from the regression model showing that heroin use 
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and prescription opioid use during the 30-day period prior to incarceration significantly increased the 
likelihood of observing later heroin use; the relationship was strongest between heroin use prior to 
incarceration and heroin use subsequent to incarceration. 
These findings illustrate some of the concepts discussed in earlier chapters describing how past 
drug use, particularly when it constituted a regular behavior, and certainly when it constituted a habituated 
behavior, has the capacity to influence people’s ability to think and behave differently in respect to the 
same drugs in the future. Put simply, prior opioid and stimulant use can lead to continued or increased use 
(Ahmed, Walker, & Koob, 2000). While it is possible that anyone might decide to use heroin, it is far more 
probable that people who have previously used heroin would make such a decision. Even for drugs with 
extreme danger or stigma associated with them, use may become ritualized and normalized (Brown, 2015; 
Mars, Bourgois, Karandinos, Montero, & Ciccarone, 2014; Waldorf et al., 1992; Zinberg, 1984). That drug 
use subsequent to incarceration was associated with frequent use of similar drugs prior to incarceration is 
not surprising. Decisions and behaviors that have been previously made or preformed are easier to persist in 
than initiation of novel decisions and behaviors (Ronis, Yates, & Kirscht, 1989). Recall that habits can be 
strengthened or weakened over time, with behaviors preformed repeatedly instantiated in the brain in a 
manner that an infrequently preformed behavior would not be, potentially making choice and behavior 
cognitively “easier”, particularly amidst the same or similar environmental conditions, and particularly if 
the behavioral outcome is highly rewarding (e.g., greater automaticity and less deliberation) (Everitt & 
Robbins, 2016; Gardner, 2015; Graybiel, 2008; Robbins & Everitt, 1999; Sebold et al., 2017; Wood & 
Rünger, 2016). Conversely, decisions and behaviors that were dissimilar to previously made decisions and 
previously performed behaviors would require more deliberation and more effort. 
Even if time spent in a controlled environment disrupted participants’ ability to perform a behavior 
pertaining to opioids, upon release that behavior would have the potential to be resumed and would be 
more likely to be resumed if participants were exposed to the same or very similar environments in which 
they previously obtained and used opioids, and certainly more likely if they were exposed to the drugs 
themselves (Childress et al., 1993; Crombag, Bossert, Koya, & Shaham, 2008; de Wit, 1996). That most 
participants returned to the same county that they resided in prior to incarceration means that it is not only 
possible, but probable, that some participants were exposed to places and people which would have had the 
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potential to produce a conditioned-response (Childress, et al., 1993; Lee, Milton, & Everitt, 2006; 
Leverentz,, 2010). Among participants who had regularly used opioids and stimulants, exposure to drug-
related cues, both before and after incarceration, would have had the potential to influence  decision-
making about these drugs, in part by constraining the cognitive and behavioral repertoire with which 
participants might have flexibly responded (Bechara, 2005; Monti, Schoenbaum et al., 2006; Tiffany, 1999; 
Rohsenow, & Hutchison, 2000). Exposure to cues associated with opioids and stimulants could have 
influenced not only the frequency with which these drugs were thought about explicitly, meaning that 
greater cognitive attention is directed toward drugs, but also could have produced visceral states (e.g., 
craving, stress, arousal, etc.) and further biased attention to drug-related cues in the environment (Field, 
Munafò, & Franken, 2009; Franken, Kroon, Wiers, & Jansen, 2000; Lubman, Peters, Mogg, Bradley, & 
Deakin, 2000). Craving and attentional bias to drug-related cues have been shown to predict use (Franken, 
2003; Marissen et al., 2005, 2006).  
Visceral states, even if people are not always fully aware of their presence and are not able to 
articulate their exact nature or origin, may nevertheless influence mood, affect, cognition, and decision-
making (Cooney, Litt, Morse, Bauer, & Gaupp, 1997; Critchley, Wiens, Rotshtein, Öhman, & Dolan, 2004; 
Drummond, 2001; Monteroso & Luo, 2010; Wiers, Field, & Stacy, 2016). Recall that a racing heart, sweaty 
palms, and queasy stomach might be as easily attributable to fear as it is to excitement or happy 
anticipation (Garfinkel & Critchley, 2016). Recall, too, that disruptions in somatic signaling and 
interoceptive awareness have been associated with drug use, meaning that it may have been difficult for 
some participants to have adaptively navigated somatic, affective, and cognitive states during times in 
which it would have been most crucial (Bechara & Damasio, 2002, de la Fuente et al., 2019; Paulus & 
Stewart, 2014; Sönmez, Kahyacı Kılıç, Ateş Çöl, Görgülü, & Köse, 2017). Irrespective of any disruption, 
interceptive awareness, necessary for adaptive human functioning, can compel a person’s attention and 
potentiate action, potentially exacerbating visceral sensations of craving, desire, or temptation (Naqvi, 
Rudrauf, Damasio, & Bechara, 2007; Turel et al. 2014; Van den Bergh et al., 2018). When interoceptive 
awareness is activated, top-down cognitive capacities needed for deliberation and inhibition may be 
weakened, while bottom-up impulses and urges may be excited, thus potentially enabling action without 
forethought (Noël, Brevers, & Bechara, 2013; Turel & Bechara, 2016).  
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 In summary, opioid and stimulant drugs used with regularity prior to incarceration were 
associated with use of similar drugs subsequent to incarceration. During both time periods, drug-related 
cues in the environment, along with other stressors that may have been present, would have had the 
potential to influence participants’ physiological, cognitive, and affective states, making higher-level 
cognition needed for impulse control and adaptive decision-making more challenging (Sinha et al., 2003; 
2005; Snyder & Hankin, 2016; Tice et al. 2001). Some of these additional influences will be discussed 
further below.  
Versatile Drug Use, Preference, and Drug Use Severity 
Many participants in this sample can be considered as polydrug users. Drug use versatility, 
indicated by the total number of different drugs used during the one-year periods prior and subsequent to 
incarceration, was higher among participants who reported concomitant and opioid use for the 30-day 
period prior to incarceration and the one-year period subsequent to incarceration. Concomitant use during 
the 30-day period, rather than separate use of either opioids or stimulants, might lead one to intuit that the 
total number of drugs used for the entire one-year period prior to incarceration would be greater compared 
to other groups, and this was indeed the case. But this was not a foregone conclusion. Participants who 
reported past 30-day opioid, stimulant, or other drug use could have used alcohol, cannabis, sedatives, 
hallucinogens, or synthetic drugs during that year, meaning that they would have used five or more drugs. 
Participants who reported past 30-day concomitant use could have only used opioids and stimulants for that 
year, making them less versatile users by comparison. That this wasn’t the case, but instead that 
concomitant use of two high-risk drugs was associated with overall greater drug use versatility, hints at the 
possibility that there is a subgroup of participants who are less discriminant in their drug selection and 
possibly more risk-prone.  
This idea is partially supported by the finding that participants who reported concomitant use had 
the highest rates of drug use severity followed by participants who reported past 30-day opioid use. This 
means that during the 30-day period prior to incarceration, participants who co-used opioids and stimulants, 
or who used opioids (either alone or contemporaneously with non-stimulant drugs), more often experienced 
drug-related problems, craving, a desire but inability to quit using, and withdrawal. The presence of craving 
and withdrawal among some participants is especially significant, as these qualities indicate that 
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participants were possibly dependent on certain drugs, which would imply that the local utility of these 
drugs was high, the discount rate of future, non-drug rewards was steep, and that decision-making may 
have been more impulsive and less deliberative (Bickel, Koffarnus, Moody, & Wilson, 2014; Giordano et 
al., 2002; Mitchell, 2004; Franken, 2003).  
While higher rates and greater frequency of drug use across many classes does not necessarily 
correspond to drug use severity in a linear way, using more drugs more often does mean that a person is 
exposed to the rewarding, and behaviorally reinforcing, effects of drugs with greater regularity. 
Participants’ ability to flexibly make intertemporal decisions, particularly about higher-risk drugs, would 
likely be impaired with regular use of opioids, stimulants, and other drugs, but so too would their ability to 
make adaptive, less-risky decisions in general due to any direct effects of drug intoxication (Cromer,  
Cromer, Maruff, & Snyder, 2010; Gilman, Smith, Ramchandani, Momenan, & Hommer, 2012; Goldstein et 
al., 2009; Ramaekers et al., 2006; Rogers et al., 1999). The initial use of one drug may precipitate further 
drug use and, among all drugs used, those associated with the greater perceived value or preference may 
continue to be used at higher rates (Aharonovich et al., 2005; Greenwald, 2008). This is indirectly 
evidenced in this sample by the correspondence between preferred drugs and drug use outcomes, with 
greater preference for heroin, prescription opioids, and buprenorphine associated with opioid use, greater 
preference for cocaine/crack cocaine and amphetamine use associated with stimulant use, and some 
preference for all of these drugs associated with concomitant use. Although participants who reported other 
drug use during the 30-day period prior to incarceration did prefer opioid and stimulant drugs, rates were 
lower compared to other groups based on drug type.  
Drug use versatility was greatest among the concomitant use group, both before incarceration and 
after. However, in the regression model examining concomitant, opioid, and stimulant use during the 30-
day period prior to incarceration, the odds of observing an outcome of concomitant, opioid, or stimulant use 
increased across all groups as a function of drug use versatility. In other words, the more drugs that were 
used, the more likely it was that a participant would use opioids or stimulants, or to co-use them, during 
this 30-day period prior to incarceration, rather than use non-opioid and non-stimulant drugs such as 
alcohol, cannabis, prescription sedatives, etc. Polydrug use, and particularly use of a greater number of 
different drugs across drug classes, may indicate a willingness to try new drug experiences even if regular 
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use of all drugs is not adopted (Smith & Staton, 2019; Smith & Stoops, 2019; Sutherland et al., 2016; 
Wagner et al., 2014). Regular, versatile, and overall more severe drug use that was more common among 
participants who reported concomitant and opioid use during the 30-day period prior to incarceration may 
indirectly indicate the possible presence of traits and/or states that would incline a person toward more 
diverse experimentation, such as greater impulsivity, higher propensity for novelty- or sensation-seeking, 
and less risk-aversion which, as previously discussed, are all strongly associated with opioid and stimulant 
use specifically and less adaptive decision-making generally (Bardo, Donohew, & Harrington, 1996; Butler 
& Montgomery, 2004; Galizio & Stein, 1983; Jentsch et al., 2014; Kirby & Petry, 2004; Verdejo-García, 
Perales, & Pérez-García, 2007; Wingo et al., 2016). Being more versatile and less discriminate in respect to 
drug experiences would also influence decision-making about opioids or stimulants by virtue of the fact 
that all drug options remain open for selection, thereby increasing the probability that opioids and 
stimulants would be used, or used concomitantly, irrespective of overall preference.  
Worth emphasizing is that drug use severity was measured so as not to pertain to any one drug. 
Had severity of use for each drug type been assessed, it would have likely helped to clarify drug selection 
among participants who reported concomitant use prior and subsequent to incarceration, though doing so 
would not have explicated the overall greater propensity toward versatile drug use. For instance, a person 
could have a higher drug use severity score, but also ever only use crack cocaine, meaning that severity 
itself cannot explain the phenomenon a using a more diverse range of drugs. Of additional interest is the 
higher average number of previous drug treatment episodes among participants who reported concomitant 
use for the 30-day period prior to incarceration and among participants who reported past-year concomitant 
and opioid use for the one-year period subsequent to incarceration, as this may further indicate drug use 
severity. For instance, participants in these groups may have experienced psychosocial or medical problems 
that precipitated or otherwise motivated treatment entry or may have engaged in problematic drug 
behaviors that resulted in treatment being mandated (Cacciola, Dugosh, Foltz, Leahy, & Stevens; 2005; 
Cosden et al., 2006; DiClemente, 2018; Hser, Grella, Chou, & Anglin,1998). 
Abstinence Self-efficacy 
Interestingly, participants who reported concomitant use subsequent to incarceration also had the 
lowest rates of reporting moderately or very good abstinence self-efficacy prior to treatment initiation. This 
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group also had the lowest proportion of participants reporting “moderately” or “very good” abstinence self-
efficacy approximately one-year post-release. It is important to note that the abstinence self-efficacy 
question (e.g., “Based on what you know about yourself and your situation, how good do you think the 
chances are that you can stay off drugs and alcohol?”) was phrased in a manner that may confuse 
interpretation of findings. Specifically, the question implies that it is the intention of participants to “stay 
off drugs and alcohol”. It may be that some participants had an intention to abstain from some drugs but 
use others in moderation and that others had no intention of trying to abstain from any drug and were 
uncommitted to treatment (Kelly & Greene, 2014; Laudet & Stanick, 2010). Other information obtained 
from the survey could not clarify this ambiguity. This limitation notwithstanding, the fact that abstinence 
self-efficacy at two different time periods was lowest among participants who reported concomitant use 
and highest among participants who used other/no drugs may indicate that one possible factor influencing 
later drug-related decision-making was participants’ belief that abstinence was in fact possible. Self-
efficacy beliefs are considered cognitively instrumental in intention formation, decision-making, and 
behavioral control (Ajzen, 2002; Bandura, 1982; Bandura, 1999). Participants who believed that abstinence 
was both possible and likely to be achieved may have been primed and enabled to later actualize those self-
efficacy beliefs. These participants may have believed that they were capable of making different decisions, 
controlling their behavior, or engaging in recovery or non-drug behaviors (Bandura, 1989, 1991; Marlatt, 
Baer, & Quigley, 1997). For participants who may not have intended to abstain from all drugs, and 
therefore may have been more likely to respond “uncertain”, “moderately poor”, or” very poor” to this 
question (as opposed to responses of “moderately good” or “very good”), findings of greater drug use 
among these participants would still be in keeping with the idea that earlier ambivalence about using or 
earlier intention to keep using would have had the potential to later influence decisions to use, rather than 
abstain. In other words, decisions to use could reflect both lower perceived abstinence self-efficacy or the 
absence of intention to quit using. 
Drug Substitutes, Compliments, and Risk Amidst Changing Markets 
Concomitant use of opioids and stimulants during the one-year period prior to incarceration was 
most common among participants who reported concomitant use during the 30-day period prior to 
incarceration, but was also found among participants that used opioids-only during the 30-day period prior 
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to incarceration. Other than participants who reported concomitant use prior and subsequent to 
incarceration, participants who reported using opioids during the 30-day period prior to incarceration and 
the one-year period subsequent to incarceration used more drugs across drug classes compared to 
participants who used stimulants-only for these same time periods.  
Although greater drug use versatility was also associated with increased odds that stimulant-only 
use would be observed during the 30-day period prior to incarceration, participants who used stimulants, 
but not opioids, during this time period had the lowest rates of past-year opioid use, even when compared 
to participants who reported past 30-day other drug use. Stimulant users in this and other samples, while 
still predominantly polydrug users, may be less likely to use opioids as either compliments or substitutes, or 
to use opioids only infrequently (Harrell, Mancha, Petras, Trenz, & Latimer, 2012). Older stimulant users 
in this sample may have been using stimulants for a longer period of time and, as a result, may have 
transitioned from use to dependence, or may have simply had more well-established drug preferences and 
use patterns (Booth et al., 2006; Brecht et al., 2008; Lee, Vivier, & Diercks, 2009; Lopez-Quintero et al., 
2011; Wu et al., 2009). Alcohol or cannabis may have been treated as compliments among stimulant users 
in this sample, as evidenced by past-year rates of use for these drugs that were comparable to those of other 
groups, unlike rates of past-year opioid use, which were far lower among participants who reported past 30-
day stimulant use. Alcohol and cannabis were also preferred by a greater proportion of participants who 
reported past 30-day stimulant use, compared to participants who reported past 30-day concomitant or 
opioid use. Alcohol and cannabis have been documented as compliments to cocaine and are often co-used 
with cocaine (John & Wu, 2017; Lindsay, Stotts, Green, Herin, & Schmitz, 2009; Midanik, Tam, & 
Weisner, 2007; McCance-Katz et al., 1993; Williams & Parker, 2001).  
Contemporaneous use of alcohol and cannabis is not uncommon among people who use multiple 
drugs, even among people who prefer drugs other than alcohol and cannabis (Barrett, Darredeau, & Pihl, 
2006; Smith and Lawson, 2017; Yurasek, Aston, & Metrik, 2017). This study produced similar findings, 
with alcohol and cannabis not overwhelmingly preferred, but still used, by a majority of participants. This 
phenomenon may be due in part to the greater availability and affordability of alcohol and cannabis 
compared to other drugs. Cannabis is increasingly legal in some form throughout the US and has fewer 
social and legal risks associated with it than it did during previous decades (Carliner, Brown, Sarvet, & 
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Hasin, 2017; Hall & Lynskey, 2016; Hathaway, Mostaghim, Erickson, Kolar, & Osborne, 2018). 
Interestingly, a slightly higher proportion of participants who reported past-year stimulant use subsequent 
to incarceration resided in a county with restricted alcohol sales, though differences in alcohol accessibility 
did not differ appreciably by drug use outcome group. 
Alcohol, cannabis, prescription sedatives, cocaine/crack cocaine, and amphetamines were used at 
fairly high rates among participants who also used opioid drugs, which raises the possibility that these 
drugs may have been treated as compliments or as substitutes among participants who co-used them (Lucas 
et al., 2016; Petry & Bickel, 1999; Reiman, 2009; Sumnal et al., 2004). As previously discussed, 
cocaine/crack cocaine and amphetamines are co-used with heroin and prescription opioids at fairly high 
rates (e.g., “speedball”, “goofball”) among polydrug users due to their mutually reinforcing effects, 
meaning that for some participants they may have been more often treated as compliments (Bickel et al., 
1995; Jasinski & Preston, 1986; Guzman & Ettenberg, 2004; Leri, Bruneau, & Stewart, 2003; Lorvick, 
Browne, Lambdin, & Comfort, 2018; Wade-Galuska, Winger, & Woods, 2007). Due to their distinct 
subjective psychoactive effects, it may be less likely that regular drug users, and drug users with greater 
preference for either opioids or stimulants, but not both, would treat drugs within these two classes as 
substitutes.  
Heroin and…Buprenorphine 
That approximately one-third of participants who reported past-year heroin use subsequent to 
incarceration also reported using prescription opioids and buprenorphine for this same time period raises 
the possibility that drug substitution within the same drug class occurred or that during this time period 
some participants made a decision to transition from prescription opioids to heroin (Evans et al., 2018; 
Monti, 2019; Peavy et al., 2012). Many people who currently use heroin in the US transitioned to heroin as 
a substitute for prescription opioids, and it has been shown elsewhere that opioid users are willing to 
substitute preferred opioids with other, less preferred opioids, such as buprenorphine (Compton et al., 2016; 
Kanouse & Compton, 2015; Lankenau et al., 2012; Smith et al., 2017). This was partially evidenced in this 
study by high rates of multiple opioid drug use among participants who reported concomitant and opioid 
use prior and subsequent to incarceration. It could be that at various times during the one-year post-release 
period that prescription opioids were substituted for heroin or vice versa, due to periods of greater or lesser 
 214 
availability of either drug, increases or decreases in price, changes in drug quality, or fluctuations in 
participant income (Goudie, Sumnall, Field, Clayton, & Cole, 2007; Greenwald & Hursh, 2006; Chalmers 
et al., 2010; Petry, 2000).  
While use of heroin, prescription opioids, amphetamines, and cocaine during the 30-day period 
prior to incarceration were all associated with changes in the likelihood of opioid, stimulant, and 
concomitant use during the one-year period subsequent to incarceration, buprenorphine was not 
significantly associated with these post-release outcomes. Similarly, buprenorphine use during the 30-day 
period prior to incarceration was not associated with a change in odds for observing heroin use during the 
one-year period subsequent to incarceration. For the 30-day period prior to incarceration, buprenorphine 
was used by 25.0% of participants who reported using heroin during the one-year period subsequent to 
incarceration. Subsequent to incarceration, however, buprenorphine use increased to 33.3% among 
participants who reported heroin use, far higher than rates found among participants who did not report 
heroin use subsequent to incarceration (only 6.5% reported buprenorphine use). Buprenorphine use during 
the one-year period subsequent to incarceration was associated with a 266% increase in odds of observing 
heroin use for this same time period, whereas use of prescription opioids was associated with a 73% 
increase in odds of heroin use. Although prior to incarceration buprenorphine was used at higher rates 
among participants who resided in rural counties, subsequent to incarceration rates of buprenorphine use 
were slightly higher in urban areas. Rates of heroin use both prior and subsequent to incarceration were 
higher among participants who resided in urban areas, increasing during the 2012-2017 post-release period. 
It may be that proliferation of MAT providers in urban areas provided greater access to diverted 
buprenorphine during a time when heroin was also becoming more ubiquitous in urban areas.  
For some participants, buprenorphine could have served as a substitute and may have been chosen 
by heroin-using participants for purposes such as self-adopted harm-reduction or informal OUD self-
treatment, as such use has been documented elsewhere (Bazazi, Yokell, Fu, Rich, & Zaller, 2011; 
Daniulaityte, Falck, Wang, & Carlson, 2009; Furst, 2013; Gwin-Mitchell et al., 2009; Jayadeva et al. 2017; 
Schuman-Olivier et al., 2010). Buprenorphine may have also been selected by some participants to achieve 
pleasant subjective effects, though evidence remains mixed as to whether buprenorphine should be 
regarded as a serious drug of abuse and as a preferred drug among polysubstance users given its ceiling 
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effects (Cicero, Surratt, & Inciardi, 2007; Smith et al., 2019). Because buprenorphine was preferred by only 
2.6% of the entire sample, and 1.2% of participants who reported using heroin subsequent to incarceration, 
it may be less likely that participants decided to use buprenorphine primarily as a means of achieving states 
of intense euphoria or pleasure. That the survey question pertaining to buprenorphine included both 
Suboxone and/or Subutex, but made no distinction between them, makes speculation difficult due to the 
fact that these drugs differ in their effects. Buprenorphine, an agonist and/or antagonist at different opioid 
receptors, is found in both brand-name drugs; Suboxone also contains naloxone, an opioid antagonist, 
whereas Subutex contains only buprenorphine (Lobmaier, Gossop, Waal, & Bramness, 2010; Lufty & 
Cowan, 2004). 
Although buprenorphine might not ordinarily have high local utility for many polydrug users, its 
perceived value might increase significantly among participants who regularly used heroin or prescription 
opioids, but then encountered a period of supply disruption. It may also have been more valued among 
participants using buprenorphine to self-treat OUD. This relationship between heroin and buprenorphine 
may also reflect broader changes in the illicit drug market. Over the past eight years, opioid prescribing has 
decreased and prescription opioid monitoring has increased, driving up the price of prescription opioids in 
illicit drug markets (Lebin et al., 2019; Mallatt, 2018). Conversely, buprenorphine prescribing has 
increased significantly in the US, with prescribing rates higher among states that adopted Medicaid 
expansion under the Patient Protection Affordable Care Act (ACA), Kentucky being one such state (CHFS, 
2019; Clemans-Cope, Epstein, & Kenney, 2017; Wen, Hockenberry, Borders, & Druss, 2017). Prescription 
drug diversion is a perennial problem in the US and there is often a positive relationship between rates of 
drug prescribing and prescription drug diversion (Cicero et al., 2007; Daniulaityte et al., 2006; Kurtz, 
Buttram, Margolin, & Wogenstahl, 2019). Use of diverted buprenorphine has been found among many 
samples, including among other corrections-involved samples in Kentucky, (Cicero et al., 2018; Lofwall & 
Havens, 2012; Molfenter et al., 2019; Smith et al., 2019).  
Given the high rates of any opioid use prior to incarceration, it is worth considering two related 
questions. First, why did so many participants decide not to use heroin subsequent to incarceration? Nearly 
22% of the sample reported using heroin during the one-year period prior to incarceration, but this declined 
to 10.7% during the one-year period subsequent to incarceration. Participants were released during a time 
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when prescription opioids were becoming more expensive and heroin was becoming more ubiquitous, 
cheaper, and potent, making it a potentially more attractive opioid substitute. Second, why did so many 
participants in this sample decide to use heroin subsequent to incarceration? Participants were released 
during a time when heroin was becoming more adulterated, dangerous, and deadly (Jalal et al., 2018; 
Marshall et al., 2017; Ruhm, 2018). The penalties for selling even small quantities of heroin, which is one 
way that heroin users can help generate the funds needed to support their own heroin use, increased during 
this time (Biernaki, 1979; Duncan, 2013; Offices of the United States Attorneys, 2017). These increased 
sanctions, coupled with the increased risk of heroin-related overdose and death, still did not deter about 
10% of participants. Heroin is a drug associated with great reward as well as great risk. That heroin was 
more available in Kentucky during the 2012-2017 post-release period than in any previous decade (thus 
including any pre-incarceration period), but that use declined among participants in this sample, suggests 
that, for some participants, the risks associated with use may have been perceived as too great (Ciccarone, 
Ondocsin, & Mars, 2017; Votaw, Wittenauer, Connery, Weiss, & McHugh, 2017). 
Greatest Risk 
One disquieting finding is that the use of prescription sedatives, cocaine/crack cocaine, 
prescription opioids, and amphetamines during the one-year period subsequent to incarceration was 
associated with increased likelihood of also observing heroin use for this same time. Put differently, the 
single most dangerous drug that could be used during this time period was significantly associated with 
contemporaneous use of drugs most likely to result in an acute adverse event when used with it (Clinton, 
Hunter, Logan, & Lapidus, 2019; Hobelmann et al., 2016; Mital, Windle, Cooper, & Crawford, 2017; 
Yamamoto et al., 2019). That rates of opioid and stimulant use among participants reporting past-year 
heroin use were higher both prior and subsequent to incarceration means that these 168 participants may be 
appropriately considered as polydrug users across time periods and arguably the highest-risk users of the 
sample. Participants who did not use heroin, but who used prescription opioids contemporaneously or 
concomitantly with other drugs were still engaging in high-risk form of drug use, in that co-use of opioids 
with stimulants, benzodiazepines, or alcohol is associated with increased likelihood of adverse outcomes, 
including overdose and death (Calcaterra et al., 2013; Hobelmann & Clark, 2016; Jones et al., 2012; Kaye 
& Darke, 2004; Warner et al., 2016).  
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Intravenous Administration 
High-risk drug decisions can also be reflected by the route of administration. Approximately 40% 
of participants in this sample had some history of IDU. Participants who reported past 30-day concomitant 
and opioid use prior to incarceration had the highest rates of IDU history, with rates highest among 
participants who reported concomitant use. During the one-year period subsequent to incarceration, rates of 
IDU history were approximately equal between concomitant and opioid users. While history of IDU was 
associated with increased odds of concomitant, opioid, and stimulant use during the 30-day period prior to 
incarceration, it was associated only with increased likelihood of observing past-year concomitant and 
opioid use subsequent to incarceration. This means that opioids, either used in isolation or in combination 
with other drugs, were associated with history of IDU, a relationship that has been observed elsewhere for 
both prescription opioids and heroin (Al-Tayyib, Koester, & Riggs, 2017; Warner‐Smith, Darke, Lynskey, 
& Hall, 2001).  
Differences in history of IDU between participants who reported past-year heroin use and those 
who did not were stark. In separate analyses (results not displayed), among participants who reported any 
drug use during the one-year period subsequent to incarceration (N=869), participants who reported using 
heroin were significantly more likely than participants who reported other drug use to report IDU during 
the one-year period subsequent to incarceration (17.2% vs. 6.9%, X2=14.6; p<.001). This may be partially 
attributable to preferred routes of administration that includes intravenous injection. A person who prefers 
this method may be influenced in their decision-making, being inclined to choose more readily injectable 
drugs, such as heroin, and less inclined to choose drugs that involve more preparatory steps, such as 
prescription opioids (Ponton & Scott, 2004).  
In illicit drug markets, there has been a decrease in availability of many popular prescription 
opioids that were once commonly injected (e.g., original formulation OxyContin) (Alpert et al., 2018). 
These prescription opioids, while not eliminated from illicit drug markets, are nevertheless being 
increasingly replaced with tamper-resistant prescription opioid formulations intended to deter abuse, 
meaning that they are far more difficult to prepare for injection (Alpert, et al., 2018; Chilcoat, Coplan, 
Harikrishnan, & Alexander, 2016; Patrick, Fry, Jones, & Buntin, 2016). Although earlier generation 
prescription opioids required several steps of preparation prior to injection, and certainly more steps than 
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heroin, participants who may have attempted injecting formulations brought to market after 2010 would 
have needed peer-based instruction on how to prepare these pills for injection or would have needed to 
undertake extensive research and trial-and-error (Duxbury, 2018; Rönkä & Katainen, 2017; Vosburg, 
Haynes, Besharat, & Green, 2017). They may have also needed to acquire additional chemical compounds 
required for the refinement of pills into injectable form. In short, while abuse-deterrent prescription opioids 
might be less expensive than original formula prescription opioids (though still more expensive than 
heroin), they would cost more in effort and time (Lebin et al., 2019). The potential for wasted product or 
weaker effects, in cases where pills were not prepared properly or were unable to be injected successfully, 
coupled with the increased cost in time, could have made heroin, rather than prescription opioids, a more 
attractive drug among participants with a preference for this route of administration (Vosburg et al., 2013). 
For people who inject drugs, time might be considered a cost due to the fact that one of the appeals of IDU 
is that drug effects are extreme and felt nearly instantaneously (3-7 seconds), particularly when compared 
to swallowing or even insufflation (Zering et al., 2003). However, increased tolerance and variability in 
potency may have made heroin less desirable over the long-term among some participants (Monico & 
Mitchell, 2018). 
Cocaine and amphetamines are also more readily injectable than other drugs, one reason why 
concomitant use of heroin and cocaine or heroin and amphetamine remain popular among some IV 
polydrug users (Al-Tayyib, Koester, Langegger, & Raville, 2017; Dolan et al., 1991; Harrell, Mancha, 
Petras, Trenz, & Latimer, 2012; Sanders, Lankenau, Jackson-Bloom, & Hathazi, 2008). Crack cocaine may 
also be injected, though requires more steps to prepare, meaning that some participants may have preferred 
to smoke rather than inject crack cocaine (Lankenau, Clatts, Goldsamt, & Welle, 2004; Waninger, Gotsch, 
Watts, & Thuahnai, 2008).  
Although high-risk drug use was common across this sample, participants with a with a history of 
IDU may be considered as even less risk-averse compared to participants without such history. Risk-
aversion may be less pronounced still among people with a history of IV heroin administration, versus IV 
prescription opioid administration, as IV heroin administration entails the highest risk of all for this 
generation of drug users. Though heroin and prescription opioids are more often associated with IV 
administration and, to a lesser extent, cocaine and amphetamines, IV buprenorphine use is an increasingly 
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well-documented phenomenon that warrants closer examination (Brecht, O'Brien, Von Mayrhauser, & 
Anglin, 2004; Fischer et al., 2018; Kelly et al., 2017; Novak & Kral, 2002; Yokell et al., 2011). 
Additional Endogenous Factors with the Potential to Influence Decision-making 
Age of Drug Use Initiation 
Participants who reported concomitant use prior and subsequent to incarceration were <14 years 
old on average when they first used drugs. The relationship remained significant in the regression model, 
with younger age associated with slightly increased odds of use. Participants who reported using heroin 
during the one-year period subsequent to incarceration were 13.8 years-old on average when drug use was 
initiated, a full year younger than the average age of drug use initiation among participants who did not 
report heroin use, though this association did not remain significant in the regression model. Participants 
who reported other drug use prior to incarceration were on average 14.5 years old when they first used 
drugs and those who reported other/no drug use during the one-year period subsequent to incarceration 
were 15.3.  
These average ages associated with other drug and/or no drug use, while all >14 years old, are still 
young. Even though age 14 is regarded as a critical neurodevelopmental juncture, with drug use and other 
insults to the brain prior to age 14 having more enduring effects, there does not exist any clear line; what 
can be considered normative development still allows for variation. It may be that, for some, the 
neurodevelopmental implications of drug use initiation at age 15 differs little than use which began at age 
13. It may be more important to understand that, overall, a positive relationship between earlier age of drug
use inhiation and problems associated with drug use in later adolescence and adulthood is commonly 
observed (Chen et al., 2009; King & Chassin, 2007; Labouvie & White, 2002; Walters & Urban, 2014). 
Even this understanding should be contextualized by other factors, such as the frequency of use at young 
ages, social conditions (e.g., trauma, poverty, and structural inequality), or by a number of other 
endogenous or exogenous factors with demonstrated capacity to adversely influence neurodevelopment and 
impair later cognitive-behavioral functioning (Bergen, Gardner, & Kendler, 2007; Champagne, 2010; 
Champagne & Curley, 2005; Charach, Yeung, Climans, & Lillie, 2011; Dube et al., 2003 Perry et al., 1995; 
Walker et al., 2011). Information about participants’ childhood and adolescence was not available for 
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examination in this study, meaning that some important details pertaining to early drug use initiation will 
need to be more fully considered in future work. 
In separate analyses (results not displayed), differences in age of drug use initiation were 
examined by sex, history of head injury, and LD diagnosis and/or SE enrollment, as all of these factors 
might confer the possibility of less adaptive cognitive function, including poorer inhibitory control and 
working memory, and, in some cases, less risk-aversion (APA, 2013; Cottle et al., 2001; Mcallister, 
Flashman, Sparling, & Saykin, 2004; Van der Meere, Marzocchi, & De Meo, 2005). On average, 
participants who were male, had a history of head trauma, or LD diagnosis/SE enrollment initiated drug use 
at an earlier age. Males were 14.4 years-old on average, compared to females, who were 15.9 years-old on 
average (t=4.52., p<.001), reflecting possible sex-based differences in early life for impulsivity, risk-taking, 
and dose-dependent drug reward (Cross, Copping, Campbell, 2011; Eckel & Grossman, 2008; Hosseini-
Kamkar & Morton, 2014; Vansickel, Stoops, & Rush, 2010). Participants with a history of head injury were 
14.2 years-old on average when drug use was initiated, compared to those without, who were 15.1 years-
old on average (t=3.51, p<.001). Participants with a history of LD diagnosis and/or SE enrollment were 
14.2 years-old on average when they initiated drug use, compared to those without this history, who were 
14.9 years-old on average (t=2.22, p=0.27). Thus, there is some limited evidence to suggest that 
participants who initiated drug use at an earlier age may have had traits and states that biased them toward 
riskier decision-making and/or decreased their ability to inhibit acting on the urges which precipitated these 
decisions. However, because temporal order cannot be established, these associations cannot be considered 
past the point of conjecture and are presented primarily to draw attention to the idea that any initial decision 
to use a drug is not made in isolation and that many factors beyond the age of initiation are important to 
examine with greater sophistication in future work.  
That the average age of drug use initiation for the entire sample was 14.7 years, does mean that 
drug use occurred for most participants at a fairly young age in terms of neurolocognitive and psychosocial 
development (Gogtay et al., 2004; Shaw et al., 2008; Sorrells et al., 2018). Early age of drug use may 
indirectly indicate that some participants in this sample may be higher in trait impulsivity compared to 
people who either do not elect to use drugs, or who initiate use later in life (Petry, 2001; Verdejo-García, 
Lawrence, & Clark, 2008). Though as discussed previously, novelty-seeking, impulsiveness, risk-taking, 
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and poorer intertemporal decision-making are more prominent in childhood and adolescence, meaning that 
early drug experimentation cannot be taken as a clear indicator of the presence of traits often associated 
with greater risk-taking, impulsiveness, or poorer decision-making at later times. Findings should be 
interpreted with that in mind.  
Age and Sex 
Overall, younger age was most often associated with concomitant and opioid use both prior and 
subsequent to incarceration, including among participants who reported past-year heroin-use. That 
participants who reported other/no drug use subsequent to incarceration were slightly older is in keeping 
with previous research documenting that drug use and other high-risk behaviors are more prominent in 
early adulthood, decreasing or moderating with age (Gfroerer & Brodsky, 1992; Fleming, White, Catalano, 
2010). It may be that slightly older participants had other factors, such as a spouse, children, and other 
investments in everyday life that helped establish greater stability, serving to reinforce less risky behavior; 
though this trend is not always uniform, with minority groups sometimes continuing to use drugs in 
adulthood due to inequitable access to non-drug alternatives and other stabilizing resources (Duncan, 
Wilkerson, & England, 2006; Sampson, Laub, & Wimer, 2006; Visher, Knight, Chalfin, & Roman, 2009; 
Vogt Yuan, 2010; Zapolski, Baldwin, Banks, & Stump, 2017). For participants who were younger than 27 
years-old during the time periods examined, and particularly those who were younger than 23 years-old, 
frontocortical areas crucial for deliberative decision-making and inhibition would have been less 
developed, meaning that they would have had comparatively less capacity for adaptive decision-making 
during intertemporal choice (Gogtay et al., 2004; Spear, 2007). 
Although drug use for the 30-day period prior to incarceration differed by sex, with slightly more 
males found among the stimulant use and other drug use groups, the proportion of males among drug use 
groups did not differ subsequent to incarceration, including for heroin use. That a greater proportion of 
females were found among the higher risk drug using groups (concomitant, opioid, and heroin), compared 
to stimulant and other/no drug use groups, suggests that greater propensity for risk-taking based on sex was 
not a meaningful influence among participants in this sample, even though elsewhere in Kentucky males 
have found to use a greater variety and quantity of drugs (Shannon, Havens, Mateyoke-Scrivner, & Walker, 
2009). 
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 It may also be that other factors influenced the use of these generally higher risk opioid drugs 
among female participants. Some factors that might have influenced cognitive capacity and drug-related 
decision-making include higher rates of prior or ongoing sexual and physical violence, childhood adversity 
and trauma, physical and psychological health symptoms, chronic pain, disability, and poverty, as these 
characteristics have been found at high rates among corrections-involved women with a history of drug use, 
including samples in Kentucky (Binswanger, Krueger, & Steiner, 2009; Champagne & Curley, 2005; 
Bronson, Maruschak, & Berzofsky, 2015; Golder, Engstrom, Hall, Higgins, & Logan, 2015; Hall et al., 
2016; Logan, Walker, Jordan, & Leukefeld, 2006; Lynch, DeHart, Belknap, & Green, 2012; Staton, 
Leukefeld, & Logan, 2001; Staton-Tindall et al., 2015; Smith et al., 2019). Not only have many stress-
related states and conditions been shown to influence drug-taking among women differently, and in some 
ways disproportionally, then men, but psychological problems associated with drug use are typically 
greater among women than men (Fox & Sinha, 2009). 
Additional analyses (results not displayed) showed that during the one-year period prior to 
incarceration female participants experienced higher rates of depressive (68.8% vs. 40.9%, X2=74.5, 
p<.001) and anxiety symptoms (60.1% vs. 40.9%, X2=35.2, p<.001), suicidal ideation (17.4% vs. 10.3%, 
X2=11.4, p<.001), unemployment (47.3% vs. 31.1%, X2=31.3, p<.001), chronic pain (34.2% vs. 22.5%, 
X2=17.1, p<.001), and higher stress-related health symptom scores (27.1 vs. 22.6, t=8.81, p<.001). Perhaps 
unsurprisingly, rates of misregulation were slightly higher among women (87.9% vs. 82.0%, X2=5.2, 
p=0.19). Though, fewer women than men reported LD diagnosis/SE enrollment (22.8% vs. 30.0%, X2=5.7, 
p=.017). During the one-year period subsequent to incarceration, female participants experienced higher 
rates of depressive (38.9% vs. 31.3%, X2=6.02, p=.014) and anxiety symptoms (56.7% vs. 37.0%, X2=38.0, 
p<.001), cognitive difficulties (35.9% vs. 24.2%, X2=16.4, p<.001), and unemployment (42.6% vs. 34.2%, 
X2=7.02, p=.008), though rates of chronic pain (36.6% vs. 31.6%, X2=2.48, p=.116) and suicidal ideation 
(5.0% vs. 4.3%, X2=0.13, p=.719) did not differ significantly between men and women subsequent to 
incarceration. These findings may help to explain why rates of high-risk drug use were similar among male 
and female participants. While men tend to be less risk-averse then women, certain conditions in the lives 
of corrections-involved women, including greater stress, may have contributed to decisions to use drugs 
with high risk, either by influencing cognitive capacities needed for adaptive decision-making or by 
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increasing the likelihood that drugs would be used in an attempt to help reduce stress, anxiety, fear, or other 
unpleasant states (Logan et al., 2006; Zlotnick, Najavits, Rohsenow, & Johnson, 2003). It is important to 
keep in mind that responses for some survey questions (e.g., anxiety, pain, suicidal ideation) may reflect 
gender-based differences in self-report (Herbert et al., 1997; Sigmon et al., 2005). Ultimately, continued 
work is needed to better understand sex-based differences in high-risk drug-related decision-making among 
corrections-involved people.  
Psychiatric Symptoms, Stress, Misregulation 
Past-year anxiety and depressive symptoms were higher among participants who reported 
concomitant use during the 30-day period prior to incarceration, as were rates of suicidal ideation. 
Participants who reported concomitant use also had significantly higher stress-related health effects scores, 
whereas scores were lowest among participants who reported other drug use. Higher stress-related health 
effects served as an indirect measure of stress among participants prior to incarceration. Higher scores 
would be indicative of greater psychological stress, as well as heightened stress response, meaning that 
both the manifestation and phenomenology of stress would have likely varied considerably between 
participants.  
That participants who evidenced the greatest drug use versatility and severity and higher rates of 
psychiatric symptoms (e.g., the concomitant group) also experienced greater stress-related health effects, 
but that participants who evidenced the least drug use versatility and severity and lowest rates of 
psychiatric symptoms (e.g., other drug use group) evidenced the fewest, may not be surprising. For one, 
two stress-related health effects items measured the presence or absence of anxiety and depressive 
symptoms, and the relationship between stress and psychiatric symptoms is well-established, meaning there 
should be positive relationship between these measures (Turner, Wheaton, & Lloyd, 1995). Moreover, 
while subjective stress, stress response, and depressive and anxiety symptoms all have the potential to 
contribute to drug craving, seeking, and use (though not always uniformly), they can also develop as a 
result of these and other drug-related conditions (e.g., withdrawal, exposure to drug-related cues) (Epstein 
et al., 2009; Mantsch, Baker, Funk, Lê, & Shaham, 2016; Shaham & Stewart, 1995; Sinha, Fuse, Aubin, & 
O'Malley, 2000; Sinha & Li, 2007). Regular drug use, and certainly addiction, can be conceptualized as a 
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protracted state of chronic stress (i.e., allostasis), the body working to maintain homeostasis and the person 
taking more drugs in response (George, Le Moal, & Koob, 2012; Koob, 2008; 2009).  
Whereas rates of misregulation were lowest among participants who reported other drug use, rates 
were highest among participants who reported concomitant use prior to incarceration and were associated 
with increased odds of concomitant, opioid, and stimulant use during this same time. This suggests that 
among these groups, at least one decision to use drugs during the 30-day period prior to incarceration 
involved a specific intention of trying to mitigate negatively valanced states, as the variable 
“misregulation” reflected the use of drugs as an attempt to “reduce stress, anxiety, worry or fear”, possibly 
because participants believed these drugs would produce an ameliorating effect, despite overall risk of use 
(Baumeister & Heatherton, 1996; Doweiko, 1999). The association between stress, craving, and drug use, 
including relapse, is well documented (Mulia et al., 2008; Hyman et al., 2007; Preston & Epstein, 2011; 
Sinha, 2008, 2012). Decisions to use drugs as a form of “self-medication” are not uncommon and may not 
necessarily be considered, under the right conditions, as irrational, per se, even if, over time, the utility 
associated with a drug has the potential to decrease, the states that the drug was used to alleviate have the 
potential to intensify, and additional drug-related problems have the potential to develop as a result of 
continued “self-medication” (for differing viewpoints on this topic see Becker & Murphy 1988, Darke, 
2013; Khantzian, 1997, 2013; Tomer, 2001). Because costs of drug use are often delayed and uncertain, but 
because unpleasant anticipatory states, such as anxiety or fear, are certain, experienced in the moment, 
means that opioids and stimulants would likely have been weighted differently compared to non-drug 
choices for which ameliorating or otherwise rewarding effects may not have been either immediate or 
certain (Bickel et al., 2007; Green, Myerson, & McFadden, 1997). For these participants experiencing 
negatively valanced states, the local utility of opioids and stimulants may have simply been higher than 
other options. With drugs selected in an attempt to reduce unpleasant states, use might be considered 
utilitarian rather than hedonic (O'Curry & Strahilevitz, 2001).  
Subsequent to incarceration, rates of psychiatric symptoms were still most prevalent among 
participants who reported concomitant use, followed by participants who reported stimulant use. For both 
groups, depressive symptoms were associated with increased odds of use. Among participants who reported 
past-year heroin use specifically, rates of past-year depressive symptoms were far higher than those of 
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participants who did not use heroin. Suicidal ideation was still highest among those who reported 
concomitant use, followed by those who reported stimulant use. Interestingly, past-year suicidal ideation 
was over twice as high among participants who reported heroin use, with suicidal ideation associated with a 
154% increase in odds of observing heroin use. Again, participants who reported other drug/no drug use 
subsequent to incarceration had the lowest rates for all symptoms, including lowest rates of suicidal 
ideation.  
As noted in Chapter 2, depression and anxiety symptoms can influence cognition, present-bias, 
risk assessment, goal pursuit, intertemporal choice, and the degree to which outcomes are rewarding or 
punishing (Dias-Ferreira et al., 2009; Furman et al., 2013; Gohier et al., 2009; Harvey et al., 2004; Lerner, 
Li, & Weber, 2012; Marazziti et al., 2010; Nebes et al., 2000; Schulz & Vögele, 2015; Pulcu et al., 2013; 
Schwabe & Wolf, 2013; Scott et al., 2015; Shackman et al., 2006; Wittmann & Paulus, 2008). However, 
there is insufficient evidence to suggest that anxiety or depressive symptoms influenced opioid and 
stimulant use among participants in this sample in any definitive way. Still, one idea of interest is that 
depression may contribute to a person being more present-biased due to the fact that they perceive time 
passing more slowly, have diminished capacity to feel sufficiently attached to notions of their future self, or 
to believe that affective states experienced during depressive episodes will ever be other than they currently 
are (Bschor et al., 2004; Dombrovski et al., 2011). This unpleasant myopic orientation to the present has 
been described poignantly among people who have experienced depression (Soloman, 2014; Styron, 2010). 
That suicidal ideation was highest among participants who reported concomitant use prior and subsequent 
to incarceration, and who reported heroin use subsequent to incarceration, suggests that for a portion of 
opioid and stimulant users in this sample the idea of a future self might have been not only less salient and 
less behaviorally motivating during decision-making, in that delayed outcomes of use may not have been 
expected to be cashed in. Choosing to use drugs may in some circumstances be regarded as an act of willful 
destruction, in which the potential for adverse consequences in the short- and long-term is fully known; in 
the extreme, this may extend to self-harm and suicide (Flanagan, 2016; Pickard & Ahmed, 2016; Oquendo 
& Volkow, 2018). If future consequences are not only more difficult to envision, but also something that a 
person might not expect to be alive long enough to experience, then risk and utility beyond the present 
moment lose coherent meaning. For a small minority of participants, use of these high-risk drugs may have 
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even been considered as a possible means to an end, as intentional drug overdoses are a real, if all-too 
underexplored, phenomena (Austin, Proescholdbell, Creppage, & Asbun, 2017; Brådvik, Frank, Hulenvik, 
Medvedeo, & Berglund, 2007; Heale, Dietze, & Fry, 2003; Roxburgh et al., 2017).  
Indirect Indicators of Cognitive Functioning 
 Just under one-third of the entire sample reported a LD diagnosis or SE enrollment history, with 
no observed difference between groups. Rates of self-reported cognitive difficulties (e.g., difficulties 
understanding, concentrating, and remembering) that occurred during the one-year period subsequent to 
incarceration were highest among participants who reported concomitant use and lowest among 
participants who reported other/no drug use. Past-year cognitive difficulties increased the likelihood of 
concomitant use during the one-year post-release period by approximately 50%. As neurocognitive 
impairments and indicators of executive dysfunction commonly associated with poorer decision-making 
and inhibitory control are found among people with a history of opioid and stimulant use, it is unsurprising 
that participants who reported concomitant use had higher rates of poorer cognitive functioning compared 
to participants who reported less drug use. Unfortunately, the question pertaining to past-year cognitive 
difficulties asked as part of the follow-up survey did not appear on the baseline survey. It is possible that 
participants who reported concomitant use prior to incarceration would also have had high rates of self-
reported cognitive difficulties.   
Participants who reported concomitant use both prior and subsequent to incarceration had the 
highest rates for history of head trauma as well, whereas rates were again lowest among participants who 
reported other drug use prior to incarceration. That both history of head trauma and past-year cognitive 
difficulties were represented at higher rates among participants who reported more versatile and severe 
drug use provides further indirect support for the idea that indicators of poorer cognitive function may 
correspond to greater impulsiveness and risk-taking, and decreased capacity for advantageous decision-
making during intertemporal choice. However, findings cannot explicate causality, meaning that poorer 
cognitive functioning could have pre-dated opioid and stimulant use, or developed as a result of use.  
Chronic Pain 
 Chronic pain rates were highest among participants who reported concomitant and opioid use prior 
and subsequent to incarceration. As discussed in earlier chapters, chronic pain can significantly alter and 
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impair cognitive functioning and contribute to less adaptive decision-making (Apkarian et al., 2004; 
Elvemo, et al., 2017; Landrø et al., 2013; Walteros et al., 2011). Experiencing chronic pain may also 
increase the perceived value of opioid drugs due to their analgesic properties (Trescot, Datta, Lee, & 
Hansen, 2008). Although rates of chronic pain were higher among participants who used opioids, including 
concomitantly with stimulants, chronic pain was, somewhat unexpectedly, not associated with increased 
odds of opioid or concomitant use either prior or subsequent to incarceration. No differences in chronic 
pain rates were observed between participants who reported heroin use subsequent to incarceration and 
those who did not. It is possible, then, that chronic pain may correspond to use of specific types of opioids, 
but not opioid use more generally. Additional examination (results not displayed) of differences in chronic 
pain by heroin, prescription opioid, and buprenorphine use revealed that chronic pain rates differed for 
prescription opioids, with slightly more participants who reported chronic pain prior (64.2% vs. 53.1%, 
X2=13.0, p<.001) and subsequent to incarceration (17.7% vs. 12.7%, X2=6.3, p=.014) reporting prescription 
opioid use; though no statistically significant differences were found for heroin or buprenorphine.  
People who experience chronic pain experience pain symptoms that can increase or decrease in 
severity over a period of time, with some non-cancer chronic pain conditions having the potential to 
continue for years or an entire lifetime (Fine, 2011; Goldberg & McGee, 2011). Given this, it is possible 
that participants who reported chronic pain had previously been prescribed opioids for pain symptoms. 
Particularly for pain that was treated prior to revised opioid prescribing guidelines and prior to 2012, when 
opioid prescriptions per 100 persons peaked in the US (CDC, 2019). Subsequent analysis revealed that 
4.2% of participants who reported illicit drug use prior to incarceration also reported that they were 
introduced to drugs by a doctor or physician, meaning that illicit opioid use, dependence, or addiction may 
have been iatrogenic for some participants (Ballantyne & LaForge, 2007; Keller et al., 2012). Prior 
exposure to prescription opioids, even if initially used as prescribed and not misused, has the potential to 
contribute to dependence or OUD (Cerdá, Santaella, Marshall, Kim, & Martins, 2015; Edlund et al., 2014; 
Volkow & McLellan, 2016). In general, people with OUD are often undertreated for their pain symptoms 
and routinely encounter stigma, discrimination, and other obstacles in accessing medical care (Baldacchino, 
et al.2010, Dunn et al., 2014; Hines et al., 2008; Karasz et al., 2004; Rosenblum et al., 2003; van Boekel, 
Brouwers, van Weeghel, & Garrestsen, 2013; van Boekel, van Weeghel, & Garrestsen, 2014). Under such 
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conditions, participants with OUD who experience chronic pain might continue to use prescription opioids 
illicitly to self-treat their pain symptoms in addition to other reasons (e.g., producing a euphoric effect, 
relieving withdrawal symptoms) (Cicero, Lynskey, Todorov, Inciardi, & Surratt, 2008; Leukefeld, Walker, 
Havens, 2007). The local utility of opioids for such participants would likely be extremely high, and the 
long-term risks of use not weighted similarly.  
Scarcity and Economic Hardship 
Participants who reported past 30-day concomitant and opioid use prior to incarceration 
experienced a greater number of economic hardships on average during the one-year period prior to 
incarceration, with the former reporting double that of participants who reported other drug use. Similarly, 
rates of having experienced past-year homelessness were twice as high among participants who reported 
concomitant use compared to those who reported other drug use. This association may not be surprising, 
insofar as homelessness is associated with psychiatric health symptoms, history of head injury, and greater 
drug use severity (Galea & Vlahov, 2002; Lafferty, 2010; Oddy, Moir, Fortescue, & Chadwick; 2012; 
Watson Crawley, & Kane, 2016). While disruption in economic stability can produce a scarcity mentality, 
in which cognition, valuation, and decision-making abilities become impaired, homelessness may be 
considered an extreme form of scarcity, as it involves protracted uncertainty and hardship in addition to 
having fewer tangible resources and social supports (Mani et al., 2013; Phelan, Link, Moore, & Stueve, 
1997; Hwang et al., 2009; Shah et al., 2015). Homelessness is associated with a low social rank and 
stigmatized status, which can influence psychiatric functioning among people experiencing homelessness 
(Caton, Wilkins, & Anderson, 2007; Link, Struening, Rahav, Phelan, & Nuttbrock,1997; Roschelle & 
Kaufman, 2004; Skosireva et al., 2014). Additionally, homelessness reflects a state in which basic needs 
are unmet, or under threat of not being met, and in which existential uncertainty is elevated due to greater 
exposure to unsafe conditions. Taken together, experiencing homelessness has similar characteristics of 
living in a harsh environment, and has the potential to not only produce an acute stress response, but also to 
keep states of arousal sustained at elevated levels over a period of time (Frankenhuis et al., 2016). Present-
bias and reflexive decision-making would likely increase under these uncertain conditions, with cognition 
directed toward the capture of certain and immediate, versus uncertain and delayed, reward (Frankenhuis et 
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al., 2016; see also optimal foraging theory: Abarca & Fantino, 1982; Brown, Laundré, & Gurung, 1999; 
Kagel et al., 1986).  
During the one-year period subsequent to incarceration, participants reported their total income 
(before taxes) from all sources for the 30-day period prior to completing the follow-up interview. This 
means that most participants would have been out of jail or prison for approximately 10-14 months when 
this income was reported. Past 30-day income was low sample-wide, with $1,290 the average income 
before taxes; approximately $15,480 annually. Assuming that this was taxable income, which is not the 
case for some types of reported income (e.g., SNAP benefits, Social Security Insurance), average monthly 
take-home pay was $1,049, or approximately $12,588 annually, just $448 above the Federal Poverty 
Guideline for a household of one (U.S. Department of Health and Human Services, 2019). However, the 
mean number of people who were listed as being dependent on this income was 2.1 (range 0-6), meaning 
that some participants may have been living below the Federal Poverty line. Because participants were not 
asked to report income from other household members, such as a spouse or parent, a more precise estimate 
could not be made. It may be that other family members had high monthly earnings. What is known, is that, 
participant earnings were low overall and unemployment rates were high. These conditions would have had 
the potential to produce stress and a scarcity mentality, both of which can disrupt adaptive decision-making 
(Bratanova, Loughnan, Klein, Claassen, & Wood, 2016; Mani et al., 2013; Pearlin, Menaghan, Lieberman, 
& Mullan, 1981). Lower income subsequent to incarceration could have also influenced drug purchasing, 
by potentially restricting the overall flexibility with which participants could make purchasing decisions 
about preferred drugs and non-drug goods, as well as respond to short- and long-term changes in drug 
markets related to perceived drug quality, drug risk, and drug cost (Becker, Murphy, & Grossan, 2004; 
Carroll & Rodefer, 1993; Goudie et al., 2007; Ornstein & Levy, 1983; Petry, 2002). Though past-month 
income was lowest among participants who reported past-year concomitant use subsequent to incarceration 
and highest among those who reported other/no drug use, the low income across groups makes it difficult 
to discern the extent to which income may have influenced drug-related decision-making differentially 
across groups, given that the lower income associated with concomitant drug use was marginal. 
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Subjective Socioeconomic Status  
The average perceived subjective socioeconomic rank that participants reported was 5.0, though 
for participants who reported past 30-day concomitant or opioid use prior to incarceration, it was slightly 
below that. Differences in rank were statistically significant, but it is unclear if there are substantive 
differences between groups, as lower perceived subjective socioeconomic status was not associated with 
changes in odds for any outcome. Considering that participants in this sample believed, on average, that 
they were ranked--in terms of education, money, desirable employment-- below approximately one-half of 
the rest of society, but above approximately another one-half, means that, similar to all people, participants’ 
stress response and cognition likely varied dynamically as a function of context, engaging in downward or 
upward social comparison, increased or decreased vigilance, and arousal or ease depending on the social 
context (Collins, 1996; Fiske & Taylor, 2013; Kraus, Horberg, Goetz, & Keltner, 2011 Taylor & Lobel, 
1989). Examining the frequencies of responses for this variable showed that 35.3% of the sample reported a 
rank 4<, meaning that a subgroup of participants perceived themselves as having a lower perceived 
socioeconomic status11.  
Across the life course, lower actual and perceived social and/or economic status is associated with 
poor physical (e.g., increased cortisol, impaired immunological function) and psychological health (e.g., 
anxiety), higher stress, and impairments in executive function (Abbott et al., 2003; Adler et al., 2000; Derry 
et al., 2013; Hackman, Farah, & Meaney, 2010; McEwen & Gianaros, 2010; Ursache, Noble, & Blair, 
2015; Wilkinson & Pickett, 2003). Though differing somewhat between stable and unstable social 
hierarchies and populations, being and/or perceiving oneself as lower-ranking (or subordinate) in a social 
hierarchy is often associated with increased stress response and less adaptive neurocognitive functioning, 
whereas being higher ranking (or superordinate) is associated with decreased stress response and more 
adaptive neurocognitive functioning (Gesquiere et al., 2011; Noonan et al., 2014; Sapolsky, 2017; Sallet et 
al., 2011). Even a rank of 5, indicating perception of oneself as lower than half of all others in a society 
where higher socioeconomic status is associated with increased power, opportunity, prestige, and social 
worth, would have had the potential to contribute to negatively valanced states and increased stress 
 
11 A breakdown of this 35.3% of participants: 6.7% reported a rank of 1, 5.0% reported a rank of 2, 10% 
reported a rank of 3, and 13.6% reported a rank of 4.  
 231 
response, particularly during interaction with a supraordinate, all of which could have influenced cognition 
and behavior related to drugs, including increased drug taking and relapse (Caldwell & Riccio, 2010; 
Covington et al., 2005; Covington & Miczek, 2001; Cruz, Quadros, Hogenelst, Planeta, & Miczek, 2011; 
Do Couto et al., 2006, 2009; Weiss, 2005).  
That the entire sample is comprised of corrections-involved people with a history of drug use 
means that some participants may have experienced social, affective, cognitive, and physiological effects 
associated with lower status in respect to these stigmatized characteristics, as both groups are openly 
castigated and routinely experience discrimination, rejection, and marginalization (Fiske, 2005; Moore, 
Tangney, & Stuewig, 2016; Harris & Fiske, 2007; Major, Dovidio, & Link, 2017; Pachankis et al., 2017). It 
is possible that had participants been asked to rank their perceived socioeconomic status  during the one-
year period subsequent to incarceration that mean ranks would have decreased across groups as a result of 
having a stigmatized “felon” status, which was not necessarily the case for all participants prior to 
incarceration (Behrens, 2004; Copenhaver, Edwards-Willey, & Byers, 2007; Moore, Stuewig, & Tangney, 
2013, 2016).  
Non-drug Alternative Reinforcers 
Social Satisfaction and Social Worth 
Participants did not differ either prior or subsequent to incarceration in terms of social interaction, 
with >80% participants reporting spending the majority of their free time in some social capacity (e.g., with 
friends or family). Participants who used other drugs and stimulants during the 30-day period prior to 
incarceration had, on average, a greater number of close relationships and also reported receiving greater 
satisfaction from these relationships. It may be of some interest that stimulants, alcohol, and cannabis, used 
at high rates among these groups, are more often conceptualized as social or “party” drugs compared to 
opioids, meaning that some drug use among these groups may have been social (Freese, Miotto, & Reback, 
2002; Green, Pickering, Foster, Power, & Stimson; 1994; Waldorf et al.,1992).  
Reported social satisfaction was lower among participants who reported past 30-day concomitant 
and opioid use, with both groups also having slightly fewer close relationships on average. Although 
receiving satisfaction from social interaction was not associated with a change in odds of observing 
concomitant, opioid, or stimulant use prior to incarceration, receiving satisfaction from social interaction 
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was associated with a 50-60% decrease in the likelihood that concomitant, opioid, and stimulant use during 
the one-year post-release period would be observed. This was found when examining past-year heroin use 
as well; the odds of heroin use decreased by approximately 59% when social satisfaction was reported.  
Sample-wide, the average number of close relationships decreased from 7.1 prior to incarceration 
to 6.1 subsequent to incarceration. While it is possible that fewer available non-drug choices, such as close 
relationships, may have contributed to drug use initiation and continued use, it is also possible that as a 
result of continued drug use and incarceration the real and perceived number of non-drug alternatives 
needed to help reinforce behavior away from continued drug use declined (Ahmed et al., 2010; Bickel et 
al., 2014; Lenoir & Ahmed, 2008; Staton-Tindall, Royse, & Leukfeld, 2007). As noted earlier, one possible 
result of continued drug use is that the number of avenues for pursuing non-drug opportunities decreases, as 
does the degree of support received from others. It can be challenging to be in a relationship with a person 
who continues to use high-risk drugs, in part due to the higher level of social dysfunction found among 
regular drug users (Cunha, Bechara, de Andrade, & Nicastri, 2011). As use persists, relationships, which 
may in some cases have already been defined by dysfunction or discord, can become strained further, less 
satisfying, and possibly terminated (Collins et al., 2007; Mowen & Visher, 2015; Wallace et al., 2016). 
Fewer, and poorer quality, relationships would decrease some of the opportunity costs associated with 
continued use. This idea is partially reflected by the negative relationship observed between receiving 
satisfaction from social interactions and high-risk drug use that occurred during the one-year period 
subsequent to incarceration. 
In addition to having the highest number of relationships on average subsequent to incarceration, 
participants who reported other/no drug use had the highest rates of social worth, meaning that a greater 
proportion of this group reported feeling “valued, supported, and cared about” by other people in their life 
compared to other groups. Conversely, participants who reported concomitant use subsequent to 
incarceration, who had the fewest close relationships on average, reported the lowest rates of social 
satisfaction. Although a majority of all groups reported feeling at least “somewhat” cared about or 
supported by people in their lives, the fact that rates differed by groups who reported more or less use helps 
to articulate the idea that family and friends may be less willing to remain invested in and supportive of 
people who continue to use high-risk drugs and also the idea that people who feel less cared about and 
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supported by others may come to believe that they have fewer reasons to moderate opioid and stimulant use 
and fewer avenues for accessing help. As noted earlier, positive social interaction can have a powerful 
influence on a person’s perceived sense of well-being, psychological health, and cognitive functioning, 
whereas social isolation, social exclusion, withdraw of social support, and other forms of social stress can 
produce cognitively damaging effects along with increases in drug craving and use (Abbott et al., 2003; 
Cole et al., 2011; Stein, van Honk, Ipser, Solms, & Panksepp, 2007; also see Heilig et al., 2016 for further 
discussion).  
Education, Employment, and Leisure Time 
Past-year educational and/or vocational involvement was similar across all drug use outcome 
groups prior and subsequent to incarceration. Although post-incarceration rates of employment are often 
higher than pre-incarceration rates among corrections-involved samples, educational/vocational 
involvement increased by only 2.0% between time periods, even though alcohol and other drug use 
decreased substantially, perhaps suggesting that participants’ felony status made obtaining employment and 
entry into post-secondary education more challenging (Copenhaver et al., 2007; Duwe & Clark, 2017; 
Flake, 2015; Halkovic et al., 2013; Lam & Harcourt, 2003; Pager, 2003). This is a particularly compelling 
possibility given that the period subsequent to incarceration was after the 2007 economic crisis had 
stabilized, a time when the unemployment rate in Kentucky decreased annually from 8.4% in January 2012 
to 4.4% in December 2017 (U.S. Bureau of Labor Statistics, 2019).  
That a majority of participants who reported concomitant, opioid, and stimulant use both prior and 
subsequent to incarceration were employed or otherwise engaged in educational pursuits during the same 
time period raises the important point that drug use, licit or illicit, is not always mutually exclusive with 
other behaviors (Kowalski-McGraw, Green-McKenzie,  Pandalai, & Schulte, 2017; Tiesman, Konda, 
Cimineri, & Castillo, 2019). Potentially rewarding non-drug alternatives, such as work and education, 
comprise activities, as does drug use, meaning that they are extended over time and are comprised of many 
temporally connected choices and behaviors (Baum, 2004). Many behaviors must be executed in a 
particular order prior to and during an activity, such as “going to work” and “being employed” or “using 
amphetamines” (Baum, 2004; Rachlin, 1995). Drug use, over a day or year, can be chosen or not chosen at 
different intervals, meaning that it can be avoided or approached in terms of trade-offs with family 
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obligations, employment, school, or other roles (Waldorf et al., 1992). A person may therefore choose to 
use amphetamines to excess, miss work or school, but then subsequently choose to put in extra hours or 
effort at work or school to offset this earlier decision to binge. For some participants, opioid and stimulant 
use might have continued to the point where the loss off a job or academic suspension from school became 
a credible threat or probable outcome, making them, at that point, mutually exclusive choices. That such 
patterns could not be discerned in this study, makes it an important avenue of investigation in future work.  
Labor as Labor, and the Indignity of Work 
An important possibility not to overlook is the fact that work may influence a person’s willingness 
or desire to use opioids or stimulants. Although employment and educational involvement have been 
framed in terms of potentially rewarding non-drug alternatives, it may be that for some participants in this 
sample neither work nor school were associated with anything rewarding, and not contemplated of in terms 
of feeling more vested in their everyday lives and future. Instead, it may be that employment was simply an 
unpleasant means to achieving some meager economic end or fulfilling a stipulation of community 
supervision (Gurusami, 2017; Travis & Stacey, 2010). Because jobs are demanding and can be perceived, 
particularly by people with lower socioeconomic status, as something over which they can exert little 
control, means that employment can also be considered a possible source of stress (Kunz-Ebrecht, 
Kirschbaum, & Steptoe, 2004). That work is hard and not always rewarding should also not be overlooked. 
It is possible that the labor expended by participants in this sample was disproportionate to social and 
economic gains. Rather than contributing to participants’ feeling as though they have “stake in the 
conventional life”, disparities between effort and compensation may have, for some, produced a sense of 
disillusionment (Buck, 2001; Kahn, 2018; Shipler, 2005; Waldorf et al., 1992).   
The histories of drug use and labor are indeed closely linked. The term “skid row” originates from 
logs being “skidded” toward lumber mills along stretches of road in the Pacific Northwest, where the 
supply of alcohol, opium, and other drugs proliferated to serve the many timber laborers who resided in the 
area and who routinely worked themselves to exhaustion under difficult conditions (Keniston-Longrie, 
2009). Prior to incarceration, participants who reported past 30-day other drug use reported having more 
leisure days on average on a given week in which they could pursue hobbies or other activities of interest to 
them, whereas participants who reported past 30-day concomitant use had the fewest, even though the rate 
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of educational and/or vocational involvement between these two groups was similar. This means that 
having fewer leisure days was associated with overall greater drug use. Stimulant and opioid use as a form 
of misregulation may not be uncommon among employed people, particularly among people employed in 
physically and psychologically taxing, or otherwise tedious and dangerous, occupations, in which reducing 
pain and increasing stamina can be central to a person’s ability to work or to work longer hours (Anglin, 
Burke, Perrochet, Stamper, & Dawud-Noursi, 2000; Dalla, Xia, & Kennedy, 2003;  Gibson, Leamon, & 
Flynn, 2002). Indeed, some decisions to use opioids and stimulants may have been influenced by a 
perceived need to function or enhance performance in vocational or educational roles (Ahmad & Aziz, 
2012; Arria et al., 2018; Dalla et al., 2003; Liu, Elliott, Striley, Gurka, & Cottler, 2019). 
 For participants without a high school or college degree, and particularly after a felony record was 
established, it is possible that many of the occupations that they were engaged in were challenging, 
exhausting, stressful, and associated with lower prestige, compared to people with high school and college 
degrees and no criminal record (Bridgeland, DiIulio, & Morison, 2006; Liker, 1982). Labor exploitation 
(e.g., forced day labor, temporary employment, percentage cut of hourly pay) among people with criminal 
histories, including among people on community supervision, is not uncommon (Elcioglu, 2010; Purser, 
2012) and is reflected in some routine practices among US companies (e.g., PeopleReady, LaborReady) 
(Capstone Law, 2019; Theirman Buck Law Firm, 2019). It is not inconceivable, then, that some 
participants may have found it difficult to feel a sense of reward from working at Wal-Mart, picking up 
garbage, or toiling in a factory, let alone to achieve the feeling of having “a stake in the conventional life”, 
and therefore more vested in their everyday life. The idea of working at Wal-Mart for the rest of one’s life, 
assuming that working at Wal-Mart is not a person’s life ambition, may contribute to depression or anxiety, 
feelings of resentment and disenfranchisement from the wealth of society in which they do not equitably 
share despite their hard work, and feelings of estrangement from their own future (Kraus et al., 2011; 
Shipler, 2005). Having a job in which one knows that they are easily replaceable, as is the case with almost 
all menial work in the US, also has the potential to create a sense of uncertainty. A belief that a bleak 
present will not give way to a brighter future may have the capacity to increase decisions to use high-risk 
drugs in the present (Buer et al., 2016). “Deaths of despair”, which include premature mortalities associated 
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with drugs, have increased in the US, particularly among men without college degrees in economically 
depressed areas with high drug accessibility (Ruhm, 2019; Stein et al., 2017).  
Central Appalachia 
Central Appalachia is a geographic region spanning four states, Western North Carolina, Eastern 
Tennessee, Eastern Kentucky, and all of West Virginia. Fifty-four of Kentucky’s 120 counties comprise 
part of this Central Appalachian region (ARC, 2019). Central Appalachia, and Eastern Kentucky in 
particular, have experienced historic disadvantage compared to other areas of the US and continue to 
experience economic and social hardship and collective uncertainty about the future (Billings & Blee, 
2000; Eller, 2008; Greenberg, 2018; Hayes, 2018; Mather, 2004). There remain significant psychological 
and physical health disparities between Eastern Kentucky and the rest of the state, as well as the rest of the 
country (Crosby, Wendel, Vanderpool, & Casey, 2012; Hendryx, 2010). These are reflected by 
significantly higher rates psychological, developmental, and learning disorders, SUDs (including for 
nicotine), chronic illness, chronic pain conditions, cancer, obesity, and disability (Herath & Brown, 2013; 
Lane et al., 2012; Pugh, 2014;  Rodriguez, Vanderford, Huang, & Vanderpool, 2018; Schoenberg, Huang, 
Seshadri, & Tucker, 2015). In Eastern Kentucky counties, the life expectancy is 9-12 years younger than 
counties in other parts of the state; between 2014 and 2017 the average life expectancy actually decreased, 
despite Kentucky’s adoption of Medicaid expansion under the ACA, which increased access to care for 
many in the region (University of Wisconsin Population Health Institute, 2019). These disparities are 
partially attributable to greater difficulties in accessing preventative medical services or interventions, 
including for SUD (Hill, Cantrell, Edwards, & Dalton Sexton, Carlson, 2016; Leukefeld, Booth, 2008; 
Patrick et al., 2018; Staton-Tindall et al., 2015).  
However, some disparities may also be attributable to economic conditions in the region, as 37 out 
of the 54 Kentucky counties within Central Appalachia are economically distressed (ARC, 2018). These 
counties rank in the bottom 10% of all counties in the US in terms of poverty and employment (ARC, 
2018). Nationally, the poverty rate between 2011-2016 was approximately 16%, whereas for Central 
Appalachian Kentucky counties during this same time period, it was approximately 26%; in 2015, per 
capita income in these counties was $19,204, sharply lower than the national per capita income of $39,778. 
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For these reasons, Appalachian Kentucky may be conceptualized as a “harsh” environment (Frankenhuis et 
al., 2016; Meit et al., 2017). 
Carpe Diem  
Beyond the fact that these conditions may contribute to a scarcity mentality, residing in a harsh 
environment, such as Central Appalachia, has the potential to decrease opportunities for accessing 
rewarding non-drug alternatives, particularly when they require more effort or cost to obtain (e.g., needing 
to drive long distances, but not having a vehicle). Residing in a more rural part of Central Appalachia may 
present unique barriers for accessing non-drug alternatives, such as higher education, employment and 
economic advancement, civic organizations, sports clubs, mutual aid groups, and many types of leisure 
activities ubiquitous in urban and suburban areas (Buck, 2001; Denk, 2019; Nelson & Smith, 1999; Petry et 
al., 2001). Residing in a harsh region characterized by wide-spread hardship, premature mortality, restricted 
opportunity, and overall greater uncertainty about the future, would have had the potential to influence 
participants by increasing present-bias and decreasing risk-aversion in order to facilitate the immediate 
capture of rewards despite risk (Frankenhuis et al., 2016; Pepper & Nettle, 2013; Smith & Tickamyer, 
2011). Though the future is always uncertain, and therefore less motivating when making decisions in the 
present, for participants in Central Appalachia, this uncertainty may be perceived as even greater. Why wait 
to enjoy something that may never materialize, when relief can be found in the present? In this way, living 
in a harsh environment might also engender propensity toward misregulation, with opioids and stimulants a 
possibly appealing anesthetic to bleak conditions (Buer et al., 2016).12 
12 Interestingly, factors that might be expected to differ between participants who resided in Central 
Appalachian and those who did not (e.g., chronic pain, misregulation, depressive symptoms, suicidal 
ideation) evidenced very few statistically significant between-group differences when examined (results not 
displayed). One difference, though, included higher unemployment among participants who resided in 
Central Appalachia prior (41.4% vs. 30.8%, X2=18.0, p<.001), but not subsequent to incarceration (38.7% 
vs. 34.6%, X2=2.1, p=.146). Other modest differences, though not statistically significant, were reflected by 
the fact that past 30-day income among participants who resided in Central Appalachia was slightly lower 
($1,194 vs. $1,332, t=1.43, p=.109) and that a greater average portion of income was received through 
Social Security Disability Insurance benefits ($862 vs. $792, t=.671, p=.503). Participants who resided in 
Central Appalachia reported having more close relationships subsequent to incarceration (6.7 vs. 5.9, 
t=2.30, p=.022), though groups were approximately equal for the year prior to incarceration (7.0 vs. 7.1, 
t=1.79, p=.858). While there were no between-group differences for rates of feeling cared about or 
supported by others, there were differences for social interaction subsequent to incarceration, with a larger 
proportion of participants who resided in Central Appalachia reporting that they spent more free time with 
others, versus alone (91.1% vs. 87.2% , X2=4.5, p=.033). Participants who resided in Central Appalachia 
during this same time also reported higher rates of social satisfaction (92.8% vs. 87.0%, X2=9.93, p=.002).  
 238 
Additional analyses (results not displayed) showed that participants differed across several drug-
related variables depending on whether they resided within or outside of Central Appalachia. Participants 
who resided in Central Appalachia were more versatile users, using a greater number of different drugs on 
average during the one-year periods prior (4.1 vs. 3.6, t=2.7, p=.007) and subsequent (1.5 vs. 1.2, t=2.44, 
p=.011) to incarceration, had higher drug use severity scores (25.2 vs. 22.3, t= 3.4, p<.001), and had higher 
rates of being intoxicated at the time that they committed their offense (81.5% vs. 76.6%, X2=4.39, p=.036). 
Older average age of drug use initiation, however, was found among participants who resided in Central 
Appalachia (15.1 vs. 14.5, t=2.31, p=0.20). Participants who resided in Central Appalachia had higher rates 
of IDU history (56.6% vs. 37.0%, X2=50.6, p<.001), though rates of IDU reported subsequent to 
incarceration were equivalent (7.2% vs. 10.8%, X2=2.64, p=.881). Because of the difference in IDU history 
by Central Appalachia residence, infectious disease was also explored. Participants who resided in Central 
Appalachia prior to incarceration were significantly more likely to report having Hepatitis C (15.3% vs. 
7.1%, X2=22.6, p<.001), though no participants who resided in Central Appalachia reported having HIV.  
As presented in Chapter 4, a greater proportion of participants who reported opioid use prior and 
subsequent to incarceration resided in Central Appalachia, whereas a greater proportion of participants who 
reported stimulant use resided outside of Central Appalachia. This relationship was evidenced further by 
the finding that Central Appalachian residence prior to incarceration was associated with a 64% increase in 
odds of past 30-day opioid use and a 37% decrease in odds of past 30-day stimulant use. Subsequent to 
incarceration, Central Appalachian residence was associated with a nearly 117% increase in the likelihood 
of past-year prescription opioid use. Heroin and cocaine/crack cocaine were used at lower rates among 
participants residing in Central Appalachia, potentially reflecting overall greater availability and use of 
these drugs in urban areas (Habecker, Welch-Lazoritz, & Dombrowski, 2018; Jalal et al., 2018). Odds of 
observing past-year heroin use decreased by approximately 62% subsequent to incarceration by Central 
Appalachian residence. At both time periods, rates of prescription opioid and buprenorphine use were 
higher among participants residing in Central Appalachia, potentially attributable to the significantly higher 
per 1,000 rates of opioid and buprenorphine prescribing found in Eastern Kentucky and wider-spread 
acceptability of prescription opioid use found in rural areas of Kentucky (Havens, Talbert, Robert, Cynthia, 
& Leukefeld, 2006; CHFS, 2019; Havens, Young, Havens, 2011). Amphetamine use did not differ 
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significantly between Appalachian and non-Appalachian regions, suggesting that this drug may be equally 
accessible, or manufacturable, across regions (Weisheit & Brownstein, 2016; Sexton, Carlson, Leukefeld, 
& Booth, 2006; Stoops et al., 2011). That amphetamine drugs include both “street meth” as well as 
prescription stimulants means that it is also possible that some amphetamine use among participants who 
resided in Central Appalachia was attributable to diverted prescription stimulants, though this may have 
only accounted for a small portion of stimulant use and may have been more common among younger 
participants (Cassidy et al., 2015; Kroutil et al., 2006). 
Kentucky counties in Central Appalachia are predominately rural, meaning that they are not 
proximate to major urban drug markets, such as Louisville or Cincinnati, which borders Kentucky and 
continues to be a source of heroin for Northern and Central Kentucky (Stewart, Cao, Hsu, Artigiani, & 
Wish, 2017).13 Accessibility to drugs based on urban influence was highlighted by some of the findings in 
this study. For instance, prior to incarceration, rates of prescription opioid use were highest among 
participants who resided in more rural counties compared to heroin, which was used at higher rates among 
participants who resided in urban counties. Subsequent to incarceration, rates of heroin use were still 
highest among participants who resided in urban counties and prescription opioids, while still used at high 
rates in rural areas, decreased from pre-incarceration rates, likely reflecting decreases in opioid prescribing 
that began in 2012. Buprenorphine was used at higher rates in rural areas during the period prior to 
incarceration, but not subsequent. Heroin availability and use continues to increase in rural Appalachia, but 
during the time that data were collected was simply less available than prescription opioids and other drugs 
(Cloud, Ibragimov, Prood, Young, & Cooper, 2019; Moody, Satterwhite, & Bickel, 2017).  
As noted in earlier chapters, accessibility has the potential to shape drug preferences, not only 
because it exposes a person to a drug more regularly, thus increasing the probability of use and later 
possible dependence, but also because it decreases the effort needed to obtain the drug. Driving 80 miles to 
buy heroin costs more in time, effort, energy, and risk for contact with law enforcement then driving 10 
miles to buy prescription opioids. It may be that among participants who resided in Central Appalachia, 
proximity to drugs was an influence on decision-making and the development of drug preferences. This is 
13 The mean urban influence for non-Appalachian counties was 3.1, whereas the mean urban influence for 
Appalachian counties was 7.7 (range=1-12). 
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partially reflected by the fact that rates of county-wide opioid and buprenorphine prescribing were higher in 
Central Appalachia during the time periods examined in this study, and that rates of prescription opioid and 
buprenorphine use were higher among participants who resided in these counties (CHFS, 2019). It is 
further reflected by the fact that prescription opioids (39.6% vs. 18.4%), buprenorphine (6.5% vs. 0.8%), 
and prescription sedatives (4.4% vs. 2.3%) were more often preferred among participants who resided in 
Central Appalachia, whereas heroin (4.8% vs. 12.1%), cocaine (5.2% vs. 10.3%), and alcohol (8.5% vs 
15.3%), were more often preferred among participants who resided outside of Central Appalachia 
(X2=164.2, p<.001). Unrestricted alcohol sales did differ significantly by residence within or outside of 
Central Appalachia, with the latter having overall greater access to unrestricted alcohol sales (72.8% vs. 
19.6%, X2=375.78, df=1, p<.001). This may account for slightly lower preference for alcohol. 
Amphetamines were preferred approximately equally across regions (15.1% vs. 15.2%) and used at similar 
rates across regions.  
Ambiguous Risk 
It is unclear, though, the extent to which participants’ decisions to use high-risk drugs 
meaningfully differed according to living within a harsh region, such as the Central Appalachian region of 
Kentucky. However, other studies have documented risky drug practices among people in Kentucky who 
reside in rural Appalachia and have found associations between high-risk drug use in this region and 
economic distress (Cloud et al., 2019; Havens, Oser, & Leukefeld, 2011; Staton-Tindall, Webster, Oser, 
Havens, & Leukefeld, 2015). Though Central Appalachia and other distressed rural areas continue to be 
associated with “deaths of despair”, hardship, and widespread uncertainty, there were also other factors 
present among participants who resided in Central Appalachia that could have influenced drug-related 
decision-making (Erwin, 2017; Meit et al., 2017; Segal et al., 2017; Woolf, Schoomaker, Hill, & Orndahl, 
2019). For instance, many participants who resided in Central Appalachia reported having close 
relationships, social interaction, and social satisfaction, which could all be considered as rewarding non-
drug alternatives.  
Still, drug use and involvement with family, friends, work, or other activities is not mutually 
exclusive, and it could be that some participants were interacting with friends, family, or intimate partners 
who also used high-risk drugs (Fleming et all., 2010; Havassy, Hall, & Wasserman, 1991; Mayock, Cronly, 
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& Clatts, 2015;  McCrady, 2004; Staton et al., 2018). Family-wide drug use and greater cultural acceptance 
of drug misuse is not uncommon in the Central Appalachian region of Kentucky (Jonas et al., 2012; Keyes 
et al., 2014; Leukefeld et al., 2007; Young, Havens, & Leukefeld, 2010). In fact, some rural, drug-using 
women in Appalachian Kentucky have reported feeling “stuck” to the region, other people within the 
region, and to prescription opioids as a fixture of the region and relationships, with myriad constraints on 
their ability to make different drug-related decisions (Buer, Leukefeld, & Havens, 2016).   
It should not be overlooked that some participants who resided outside of Central Appalachia 
resided in regions that, while not broadly and diffusely harsh, nevertheless may have contained 
concentrated harsh locales that influenced decisions to use opioids and stimulants (e.g., blocks, 
neighborhoods, zip codes) (Boardman, Finch, Ellison, Williams, & Jackson, 2001; Dear & Wolch, 2014;  
Schroeder et al., 2001; Stull et al., 2019). That participants did not differ by region for characteristics such 
as psychiatric symptoms, chronic pain, suicidal ideation, stress-related health effects, and financial distress 
may not discredit the notion that Central Appalachia constitutes a harsh region with the potential to 
influence cognition and choice, so much as lend support to the idea that participants who resided outside of 
Central Appalachia may have also resided in harsh urban and suburban areas. This is reflected by the fact 
that, compared to the general population, the entire sample had higher rates for many factors with the 
potential to unfavorably influence decision-making in relation to high-risk drugs. 
Overall, findings indicate that drug use may not have been necessarily or straightforwardly risker 
among participants who resided in Central Appalachia, but rather that it had a different tenor. Participants 
who resided in Central Appalachia did evidence overall greater drug use severity and versatility, using 
more drugs on average compared to participants who resided outside of Central Appalachia. These 
participants not only used prescription opioids with or contemporaneous to amphetamines, alcohol, 
prescription sedatives, buprenorphine, and to a lesser extent cocaine and heroin, but also reported 
significantly higher rates of IDU. That said, participants who resided outside of Central Appalachia also 
reported high rates of opioid and stimulant use, with heroin, perhaps the riskiest drug that could be used 
during the time periods explored in this study, used at higher rates. Considered together, and in 
combination with findings previously discussed, it may be reasonable to suggest that high-risk drug use is 
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endemic across the sample, even as it varied by time period, specific drug type, residence in or outside of 
Central Appalachia, and other factors already highlighted.  
 
Broader Implications and Future Directions 
 
The Road Back to Hell is Still Paved with Good Intentions 
 
The idea that guided this exploratory study is that there are many endogenous and exogenous 
factors with the ability to influence and constrain drug-related decision-making and behavior. This pertains 
to people before they choose to take their first drug and at all points thereafter. As prior decisions to use 
drugs accumulate, a person’s capacity to choose to do otherwise in relation to drugs becomes more, not 
less, difficult. In the extreme, and under the right conditions, choosing drugs over all other choices is not 
unthinkable, meaning that it is imperative to understand what motivates continued drug use despite great 
risk and great cost.  
Part of the behavioral economic perspective of drug use includes an understanding that many 
psychological, affective, and neurophysiological states and changes occur when addictive drugs such as 
opioids and stimulants are used. Brain changes are, after all, endogenous to the person and can contribute to 
the person’s pathological overvaluing of drugs and their continued use despite costs (Heyman & Mims, 
2015). In this way, there is some harmony between the behavioral economic/neuroeconomic 
conceptualization of drug use that persists despite adverse consequences and the BDMA conceptualization, 
suggesting possible common ground for advancing a more nuanced understanding of the nature of the 
problem (Fenton & Wiers, 2017). But, in order to better make sense of and intervene on these endogenous 
factors, and to better understand how decisions to use high-risk drugs can continue despite adverse 
consequences, it may also be necessary to identify and examine people’s overall set of available capacities 
and choices prior to and during a period of problematic use, along with the contexts in which drug-related 
decisions are being made (Bickel et al., 2014).  
This study used a molar view of choice (Baum, 2004; Vuchinich & Heather, 2003) to identify and 
explore several factors with the potential to influence decision-making about high-risk drugs among a 
sample of corrections-involved adults using available survey data. In so doing, it was able to help articulate 
the idea that endogenous and exogenous conditions have the capacity to constrain choice and behavior. 
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Broadly and indirectly, some study findings helped to illustrate the important idea that influences on 
decision-making and behavior are not always in the direct awareness or control of people. These ideas may 
be extended in future work to consider how endogenous and exogenous conditions also have the capacity to 
influence and constrain the formation of desires and intentions, both of which are important for 
understanding high-risk drug use. As discussed earlier, a person’s preferences may be ordered:  
1) Not be addicted to heroin.
2) Inject heroin.
3) Do not inject heroin.
This could also be reflected as conflicting desires that constrain a person’s will, in which a first-
order desire constrains a second-order desire, making it impossible for a person to act on their desire 
(Mann, 2004)14:  
1) Wants to inject heroin.
2) Does not want to inject heroin.
A better understanding of the ranked preferences and desires of people who use drugs would help 
to clarify choice and behavior in respect to use. There is an important clinical difference between:  
1) Continued drug-taking despite a person’s desire to stop
2) Continued drug-taking because of a person’s desire to continue.
There is also an important clinical difference between: 
1) Remitted drug-taking despite a person’s desire to take drugs.
2) Remitted drug-taking because of a person’s desire to not take drugs.
If facilitating a state of remission or achieving a state of abstinence is a principal goal when 
addressing SUD, then both cases of the latter example might be considered treatment success. But it is easy 
to see why the differences between the two matter. Achieving a behavioral change without also achieving a 
change in desire or intention, assuming it is even possible, may be missing the bigger point: most of us 
14 “One has freedom of will if one is free to want what one wants to want; if, that is, there is harmony
between one’s first-order desires and one’s second-order desires. A narcotics addict who takes drugs 
because he wants to has freedom of action. Nonetheless, he lacks freedom of will if his second-order desire 
not to have a first order-desire for narcotics is powerless over the first-order desire” (Mann, 2004, pg. 286). 
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would rather live in a world in which people’s lives are of a quality that they no longer want to choose to 
take drugs with significant risks and at tremendous cost.  
A person’s primary and secondary intentions in relation to drugs are also of interest and warrant 
investigation. Future study of people’s ranked intentions is a potentially useful area of exploration, insofar 
as intention precedes purposeful and planned behavior and insofar as intentions cannot be formed except by 
a broader set of conditions which, in theory, have the potential to be manipulated or improved (Bratman, 
1987, 1999). For instance, a person may be able to form a primary intention to quit using drugs if 
sufficiently appealing services or non-drug options were offered. Even with this primary intention formed, 
secondary intentions (e.g., not calling the drug dealer, throwing away syringes and not buying new ones, 
developing non-drug routines etc.) would still need to be reinforced over time. Because the formation of 
intent is conditional and temporally situated, it is important that future work not only examine intentions 
related to drug-related choice and behavior, but also seek to understand what conditions influence their 
development and ability to be acted upon (Bratman, 1987, 1990). Further examination of intentions related 
to drugs may also help bridge some of the conceptual divide between the BDMA and behavioral 
economic/neuroeconomic model. While the BDMA does emphasize desire and behavior, choice and 
intention are de-emphasized.  
Detailed study of discrepancies between desires, intentions, choice, and behavior in relation to 
drug use, moderation, and cessation may begin to reduce some of the assumptions made during research 
and practice. For instance, it cannot be assumed that any participant in this sample wanted to use opioids or 
wanted to stop using opioids, or that they intended to keep using cocaine subsequent to incarceration or 
intended to quit using cocaine subsequent to incarceration. Even though participants’ drug-related decisions 
were implied by their behaviors, participants’ desires and intentions, and the exogenous and endogenous 
conditions which may have influenced and constrained their development, could not be inferred from any 
study data. Nor could any conflict or agreement between ordered preferences, desires, and intentions be 
discerned, leaving many fundamental questions to be addressed in future studies. This is important to work 
towards, because, ultimately, rates of drug use or abstinence subsequent to any intervention lose much of 
their meaning if the degree of concordance or discordance between the goals of treatment and the goals of 
the people receiving treatment are not also known. Insofar as there is discordance between the two, policies 
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and practices may continue to fall short, and people who may otherwise benefit from tailored treatment or 
from harm-reduction intervention may not been given access to potentially beneficial services that take into 
account what it is that they as people want and intend.  
Additional Considerations for Future Work 
This study identified many factors with the potential to have influenced decisions about opioids 
and stimulants, but because of this broadness of scope, both conceptually and from a measurement 
standpoint, there was no way define what was of greatest influence on decisions to use. Because there are 
in reality even more factors with the potential to influence drug-related decision-making then were 
discussed or examined here, it will be important moving forward to develop a more parsimonious study of 
what remains a complex phenomenon.  
This may be accomplished, in part, by significantly narrowing the scope of future investigation 
and improving data collection methods, but also by examining a few select  aspects of drug-related 
decision-making from different angles. For instance, the use of ecological momentary assessment and other 
sophisticated data collection methods that allow for passive and active data collection, coupled with 
structured interviewing, would facilitate measurement of some proximate influences over a period of time, 
but also more nuanced exploration of participants’ desires and intentions (Buckner, Crosby, Silgado, 
Wonderlich, & Schmidt, 2012; Epstein et al., 2009; Moore et al., 2014; Onnela & Rauch, 2016; Roth, et al., 
2017; Shiffman, Stone, & Hufford, 2008). Despite some of the inherent limitations of using qualitative 
data, this type of information has the potential to reduce the burden of interpretation for some findings (or 
rather add an additional layer of data for interpretation, depending on how one wishes to view this). Had 
such data been available for examination in this preliminary study, they would have likely helped to 
provide a fuller picture of drug-related decision-making than was able to be established. In addition to 
EMA and structured interviewing, neuroimaging, biosensors, and biological measures could also be used in 
a limited capacity, helping to provide a fuller picture of how people’s decision-making may be influenced 
during a particular period of time. Longitudinal studies (particularly those beginning during childhood and 
adolescence), though more challenging and costly to conduct, are particularly needed to help move this area 
of research forward. Aiming for data collection across multiple levels and time scales would help to 
establish a line of research that gives primacy to understanding endogenous and exogenous factors that can 
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constrain choice and behavior in real-time and over time, and may permit study of how people’s desires 
and intentions can vary as a function of broader conditions. 
Of particular interest would be to investigate if the conditions of incarceration, which often 
include enforced abstinence, change cognition in respect to drugs. People with a history of opioid and 
stimulant use who are on community supervision or who are participating in drug court programs would be 
more likely to become incarcerated than other drug-using populations. These populations might be studied 
over time to see how cognition, desires, and intentions change as a function of being in a controlled 
environment where abstinence is enforced. Confinement in jail or prison might conceivably have the 
potential to decrease present-bias and increase future-oriented cognition. For some, time spent in a 
controlled environment may help achieve, at least temporarily, greater consonance between what their 
current self and future self value. Presently, these possibilities are offered here as speculation. However, 
should a study of drug-related cognition and temporal perception among people residing for long periods of 
time in a controlled environment be developed, it may be able to inform how interventions for corrections-
involved populations are developed. Measuring present-bias, craving intensity, attentional bias, and 
temporal perception, along with ranked desires and intentions, during periods of incarceration might help to 
explain differences in lapses and relapses following release. As noted by Epstein et al. (2006), there is an 
important difference between abstinence that is imposed by external circumstances and abstinence that 
occurs under conditions which permit volitional drug use as well as volitional abstinence. Focusing on 
preferences, motivations, and intentions across contexts during future research will be crucial for 
developing a more well-rounded understanding of drug use that occurs subsequent to people’s release from 
controlled environments. 
Future work would also benefit from more diverse sample, not just in terms of race, sex, and age, 
but also in terms of educational status, income, and geographic location of participant residence. Greater 
heterogeneity of residence would permit further exploration of the idea that residing in harsh environment 
might influence drug-related decision-making. Such work might be undertaken in Tennessee, West 
Virginia, and Kentucky to examine differences between people who reside within or outside of Central 
Appalachia, but might also be undertaken in highly urban areas, such as Chicago or Baltimore, based on the 
block, neighborhood, or zip code (Furr-Holden et al., 2010; Stockdale et al., 2007; Stull et al., 2019). 
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Finding Common Ground? 
Regardless of whether addiction is ultimately conceptualized as a reinforcer pathology or as a 
brain disease, if the major approaches for understanding drug use and addiction can agree on the premise 
that people who use high-risk drugs do not have direct awareness or control over many of the factors that 
influence their ultimate behavior, and that as a result of repeated use they have fewer degrees of freedom in 
thought and action in respect drugs, then there may be agreement enough to move forward in collectively 
asking and answering the question of how intervention of high-risk drug use may be improved ethically in 
light of shared belief in this premise (Hyman, 2017). Presently, bioethical frameworks for clinical decision-
making in SUD intervention are not well-developed and may be wholly absent within some settings, such 
as peer-delivered recovery services and mandated programs affiliated with 12-Step models of recovery 
(Bassuk, Hanson, Greene, Richard, & Laudet, 2016; Bøg, Filges, Brännström, Jørgensen, & Fredriksson, 
2017; Logan, Miller, Cole, & Scrivner, 2018). This means that certain practices, such as collaborative 
treatment planning or obtaining informed consent that is truly informed, cannot be taken for granted 
(Walker, Logan, Clark, & Leukefeld, 2005).  
Significant heterogeneity among SUD interventions is not necessarily a bad thing, as the factors 
that influence drug use differ across people. However, across mandated and voluntary SUD interventions 
there remain shortfalls in evidence-based practice (with some research-informed interventions unable to be 
implemented with fidelity to the underlying science), and continued reliance on non-professional services 
(Alcoholics Anonymous, 1994; Bøg et al., 2017; Butler, Chapman, Forman, & Beck, 2006; De Leon, 
Perfas, Joseph, & Bunt, 2015; Logan, Miller, Cole, & Scrivner, 2018; Oser, Harp, O'Connell, Martin, & 
Leukefeld, 2012; Walker, Godlaski, & Staton-Tindall, 2013). Beyond this, evidence-based practice 
constitutes a process that includes taking into account not only scientific findings, but also the goals, 
preferences, and needs of people on an individual basis (Elwyn et al., 2012; Gambrill, 2006; Sackett, 1997). 
The wide-spread awareness of the BDMA and the lack of awareness about the behavioral 
economic/neuroeconomic model of addiction across many service providers may, however unintentionally, 
encourage an overly simplistic view of and morally ambiguous response to the problem of high-risk drug 
use (Hall, Carter, & Forlini, 2015; Hammersley, 2019 Kirby, Benishek, Dugosh, & Kerwin, 2006). This 
may be partially due to the BDMA’s narrower scope, but also due to the language commonly associated 
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with this perspective that de-emphasizes the roles of intention, choice, and agency (NIDA, 2018). Because 
the BDMA, however unintentionally, finds itself in some rough conceptual agreement with 12-Step models 
of addiction (i.e., alcoholics and addicts have “an allergy” to alcohol and drugs, but continue to use despite 
this allergy because of spiritual estrangement), an overly simplistic, and still not quite clear, view of the 
problem might continue to persist among treatment providers and treatment-seekers alike (Alcoholics 
Anonymous, 2008; 2009, 2014; NIDA, 2018). Worryingly, the BDMA’s de-emphasis of choice, intention, 
and agency does not yet seem to have resulted in fundamental transformations in how people with SUD are 
treated socially or within systems of intervention (Carter & Hall, 2017). This is partially reflected by the 
continued practice of incarcerating people for using drugs, even though drug use is, by definition, part of 
the disease (Bureau of Justice Statistics, 2018). That addiction is considered to be a disease that is both 
chronic and relapsing may also inadvertently influence the degree to which the public, policy makers, 
clinicians, and people who use drugs believe that meaningful change is possible, even though evidence 
suggests it is (Heyman & Mims, 2016; Wiens & Walker, 2015).  
Seeking to better understand drug use within a system of constraint, in which constraints on desire, 
intention, choice, and behavior are all more unequivocally considered, may permit, perhaps a bit 
paradoxically, some exoneration, while also better allowing for the person’s humanity and dignity to be 
present in a way that the BDMA less readily permits. By directly acknowledging and purposefully studying 
people’s capacities for forming desires and intentions, making decisions, and undertaking action, the lines 
of their personhood may become more evident and the factors which influence their decision-making about 
drugs more readily addressed. The degree to which investigation of and discussion about drug use involves 
or omits the idea of a decision-making agent is the degree to which people’s values, preferences, and goals 
may be neglected during intervention. Omitting some of these central ideas may incline treatment providers 
to aim primarily for the problem behavior, without also aiming to identify and better understand the 
conditions that make that behavior possible. It also means that, in theory, decrease in substance use might 
be sought as an isolated target outcome without ever treating the person who decided to use drugs and 
without asking them what they desire and intend, and under what conditions they believe fulfilling those 
desires and intentions are possible. Many SUD interventions and recovery services in the US, especially 
mandated ones, do not commonly take into account what the person using drugs actually wants or desires, 
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or how those desires may be at odds. It may be that because of the externalizing nature of SUD there is 
little sympathy for what the person using drugs wants or intends. Or it may be that, due to the increasingly 
accepted notion that drug users have a chronic and relapsing brain disease, there is a belief that drug users 
cannot be trusted to know what it is they want or intend, or that there is little point in asking due to the 
putative permeance of the condition. 
It is in some ways easier to talk about, research, and moderate certain behaviors (e.g., “using” 
versus “not using”) than it is to talk about, research, and target cognitive states (e.g., desire, intention), even 
though the two are inextricably linked (Bandura, 1986; Beck & Haigh, 2014; Bratman, 1999). But it may 
be unwise to think that behaviors can be understood and moderated in the long-term, versus achieving a 
short period of remitted abstinence, without first seeking to better understand, clarify, and moderate 
people’s desires, intentions, cognitive capacities, and conditions prior to choice. Aiming to better 
understand and address people’s desires, intentions, and cognitive capacities in relation to drug-related 
decision-making, and aiming to improve the conditions in which these states and decisions are formed, has 
the potential to produce outcomes that are more expansive and enduring, as well as more faithful to the 
concept of person-centered care, compared to efforts that seek primarily to achieve just the behavioral 
outcome (e.g., remission or abstinence). It would also imply that prevention is equally if not more 
important than intervention.  
Limitations 
There were many important limitations to this exploratory study. First, because this sample was a 
comprised of corrections-involved participants in Kentucky, generalizability of any finding is limited. 
Second, using data from a survey that was not designed with the primary concern of establishing the 
intercorrelation of variables, or their relation to the outcomes examined in this study, poses a threat to 
validity in terms of temporal ambiguity (Langley, 1999; Shadish et al., 2002). Here, the temporal order of 
some factors and their influence on opioid and stimulant use outcomes cannot be established within or 
across given time periods (e.g., past-year, past 30-days, past 7-days). For instance, if someone experienced 
depressive symptoms during the past year, the relationship to an outcome of past 30-day use is far from 
direct. This is related to the fact that the CJKTOS surveys used to collect data contained measures created 
for other purposes and were unconcerned with theoretically-informed causal modeling. This may not be a 
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limitation, per se, as this study was exploratory and sought principally to identify and describe some 
approximate contiguity or coincidence between endogenous and exogenous factors and high-risk drug use, 
making it agnostic about which constructs were “crucial” for causation (Bagozzi & Yi, 2012; Hume, 2007; 
Shadish, 2002). This is noted simply as an acknowledgement that the measures used to collect data were 
not developed or implemented for purposes other than clinical use and program evaluation. This is a fact 
that may be applied to several other study limitations discussed in this and in previous sections. 
Third, opioid and/or stimulant use (or no use) during a particular time period represents not just 
one decision, but many. It is likely that most in this sample did not decide to use a given drug only one time 
per day or month during the 30 days prior to incarceration or the one-year period subsequent to 
incarceration, but rather multiple times over these time periods, potentially dosing one or more drugs 
dozens of times per day, or even hour. For powder and crack cocaine, it is likely that the number of the 
decisions made to use the drug is greater than other drugs, given the pharmacological differences of cocaine 
relative to other drugs whose subjective psychoactive effects and half-life are relatively longer (Cone, 
1995; Gawin, 1991, Jenkins, Oyler, & Cone, 1995). It should be understood, then, that many drug-related 
decisions were being made contemporaneous to each other, in relation to proximate factors with the 
potential to influence decision-making (e.g., anxiety symptoms, chronic pain, living in Central Appalachia), 
and in relation to other, more distal factors (e.g., age of drug use initiation) with the potential to influence 
decision-making.  
Fourth, random error is an inevitable part of any measurement process, but in this study, there are 
potentially several sources of nonrandom error, wherein instruments do not measure what they purport to 
measure, either in regard to states of the world at certain time points, or in regard to abstract concepts 
(Althauser & Heberlein, 1970, Carmines & Zeller, 1979; Werts & Linn, 1970). For example, participant 
self-report in the form of discrete descriptions, that can only be one particular way or another (e.g., sex, 
age), or in the form of descriptions of their life during a given time period (e.g., nights spent in a controlled 
environment), can result in measurement error by only allowing participants to select from prefigured 
categories. These categories may not provide a full range of response options that accurately reflect the 
participant’s lived experience (Coughlan, Cronin, & Ryan, 2009). For instance, powder cocaine and crack 
cocaine could not be examined as separable decisional outcomes, as the CJKTOS survey combines the two 
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in both baseline and follow-up surveys. It is likely that different factors would influence the likelihood of 
observing a decisional outcome for powder cocaine versus crack cocaine (Guindalini, Vallada, Breen, & 
Laranjeira, 2006; Hatsukami & Fischman,1996).  
Additionally, measurement at other levels, such as the availability of alcohol within counties, was 
imprecise given the heterogeneity of alcohol prohibitions at the city and county-level across Kentucky. 
Although alcohol was considered as either “restricted” or “unrestricted”, there was inevitably some 
variation between restricted counties, due to within-county differences in city statutes for the conditions of 
permissible alcohol sales, including by type of alcohol and type of establishment in which alcohol may or 
may not be distributed. The question pertaining to “current marital status” did not capture current 
relationship status, making it impossible to know if participants were in a committed relationship outside of 
legal marriage.  
Nonrandom error was also possible, and perhaps more probable, in the measurement of variables 
indirectly indicating abstract concepts (e.g., impulsiveness), variables indicating the presence or absence of 
psychiatric constructs (e.g., anxiety symptoms), or variables indicating severity of somatic states (e.g., 
chronic pain). Nonrandom error may have also been introduced by the ways survey questions were worded. 
For instance, participants’ response to items with ambiguous terminology (e.g., the number of close 
relationships participants believe they had, for which the concept of “close” is utterly subjective) and for 
which the surveys did not attempt to establish greater objectivity or linguistic coherence by defining terms 
(Searle, 2008). That the question pertaining to abstinence self-efficacy did not permit a response that 
clarified if participants intended to remain abstinent makes interpretation of that variable oblique at best.  
Fifth, this exploratory study used single-item indicators and composite variables. Both have their 
limitations. Although the validity and reliability of single-item indicators have been questioned, and their 
use cautioned against in some instances, there is growing evidence and support for their limited use (Abdel-
Khalek, 2006; Bergkvist & Rossiter, 2007; Nagy, 2002; Sarstedt & Wilczynski, 2009). Some studies have 
found that single-item indicators have acceptable performance for reliability and construct and criterion 
validity (Gardner, Cummings, Dunham, & Pierce, 1998; Elo, Leppänen, & Jahkola, 2003; Ruekert & 
Churchill, 1984; Wanous & Hudy, 2001;Wanus & Reichers, 1996; Youngblut & Casper, 1993). After 
consulting various sources, it is reasonable to state that single-item indicators--while not always preferable 
 252 
and not equal to multi-item measures in predictive validity-- may still be used with caution and with 
understanding of their limitations. Single-item indicators can be helpful, and are sometimes necessary to 
bridge theoretical demands and problematic data collection methods that arise out of practical necessity 
(e.g., to reduce survey length, secondary data analyses; institutional and clinical considerations) (Bergkvist, 
2015; Diamantopoulos, Sarstedt, Fuchs, Wilczynski, & Kaiser, 2012; Fuchs & Diamantopoulos, 2009; Loo, 
2002; Wanous, Reichers, & Hudy, 1997). Use of single-item indicators in this study was therefore 
undertaken with appropriate caution and with an understanding for how they may have the potential to 
weaken conceptual claims made upon the data and hinder interpretation.  
Although composite variables created for use in this study were evaluated for internal consistency 
reliability, there is no way to measure criterion validity, just as criterion validity could not be assessed for 
the single-item indicators used (Carmines & Zeller, 1979; Messick, 1975). It is also important to note that 
while some validated instruments, or items from validated instruments, were adapted for use as part of the 
CJKTOS surveys, these changes did not undergo validity or reliability testing. Other composite variables 
used consisted of CKTOS survey questions that were created by CDAR researchers and the KY DOC 
Substance Use Treatment Director during survey development. It is important to emphasize the fact that 
CJKTOS surveys are intended for use both clinically and as an outcome study evaluation tool. Therefore, 
there is no established validity for CJKTOS surveys nor survey sections, even as they are standardized in 
their content format during a given FY so as to minimize burden on participants (Dillman, Smyth, & 
Christian, 2014; Tourangeau, Couper, & Conrad, 2004).  
Sixth, additional potential threats to validity due to other issues. Some of these issues include the 
possibility of: 1) social desirability bias or interviewer effects, 2) test fatigue/survey length, 3) instrument 
changes between baseline and follow-up, 4) possible participant difficulties with verbal and reading 
comprehension, mendacity, or poor recall, and 5) other conditions present during data collection and testing 
that cannot be known or accounted for (Cook & Cshadish, 1994; Davis, Couper, Janz, Caldwell, & 
Resnicow, 2009; Lavrakas, 2008a; Pedhazur, & Pedhazur-Schmelkin, 1991; Holbrook, Green, & Krosnick, 
2003; Richman, Kiesler, Weisband, & Drasgow, 1999; Shadish, Cook, & Campbell, 2002). However, 
among samples of drug users, including those who are corrections-involved, self-report of drug use and 
drug-related behaviors has been found to be reliable (Del Boca & Darkes, 2003; Del Boca & Noll, 2000; 
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Denis et al., 2012; Zanis, McLellan, & Randall, 1994). In this study, the probability of nonrandom error 
being introduced was likely higher at baseline, as there were a greater number of different SAP clinicians 
collecting baseline data across multiple institutional settings, compared to the fewer number of different 
CDAR research staff collecting follow-up data via telephone in a non-clinical capacity (Dillman, 1978; 
Fink, 2015; Holbrook et al., 2003). Further, at baseline, some participants may have self-administered the 
survey, whereas others provided verbal responses to survey items read by SAP clinicians. This variation in 
survey administration and response format, within baseline data collection and between baseline and 
follow-up data collection, is one potential source of error (Carmines & Zeller, 1979).  
Seventh, despite that this study was developed with the idea of exploring the possible influence of 
participant residence as an important exogenous factor with the potential to influence decision-making 
about high-risk drugs, it was unable to be investigated with the depth or precision needed due to 
insufficient sample size, and in some cases insufficient variance. Accordingly, county-level measures 
initially proposed for examination (e.g., wealth inequality, poverty, opioid prescribing rates) were unable to 
be explored. However limited, urban influence and residence in Central Appalachia did reveal some 
important differences in opioid and stimulant use.  
Eighth, using a behavioral economic approach for thinking about drug-related decision-making 
and drug use was a necessarily expansive approach, as it explicates drug use from a molar perspective of 
choice. The potential expansiveness of behavioral economics and a molar account of choice reflects, among 
other things, a conceptual sensitivity to the complexities involved, including context and time. This 
expansiveness opens the door to narrow and broad investigation alike (Tomer, 2007). Conceptual breadth 
permits researchers a fair degree of empirical latitude, as well as use of a variety of methodologies and data 
sources, including survey data (Katona, 1951, 1975; Tomer, 2007). But with breadth and inclusiveness, 
comes the potential for loss of specificity of inquiry, decreased likelihood for incremental advancement of 
parochial subareas, and, in some cases, an inability to reproduce or replicate methods or findings. Given 
that this exploratory study was not designed with reproducibility or replicability in mind, but rather with 
conceptual breadth in mind (even at the expense of specificity), some allowances for investigating the 
problem of high-risk drug use in a coarse-grained manner might be made. This coarse-grained approach 
may be considered as a starting point for future work.  
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Because the outcome variables used in this study are understood from a molar view of choice as 
the behavioral indicator of a drug-related decision, but because participants were not asked specific 
questions about some of the important factors that may have influenced decision-making, such as drug 
price, drug availability, intent, perceived risks, etc., important gaps between conceptualization and 
measurement remain. Opioid and stimulant use explored in this study reflect the fact that a drug-related 
decision occurred prior to the behavior (e.g., heroin use during the one-year period subsequent to 
incarceration is the behavioral referent of a heroin-related decision that occurred during that one-year 
period). One limitation already noted is that the frequency of decisions could not be quantified. Another is 
that many other non-drug choices that would have been of interest to explore were likely made during these 
time periods, but were not able to be indicated with available data. Again, due to temporal ambiguity, it 
was not possible to discern the temporal relation between “an influence” and “that which was influenced”, 
but rather only possible to understand that there was co-occurrence during a given time period (30 days, 
one year, or a lifetime) of potential influences and decisions involving high-risk drugs.  
Finally, in seeking improved understanding of choice and behavior in relation to high-risk drugs, 
the identification of an appropriate stopping point for data collection, statistical modeling, and discussion 
was not always clear. The premise underlying this exploratory study, that endogenous and exogenous 
factors of a participants’ lives influenced and constrained drug-related decision-making and behavior, 
paved the road generously toward narrow and precise investigation, as well as and broad and coarse 
investigation. One potential strength of this study, its broadness in conceptual scope, was also a limitation 
in terms of how data were selected for examination and in terms of how such broad conception could be 
statistically modeled. Using institutional survey data, many self-reported factors of participants’ lives were 
able to be explored and, to a limited extent, indirectly discerned, thus illustrating some important concepts. 
Doing this, though, did not encourage recognition or emphasis of what factors mattered most; nor could it 
have. The absence of focus on any one factor or set of factors stemmed partially from measurement 
limitations, but also from the fact that from this study’s outset nothing was presumed to be irrelevant. With 
this study’s conclusion, this presumption has not changed.  
What has changed is understanding that the inherent tension between theory and measurement will 
need to be approached differently, and more parsimoniously, in future research, with greater emphasis 
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placed on streamlining study aims, questions, and data collection and scaling these differently than the 
conceptual model itself. The dynamic, self-organizing complexity of human cognition and behavior that is 
of most interest when seeking to better describe and understand high-risk use within a system of constraint 
is also what is least measurable by its nature, requiring appropriate use of simple mental models in places 
where elaborate data collection methods and statistical models are not yet developed. While a small degree 
of complexity was approachable in this exploratory study conceptually, it was not approachable from a 
measurement standpoint. This study can therefore be considered, in part, as a conceptual gesture, 
undertaken in the spirit and recognition of the need to move toward greater integration of information and 
theory, as well as more rigorous methods and more fine-grained measurement. Study methodology did 
permit a coarse-grained snapshot of some of the factors that may have influenced decision-making about 
high-risk drugs among this corrections-involved sample. Study limitations notwithstanding, findings may 
still have value when considered from a behavioral economic perspective, insofar as they may help 
facilitate a discussion about the complicated and challenging lives of people who choose to use opioids and 
stimulants despite associated risks and who continue to use despite adverse consequences.  
Conclusion 
This exploratory study provided a descriptive profile of a sample of adults in Kentucky with a 
history of drug use using self-report data collected prior and subsequent to incarceration and established the 
prevalence of opioid, stimulant, and concomitant opioid and stimulant use at both time periods. Description 
of and differences between groups who reported opioid, stimulant, and concomitant use was presented. 
Endogenous and exogenous factors that demonstrated an association with opioid and stimulant use were 
explored in order to further understand the relationship between these factors and outcomes involving 
opioids and stimulants. These factors were described in terms of their potential to influence and constrain 
cognition and choice related to high-risk drug use.  
Overall, opioids and stimulants were used at high rates among participants in this sample and were 
often used contemporaneously with other drugs. While polydrug use in was a feature of this sample 
generally, greater drug use versatility was observed primarily among people who reported using opioids, 
and using them concomitantly with stimulants. This is concerning due to the fact opioids used in 
combination with other drugs entails significant risk. Concomitant use and heroin use, both associated with 
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greater drug use versatility, were positively correlated with many factors with the potential to adversely 
influence cognition and constrain choice. Similar relationships between many of these factors and 
outcomes involving other/no drug use were not observed. The primary take-away is that risker use was 
associated with a greater number of factors with the potential to constrain choice and behavior, whereas 
other/no drug use was less frequently associated with these factors. Still, these relationships were not 
unambiguous and should be interpreted cautiously. More work is required to better understand when the 
presence of certain factors has the capacity to influence choice in respect to opioids and stimulants, 
including the strength of any observed effect. 
Although use of specific opioid and stimulant drugs was found to vary based on participants’ 
residence within or outside of Central Appalachia and by urban proximity, ongoing investigation of these 
influences is needed as drug markets continually change. For instance, it may be that heroin is now more 
available in Central Appalachia and rural locations than it was when follow-up data were collected. The 
increased presence of fentanyl in the drug supply also means that many of the drugs used by participants 
prior and subsequent to incarceration are possibly risker now than when data were collected.  
Despite differences in opioid and stimulant use among participants, there was some sample-wide 
homogeneity that may be reflective of the overall greater disadvantage found among corrections-involved 
people in the US. Seeking to understand high-risk drug use among a sample of corrections-involved people 
is in some ways synonymous with seeking to understand high-risk drug-use among a vulnerable and 
stigmatized population. Because of this population’s marginalized and disempowered status in the US, it is 
of particular importance to better understand how certain conditions influence desire, intention, choice, and 
behavior in relation to opioids and stimulants, as the potential consequences of such high-risk use may be 
disproportionate among this population and less easy to reverse, compared to populations with greater 
access to flexible resources (Phelan et al., 2010).  
Through examination of available survey data and broad review of related literature this 
exploratory study identified many factors with the potential to influence decision-making about high-risk 
drugs. It left many other factors unexplored. Given the preponderance of possible influences on drug-
related decision-making, policy-makers and clinicians might better consider how they can aim for two 
moving targets simultaneously: advance interventions that assist people in critical moments as they decide 
 257 
to use drugs or not (interventions could include decreasing craving or decreasing present-bias, 
pharmacotherapies, etc.), but also better develop and expand access to interventions that may help people 
acquire capacities and competencies across multiple life domains (e.g., mindfulness-based interventions, 
cognitive-behavioral interventions, working-memory training, intensive case management, memory 
reconsolidation, etc.), stabilizing them over time by increasing opportunities for engaging with non-drug 
alternative reinforcers and by helping them reduce stress while habits of daily living are strengthened 
(Bickel et al., 2011; Bowen et al., 2006; D’Onofrio et al., 2015; Fjorback, Arendt, Ørnbøl, Fink, & Walach, 
2011; Gorelick, Zangen, & George, 2014;  Himelstein, Saul, & Garcia-Romeu, 2015; Jarlais et al., 2015; 
Laudet, 2011; Peiper et al., 2019; Tobin, Davey, & Latkin, 2005; Volkow, Frieden, Hyde, & Cha, 2014; 
Wheeler, Davidson, Jones, & Irwin, 2019; Witkiewitz, Marlatt, & Walker, 2005). Longer-term stabilizing 
forces (i.e., improved cognitive capacities, greater choice) can, in part, develop as a result of aggregated 
instances of inhibiting urges to use opioids and stimulants to excess. As stability increases, these critical 
moments of craving would become less frequent, and more cognitively and behaviorally manageable. 
Successful intervention would need to gain purchase on both developments, at both time scales.  
Ultimately, the idea that people choose to use high-risk drugs, but that their capacities for 
decision-making are constrained by many endogenous and exogenous factors, is not only conceptually 
coherent, but also optimistic. It is coherent insofar as intention and choice precede action. It is optimistic 
because many of the conditions of people’s lives before, during, and after drug use have the potential to be 
changed. That the idea of constraint is in some way represented in both the BDMA and the behavioral 
economic/neuroeconomic model may be an important bit of common ground to exploit moving forward, 
even if, for now, there remains disagreement about what specifically is being constrained. This point of 
modest agreement, though, indicates that in seeking to change people’s use of high-risk drugs, it is also 
necessary to change the conditions, the constraints, that give rise to the problem. If all organisms operate 
within a system of constraint, then there are practical and moral reasons for investing in efforts aimed at 
making that system of constraint one in which people are more likely flourish and less likely to suffer as a 
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Figure 3.0. Participant counties of residence prior to incarceration with <10 observations per county 
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Figure 3.1. Participant counties of residence subsequent to incarceration with <10 observations per 
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Figure 4.0  
Participant counties of residence prior to incarceration with >10 observations per county 
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PROFESSIONAL EXPERIENCE 
INTRAMURAL RESEARCH TRAINING AWARD,  2019- 
POST-DOCTORAL FELLOW 
National Institutes of Health, National Institute on Drug Abuse 
Real-world Assessment, Prediction, and Treatment Unit, 
Clinical Pharmacology and Therapeutics Research Branch 
Baltimore, Maryland 
DATA COORDINATOR/ANALYST   2018-2019 
University of Kentucky, Center on Drug and Alcohol Research 
Lexington, Kentucky
Major Responsibilities: Conducted baseline interviews and consolidated tracking and locating efforts for 
post-intervention follow-up data collection among a clinical sample of substance users residing in rural 
Appalachia. Track and locate difficult-to-reach participants for follow-up data collection as part of the 
Criminal Justice Kentucky Treatment Outcome Study (CJKTOS), an ongoing study examining 
effectiveness of the KY Department of Correction’s (DOC) Substance Abuse Treatment Program (SAP) 
and KY DOC-referred medication-assisted treatment pilot programs. Assisted in data management and 
analyses for five ongoing outcome evaluations. Prepared annual technical reports and manuscripts for 
academic publication.  
RESEARCH ASSISTANT 2016-2018
Kent School of Social Work, University of Louisville 
Louisville, Kentucky  
Major Responsibilities: To fulfill objectives for a SAMHSA-funded grant, conducted follow-up 
interviews pertaining to substance use, mental health, victimization, and perinatal/postnatal health 
behaviors among a sample of drug-using women exiting residential treatment. Oversaw data collection 
tasks of 1 Masters-level student. Assisted with statistical analyses and manuscript preparation using 
longitudinal Women’s Health Study (NIDA R01DA027981) data which captures health behaviors of 
women on probation/parole with a history of victimization.  
SENIOR DATA COORDINATOR    2015-2016 
University of Kentucky, Center on Drug and Alcohol Research 
Lexington, Kentucky
Major Responsibilities: Tracked and located difficult-to-reach study participants for post-intervention data 
collection as part of the Criminal Justice Kentucky Treatment Outcome Study (CJKTOS), an ongoing study 
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examining effectiveness of the KY DOC SAP program. Conducted follow-up interviews with paroled and 
incarcerated individuals. Drafted annual reports for state legislators. Trained DOC clinicians to conduct 
baseline assessments of incarcerated SAP participants. Created a pilot assessment instrument for DOC 
clinical training workgroups on substance use intervention practices. Assisted in data management, 
analyses, and manuscript preparation. 
RESEARCH ASSISTANT  2016 
University of Kentucky College of Social Work, Lexington, Kentucky
Major Responsibilities: Helped prepare academic presentations and publications on issues pertaining to 
substance use, incarceration, health care policy, and use of social media in conducting research with hard-
to-reach populations. Assisted with transcribing, coding, and rating data obtained under an ongoing project 
concerned with harm-reduction interventions for rural, female substance users involved with the criminal 
justice system (NIDA R01DA033866 & K02DA035116). 
MASTER’S PRACTICUM    2014-2015
Hope Center Recovery Program for Men, Lexington, Kentucky
Major Responsibilities: Conducted strengths-based, trauma-informed biopsychosocial assessments for 
incoming clients. Founded and facilitated weekly process group and led classes for Phase I clients. Created 
curriculum for and taught a monthly psychoeducational class pertaining to the neurobiology of addiction.  
Established therapeutic alliances with clients and collaboratively explored issues related to reentry, relapse 
prevention, and strategies for improving self-efficacy.  
UNDERGRADUATE PRACTICUM     2014
United Way of the Bluegrass, Lexington, Kentucky      
Major Responsibilities: Worked as part of an interdisciplinary financial stability team to assist 
economically marginalized clients with establishing individualized development accounts (IDAs). Revised 
UWBG participant follow-up survey. Collected and analyzed UWBG participant data and prepared for 
quarterly and annual reports. Conducted client orientations, helped participants complete individualized 
savings plans and establish financial goals. Coordinated financial literacy and education opportunities with 
community partners. Participated in community outreach events and grant reviews. 
UNDERGRADUATE PRACTICUM 2013
Chrysalis House, Inc. Lexington, Kentucky 
Major Responsibilities: Assisted in client admission screening, intake. Conducted psychosocial and drug 
history assessment. Assisted with weekly home visits at off-site housing and administered urine analysis 
tests. Facilitated weekly cognitive behavioral therapy group. Updated electronic client files with progress 
notes and assessed for relapse risk. Helped prepare clients for GED testing, job-seeking, and independent 
living.  
TEACHING     2018 
Teaching Practicum 
University of Louisville, Kent School of Social Work     
Louisville, Kentucky 
SW 662-75 Substance Use and Substance Use Disorders 
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ACADEMIC AND PROFESSIONAL AWARDS 
Academic and Health Policy Conference on Correctional Health  2019 
Travel award          
College on Problems of Drug Dependence   2018 
Early Career Investigator travel award
Society for Social Work & Research    2018 
Travel award 
Academic and Health Policy Conference on Correctional Health 2018 
Travel award    
University of Louisville 2016-2018 
Doctoral scholarship & Research assistantship 
Idea Festival Scholarship award  2017 
University of Kentucky  2012-2013 
Virginia Lane Award, full undergraduate scholarship 
University of Kentucky 2013-2014 
Virginia Lane Award, full undergraduate scholarship 
University of Kentucky  2012-2014 
Two-time recipient of the Academic Excellence Scholarship 
FUNDING 
University of Louisville Graduate Student Research  2017 
Fund Grant Recipient        
MEMBERSHIPS & AFFILIATIONS 
College on Problems of Drug Dependence, member-in training 2018-Present 
Academic Consortium on Criminal Justice Health   2017-Present
American Society of Criminology      2017-Present 
Society for Social Work and Research   2017-2019 
Sociologists for Women in Society    2016-Present 
Students for Sensible Drug Policy, University of Kentucky   2015-2016 
National Association of Social Workers   2014-2016 
Center for Inquiry       2016-Present 
American Humanist Association  2015-Present 
SERVICE WORK  
Volunteer instructor, Hope Center Women’s Recovery Program 2018-2019 
Bluegrass Reentry Council 2016-2018 
Disability Resource Center  2016-2017 
Guest lecturer, University of Kentucky College of Social Work 2014-2016 
Volunteer, United Way of the Bluegrass      2014-2015 
Volunteer, AIDS Volunteers of America Inc. 2013 
Volunteer instructor, Hope Center Men’s Recovery Program    2012-2019 
Volunteer, Lexington Rescue Mission, Lexington, KY  2012 
